

PI 1141167

RECEIVED
10 MAR 2004

WIPO PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office


March 05, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/487,064

FILING DATE: July 11, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/41273



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

W. Montgomery
W. MONTGOMERY
Certifying Officer

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

PART (1) OF (2) PART(S)

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

07/16/2003 KZEWDIE 00000025 60487064

01 FC:2005

80.00 DP

PTO-1556
(5/87)

IN THE U.S. PATENT AND TRADEMARK OFFICE
Provisional Application Cover SheetCOMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

INVENTOR(S)/APPLICANT(S)

Last Name	First Name, MI	Residence (City and Either State or Foreign Country)
Hickey	Magali Bourghol	Medford, MA
Peterson	Matthew	Framingham, MA
Almarsson	Om	Shrewsbury, MA

TITLE OF THE INVENTION

PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

CORRESPONDENCE ADDRESS

Customer No. 34846
John Lucas
Transform Pharmaceuticals, Inc.
29 Hartwell Avenue
Lexington, MA

ENCLOSED APPLICATION PARTS (check all that apply)

- (X) Specification Number of Pages 718
(X) Drawing(s) Number of Pages 513
() Power of Attorney
() Additional inventors are being named on separately numbered sheets attached hereto.

METHOD OF PAYMENT

A check in the amount of \$ 80.00 to cover the filing fee is enclosed.

Charge \$ _____ to Deposit Account _____

"Express Mail" label no. EV331911901USDate of Deposit: July 11, 2003

I hereby certify that this is being deposited with the United States Postal Service 'Express Mail Post Office to Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

By Jacqueline M. Vo
Typed Name: Jacqueline M. Vo

Respectfully submitted,

John Lucas
John Lucas
Attorney/Agent for Applicant(s)
Reg. No. 43373

Date: July 11, 2003Telephone No.: 781-674-7852

Attorney Docket No: TPIP035A+

PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS

Inventors: Magali Bourghol Hickey
342 Malden Street
Medford, MA 02155
Citizenship: US

Matthew Peterson
60 Linda Avenue
Framingham, MA 01701
Citizenship: US

Orn Almarsson
22 Farmington Drive
Shrewsbury, MA 01545
Citizenship: Iceland

Pharmaceutical Compositions

INCORPORATION BY REFERENCE

The content of US Patent Application No. 60/451,213 filed on February 28, 2003 is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to co-crystal api-containing compositions, pharmaceutical compositions comprising such apis, and methods for preparing the same.

BACKGROUND OF THE INVENTION

Active pharmaceutical ingredients (api or apis (plural)) in pharmaceutical compositions can be prepared in a variety of different forms. Such apis can be prepared so as to have a variety of different chemical forms including chemical derivatives or salts. Such apis can also be prepared to have different physical forms. For example, the apis may be amorphous or may have different crystalline polymorphs, perhaps existing in different solvation or hydration states. By varying the form of an api, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapour pressure, density, colour, and compressibility. Accordingly, variation of the crystalline state of an api is one of many ways in which to modulate the physical properties thereof.

It would be advantageous to have new forms of these apis that have improved properties, in particular, as oral formulations. Specifically, it is desirable to identify improved forms of apis that exhibit significantly improved properties including increased aqueous solubility and stability. Further, it is desirable to improve the processability, or preparation of pharmaceutical formulations. For example, needle-like crystal forms or habits of apis can cause aggregation, even in compositions where the api is mixed with other substances, such that a non-uniform mixture is obtained. It is also desirable to

increase the dissolution rate of api-containing pharmaceutical compositions in water, increase the bioavailability of orally-administered compositions, and provide a more rapid onset to therapeutic effect. It is also desirable to have a form of the api which, when administered to a subject, reaches a peak plasma level faster, has a longer lasting therapeutic plasma concentration, and higher overall exposure at high doses when compared to equivalent amounts of the api in its presently-known form.

SUMMARY OF THE INVENTION

It has now been found that new co-crystalline forms of apis can be obtained which improve the properties of apis as compared to the apis in a non-co-crystalline state (free acid, free base, zwitter ions, salts, etc.).

Accordingly, in a first aspect, the present invention provides a co-crystal pharmaceutical composition comprising an api compound and a co-crystal forming compound, such that the api and co-crystal forming compound are capable of co-crystallizing from a solid or solution phase under crystallization conditions.

Another aspect of the present invention provides a process for the production of a pharmaceutical composition, which process comprises:

(1) providing an api which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(2) providing a co-crystal forming compound which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic

ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (3) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions, and
- (4) isolating co-crystals formed thereby; and
- (5) incorporating the co-crystals into a pharmaceutical composition.

A further aspect of the present invention provides a process for the production of a pharmaceutical composition, which comprises:

- (1) grinding, heating or contacting in solution an api compound with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In a further aspect, the present invention provides a process for the production of a pharmaceutical composition, which comprises:

- (1) providing (i) an api or a plurality of different apis, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the api and the co-crystal forming compound is provided as a plurality thereof;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Solubility Modulation:

In a further aspect, the present invention provides a process for modulating the solubility of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;

(2) isolating co-crystals comprising the api and the co-crystal forming compound.

Dissolution Modulation:

In a further aspect, the present invention provides a process for modulating the dissolution of an api, whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid or in simulated intestinal fluid, or in a solvent or plurality of solvents is increased or decreased, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In a preferred embodiment, the dissolution of the api is increased.

Bioavailability Modulation:

In a further aspect, the present invention provides a process for modulating the bioavailability of an api, whereby the AUC is increased, the time to T_{max} is reduced, the length of time the concentration of the api is above $\frac{1}{2} T_{max}$ is increased, or C_{max} is increased, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Dose Response Modulation:

In a further aspect the present invention provides a process for improving the linearity of a dose response of an api, which process comprises:

- (1) contacting in solution an api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Increased Stability:

In a still further aspect the present invention provides a process for improving the stability of a pharmaceutical salt, which process comprises:

- (1) grinding, heating or contacting in solution the pharmaceutical salt with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Difficult to Salt or Unsatable Compounds:

In a still further aspect the present invention provides a process for making co-crystals of difficult to salt or unsatable api which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Decreasing Hygroscopicity:

In a still further aspect the present invention provides a method for decreasing the hygroscopicity of an api, which method comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;

(2) isolating co-crystals comprising the api and the co-crystal forming compound.

Crystallizing Amorphous Compounds:

In a still further embodiment aspect the present invention provides a process for crystallizing an amorphous compound, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Decreasing Form Diversity:

In a still further embodiment aspect the present invention provides a process for reducing the form diversity of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Morphology Modulation:

In a still further embodiment aspect the present invention provides a process for modifying the morphology of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Co-Crystal Compositions:

In a further aspect, the present invention provides a co-crystal composition comprising a co-crystal, wherein said co-crystal comprises an api compound and a co-crystal forming compound. In further embodiments the co-crystal has an improved property as compared to the free form (including a free acid, free base, zwitter ion, hydrate, solvate, etc.) or a salt (which includes salt hydrates and solvates). In further embodiments, the improved property is selected from the group consisting of: increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, a crystalline form of a normally amorphous compound, a crystalline form of a difficult or unsaltable compound, decreased form diversity, more desired morphology, or other property described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 PXRD pattern for a co-crystal of carbamazepine and saccharin

Fig. 2 DSC thermogram for a co-crystal of carbamazepine and saccharin

Fig. 3 PXRD pattern for a co-crystal of carbamazepine and Nicotinamide

Fig. 4 DSC thermogram for a co-crystal of carbamazepine and Nicotinamide

Fig. 5 PXRD pattern for a co-crystal of carbamazepine and trimesic acid

Fig. 6 PXRD pattern for a co-crystal of topiramate and 18-crown-6

Fig. 7 DSC thermogram for a co-crystal of topiramate and 18-crown-6

Fig. 8 PXRD pattern for a co-crystal of Olanzapine and Nicotinamide

Fig. 9 DSC thermogram for a co-crystal of Olanzapine and Nicotinamide

Fig. 10 PXRD pattern for a co-crystal of Celecoxib and 18-crown-6

Fig. 11 DSC thermogram for a co-crystal of Celecoxib and 18-crown-6

Fig. 12 PXRD pattern for a co-crystal of Itraconazole and Succinic acid

Fig. 13 DSC thermogram for a co-crystal of Itraconazole and Succinic acid

Fig. 14 PXRD pattern for a co-crystal of Itraconazole and Fumaric acid

Fig. 15 DSC thermogram for a co-crystal of Itraconazole and Fumaric acid

Fig. 16 PXRD pattern for a co-crystal of Itraconazole and tartaric acid

Fig. 17 DSC thermogram for a co-crystal of Itraconazole and tartaric acid

Fig. 18 PXRD pattern for a co-crystal of Itraconazole and malic acid

Fig. 19 DSC thermogram for a co-crystal of Itraconazole and malic acid

Fig. 20 PXRD pattern for a co-crystal of Itraconazole.HCl and tartaric acid

Fig. 21 DSC thermogram for a co-crystal of Itraconazole.HCl and tartaric acid

Fig. 22 PXRD pattern for a co-crystal of modafinil and Nicotinamide

Fig. 23 PXRD pattern for a co-crystal of modafinil and Benzamide

Fig. 24 PXRD pattern for a co-crystal of modafinil and Mandelic acid

Fig. 25 PXRD pattern for a co-crystal of modafinil and glycolic acid

Fig. 26 PXRD pattern for a co-crystal of modafinil and Fumaric acid

Fig. 27 Dissolution profile for a co-crystal of Celecoxib and Nicotinamide vs. Celecoxib free base

Fig. 28 Dissolution profile for co-crystals of itraconazole and Succinic, tartaric and malic acid vs. itraconazole free base

Fig. 29 Hygroscopicity profile for a co-crystal of itraconazole.HCl and tartaric acid vs. itraconazole.HCl

Fig. 30 Hygroscopicity profile for a co-crystal of Celecoxib and Nicotinamide vs. Celecoxib sodium

Fig. 31 PXRD pattern for a co-crystal of olanzepine and Nicotinamide (Form III).

DETAILED DESCRIPTION OF THE INVENTION

The term "co-crystal" as used herein means a crystalline material comprised of two or more unique solids at room temperature, each containing distinctive physical characteristics, such as structure, melting point and heats of fusion, with the exception that, if specifically stated, the api may be a liquid at room temperature. The co-crystals of the present invention comprise a co-crystal former H-bonded to an api. The co-crystal former may be H-bonded directly to the api or may be H-bonded to an additional molecule which is bound to the api. The additional molecule may be H-bonded to the api, bound or bound ionically or covalently to the api. The additional molecule could also be a different api. Solvates of api compounds that do not further comprise a co-crystal forming compound are not co-crystals according to the present invention. The co-crystals may however, include one or more solvent molecules in the crystalline lattice. That is, solvates of co-crystals, or a co-crystal further comprising a solvent or compound that is a liquid at room temperature, is included in the present invention, but crystalline material comprised of only one solid and one or more liquids (at room temperature) are

not included in the present invention. The co-crystals may also be a co-crystal between a co-crystal former and a salt of an api, but the api and the co-crystal former of the present invention are constructed or bonded together through hydrogen bonds. Other modes of molecular recognition may also be present including, π -stacking; guest-host complexation and Van-Der-Waals interactions. Of the interactions listed above, hydrogen-bonding is the dominant interaction in the formation of the co-crystal, (and a required interaction according to the present invention) whereby a non-covalent bond is formed between a hydrogen bond donor of one of the moieties and a hydrogen bond acceptor of the other. An alternative embodiment provides for a co-crystal wherein the co-crystal former is a second api. In another embodiment, the co-crystal former is not an api. In another embodiment the co-crystal comprises two co-crystal formers. Co-crystals may also be formed where the api is a "guest" molecule in regions of a crystalline lattice formed by the co-crystal forming compound, thus forming an inclusion complex. For purposes of the present invention, the chemical and physical properties of an api in the form of a co-crystal may be compared to a reference compound that is the same api in a different form. The reference compound may be specified as a free form, or more specifically, a free acid, free base, or zwitterion; a salt, or more specifically for example, an inorganic base addition salt such as sodium, potassium, lithium, calcium, magnesium, ammonium, aluminum salts or organic base addition salts, or an inorganic acid addition salts such as HBr, HCl, sulfuric, nitric, or phosphoric acid addition salts or an organic acid addition salt such as acetic, propionic, pyruvic, malonic, succinic, malic, maleic, fumaric, tartaric, citric, benzoic, methanesulfonic, ethanesulfonic, stearic or lactic acid addition salt; an anhydrate or hydrate of a free form or salt, or more specifically, for example, a hemihydrate, dihydrate, trihydrate, quadrhydrate, pentahydrate; or a solvate of a free form or salt. The reference compound may also be specified as crystalline or amorphous.

It has surprisingly been found that when an api and a selected co-crystal forming compound are allowed to form co-crystals, the resulting co-crystals give rise to improved properties of the api, as compared to the api in a free form (including free acids, free bases, and zwitter ions, hydrates, solvates, etc.), or an acid or base salt thereof particularly with respect to: solubility, dissolution, bioavailability, stability, C_{max} , T_{max} ,

processability, longer lasting therapeutic plasma concentration, hygroscopicity, crystallization of amorphous compounds, decrease in form diversity (including polymorphism and crystal habit), change in morphology or crystal habit, etc. For example, a co-crystal form of an api is particularly advantageous where the original api is insoluble or sparingly soluble in water. Additionally, the co-crystal properties conferred upon the api are also useful because the bioavailability of the api can be improved and the plasma concentration and/or serum concentration of the api can be improved. This is particularly advantageous for orally-administrable formulations. Moreover, the dose response of the api can be improved, for example by increasing the maximum attainable response and/or increasing the potency of the api by increasing the biological activity per dosing equivalent.

Accordingly, in a first aspect, the present invention provides a pharmaceutical composition comprising a co-crystal of an api and a co-crystal forming compound, such that the api and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions or from the solid-state, for example, through grinding or heating. In another aspect, the api has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto, methyl thio, or a functional group in a Table herein, such that the api and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions.

The co-crystals of the present invention are formed where the api and co-crystal forming compound are bonded together through a hydrogen bonds. Other non-covalent interactions, including π -stacking and van-der-waals interactions, may also be present.

In one embodiment, the co-crystal former is selected from the co-crystal formers of Table I or Table II. In other embodiments, the co-crystal former of Table I is specified as a Class 1, Class 2, or Class 3 co-crystal former (see column labeled "class" Table I). In another embodiment, the pK_a value of the co-crystal former and the api is less than 2. In other embodiments, the difference in pK_a values of the co-crystal former and api is less than 3, less than 4, less than 5, between 2-3, between 3-4 or between 4 and 5. Table I lists multiple pK_a values for co-crystal formers having multiple functionalities. It is readily apparent to one skilled in the art the particular functional group corresponding to a particular pK_a value.

In another embodiment the particular functional group of a co-crystal former interacting with the api is specified (see for example Table I, columns labeled "Functionality" and "Molecular Structure" and the column of Table II labeled "Co-Crystal Former Functional Group". In a further embodiment the functional group of the api interacting with the co-crystal former functional group is specified (see, for example, Tables II and III).

In a further embodiment, the api is selected from an api of Table IV or elsewhere herein. In further embodiments, the functional group of the particular api interacting with the co-crystal former is specified. A specific functional group of a co-crystal former, a specific co-crystal former, or a specified functional group or a specific co-crystal former interacting with the particular api may also be specified. It is noted that for Table II, the co-crystal former, and optionally the specific functionality, and each of the listed corresponding interacting groups are included as individual species of the present invention. Thus, each specific combination of a co-crystal former and one of the interacting groups in the same row may be specified as a species of the present invention. The same is true for other combinations as discussed in the Tables and elsewhere herein.

In each process according to the invention, there is a need to contact the api with the co-crystal forming compound. This may involve grinding the two solids together or melting one or both components and allowing them to recrystallize. This may also involve either solubilising the api and adding the co-crystal forming compound, or solubilising the co-crystal forming compound and adding the api. In a preferred arrangement, the api may be solubilised in the co-crystal forming compound.

Crystallisation conditions are applied to the api and co-crystal forming compound. This may entail altering a property of the solution, such as pH or temperature and may require concentration of solute, usually by removal of the solvent, typically by drying the solution. Solvent removal results in the concentration of api increasing over time so as to facilitate crystallisation. Once the solid phase comprising any crystals is formed, this may be tested as described herein.

The co-crystals obtained as a result of such process steps may be readily incorporated into a pharmaceutical composition by conventional means. Pharmaceutical compositions in general are discussed in further detail below and may further comprise a pharmaceutically-acceptable diluent, excipient or carrier.

In a further aspect, the present invention provides a process for the production of a pharmaceutical composition, which process comprises:

- (1) providing an api which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine or of Table II or III;
- (2) providing a co-crystal forming compound which has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carboxyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio or of Tables I, II, or III;
- (3) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions, and
- (4) isolating co-crystals formed thereby; and
- (5) incorporating the co-crystals into a pharmaceutical composition.

In a still further aspect the present invention provides a process for the production of a pharmaceutical composition, which comprises:

- (1) grinding, heating or contacting in solution an api with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Assaying the solid phase for the presence of co-crystals of the api and the co-crystal forming compound may be carried out by conventional methods known in the art. For example, it is convenient and routine to use powder X-ray diffraction techniques to assess the presence of the co-crystals. This may be affected by comparing the spectra of the api, the crystal forming compound and putative co-crystals in order to establish whether or not true co-crystals had been formed. Other techniques, used in an analogous fashion, include differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and Raman spectroscopy. Single crystal X-ray diffraction is especially useful in identifying co-crystal structures.

In a further aspect, the present invention therefore provides a process of screening for co-crystal compounds, which comprises:

- (1) providing (i) an api compound, and (ii) a co-crystal forming compound;
- (2) screening for co-crystals of apis with co-crystal forming compounds by subjecting each combination of api and co-crystal forming compound to a step comprising:
 - (a) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions so as to form a solid phase;
 - (b) isolating co-crystals comprising the api and the co-crystal forming compound.

An alternative embodiment is drawn to a process of screening for co-crystal compounds, which comprises:

- (1) providing (i) an api or a plurality of different apis, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at

least one of the api and the co-crystal forming compound is provided as a plurality thereof;

(2) screening for co-crystals of apis with co-crystal forming compounds by subjecting each combination of api and co-crystal forming compound to a step comprising

(a) grinding, heating or contacting in solution the api with the co-crystal forming compound under crystallization conditions so as to form a solid phase;

(b) isolating co-crystals comprising the api and the co-crystal forming compound.

Solubility Modulation:

In a further aspect, the present invention provides a process for modulating the solubility of an api, which process comprises:

(1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;

(2) isolating co-crystals comprising the api and the co-crystal forming compound.

In one embodiment, the solubility of the api is modulated such that the aqueous solubility is increased. Solubility of apis may be measured by any conventional means such as chromatography (e.g., HPLC) or spectroscopic determination of the amount of api in a saturated solution of the api, such as UV-spectroscopy, IR-spectroscopy, Raman spectroscopy, quantitative mass spectroscopy or gass chromatography.

In another aspect of the invention, the api may have low aqueous solubility. Typically, low aqueous solubility in the present application refers to a compound having a solubility in water which is less than or equal to 10mg/ml, when measured at 37°C, and preferably less than or equal to 5mg/ml or 1mg/ml. "Low aqueous solubility" can further be specifically defined as less than or equal to 900, 800, 700, 600, 500, 400, 300, 200 150 100, 90, 80, 70, 60, 50, 40, 30, 20 micrograms/ml, or further 10, 5 or 1 micrograms/ml, or further 900, 800, 700, 600, 500, 400, 300, 200 150, 100 90, 80, 70, 60, 50, 40, 30, 20, or

10 ng/ml, or less than 10 ng/ml when measured at 37°C. Aqueous solubility can also be specified as less than 500, 400, 300, 200, 150, 100, 75, 50 or 25 mg/ml. As embodiments of the present invention, solubility can be increased 2, 3, 4, 5, 7, 10, 15, 20, 25, 50, 75, 100, 200, 300, 500, 750, 1000, 5000, or 10,000 times by making a co-crystal of the reference form (e.g., crystalline or amorphous free acid, free base or zwitter ion, hydrates or solvates), or salt. Further aqueous solubility can be measured in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) rather than water. SGF (non-diluted) of the present invention is made by combining 1 g/L Triton X-100 and 2 g/L NaCl in water and adjusting the pH with 20mM HCl to obtain a solution with a final pH=1.7 (SIF is 0.68% monobasic potassium phosphate, 1% pancreatin, and sodium hydroxide where the pH of the final solution is 7.5). The pH of the solvent used may also be specified as 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.5, 4, 4.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, or 12.

Examples of embodiments includes: co-crystal compositions with an aqueous solubility, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the free form, co-crystal compositions with a solubility in SGF that is increased at least 5 fold over the free form, co-crystal compositions with a solubility in SIF that is increased at least 5 fold over the free form.

Dissolution Modulation:

In another aspect of the present invention, the dissolution profile of the api is modulated whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid or in simulated intestinal fluid, or in a solvent or plurality of solvents is increased. Dissolution rate is the rate at which api solids dissolve in a dissolution media. For apis whose absorption rates are faster than the dissolution rates (e.g., steroids), the rate-limiting step in the absorption process is often the dissolution rate. Because of a limited residence time at the absorption site, apis that are not dissolved before they are removed from intestinal absorption site are considered useless. Therefore, the rate of dissolution has a major impact on the performance of apis that are poorly soluble. Because of this factor, the dissolution rate of apis in solid dosage forms is an important, routine, quality control parameter used in the api manufacturing process.

Dissolution rate = $K S (C_s - C)$

where K is dissolution rate constant, S is the surface area, C_s is the apparent solubility, and C is the concentration of api in the dissolution media.

For rapid api absorption, $C_s - C$ is approximately equal to C_s .

The dissolution rate of apis may be measured by conventional means known in the art.

The increase in the dissolution rate of a co-crystal, as compared to the reference form (e.g., free form or salt), may be specified, such as by 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the reference form (e.g., free form or salt form) in the same solution. Conditions under which the dissolution rate is measured is the same as discussed above. The increase in dissolution may be further specified by the time the composition remains supersaturated before reaching equilibrium solubility.

Examples of above embodiments includes: co-crystal compositions with a dissolution rate, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the co-crystal compositions with a dissolution rate in SGF that is increased at least 5 fold over the free form, co-crystal compositions with a dissolution rate in SIF that is increased at least 5 fold over the free form.

Bioavailability Modulation:

The methods of the present invention are used to make a pharmaceutical api formulation with greater solubility, dissolution, and bioavailability, AUC, reduced time to T_{max} , (the time to reach peak blood serum levels), or increased C_{max} , plasma or when compared to the neutral form or salt alone.

AUC is the area under the plot of plasma concentration of api (not logarithm of the concentration) against time after api administration. The area is conveniently determined by the "trapezoidal rule": the data points are connected by straight line segments, perpendiculars are erected from the abscissa to each data point, and the sum of the areas of the triangles and trapezoids so constructed is computed. When the last

measured concentration (C_n , at time t_n) is not zero, the AUC from t_n to infinite time is estimated by C_n/k_{el} .

The AUC is of particular use in estimating bioavailability of APIs, and in estimating total clearance of APIs (Cl_T). Following single intravenous doses, $AUC = D/Cl_T$, for single compartment systems obeying first-order elimination kinetics; alternatively, $AUC = C_0/k_{el}$. With routes other than the intravenous, for such systems, $AUC = F \cdot D/Cl_T$, where F is the availability of the API.

Thus, in a further aspect, the present invention provides a process for modulating the bioavailability of an API when administered in its normal and effective dose range as a co-crystal, whereby the AUC is increased, the time to T_{max} is reduced, or C_{max} is increased, as compared to a reference form, which process comprises:

- (1) grinding, heating or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating co-crystals comprising the API and the co-crystal forming compound.

Examples of the above embodiments includes: co-crystal compositions with a time to T_{max} that is reduced by at least 10% as compared to the free form; co-crystal compositions with a time to T_{max} that is reduced by at least 20% over the free form, co-crystal compositions with a time to T_{max} that is reduced by at least 40% over the free form, co-crystal compositions with a time to T_{max} that is reduced by at least 50% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 60% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 70% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 80% over the free form, co-crystal compositions with a T_{max} that is reduced by at least 90% over the free form, co-crystal compositions with a C_{max} that is increased by at least 20% over the free form, co-crystal compositions with a C_{max} that is increased by at least 30% over the free form, co-crystal compositions with a C_{max} that is increased by at least 40% over the free form, co-crystal compositions with a C_{max} that is increased by at least 50% over the free form, co-crystal compositions with a C_{max} that is increased by at least 60% over the free form, co-crystal compositions with a C_{max} that is increased by at least 70% over the free form.

free form; co-crystal compositions with a C_{max} that is increased by at least 80% over the free form, co-crystal compositions with a C_{max} that is increased by at least 2 fold, 3 fold, 5 fold, 7.5 fold, 10 fold, 25 fold, 50 fold or 100 fold, co-crystal compositions with an AUC that is increased by at least 10% over the free form, co-crystal compositions with an AUC that is increased by at least 20% over the free form, co-crystal compositions with an AUC that is increased by at least 30% over the free form, co-crystal compositions with an AUC that is increased by at least 40% over the free form, co-crystal compositions with an AUC that is increased by at least 50% over the free form, co-crystal compositions with an AUC that is increased by at least 60% over the free form, co-crystal compositions with an AUC that is increased by at least 70% over the free form, co-crystal compositions with an AUC that is increased by at least 80% over the free form or co-crystal compositions with an AUC that is increased by at least 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, and 10 fold. Other examples include wherein the reference form is crystalline, wherein the reference form is amorphous wherein the reference form is an anhydrous crystalline sodium salt or wherein the reference form is an anhydrous, crystalline HCl salt.

Dose Response Modulation:

In a further aspect the present invention provides a process for improving the dose response of an api, which process comprises:

- (1) contacting in solution an api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Dose response is the quantitative relationship between the magnitude of response and the dose inducing the response and may be measured by conventional means known in the art. The curve relating effect (as the dependent variable) to dose (as the independent variable) for an api-cell system is the "dose-response curve". Typically, the dose-response curve is the measured response to an api plotted against the dose of the api

(mg/kg) given. The dose response curve can also be a curve of AUC against the dose of the api given.

In an embodiment of the present invention, a co-crystal of the present invention has an increased dose response curve or more linear dose response curve than the corresponding reference compound.

Increased Stability:

In a still further aspect the present invention provides a process for improving the stability of an api (as compared to a reference form such as its free form or a salt thereof), which process comprises:

- (1) Grinding, heating or contacting in solution the pharmaceutical salt with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In a preferred embodiment, the compositions of the present invention, including the api or active pharmaceutical ingredient (api) and formulations comprising the api, are suitably stable for pharmaceutical use. Preferably, the api or formulations thereof of the present invention are stable such that when stored at 30 deg. C for 2 years, less than 0.2% of any one degradant is formed. The term degradant refers herein to product(s) of a single type of chemical reaction. For example, if a hydrolysis event occurs that cleaves a molecule into two products, for the purpose of the present invention, it would be considered a single degradant. More preferably, when stored at 40 deg. C for 2 years, less than 0.2% of any one degradant is formed. Alternatively, when stored at 30 deg. C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed, or when stored at 40 deg. C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. Further alternatively, when stored at 60 deg. C for 4 weeks, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. The relative humidity (RH) may be specified as ambient (RH), 75% (RH), or as any single integer between 1 to 99%.

Difficult to Salt or Unsalttable Compounds:

In a still further aspect the present invention provides a process for making co-crystals of unsalttable apis which process comprises:

- (1) grinding, heating or contacting in solution an api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

Difficult to salt compounds include bases with a $pK_a < 3$ or acids with a $pK_a > 10$.

Zwitterions are also difficult to salt or unsalttable compounds according to the present invention.

Decreasing Hygroscopicity:

In a still further aspect, the present invention provides a method for decreasing the hygroscopicity of an api, which method comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions;
- (3) forming a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

An aspect of the present invention provides a pharmaceutical composition comprising a co-crystal of an api that is less hygroscopic than amorphous or crystalline, free form or salt (including metal salts such as sodium, potassium, lithium, calcium, magnesium) or another reference compound. Hygroscopicity can be assessed by dynamic vapor sorption analysis, in which 5-50 mg of the compound is suspended from a Cahn microbalance. The compound being analyzed should be placed in a non-hygroscopic pan and its weight should be measured relative to an empty pan composed of identical material and having nearly identical size, shape, and weight. Ideally, platinum pans should be used. The pans should be suspended in a chamber through which a gas, such as air or nitrogen, having a controlled and known percent relative humidity (%RH) is flowed until equilibrium criteria are met. Typical equilibrium criteria include weight

changes of less than 0.01 % change over 3 minutes at constant humidity and temperature. The relative humidity should be measured for samples dried under dry nitrogen to constant weight (<0.01 % change in 3 minutes) at 40°C unless doing so would de-solvate or otherwise convert the material to an amorphous compound. In one aspect, the hygroscopicity of a dried compound can be assessed by increasing the RH from 5 to 95 % in increments of 5 % RH and then decreasing the RH from 95 to 5 % in 5 % increments to generate a moisture sorption isotherm. The sample weight should be allowed to equilibrate between each change in %RH. If the compound deliquesces or becomes amorphous between above 75 % RH, but below 95 % RH, the experiment should be repeated with a fresh sample and the relative humidity range for the cycling should be narrowed to 5-75 % RH or 10-75 % RH instead of 5-95 %RH. If the sample cannot be dried prior to testing due to lack of form stability, then the sample should be studied using two complete humidity cycles of either 10-75 % RH or 5-95 % RH, and the results of the second cycle should be used if there is significant weight loss at the end of the first cycle.

Hygroscopicity can be defined using various parameters. For purposes of the present invention, a non-hygroscopic molecule should not gain or lose more than 1.0%, or more preferably, 0.5 % weight at 25 degrees C when cycled between 10 and 75 % RH (relative humidity at 25 degrees C). The non-hygroscopic molecule more preferably should not gain or lose more than 1.0%, or more preferably, 0.5 % weight when cycled between 5 and 95 %RH at 25 degrees C, or more than 0.25 % of its weight between 10 and 75 % RH. Most preferably, a non-hygroscopic molecule will not gain or lose more than 0.25 % of its weight when cycled between 5 and 95 % RH.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of Callaghan et al., Equilibrium moisture content of pharmaceutical excipients, in *Api Dev. Ind. Pharm.*, Vol. 8, pp. 335-369 (1982). Callaghan et al. classified the degree of hygroscopicity into four classes.

Class 1: Non-hygroscopic

Essentially no moisture increases occur at relative humidities below 90%.

Class 2: Slightly hygroscopic	Essentially no moisture increases occur at relative humidities below 80%.
Class 3: Moderately hygroscopic	Moisture content does not increase more than 5% after storage for 1 week at relative humidities below 60%.
Class 4: Very hygroscopic	Moisture content increase may degrees occur at relative humidities as low as 40 to 50%.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of the European Pharmacopoeia Technical Guide (1999, p. 86) which has defined hygroscopicity, based on the static method, after storage at 25°C for 24 h at 80 percent RH:

Slightly hygroscopic: Increase in mass is less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Very Hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

Co-crystals of the present invention can be set forth as being in Class 1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic, or Very Hygroscopic. Co-crystals of the present invention can also be set forth based on their ability to reduce hygroscopicity. Thus, preferred co-crystals of the present invention are less hygroscopic than a reference compound. The reference compound can be specified as the api in free form (free acid, free base, hydrate, solvate, etc.) or salt (e.g., especially metal salts such

as sodium, potassium, lithium, calcium, or magnesium). Further included in the present invention are co-crystals that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are co-crystals that do not gain or lose more than 0.25% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions.

Further included in the present invention are co-crystals that have a hygroscopicity (according to Callaghan et al.) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Included are a Class 1 co-crystals of a Class 2 reference compound, a Class 2 co-crystals of a Class 3 reference compound, a Class 3 co-crystals of a Class 4 reference compound, a Class 1 co-crystals of a Class 3 reference compound, a Class 1 co-crystals of a Class 4 reference compound, or a Class 2 co-crystals of a Class 4 reference compound.

Further included in the present invention are co-crystals that have a hygroscopicity (according to the European Pharmacopoeia Technical Guide) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Slightly hygroscopic co-crystals of a Hygroscopic reference compound, a Hygroscopic co-crystals of a Very Hygroscopic reference compound, a Very Hygroscopic co-crystals of a Deliquescent reference compound, a Slightly hygroscopic co-crystals of a Very Hygroscopic reference

compound, a Slightly hygroscopic co-crystals of a Deliquescent reference compound, a Hygroscopic co-crystals of a Deliquescent reference compound.

Crystallizing Amorphous Compounds:

In a further aspect, the present invention provides a process for crystallizing an amorphous compound, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

An amorphous compound includes compounds that do not crystallize using routine methods in the art.

Decreasing Form Diversity:

In a still further embodiment aspect the present invention provides a process for reducing the form diversity of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

For purposes of the present invention, the number of forms of a co-crystal is compared to the number of forms of a reference compound (e.g. the free form or a salt of the api) that can be made using routine methods in the art.

Morphology Modulation:

In a still further embodiment aspect the present invention provides a process for modifying the morphology of an api, which process comprises:

- (1) grinding, heating or contacting in solution the api with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the api and the co-crystal forming compound;
- (2) isolating co-crystals comprising the api and the co-crystal forming compound.

In an embodiment the co-crystal comprises or consists of a co-crystal former and a pharmaceutical wherein the interaction between the two, e.g., H-bonding, occurs between a functional group of Table III of an api with a corresponding interacting group of Table III. In a further embodiment, the co-crystal comprises a co-crystal former of Table I or II and an api with a corresponding interacting group of Table II. In a further embodiment the co-crystal comprises an api from Table IV and a co-crystal former with a function group of Table III. In a further embodiment, the co-crystal api from Table I or II. In an aspect of the invention, only co-crystals having an H-bond acceptor on the first molecule and an H-bond donor on the second molecule, where the first and second molecules are either co-crystal former and api respectively or api and co-crystal former respectively, are included in the present invention. Table IV includes the CAS number, chemical name or a PCT or patent reference (each incorporated herein in their entireties). Thus, whether a particular api contains an H-bond donor, acceptor or both is readily apparent.

In another embodiment, the co-crystal former and api each have only one H-bond donor/acceptor. In another aspect, the molecular weight of the api is less than 2000, 1500, 1000, 750, 500, 350, 200, or 150 Daltons. In another embodiment, the molecular weight of the api is between 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, or 1800-2000. Apis with the above molecular weights may also be specifically excluded from the present invention.

In another embodiment, peptides, proteins, nucleic acids or other biological apis are excluded from the present invention. In another embodiment, all non-pharmaceutically acceptable co-crystal formers are excluded from the present invention. In another embodiment, organometallic apis are excluded from the present invention. In another embodiment, a co-crystal former comprising any one or more of the functional

groups of Table III may be specifically excluded from the present invention. In another embodiment, any one or more of the co-crystal formers of Table I or II may be specifically excluded from the present invention. Any apis currently known in the art may also be specifically excluded from the present invention. For example, carbanazepine, itraconazole, nabumetone, fluoxetine, acetaminophen and theophylline can each be specifically excluded from the present invention. In another embodiment, the api is not a salt, is not a non-metal salt, or is not a metal salt, e.g., sodium, potassium, lithium, calcium or magnesium. In another embodiment, the api is a salt, is a non-metal salt, or is a metal salt, e.g., sodium, potassium, lithium, calcium, magnesium. In one embodiment, the api does not contain a halogen. In one embodiment, the api does contain a halogen.

Excipients employed in pharmaceutical compositions of the present invention can be solids, semi-solids, liquids or combinations thereof. Preferably, excipients are solids. Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises admixing an excipient with an api or therapeutic agent. A pharmaceutical composition of the invention contains a desired amount of api per dose unit and, if intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. If intended for parenteral administration, it can be in the form, for example, of a suspension or transdermal patch. If intended for rectal administration, it can be in the form, for example, of a suppository. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the api, such as tablets or capsules.

Non-limiting examples follow of excipients that can be used to prepare pharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients. Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., CelutabTM and

EmdexTM); mannitol; sorbitol; xylitol; dextrose (e.g., CereloseTM 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha- and amorphous cellulose (e.g., Rexcel^J), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium carbonate; glycine; bentonite; block co-polymers; polyvinylpyrrolidone; and the like. Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition. The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are preferred diluents. These diluents are chemically compatible with celecoxib. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of celecoxib, stability, pre-compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densification during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in combination, starches, including sodium starch glycolate (e.g., ExplotabTM of PenWest) and pregelatinized corn starches (e.g., NationalTM 1551 of National Starch and Chemical Company, NationalTM 1550, and ColocornTM 1500), clays (e.g., VeegumTM HV of R.T. Vanderbilt), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose,

croscarmellose sodium (e.g., Ac-Di-Sol™ of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2% to about 30%, preferably about 0.2% to about 10%, and more preferably about 0.2% to about 5%, of the total weight of the composition.

Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2% to about 10%, more preferably about 0.2% to about 7%, and still more preferably about 0.2% to about 5%, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions of the present invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of a co-crystal of the present invention once the salt has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., National™ 1511 and National™ 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., Tylose™); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., Klucel™ of Aqualon); and ethylcellulose (e.g., Ethocel™ of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5% to about 25%, preferably about

0.75% to about 15%, and more preferably about 1% to about 10%, of the total weight of the pharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units' ratios in a given polymer affects properties and performance. Examples of block co-polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASF Corporation).

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Such wetting agents are preferably selected to maintain the celecoxib in close association with water, a condition that is believed to improve bioavailability of the composition. Such wetting agents can also be useful in solubilizing or increasing the solubility of co-crystals.

Non-limiting examples of surfactants that can be used as wetting agents in pharmaceutical compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and degrees Ctoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., LabrasolTM of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (e.g., TweenTM 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e.g., LauroglycolTM of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan

monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, constitute in total about 0.25% to about 15%, preferably about 0.4% to about 10%, and more preferably about 0.5% to about 5%, of the total weight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. sodium lauryl sulfate is a particularly preferred wetting agent. sodium lauryl sulfate, if present, constitutes about 0.25% to about 7%, more preferably about 0.4% to about 4%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behapate (e.g., CompritolTM 888 of Gattefosse); stearic acid and salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e.g., SterotexTM of Abitec); colloidal silica; talc; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., CarbowaxTM 4000 and CarbowaxTM 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, constitute in total about 0.1% to about 10%, preferably about 0.2% to about 8%, and more preferably about 0.25% to about 5%, of the total weight of the pharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.

Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1% to about 10%, more preferably about 0.25% to about 5%, and still more preferably about 0.5% to about 2%, of the total weight of the pharmaceutical composition.

Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic

calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.

Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated. Compositions of the invention can further comprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions of the invention. When present in pharmaceutical compositions of the invention to promote dosage form disintegration, one or more effervescent agents are preferably present in a total amount of about 30% to about 75%, and preferably about 45% to about 70%, for example about 60%, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the api in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the api from the dosage form in the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition of the invention to promote intragastric dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1% to about 20%, more preferably about 2.5% to about 15%, and still more preferably about 5% to about 10%, by weight of the pharmaceutical composition.

An "effervescent agent" herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.

Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e.g., calcium carbonate), bicarbonate salts

(e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base.

Non-limiting examples of suitable acids as components of effervescent agents and/or solid organic acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid (as D-, L-, or DL-malic acid), maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.

In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1:100 to about 100:1, more preferably about 1:50 to about 50:1, and still more preferably about 1:10 to about 10:1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.

Excipients which solubilize APIs typically have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially-amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhydride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e.g., poloxamer 237), polyalkylene glycolated esters of tocopherol (including esters formed from a di- or multi-functional carboxylic acid; e.g., d-alpha-tocopherol polyethylene glycol-1000 succinate), and macroglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di- and tri-glycerides and mono- and di-esters; e.g., stearyl macrogol-32 glycerides). Such pharmaceutical compositions are advantageously administered orally.

Pharmaceutical compositions of the present invention can comprise about 10% to about 50%, about 25% to about 50%, about 30% to about 45%, or about 30% to about 35% by weight of a co-crystal; about 10% to about 50%, about 25% to about 50%, about 30% to about 45%, or about 30% to about 35% by weight of an excipient which inhibits

crystallization; and about 5% to about 50%, about 10% to about 40%, about 15% to about 35%, or about 30% to about 35% by weight of a binding agent. In one example, the weight ratio of the co-crystal to the excipient which inhibits crystallization to binding agent is about 1 to 1 to 1.

Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein.

An illustrative process comprises (a) a step of blending an api of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.

In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a co-crystal of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and (c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A salt of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under low or high shear. A process is preferably selected that forms a granulate that is uniform in api content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein an api is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay.

The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings.

EXEMPLIFICATION

General Methods for the Preparation of Co-Crystals

a) High Throughput crystallization using the CrystalMax platform^{1,2}

CrystalMax™ comprises a sequence of automated, integrated high throughput robotic stations capable of rapid generation, identification and characterization of polymorphs, salts and co-crystals of drugs and drug candidates.

Worksheet generation and combinatorial mixture design is carried out using proprietary design software InForm™. Typically, a drug or drug candidate (API) is dispensed from an organic solvent into tubes and dried under a stream of nitrogen. Salts and/or co-crystal formers may also be dispensed and dried in the same fashion. Water and organic solvents may be combinatorially dispensed into the tubes using a multi-channel dispenser. Each tube in a 96-tube array is then sealed within 15 seconds of combinatorial dispensing to avoid solvent evaporation. The mixtures are then rendered supersaturated by heating to 70 °C for 2 hours followed by a 1 °C/minute cooling ramp to 5 °C. Optical checks are then conducted to detect crystals and/or solid material. Once a solid has been identified in a tube, it is isolated through aspiration and drying. Raman spectra are then obtained on

the solids and cluster classification of the spectral patterns is performed using proprietary software (QForm™).

b) Crystallization from solution

Co-crystals may be obtained by dissolving the separate components in a solvent and adding one to the other. The co-crystal may then precipitate or crystallize as the solvent mixture is evaporated slowly. The co-crystal may also be obtained by dissolving the two components in the same solvent or a mixture of solvents.

c) Crystallization from the melt

A co-crystal may be obtained by melting the two components together and allowing recrystallization to occur. In some cases, an anti-solvent may be added to facilitate crystallization.

d) Thermal microscopy³

A co-crystal may be obtained by melting the higher melting component on a glass slide and allowing it to recrystallize. The second component is then melted and is also allowed to recrystallize. The co-crystal may form as a separated phase/band in between the eutectic bands of the two original components.

e) Mixing and/or grinding

A co-crystal may be obtained by mixing or grinding two components together in the solid state.

Analytical Methods

Procedure for DSC analysis

DSC analysis of the samples was performed using a Q1000 Differential Scanning Calorimeter (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (©2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E; Build 3.1.0.40 (©2001 TA Instruments-Water LLC).

For the DSC analysis, the purge gas used was dry nitrogen, the reference material was an empty aluminum pan that was crimped, and the sample purge was 50 mL/minute.

DSC analysis of the sample was performed by placing ≤ 2 mg of sample in an aluminum pan with a crimped pan closure. The starting temperature was typically 20°C with a heating rate of 10°C/minute, and the ending temperature was 300°C.

Procedure for TGA analysis

TGA analysis of samples was performed using a Q500 Thermogravimetric Analyzer (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 ([®]2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E; Build 3.1.0.40 ([®]2001 TA Instruments-Water LLC).

For all of the TGA experiments, the purge gas used was dry nitrogen, the balance purge was 40 mL/minute N₂, and the sample purge was 60 mL/minute N₂.

TGA of the sample was performed by placing ≤ 2 mg of sample in a platinum pan. The starting temperature was typically 20°C with a heating rate of 10°C/minute, and the ending temperature was 300°C.

Procedure for PXRD analysis

A powder X-ray diffraction pattern for the samples was obtained using a D/Max Rapid, Contact (Rigaku/MS, The Woodlands, TX, U.S.A.), which uses as its control software RINT Rapid Control software, Rigaku Rapid/XRD, version 1.0.0 ([®]1999 Rigaku Co.). In addition, the analysis software used were RINT Rapid display software, version 1.18 (Rigaku/MS), and JADE XRD Pattern Processing, versions 5.0 and 6.0 ([®]1995-2002; Materials Data, Inc.).

For the PXRD analysis, the acquisition parameters were as follows: source was Cu with a K line at 1.5406 Å; x-y stage was manual; collimator size was 0.3 or 0.8 mm; capillary tube (Charles Supper Company, Natick, MA, U.S.A.) was 0.3 mm ID; reflection mode was used; the power to the X-ray tube was 46 kV; the current to the X-ray tube was 40

mA; the omega-axis was oscillating in a range of 0-5 degrees at a speed of 1 degree/minute; the phi-axis was spinning at an angle of 360 degrees at a speed of 2 degrees/second; 0.3 or 0.8 mm collimator; the collection time was 60 minutes; the temperature was room temperature; and the heater was not used. The sample was presented to the X-ray source in a boron rich glass capillary.

In addition, the analysis parameters were as follows: the integration 2-theta range was 2-40 or 60 degrees; the integration chi range was 0-360 degrees; the number of chi segments was 1; the step size used was 0.02; the integration utility was cylint; normalization was used; dark counts were 8; omega offset was 180; and chi and phi offsets were 0.

Procedure for Raman Acquisition, Filtering and Binning

Acquisition

The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an Almega™ Dispersive Raman (Almega™ Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a 10x power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table 1. (Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.)

Filtering and Binning

Each spectrum in a set was filtered using a matched filter of feature size 25 to remove background signals, including glass contributions and sample fluorescence. This is particularly important as large background signal or fluorescence limit the ability to accurately pick and assign peak positions in the subsequent steps of the binning process. Filtered spectra were binned using the peak pick and bin algorithm with the parameters

given in Table 2. The sorted cluster diagrams for each sample set and the corresponding cluster assignments for each spectral file were used to identify groups of samples with similar spectra, which was used to identify samples for secondary analyses.

Table 1. Raman Spectral acquisition parameters

Parameter	Setting Used
Exposure time (s)	2.0
Number of exposures	10
Laser source wavelength (nm)	785
Laser power (%)	100
Aperture shape	pin hole
Aperture size (μm)	100
Spectral range	104-3428
Grating position	Single
Temperature at acquisition ($^{\circ}\text{C}$)	24.0

Table 2. Raman Filtering and Binning Parameters

Parameter	Setting Used
<i>Filtering Parameters</i>	
Filter type	Matched
Filter size	25
<i>QC Parameters</i>	
Peak Height Threshold	1000
Region for noise test (cm^{-1})	0-10000
RMS noise threshold	10000
Automatically eliminate failed spectra	Yes
<i>Region of Interest</i>	
Include (cm^{-1})	104-3428
Exclude region I (cm^{-1})	
Exclude region II (cm^{-1})	
Exclude region III (cm^{-1})	
Exclude region IV (cm^{-1})	
<i>Peak Pick Parameters</i>	
Peak Pick Sensitivity	Variable
Peak Pick Threshold	100
<i>Peak Comparison Parameters</i>	
Peak Window (cm^{-1})	2
<i>Analysis Parameters</i>	
Number of clusters	Variable

The co-crystals of the present invention can be characterized, e.g., by the TGA or DSC data or by any one, any two, any three, any four, any five, any six, any seven, any eight, any nine, any ten, or any single integer number of 2-theta angle peaks listed herein or disclosed in a figure.

Example 1

1:1 Carbamazepine: Saccharin co-crystals were prepared. A 12-block experiment was designed with 12 solvent. 1152 crystallization experiments were carried out using the CMAX platform. The co-crystal was obtained from a mixture of isopropyl acetate and heptane. Detailed characterization of the co-crystal is listed in Table 7.

Example 2

1:1 Carbamazepine: Nicotinamide co-crystals were prepared. A 12-block experiment was designed with 12 solvent. 1152 crystallization experiments were carried out using the CMAX platform. The co-crystal was obtained from tubess containing toluene, acetone or isopropyl acetate. Detailed characterization of the co-crystal is listed in Table 7.

Example 3

1:1 Carbamazepine: Trimesic acid co-crystals were prepared. A 9-block experiment was designed with 10 solvents. 864 crystallization experiments with 8 co-crystal formers and 3 concentrations were carried out using the CMAX platform. The co-crystal was obtained from tubes containing methanol. Detailed characterization of the co-crystal is listed in Table 7.

Example 4

1:1 Celecoxib: Nicotinamide co-crystals were prepared. Celecoxib (100 mg, 0.26 mmol) and Nicotinamide (32.0 mg, 0.26 mmol) were each dissolved in acetone (2 mL). The two solutions were mixed and the resulting mixture was allowed to evaporate slowly

overnight. The precipitated solid was collected and characterized. Detailed characterization of the co-crystal is listed in Table 7.

Example 5

Co-crystals of topiramate and 18-crown-6 were prepared. An equimolar amount of topiramate and 18-crown-6 were dissolved in ether separately. The solution containing topiramate was then added to the solution containing 18-crown-6. A white solid precipitated after minor agitation and was collected and dried. Detailed characterization of the co-crystal is listed in Table 7.

Example 6

Co-crystals of Olanzapine and Nicotinamide were prepared. A 9-block experiment was designed with 12 solvents. 864 crystallization experiments with 10 co-crystal formers and 3 concentrations were carried out using the CMAX platform. The co-crystal was obtained from tubes containing isopropyl acetate. PXRD and DSC characterization of the co-crystal is listed in Table 7.

Example 7

Co-crystals of Celecoxib and 18-crown-6 were prepared. A solution of Celecoxib (157.8 mg, 0.4138 mmol) in Et₂O (10.0 mL) was added to 18-crown-6 (118.1 mg, 0.447 mmol). The opaque solid dissolves immediately and a white solid subsequently began to crystallize very rapidly. The solid was collected via filtration and was washed with additional Et₂O (5 mL). Detailed characterization of the co-crystal is listed in Table 7.

Example 8

Co-crystals of Itraconazole and Succinic acid were prepared. Approximately 51.1 mg of *cis*-itraconazole free base (Lot # KEO 0026, Química Sinética S.A), 0.75 ml of THF, and a magnetic stir bar were charged into a screw cap vial, heated to reflux to dissolve, and then the vial was closed with the screw cap and placed on top of a hot plate maintained at a temperature between 60 and 75°C. A solution of 77.7 mg of succinic acid in 1.58 ml of THF was prepared. 0.20 ml of the succinic acid solution was added to the *cis*-

itraconazole solution and the solution remained clear. 0.75 ml of iso-propylacetate was added and the solution was seeded with <1 mg of the L-tartaric acid co-crystal salt from Example 10 below. The heat was turned off and the sample crystallized as it cooled to room temperature. The cooled sample was suction filtered. It was rinsed with 0.2-0.3 ml of THF. The filter cake was broken-up and allowed to air-dry for 1 hour prior to analysis.

Example 9

Co-crystals of Itraconazole and fumaric acid were prepared. Approximately 500 mg of *cis*-itraconazole free base (Lot # KEO 0026, Química Sinética S.A.) was placed in a 50 ml screw top bottle along with 33.33 ml of tetrahydrofuran ("THF") (Lot # 50K1485, Sigma Chemicals Co.). 3088.7 µl of fumaric acid stock solution (prepared in Example 1) was then added to the beaker (resulting in a 1.05:1 ratio of salt former to free base). The cap was screwed on to seal the bottle and the bottle was placed in a 70°C oven (Model # 1400E, VWR Scientific) and heated for approximately 1 hour. Thereafter, the bottle was removed from the oven, the cap from the bottle was removed, and the sample was allowed to evaporate under flowing air under ambient conditions. When all but about 5 ml of the solvent had evaporated, the remaining solvent was removed by decantation and the solid was isolated by filtering over a Whatman filter using suction. This solid was returned back into the 50 ml bottle with the remaining solid and the bottle was placed into the vacuum oven at approximately 25 mm Hg and the solid was allowed to dry for 4 days.

Example 10

Co-crystals of Itraconazole and tartaric acid were prepared. Approximately 100.4 mg of *cis*-itraconazole free base (Lot # KEO 0026, Química Sinética S.A.), 0.90 ml of THF, and a magnetic stir bar were charged into a screw cap vial, heated to reflux to dissolve, and then the vial was closed with the screw cap and placed in an oil bath maintained at 70°C. A solution of 138.5 mg of L(+) tartaric acid in 1.15 ml of THF was prepared. 0.21 ml of the L(+) tartaric acid solution was added to the *cis*-itraconazole

solution and the solution remained clear. 0.90 ml of iso-propylacetate was added and the solution was seeded with <1 mg of the salt from a preparation of DL-tartaric acid co-crystal. The sample was allowed to crystallize over about 5 minutes in the 70 °C oil bath before it was removed and allowed to cool to room temperature. The cooled sample was suction filtered. It was rinsed with 0.2-0.3 ml of THF. The filter cake was broken-up and allowed to air-dry for 4 hours prior to analysis.

Example 11

Co-crystals of Itraconazole and malic acid were prepared. To prepare the L-malic acid co-crystal salt of *cis*-itraconazole, 100.4 mg of *cis*-itraconazole free base (Lot # KEO 0026, Química Sinética S.A), 0.50 ml of THF, and a magnetic stir bar were charged into a screw cap vial. A solution of 191.3 mg of L(-)-malic acid in 5.0 ml of THF was prepared. 0.50 ml of the L(-)-malic acid solution was added to the vial containing *cis*-itraconazole and the solution was heated with a heat gun to dissolve. The solution was allowed to cool and was then seeded with <1 mg of the salt from *cis*-itraconazole-L(-)-tartaric acid co-crystal. The cooled crystals were filtered in a centrifuge filter tube. The filter cake was broken-up and allowed to air-dry prior to analysis.

Example 12

Co-crystals of Itraconazole.HCl and tartaric acid were prepared. Approximately 212.7mg of L-tartaric acid and 118 µL of 37% HCl were dissolved in 25mL of hot dioxane. This solution was added to 1.0 g of *cis*-itraconazole dissolved in 50mL of hot dioxane with stirring. The resulting clear solution was filtered on a 0.2µm syringe filter into a 250 mL Erlenmeyer flask. Seed crystals from a previous preparation of the HCl-tartaric acid co-crystal salt were added, the solution was sonicated and left to stir overnight. The next day 50 mL tert-butyl methyl ether were added and the crystals were harvested by vacuum filtration on a Buchner funnel with #4 Whatman filter paper. The crystals were washed 3X with 5mL aliquots of cold tert-butyl methyl ether and left to air dry. Approximately 573 mg of a crystalline form of *cis*-itraconazole HCl-tartaric acid co-crystal were obtained.

Example 13

Co-crystals of modafinil and Nicotinamide were prepared. Modafinil (1 mg, 0.0037mmol) and Nicotinamide (0.45 mg, 0.0037 mmol) were dissolved in acetone (400 μ L). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 14

Co-crystals of modafinil and Benzamide were prepared. Modafinil (1 mg, 0.0037mmol) and benzamide (0.45 mg, 0.0037 mmol) were dissolved in 1,2-dichloroethane (400 μ L). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 15

Co-crystals of modafinil and Mandelic acid were prepared. Modafinil (1 mg, 0.0037mmol) and Mandelic acid (0.55 mg, 0.0037 mmol) were dissolved in acetone (400 μ L). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 16

Co-crystals of modafinil and glycolic acid were prepared. Modafinil (1 mg, 0.0037mmol) and glycolic acid (0.30 mg, 0.0037 mmol) were dissolved in acetone (400 μ L). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Example 17

Co-crystals of modafinil and Fumaric acid were prepared. Modafinil (1 mg, 0.0037mmol) and Fumaric acid (0.42 mg, 0.0037 mmol) were dissolved in 1,2-dichloroethane (400 μ L). The solution was allowed to evaporate to dryness and the resulting solid was characterized using PXRD. PXRD data for the co-crystal is listed in Table 7.

Table X. Detailed Characterization of Co-Crystals	
Carbamazepine: Saccharin	
PXRD: 7.01, 12.07, 14.09, 15.41, 18.47, 20.13, 22.01, 23.57, 24.41, 28.31 (Fig. 1)	
DSC: Broad endotherm at 161.9 °C (Fig. 2)	
TGA: Decomposition above 200 °C	
Raman:	
Method: CMAX	
Carbamazepine: Nicotinamide	
PXRD: 4.97, 6.67, 8.75, 10.25, 13.25, 17.91, 18.49, 19.95, 20.49, 22.73, 24.39, 26.49 (Fig. 3)	
DSC: Sharp endotherm at 156.9 °C.	
TGA: Decomposition beginning at ~150 °C	
Raman:	
Method: CMAX	
Carbamazepine: Trimesic acid	
PXRD: 10.89, 12.23, 14.83, 16.25, 17.05, 18.13, 18.47, 21.47, 21.95, 24.57, 25.11, 27.99 (Fig. 5)	
Raman:	
Method: CMAX	
Celecoxib: Nicotinamide	
PXRD: 3.77, 7.57, 9.63, 14.73, 15.21, 16.03, 17.81, 18.71, 19.33, 20.49, 21.21, 22.13	
DSC: Two phase transitions at 117.2 and 118.8 °C and a sharp endotherm at 129.7 °C	
TGA: Decomposition beginning at ~150 °C	
Raman:	
Method: Slow evaporation of a 1:1 solution from acetone	
Topiramate: 18-Crown-6	
PXRD: 10.79, 11.07, 12.17, 13.83, 16.13, 18.03, 18.51, 18.79, 19.21, 21.43, 22.25, 24.11 (Fig. 6)	
DSC: Sharp endotherm at 134.7 °C, followed by an exotherm at 203 °C (Fig. 7)	
TGA: Rapid decomposition beginning at ~ 135 °C and leveling off slightly after 200 °C	
Raman: 2994.5, 2942.7, 1471.6, 1427.4, 1261.7, 849.4, 804.5, 745.1, 629.2, 280.4, 225.9	
Method: Addition of an ether solution containing 1 equivalent of topiramate to an ether solution containing 18-crown-6. Product precipitated following minor agitation of the combined mixture and was collected.	
Olanzapine: Nicotinamide	
PXRD (Form I): 4.89, 8.65, 12.51, 14.19, 15.59, 17.15, 19.71, 21.05, 23.95, 24.59, 25.53, 26.71 (Fig. 7)	
PXRD (Form II): 6.41, 12.85, 18.67, 21.85, 24.37	
DSC (Form I): Slightly broad endotherm at 126.1 °C (Fig. 9)	
Raman:	
Method: CMAX	
Celecoxib: 18-Crown-6	
PXRD: 8.73, 11.89, 12.57, 13.13, 15.01, 16.37, 17.03, 17.75, 18.45, 20.75, 22.37, 23.11, 24.33, 24.97, 26.61, 28.15 (Fig. 10)	

<p>DSC: Sharp endotherm at 189.6 °C (Fig. 11)</p> <p>TGA: Decomposition above 200 °C with a 25% weight loss between ~190-210 °C</p> <p>Raman:</p> <p>Method: A solution containing one equivalent of Celecoxib in ether was added to a solution containing 18-crown-6. A white solid formed immediately and was collected.</p>
<p>Itraconazole: Succinic Acid</p> <p>PXRD: 3.0, 6.0, 8.1, 9.0, 17.1, 24.5 (Fig. 12)</p> <p>DSC: Single endothermic transition at 160.1 °C \pm 1.0°C (Fig. 13)</p> <p>TGA: Less than 0.1 % volatile components by weight</p> <p>Raman:</p> <p>Method: See above</p>
<p>Itraconazole: Fumaric Acid</p> <p>PXRD: 4.6, 5.9, 9.2, 10.6, 19.1, 20.8</p> <p>DSC: The material had a weak endothermic transition at 141.7 °C \pm 1 °C and a strong endothermic transition at 179.58 °C \pm 1 °C (Fig. 15)</p> <p>TGA: The sample loses 0.5 % of its weight on the TGA between room temperature and 100 °C</p> <p>Raman:</p> <p>Method:</p>
<p>Itraconazole: Tartaric Acid</p> <p>PXRD: 4.1, 6.2, 8.3, 20.7, 25.6, 26.3 (Fig. 16)</p> <p>DSC: An endothermic transition at 180.74 °C \pm 1.0 °C (Fig. 17)</p> <p>TGA: Less than 0.1 % volatile components by weight by TGA.</p> <p>Raman:</p> <p>Method: See above</p>
<p>Itraconazole: Malic acid</p> <p>PXRD: 4.4, 5.9, 8.8, 17.7, 20.0, 21.1, 22.6 (Fig. 18)</p> <p>DSC: The sample has a strong endothermic transition at 154.36 °C \pm 1.0 °C (Fig. 19)</p> <p>TGA: The sample contained less than 0.1% volatile components by weight</p> <p>Raman:</p> <p>Method: See above</p>
<p>ItraconazoleHCl: Tartaric acid</p> <p>PXRD: 3.7, 11.0, 13.8, 16.5, 17.8 (Fig. 20)</p> <p>DSC: The sample has a peak endothermic transition at 161°C \pm 1.0 °C (Fig. 21)</p> <p>TGA: The sample contained less than 0.1 % volatile components by weight</p> <p>Raman:</p> <p>Method: See above</p>
<p>Modafinil: Nicotinamide</p> <p>PXRD: 5.95, 18.61, 20.07, 20.65, 21.83, 23.19, 24.03, 25.67, 26.53, 30.75, 31.04, 32.78 (Fig. 22)</p> <p>Method: Slow evaporation from a 1:1 solution in acetone</p>
<p>Modafinil: Benzamide</p> <p>PXRD: 5.11, 9.35, 10.25, 10.79, 14.07, 16.87, 18.33, 19.53, 21.38, 22.05, 22.89, 23.57, 24.73, 25.19, 25.81, 26.51, 28.60 (Fig. 23)</p> <p>Method: Slow evaporation from a 1:1 solution in 1,2-dichloroethane</p>
<p>Modafinil: Mandelic acid</p>

PXRD: 6.11, 6.75, 9.53, 10.31, 14.77, 15.77, 16.99, 18.03, 20.01, 21.61, 22.47, 23.27, 25.27, 25.75, 27.23 (Fig. 24)

Method: Slow evaporation from a 1:1 solution in acetone

Modafinil: Glycolic acid

PXRD: 6.09, 9.51, 14.91, 15.97, 19.01, 20.03, 21.59, 22.43, 22.75, 23.75, 25.03, 25.71 (Fig. 25)

Method: Slow evaporation from a 1:1 solution in acetone

Modafinil: Fumaric acid

PXRD: 5.87, 7.19, 8.95, 12.49, 13.99, 16.13, 17.09, 18.19, 19.99, 21.57, 23.48, 25.01, 25.79, 28.17, 28.87, 29.69, 32.19 (Fig. 26)

Method: Slow evaporation from a 1:1 solution in 1,2-dichloroethane

Example 18

A co-crystal with a modulated dissolution profile has been prepared. Celecoxib:

Nicotinamide co-crystals were prepared to methods shown in example 4.

Example 19

A co-crystal with a modulated dissolution profile has been prepared. Itraconazole:

Succinic acid, tartaric acid and malic acid co-crystals were prepared to methods shown in examples 8, 10 and 11. See Fig. 2B.

Example 20

A co-crystal of a salt with a modulated dissolution profile has been prepared.

Itraconazole.HCl: tartaric acid co-crystals were prepared to methods shown in example 12.

Example 21

A co-crystal of an unsaltable or difficult to salt drug has been prepared. Celecoxib:

Nicotinamide co-crystals were prepared to methods shown in example 4.

Example 22

A co-crystal with an improved hygroscopicity profile has been prepared. Celecoxib:

Nicotinamide co-crystals were prepared to methods shown in example 4.

Example 23

A co-crystal with reduced form diversity as compared to the drug has been prepared. Co-crystals of carbamazepine and saccharin have been prepared to method shown in example

1.

CLAIMS:

1. A pharmaceutical composition comprising a co-crystal of a drug and a co-crystal forming compound; wherein the drug has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions.
2. A pharmaceutical composition according to claim 1, wherein (i) one of the drug and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.
3. A pharmaceutical composition according to claim 2, wherein the difference in Pka between the drug and the co-crystal forming compound does not exceed 2.
4. A pharmaceutical composition according to claim 1, wherein the drug is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate and modafinil.
5. A pharmaceutical composition according to claim 1, wherein the co-crystal forming compound is selected from saccharin, nicotinamide, pyridoxine(4-pyridoxic acid), acesulfame, glycine, arginine, asparagine, cysteine, glutamine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, threonine, tyrosine, valine, aspartic acid, glutamic acid, tryptophan, adenine, acetohydroxamic acid, alanine, allopurinaol, 4-

aminobenzoic acid, cyclamic acid, 4-ethoxyphenyl urea, 4-aminopyridine, leucine, nicotinic acid, serine, TRIS, vitamin K5, xylitol, succinic acid, tartaric acid, pyridoxamine, biotin, ascorbic acid, hydroquinone, salicylic acid, benzoic acid, caffeine, benzenesulfonic acid, 4-chlorobenzene-sulfonic acid, citric acid, fumaric acid, gluconic acid, glutaric acid, glycolic acid, hippuric acid, maleic, malic acid, mandelic acid, malonic, 1,5-naphthalene-disulfonic acid, clemizole, imidazole, glucosamine, piperazine, procaine, tromethamine, and urea.

6. A pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable diluent, excipient or carrier.

7. A co-crystal comprising carbamazepine and saccharin

8. A co-crystal comprising carbamazepine and nicotinamide

9. A co-crystal comprising carbamazepine and trimesic acid

10. A co-crystal comprising celecoxib and nicotinamide

11. A co-crystal comprising olanzepine and nicotinamide

12. A co-crystal comprising Olanzapine and nicotinamide

13. A co-crystal comprising Celecoxib and 18-crown-6

14. A co-crystal comprising itraconazole and Succinic acid

15. A co-crystal comprising itraconazole and fumaric acid

16. A co-crystal comprising itraconazole and tartaric acid

17. A co-crystal comprising itraconazole and malic acid
18. A co-crystal comprising itraconazole.HCl and tartaric acid
19. A co-crystal comprising modafinil and nicotinamide
20. A co-crystal comprising modafinil and benzamide
21. A co-crystal comprising modafinil and Mandelic acid
22. A co-crystal comprising modafinil and glycolic acid
23. A co-crystal comprising modafinil and Fumaric acid
24. A process for the production of a pharmaceutical composition, which process comprises:

(1) providing a drug which has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(2) providing a co-crystal forming compound which has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carboxyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio;

(3) contacting in solution the drug with the co-crystal forming compound under crystallization conditions, and

(4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition.

25. A process according to claim 24, wherein (i) one of the drug and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.
26. A process according to claim 24, wherein wherein the difference in Pka between the drug and the co-crystal forming compound does not exceed 2.
27. A process according to claim 24, wherein the drug is selected from celecoxib, carbamazepine, itraconazole, topiramate, Olanzapine and modafinil.
28. A process according to claim 24, wherein the co-crystal forming compound is selected from saccharin, nicotinamide, pyridoxine(4-pyridoxic acid), acesulfame, glycine, arginine, asparagine, cysteine, glutamine, histidine, isoleucine, lysine, methionine, phenylalanine, proline, threonine, tyrosine, valine, aspartic acid, glutamic acid, tryptophan, adenine, acetoxyhydroxyamic acid, alanine, allopurinaol, 4-aminobenzoic acid, cyclamic acid, 4-ethoxyphenyl urea, 4-aminopyridine, leucine, nicotinic acid, serine, TRIS, vitamin k5, xylito, succinic acid, tartaric acid, pyridoxamine, biotin, ascorbic acid, hydroquinone, salicylic acid, benzoic acid, caffeine, benzenesulfonic acid, 4-chlorobenzene-sulfonic acid, citric acid, fumaric acid, gluconic acid, glutaric acid, glycolic acid, hippuric acid, maleic, malic acid, mandelic acid, malonic, 1,5-napthalene-disulfonic acid, clemizole, imidazole, glucosamine, piperazine, procaine, tromethamine, and urea.
29. A process according to claim 24, which further comprises incorporating into the pharmaceutical composition a pharmaceutically acceptable diluent, excipient or carrier
30. A process for the production of a pharmaceutical composition, which comprises:
- (1) contacting in solution a drug with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
 - (2) isolating the solid phase;

(3) testing the solid phase for the presence of co-crystals of the drug and the co-crystal forming compound; and

(4) incorporating the co-crystals when formed in step (3) into a pharmaceutical composition.

31. A process for the production of a pharmaceutical composition, which comprises:

(1) providing (i) a drug or a plurality of different drugs, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the drug and the co-crystal forming compound is provided as a plurality thereof;

(2) screening for co-crystals of drugs with co-crystal forming compounds by subjecting each combination of drug and co-crystal forming compound to a step comprising

(a) contacting in solution the drug with the co-crystal forming compound under crystallization conditions so as to form a solid phase;

(b) isolating the solid phase; and

(c) testing the solid phase for the presence of co-crystals of the drug and the co-crystal forming compound; and

(3) incorporating the co-crystals when formed in step (c) into a pharmaceutical composition.

32. A process for modulating the solubility of a drug for use in a pharmaceutical composition, which process comprises:

(1) contacting in solution the drug with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the drug and the co-crystal forming compound;

(2) isolating the co-crystal;

(3) testing the co-crystal for modulated solubility as compared to the drug; and

(4) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

33. A process for modulating the dose response of a drug for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the drug with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the drug and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated dose response as compared to the drug; and
- (4) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

Abstract

Pharmaceutical Compositions

A pharmaceutical composition comprising a co-crystal of a drug and a co-crystal forming compound; wherein the drug has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp² amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions.




Figure 1




Figure 2




Figure 3

Sample: carb_389_278_C4
 Size: 0.1340 mg
 Method: Ramp

DSC

File: Y:\Carb_389_278\carb_389_278_C4001
 Operator: MSH
 Run Date: 18-Nov-02 16:00
 Instrument: DSC Q1000 V6.19 Build 227




Figure 4




Figure 5




Figure 6

Sample: topiramate_18crown8
Size: 0.8210 mg
Method: Ramp

DSC

File: Y:\DSC\Magali\topiramate_18crown8.001
Operator: MBH
Run Date: 19-May-03 05:35
Instrument: DSC Q1000 V6,19 Build 227




Figure 7




Figure 8

Sample: 1102_204_D2
Size: 0.7500 mg
Method: Ramp

DSC

File: Y:\...lotenzapine\1102\1102_204_D2.002
Operator: MBH
Run Date: 14-May-03 08:58
Instrument: DSC Q1000 V6.19 Build 227




Figure 9




Figure 10

Sample: Celecoxib/18-crown-6
Size: 0.9800 mg
Method: Ramp

DSC

File: \\LMT_143_45_A; Celecoxib 18-C-6.001
Operator: MDT
Run Date: 17-Mar-03 13:42
Instrument: DSC Q1000 V6.19 Build 227




Figure 11






Figure 14

Sample: MM_90_48_B_DSC
 Size: 2.3690 mg
 Method: Ramp

DSC

File: \1..NR_91_53_D_Mg_open_DSC.004
 Operator: MM
 Run Date: 11-Jun-02 10:46
 Instrument: DSC Q1000 V6.1 Build 191




Figure 15




Figure 16




Figure 17




Figure 18

Sample: MM_109_15_Tar
Size: 1.2140 mg
Method: Ramp

DSC

File: Y:\Ultraconazole\MM_109_15_Mal.001
Operator: MM
Run Date: 01-Aug-02 14:18
Instrument: DSC Q1000 V5.1 Build 191




Figure 19

[MM_109_38_A_HCl_Tartrate.raw] rigaku_cu, comment line




Figure 20

Sample: MM_109_38_A
Size: 1.5080 mg
Method: Ramp

DSC

File: \...Ultracinoxole\MM_109_38_A.001
Operator: MM
Run Date: 11-Sep-02 10:57
Instrument: DSC Q1000 V6.19 Build 227




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25





Figure 26

Insert Figure 27

Figure 27



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanox Beads (amorphous freebase)

I-Malate

I-Tartrate

Succinate

Crystalline Freebase

Figure 28




Fig. 31

TABLE I








Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
1-Hydroxy-2-naphthoic acid	188.18	191-192	2	Carboxylic acid, alcohol	1	2		2.7, 13.5
4-aminobenzoic acid	137.14	187-188	2	Amine, carboxylic acid	1	3		4.7, 4.8
4-aminopyridine	94.11	158-159	3	Amine, pyridine	1	2		10
4-Chlorobenzene- sulfonic acid	192.63	67	1	SO ₃ H	3	1		0-1
4-ethoxyphenyl urea	180.2	173-174	3	Amide, NH	2	3		~7-9
7-oxo-DHEA	303	190-192	1	Alcohol, Ketone	3	1		
Acesulfame	163.15	123-124	3	SO ₂ , Amide	4	1		~5-7

TABLE I







Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Acetohydroxamic acid	75.07	89-92	3	Amide, NH, OH	2	2		8,7
Adenine	135.13	220 (sub.)	1	Amine, NH	3	3		3.8
Adipic Acid	146.14	152	1	Carboxylic acid	2	2	$\text{HOOC}(\text{CH}_2)_4\text{COOH}$	4.44, 5.44
Alanine	89.09	289-291	1	Amine, carboxilic acid	1	3		2.35, 9.87
Allopurinol	136.11	> 350	3	OH, NH	4	2		10.2
Arginine	174.2	244 (dec.)	1	Amine, COOH	2	7		2.18, 9.09, 13.2
Ascorbic acid	176.12	190-192	1	C=O, OH	6	4		4.17, 11.57

TABLE I







Co-Crystal Former	MW. (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Asparagine	132.12	234-235	1	Amine, amide, COOH	3	5		2.02, 8.5
Aspartic acid	133.1	270-271	1	Amine, COOH	2	4		1.88, 3.65, 9.60
Benzenesulfonic Acid	158.18	43-44	1	SO ₃ H	2	1		0.70, 1.58
Benzoic acid*	122.12	122-123	2	COOH	1	1		4.19
caffeine	194.19	238	3	C=O	3	0		
Camphoric acid	200.23	186-189	2	Carboxylic acid	2	2		4.72, 5.83
Capric acid	172.27	31.4	1	Carboxylic acid	1	1	$\text{CH}_3(\text{CH}_2)_8\text{COOH}$	4.9

TABLE I







Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Chrysin	254.24	285	1	Phenol, ether, ketone	2	2		
Cinnamic acid	144.2	133	3	Carboxylic acid	1	1		4.4
Citric Acid	192.12	153	1	OH, COOH	4	4		3.13, 4.76, 6.40
Clemizole	325.84	167	1	Pyrrolidine	3	0		
Cyclamic acid	179.24	169-170	3	NH, SO ₃ H	2	2		-2
Cysteine	121.15	—	1	Amine, COOH, SH	2	4		1.71, 8.33, 10.78

TABLE I








Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Dimethylglycine	103.1	178-192	1	Amine, Carboxylic acid	2	1		2.5
D-Ribose	150.13	87	1	Alcohol, ether	1	4		
Fumaric acid	116.07	287	1	COOH	2	2		3.03, 4.38
Galactaric acid	210.14	255 (dec)	1	Carboxylic acid, alcohol	2	6		3.08, 3.63
Genistein	270.24	297-298	1	Alcohol, Phenol, ether, ketone	2	3		
Gentisic acid	154.12	199-200 form I, 205 form II	2	Carboxylic acid, alcohol, phenol	1	3		2.93
Glucamine, N-Methyl	195.22	128-129	1	Alcohol, Amine	5	6		8.03(B)

TABLE I







Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Gluconic acid	196.15	131	1	OH, COOH	6	6		3.76
Glucosamine	179.17	88	1	OH	5	6		6.91
Glucuronic acid	194.14	165	1	Carboxylic acid, alcohol, aldehyde	2	5		3.18
Glutamic acid	147.13	160	1	Amine, COOH	2	4		2.19, 4.25, 9.67
Glutamine	146.15	185-186	1	Amine, Amide, COOH	2	5		2.17, 9.13
Glutaric acid	132.11	98-98	1	COOH	2	2		2.7, 4.5

TABLE I








Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Glycine	75.07	182	1	Amine, COOH	2	3		2.34; 9.6
Glycolic acid	76.05	80	1	OH, COOH	2	2		3.82
Hippuric acid	179.17	187-188	1	Amide, NH, COOH	2	2		3.55
Histidine	155.16	287 (dec.)	1	Amine, COOH, Imidazole	2	4		1.78, 5.97, 8.97
Hydroquinone*	110.11	170-171	2	OH, Phenol	2	2		-10
Imidazole	68.08	90-91	1	NH	1	1		6.92
Ipriflavone	280.32	115-117	1	Ketone, ether	3	0		

TABLE I






Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Isoleucine	131.17	168-170 (sub.)	1	Amine, COOH	1	3		2.32, 9.76
Lactobionic acid	358.3	128-130	2	Alcohol, carboxylic acid, ether	1	9		3.2
Lauric acid	200.32	44-48	1	Carboxylic acid	1	1	$\text{CH}_3(\text{CH}_2)_{10}\text{COOH}$	~4.5
Leucine	131.17	145-148 (sub.)	1	Carboxylic acid, amine	1	3		2.36, 9.6
Lysine	146.19	225 (dec.)	1	Amine, COOH	1	5		2.2, 8.9, 10.28
Maleic	116.07	138-139	1	COOH	2	2		1.92, 6.23

TABLE I







Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Malic acid	134.09	131-132	1	OH, COOH	3	3		3.46, 5.1
Malonic	104.06	135	1	COOH	2	2		2.83, 5.70
Mandelic acid	152.15	119	1	OH, COOH	2	2		3.37
Methionine	149.21	280-282 (dec.)	1	Amine, COOH, S- Me	2	3		2-3, 9
Nicotinamide	122.12	128-131	1	Pyridine, amide	2	2		3.3
Nicotinic acid	123.11	236-237	2	Carboxylic acid, pyridine	2	1		2.07(B), 4.85

TABLE I







Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	pKa Values
Orotic acid	156.1	345-346	2	Carboxylic acid, lactam	3	3		5.85, 8.95
Oxalic acid	90.04	189 (dec)	2	Carboxylic acid	2	2		1.27, 4.27
Palmitic acid	256.43	63-64	1	Carboxylic acid	1	1	$\text{CH}_3(\text{CH}_2)_{14}\text{COOH}$	4.9
Pantoic	388.38	280 (dec)	2	Carboxylic acid, phenol	2	4		2.51, 3.1
Phenylalanine	165.19	283 (dec.)	1	Amine, COOH	1	3		-2, -9
Piperazine	86.14	106	1	NH	0	2		9.82(B)
Procaine	236.31	61	1	Amine, C=O	2	2		8.9(B)

TABLE I








Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Proline	115.13	220-222 (dec.)	1	COOH, NH	1	2		1.99, 10.6
p-Toluenesulfonic acid	172.2	106-107	2	Sulfonic acid	2	1		-1.34
Pyridoxamine	168	193-194	2	OH, Amine, Pyridine	3	4		~9
Pyridoxine	170	160	2	Alcohol, Pyridine	3	3		~9
Pyroglutamic acid	129.12	162	2	Carboxylic acid, Lactam	2	2		3.32
Quercetin	302.24	314 dec.	1	Phenol, ether, ketone	2	5		
Resveratrol	228.24	253-255	-1	Phenol	0	3		

TABLE I






Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Saccharin	183.19	228-230	1	Amide, C=O, S=O, N-H	3	1		2
Salicylic acid, 4-amino	153.14	150-151	3	COOH, OH, Aniline	1	4		3.25, 10, 3.5(B)
Salicylic acid	138.12	159	3	COOH, OH	2	2		2.98, 13.82
Sebacic acid	202.25	134.5	1	Carboxylic acid	2	2	HOOC(CH ₂) ₈ COOH	4.59, 5.59
Serine	105.09	228 (dec.)	1	Carboxylic acid, amine, OH	2	3		2.21, 9.15
Stearic acid	284.47	70-71	1	Carboxylic acid	1	1	CH ₃ (CH ₂) ₁₆ COOH	4.9
Succinic acid	118.09	185-187	1	Carboxylic acid	2	2		4.21, 5.64

TABLE I








Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	pKa Values
Tartaric acid	150.09	205-206	1	Carboxylic acid	4	4		3.02, 4.36
Threonine	119.12	255-257 (dec.)	1	Amine, COOH, OH	2	4		2.15, 9.12
TRIS	121.13	171-172	2	Amine, OH	3	5		5.91, 8.3
Tryptophan	204.23	289 (dec.)	1	Amine, COOH, Indole	1	4		2.38, 9.39
Tyrosine	181.19	342-344	1	Amine, COOH, OH	2	3		2.2, 9.11, 10.07
Urea	60.06	Dec.	1	C=O, NH2	1	4		~8
Valine	117.15	315	1	Amine, COOH	1	3		~4.5, ~9

TABLE I



Co-Crystal Former	MW (g/mol)	MP (°C)	Class	Functionality	# acceptors	# donors	Molecular Structure	Pka Values
Vitamin K5	209.68	280-282 (dec.)	3	Amine, OH	1	3		~9
Xylitol	152.15	93-95 (l)	2	OH	5	5		~9

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group							
1,5-Naphthalene-disulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide		
1-Hydroxy-2-naphthoic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline		
1-Hydroxy-2-naphthoic acid	alcohol	alcohol	ketone	thiol	amide	amine	aniline		
4-Aminobenzoic Acid	Amine	alcohol	ketone	thiol	amide	amine	aniline		
4-Aminobenzoic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline		
4-aminopyridine	Amine	alcohol	ketone	thiol	amide	amine	aniline		
4-aminopyridine	Pyridine	*alcohol	pyridinium	*	*amide	nitro	*amine		
4-Chlorobenzene-Sulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide		
4-ethoxyphenyl Urea	Amide	alcohol	ketone	thiol	amide	amine	aniline		
4-ethoxyphenyl Urea	Amine	alcohol	ketone	thiol	amide	amine	aniline		
7-oxo-DHEA	alcohol	alcohol	ketone	thiol	amide	amine	aniline		
7-oxo-DHEA	Ketone	alcohol		thiol	amide	amine	aniline		
Acetosulfame	Sulfone	pyridine	ketone	aldehyde	ether	ester	amide		
Acetosulfame	Amide	alcohol	ketone	thiol	amide	amine	aniline		
Acetohydroxamic Acid	Amide	alcohol	ketone	thiol	amide	amine	aniline		
Acetohydroxamic Acid	Amine	alcohol	ketone	thiol	amide	amine	aniline		
Acetohydroxamic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline		
Adenine	Amine	alcohol	ketone	thiol	amide	amine	aniline		
Adenine	N	*alcohol	pyridinium	*	*amide	nitro	*amine		
Adipic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline		
Alanine	Amine	alcohol	ketone	thiol	amide	amine	aniline		
Alanine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline		
Allopurinol	Alcohol	alcohol	ketone	thiol	amide	amine	aniline		
Allopurinol	Amine	alcohol	ketone	thiol	amide	amine	aniline		
Arginine	Amine	alcohol	ketone	thiol	amide	amine	aniline		
Arginine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline		
Ascorbic Acid	Ketone	alcohol	ketone	thiol	amide	amine	aniline		
Ascorbic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline		
Ascorbic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline		
Asparagine	Amine	alcohol	ketone	thiol	amide	amine	aniline		

TABLE II

Co-crystal Former	Carboxylic Acid	amine	metals	thioether	nitrate	sulfate	alcohol	
1,5-Naphthalene-disulfonic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	alcohol	metals
1-Hydroxy-2-naphthoic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	metals
1-Hydroxy-2-naphthoic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	metals
4-Aminobenzoic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	metals
4-Aminobenzoic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid	carboxylic acid
4-aminopyridine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	carboxylic acid
4-aminopyridine	*Carboxylic Acid	*sulfonamide	*ketone	ether	triazole		ammonium	oxime
4-Chlorobenzene-Sulfonic Acid	Carboxylic Acid	amine	metals	thioether				
4-ethoxyphenyl Urea	phenol	phosphate	sulfate	sulfone	nitrate	sulfate	alcohol	
4-ethoxyphenyl Urea	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
7-oxo-DHEA	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	metals
7-oxo-DHEA	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Acetulfame	carboxylic acid	amine	metals	thioether				
Acetulfame	phenol	phosphate	sulfate	sulfone	nitrate	sulfate	alcohol	
Acetohydroxamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Acetohydroxamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Acetohydroxamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Adenine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Adenine	*carboxylic acid	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Adenine	acid	*sulfonamide	*ketone	ether	triazole		ammonium	oxime
Adipic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Alanine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Alanine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Allopurinaol	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Allopurinaol	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Arginine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Arginine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Ascorbic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Ascorbic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Ascorbic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Asparagine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid

TABLE II

[illegible]

TABLE II

[illegible]

TABLE II

[illegible]

TABLE II

[illegible]

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group					
Asparagine	Amide	alcohol	ketone	thiol	amide	amine	aniline
Asparagine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Aspartic Acid	Amine	alcohol	ketone	thiol	amide	amine	aniline
Aspartic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Benzenesulfonic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide
Benzoic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Caffeine	Ketone	alcohol	ketone	thiol	amide	amine	aniline
Camphoric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Capric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Genistein	Ketone	alcohol	ketone	thiol	amide	amine	aniline
Genistein	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Genistein	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
Cinnamic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Citric Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Citric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Clemizole	Pyrrolidine	*alcohol	pyridinium	*	*amide	nitro	*amine
Cyclamic Acid	Amine	alcohol	ketone	thiol	amide	amine	aniline
Cyclamic Acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide
Cysteine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Cysteine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Cysteine	Thiol	carboxylic acid	sodium	aldehyde	ketone	-N	cadmium
Dimethylglycine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Dimethylglycine	Amine	alcohol	ketone	thiol	amide	amine	aniline
D-ribose	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
D-ribose	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Fumaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Galactaric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Galactaric acid	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Chrysin	Ketone	alcohol	ketone	thiol	amide	amine	aniline
Chrysin	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Chrysin	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide

TABLE II

Co-crystal Former	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Asparagine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Asparagine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Aspartic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Aspartic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Benzenesulfonic Acid	Carboxylic Acid	amine	metals	thioether		sulfate	alcohol
Benzoic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Caffeine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Camphoric acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Capric acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Genistein	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Genistein	aldehyde	phosphate	sulfate	sulfone	nitrate	pyridine	chlorine
Genistein	chlorate	chlorine	alcohol		ester	ether	n-oxide
Cinnamic acid	phenol	phosphate	sulfate	cyano	ester	amine	nitrate
Citric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Citric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Citric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Clemizole	*carboxylic acid	*sulfonamide	*ketone	ether	triazole		oxime
Cyclamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Cyclamic Acid	Carboxylic Acid	amine	metals	thioether		sulfate	alcohol
Cysteine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Cysteine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Cysteine		arsenic	chlorine	alcohol	potassium	Ru	Rb
Dimethylglycine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Dimethylglycine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
D-ribose	chlorate	chlorine		cyano	ester	amine	nitrate
D-ribose	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Fumaric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Galactaric acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Galactaric acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	metals
Chrysin	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Chrysin	aldehyde	phosphate	sulfate	sulfone	nitrate	pyridine	chlorine
Chrysin	chlorate	chlorine	alcohol	cyano	ester	ether	nitrate

TABLE II

Co-crystal Former	metals	aldehyde	ester	ether	cyano	furan	bromine
Asparagine	metals	aldehyde	ester	ether	cyano	furan	bromine
Asparagine	metals	aldehyde	ester	ether	cyano	furan	bromine
Aspartic Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Aspartic Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Benzenesulfonic Acid							
Benzolic Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Caffeine	metals	aldehyde	ester	ether	cyano	furan	bromine
Camphoric acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Capric acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Genistein	metals	aldehyde	ester	ether	cyano	furan	bromine
Genistein	fluorine	bromine	iodine	ketone	sulfonic acid	sulfate	phosphonic acid
Genistein	bromine	aldehyde	ketone	peroxide	epoxide		heterocyclic-S
Cinnamic acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Citric Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Citric Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Clemizole	*chlorine		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	hydrazone
Cyclamic Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Cyclamic Acid							
Cyclamic Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Cysteine	metals	aldehyde	ester	ether	cyano	furan	bromine
Cysteine	metals	aldehyde	ester	ether	cyano	furan	bromine
Cysteine	Sb						
Dimethylglycine	metals	aldehyde	ester	ether	cyano	furan	bromine
Dimethylglycine	metals	aldehyde	ester	ether	cyano	furan	bromine
D-ribose	bromine	aldehyde	ketone	peroxide	epoxide		heterocyclic-S
D-ribose	metals	aldehyde	ester	ether	cyano	furan	bromine
Fumaric Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Galactaric acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Galactaric acid	aldehyde	ester	ether	cyano	cyano	furan	bromine
Chrysin	metals	aldehyde	ester	ether	cyano	bromine	chlorine
Chrysin	fluorine	bromine	iodine	ketone	sulfonic acid	phosphate	phosphonic acid
Chrysin	bromine	aldehyde	ketone	peroxide	epoxide		heterocyclic-S

TABLE II

Co-crystal Former						
Asparagine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Asparagine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Aspartic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Aspartic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Benzenesulfonic Acid						
Benzoic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Caffeine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Camphoric acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Capric acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Genistein	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Genistein	carboxylic acid	nitro	sulfone	aniline	n-heterocyclic	ketone
Genistein	iodine	ester	ether	carboxylic acid	sulfate	sulfone
Cinnamic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Citric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Citric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Clemizole	thiocyanate	*bromine		hydroxamic acid	cyano	carboxamide
Cyclamic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Cyclamic Acid						
Cysteine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Cysteine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Cysteine						
Dimethylglycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Dimethylglycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
D-ribose	iodine	ester	ether	carboxylic acid	sulfate	sulfone
D-ribose	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Fumaric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Galactaric acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Galactaric acid	s-heterocyclic	pyridine	cyano	cyano	n-heterocyclic	ketone
Chrysin	chlorine	s-heterocyclic	pyridine	cyano	ketone	phosphate ester
Chrysin	carboxylic acid	nitro	pyridine	cyano	n-heterocyclic	ketone
Chrysin	iodine	ester	sulfone	aniline		
Chrysin			ether	carboxylic acid	sulfate	sulfone

TABLE II

[illegible]

TABLE II

Co-crystal Former		thiourea	iodine	epoxide	peroxide
Asparagine	N-SO ₂	thiourea	iodine		
Asparagine	N-SO ₂	thiourea	iodine		
Aspartic Acid	N-SO ₂	thiourea	iodine		
Aspartic Acid	N-SO ₂	thiourea	iodine		
Benzenesulfonic Acid					
Benzoic Acid	N-SO ₂	thiourea	iodine		
Caffeine	N-SO ₂	thiourea	iodine		
Camphoric acid	N-SO ₂	thiourea	iodine		
Capric acid	N-SO ₂	thiourea	iodine		
Genistein	N-SO ₂	thiourea	iodine		
Genistein					
Genistein					
Cinnamic acid	N-SO ₂	thiourea	iodine		
Citric Acid	N-SO ₂	thiourea	iodine	epoxide	
Citric Acid	N-SO ₂	thiourea	iodine		
Clemizole	dithiadiazocyclopentadienyl				
Cyclamic Acid	N-SO ₂	thiourea	iodine		
Cyclamic Acid					
Cysteine	N-SO ₂	thiourea	iodine		
Cysteine	N-SO ₂	thiourea	iodine		
Cysteine					
Dimethylglycine	N-SO ₂	thiourea	iodine		
Dimethylglycine	N-SO ₂	thiourea	iodine		
D-ribose					
D-ribose	N-SO ₂	thiourea	iodine	epoxide	
Fumaric Acid	N-SO ₂	thiourea	iodine		
Galactaric acid	N-SO ₂	thiourea	iodine		
Galactaric acid					
Chrysin	N-SO ₂	thiourea	iodine		
Chrysin					
Chrysin					

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group					
Gentisic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Gentisic acid	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Glucamine, N-methyl	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Glucamine, N-methyl	Amine	alcohol	ketone	thiol	amide	amine	aniline
Gluconic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Gluconic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Glucosamine	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Glucuronic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Glucuronic acid	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Glucuronic acid	Aldehyde	alcohol	ketone	thiol	amide	amine	aniline
Glutamic Acid	Amine	alcohol	ketone	thiol	amide	amine	aniline
Glutamic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Glutamine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Glutamine	Amide	alcohol	ketone	thiol	amide	amine	aniline
Glutamine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Glutaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Glycine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Glycine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Glycolic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Glycolic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Hippuric Acid	Amide	alcohol	ketone	thiol	amide	amine	aniline
Hippuric Acid	Amine	alcohol	ketone	thiol	amide	amine	aniline
Hippuric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Histidine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Histidine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Histidine	Imidazole	imidazole	chlorine	acetamide	carboxylate		thione
Hydroquinone	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Hydroquinone	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Imidazole	Amine	alcohol	ketone	thiol	amide	amine	aniline
Ipriflavone	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
Ipriflavone	Ketone	alcohol		thiol	amide	amine	aniline
Isoleucine	Amine	alcohol	ketone	thiol	amide	amine	aniline

TABLE II

Co-crystal Former	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	n-oxide	carboxylic acid
Genitisc acid	aldehyde	phosphate	alcohol		ester	ether		chlorine
Genitisc acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	metals
Glucamine, N-methyl	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glucamine, N-methyl	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Gluconic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Gluconic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Glucosamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glucuronic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid	metals
Glucuronic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxylic acid
Glucuronic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glutamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glutamic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glutamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glutamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Glutamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glutaric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glycine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glycine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Glycolic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Glycolic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Hippuric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Hippuric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Hippuric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Histidine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Histidine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Histidine	nitro	cyanamide	ketone	cyano	Carboxylic Acid	alcohol		thiol
Hydroquinone	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Hydroquinone	aldehyde		alcohol		ester	ether	n-oxide	chlorine
Imidazole	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid
Ipriflavone	chlorate	chlorine		cyano	ester	amine	nitro	nitrate
Ipriflavone	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		Carboxylic Acid
Isoleucine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine		carboxylic acid

TABLE II

Co-crystal Former		metals	aldehyde	ester	ether	cyano	sulfate	furan	bromine
Gentisic acid		fluorine	bromine	iodine	ketone	sulfonic acid		phosphate	phosphonic acid
Gentisic acid		aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glucamine, N-methyl		metals	aldehyde	ester	ether	cyano		furan	bromine
Glucamine, N-methyl		metals	aldehyde	ester	ether	cyano		furan	bromine
Gluconic Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Gluconic Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glucosamine		metals	aldehyde	ester	ether	cyano		furan	bromine
Glucuronic acid		aldehyde	ester	ether	cyano		furan	bromine	chlorine
Glucuronic acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glucuronic acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glutamic Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glutamic Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glutamine		metals	aldehyde	ester	ether	cyano		furan	bromine
Glutamine		metals	aldehyde	ester	ether	cyano		furan	bromine
Glutamine		metals	aldehyde	ester	ether	cyano		furan	bromine
Glutaric Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glycine		metals	aldehyde	ester	ether	cyano		furan	bromine
Glycine		metals	aldehyde	ester	ether	cyano		furan	bromine
Glycolic Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Glycolic Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Hippuric Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Hippuric Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Hippuric Acid		metals	aldehyde	ester	ether	cyano		furan	bromine
Histidine		metals	aldehyde	ester	ether	cyano		furan	bromine
Histidine		metals	aldehyde	ester	ether	cyano		furan	bromine
		phosphinic acid							
		hemihydrate							
Histidine		amine	aldehyde	chlorine	sulfonyl	sulfoxide	amide	fluorine	sulfonate-ester
Hydroquinone		metals	aldehyde	ester	ether	cyano		furan	bromine
Hydroquinone		fluorine	bromine	iodine	ketone	sulfonic acid	sulfate	phosphate	phosphonic acid
Imidazole		metals	aldehyde	ester	ether	cyano		furan	bromine
Ipriflavone		bromine	aldehyde	ketone	peroxide	epoxide			heterocyclic-S
Ipriflavone		metals	aldehyde	ester	ether	cyano		furan	bromine
Isoleucine		metals	aldehyde	ester	ether	cyano		furan	bromine

TABLE II

Co-crystal Former	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Gentisic acid	carboxylic acid	nitro	sulfone	aniline		
Gentisic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester
Glucamine, N-methyl	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glucamine, N-methyl	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Gluconic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glucosamine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glucuronic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glucuronic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester
Glucuronic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glutamic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glycine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glycolic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Glycolic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Hippuric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Hippuric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Hippuric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Histidine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Histidine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Histidine						
Histidine						
Hydroquinone	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Hydroquinone	carboxylic acid	nitro	sulfone	aniline		
Imidazole	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Ipriflavone	iodine	ester	ether	carboxylic acid	sulfate	sulfone
Ipriflavone	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Isoleucine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone

TABLE II

Co-crystal Former	phosphate ester	fluorine	carbamate	imidazole	BF4	alkane	aromatic
Gentisic acid							
Gentisic acid		fluorine	carbamate	BF4			
Glucamine, N-methyl	phosphate ester		carbamate	imidazole	BF4		
Glucamine, N-methyl	phosphate ester	fluorine	carbamate	imidazole	BF4		
Gluconic Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Gluconic Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glucosamine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glucuronic acid	phosphate ester	fluorine	carbamate	BF4			
Glucuronic acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glutamic Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glutamic Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glutamine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glutamine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glutamine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glutaric Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glycine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glycine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glycolic Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Glycolic Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Hippuric Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Hippuric Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Hippuric Acid	phosphate ester	fluorine	carbamate	imidazole	BF4		
Histidine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Histidine	phosphate ester	fluorine	carbamate	imidazole	BF4		
Histidine							
Histidine							
Hydroquinone	phosphate ester	fluorine	carbamate	imidazole	BF4		
Hydroquinone							
Imidazole	phosphate ester	fluorine	carbamate	imidazole	BF4		
Ipriflavone		alcohol	phosphate	cyanamide			
Ipriflavone	phosphate ester	fluorine	carbamate	imidazole	BF4		
Isoleucine	phosphate ester	fluorine	carbamate	imidazole	BF4		

TABLE II

Co-crystal Former				
Gentisic acid	N-SO ₂	thiourea	iodine	
Gentisic acid				
Glucamine, N-methyl				
Glucamine, N-methyl	N-SO ₂	thiourea	iodine	
Gluconic Acid	N-SO ₂	thiourea	iodine	epoxide
Gluconic Acid	N-SO ₂	thiourea	iodine	
Glucosamine	N-SO ₂	thiourea	iodine	epoxide
Glucuronic acid	N-SO ₂	thiourea	iodine	
Glucuronic acid				
Glucuronic acid	N-SO ₂	thiourea	iodine	epoxide
Glutamic Acid	N-SO ₂	thiourea	iodine	
Glutamic Acid	N-SO ₂	thiourea	iodine	
Glutamine	N-SO ₂	thiourea	iodine	
Glutamine	N-SO ₂	thiourea	iodine	epoxide peroxide
Glutamine	N-SO ₂	thiourea	iodine	
Glutaric Acid	N-SO ₂	thiourea	iodine	
Glycine	N-SO ₂	thiourea	iodine	
Glycine	N-SO ₂	thiourea	iodine	
Glycolic Acid	N-SO ₂	thiourea	iodine	epoxide
Glycolic Acid	N-SO ₂	thiourea	iodine	
Hippuric Acid	N-SO ₂	thiourea	iodine	epoxide peroxide
Hippuric Acid	N-SO ₂	thiourea	iodine	
Hippuric Acid	N-SO ₂	thiourea	iodine	
Histidine	N-SO ₂	thiourea	iodine	
Histidine	N-SO ₂	thiourea	iodine	
Histidine				
Hydroquinone	N-SO ₂	thiourea	iodine	epoxide
Hydroquinone				
Imidazole	N-SO ₂	thiourea	iodine	
Ipriflavone				
Ipriflavone	N-SO ₂	thiourea	iodine	
Isoleucine	N-SO ₂	thiourea	iodine	

TABLE II

Co-crystal Former	Co-crystal Former Functional Group	Interacting Group					
Isoleucine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Lactobionic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Lactobionic acid	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Lactobionic acid	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
Lauric acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Leucine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Leucine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Lysine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Lysine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Maleic	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Malic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Malic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Malonic	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Mandelic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Mandelic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Methionine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Methionine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Methionine	Thioether	-N	amide	amine	_s	Sp2 amine	sulfoxide
Nicotinamide	Pyridine	*alcohol		*	*amide	nitro	*amine
Nicotinamide	Amide	alcohol	ketone	thiol	amide	amine	aniline
Nicotinic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Nicotinic Acid	Pyridine	*alcohol		*	*amide	nitro	*amine
Orotic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Orotic acid	Lactam	alcohol	ketone	thiol	amide	amine	aniline
Oxalic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Palmitic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Pamolic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Pamolic acid	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Pamolic acid	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Phenylalanine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Phenylalanine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Piperazine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Procaine	Amine	alcohol	ketone	thiol	amide	amine	aniline

TABLE II

Co-crystal Former	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Isoleucine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Lactobionic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Lactobionic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	metals
Lactobionic acid	chlorate	chlorite		cyano	ester	amine	nitrate
Lauric acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Leucine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Leucine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Lysine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Lysine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Maleic	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Maleic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Maleic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Malonic	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Mandellic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Mandellic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Methionine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Methionine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Methionine	chlorate	chlorine		cyano	ester	amine	nitrate
Nicotinamide	*Carboxylic Acid	*sulfonamide	*ketone	ether	triazole		oxime
Nicotinamide	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Nicotinic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Nicotinic Acid	*Carboxylic Acid	*sulfonamide	*ketone	ether	triazole		oxime
Orotic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Orotic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Oxalic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Palmitic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Pantoic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Pantoic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	metals
Pantoic acid	aldehyde	alcohol			ester	ether	chlorine
Phenylalanine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Phenylalanine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Piperazine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Procaine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid

TABLE II

Co-crystal Former	metals	aldehyde	ester	ether	cyano	furane	bromine
Isoleucine	metals	aldehyde	ester	ether	cyano	furane	bromine
Lactobionic acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Lactobionic acid	aldehyde	ester	ether	cyano	epoxide	furane	heterocyclic-S
Lactic acid	bromine	aldehyde	ketone	peroxide	cyano	furane	bromine
Leucine	metals	aldehyde	ester	ether	cyano	furane	bromine
Leucine	metals	aldehyde	ester	ether	cyano	furane	bromine
Lysine	metals	aldehyde	ester	ether	cyano	furane	bromine
Lysine	metals	aldehyde	ester	ether	cyano	furane	bromine
Maleic	metals	aldehyde	ester	ether	cyano	furane	bromine
Maleic Acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Maleic Acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Malonic	metals	aldehyde	ester	ether	cyano	furane	bromine
Mandelic Acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Mandelic Acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Methionine	metals	aldehyde	ester	ether	cyano	furane	bromine
Methionine	metals	aldehyde	ester	ether	cyano	furane	bromine
Methionine	bromine	aldehyde	ketone	peroxide	epoxide	Se	heterocyclic-S
Nicotinamide	*chlorine	thiol	thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	hydrazone
Nicotinamide	metals	aldehyde	ester	ether	cyano	furane	bromine
Nicotinic Acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Nicotinic Acid	*chlorine	thiol	thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	hydrazone
Orotic acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Orotic acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Oxalic acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Palmitic acid	metals	aldehyde	ester	ether	cyano	furane	bromine
Pantoic acid	aldehyde	ester	ester	ether	cyano	furane	bromine
Pantoic acid	fluorine	bromine	iodine	cyano	sulfonic acid	phosphate	phosphonic acid
Phenylalanine	metals	aldehyde	ester	ether	cyano	furane	bromine
Phenylalanine	metals	aldehyde	ester	ether	cyano	furane	bromine
Piperazine	metals	aldehyde	ester	ether	cyano	furane	bromine
Procaline	metals	aldehyde	ester	ether	cyano	furane	bromine

TABLE II

Co-crystal Former	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Isoleucine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Lactobionic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Lactobionic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester
Lactobionic acid	iodine	ester	ether	carboxylic acid	sulfate	sulfone
Lauric acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Leucine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Leucine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Lysine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Lysine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Maleic	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Malic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Malic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Malonic	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Mandelic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Mandelic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Methionine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Methionine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Methionine	iodine	ester	ether	carboxylic acid	sulfate	sulfone
Nicotinamide	thiocyanate	*bromine		hydroxamic acid	cyano	carboxamide
Nicotinamide	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Nicotinic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Nicotinic Acid	thiocyanate	*bromine		hydroxamic acid	cyano	carboxamide
Orotic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Orotic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Oxalic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Palmitic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Pantoic acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Pantoic acid	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester
Pantoic acid	carboxylic acid	nitro	sulfone	aniline		
Phenylalanine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Phenylalanine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Piperazine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Procaline	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone

TABLE II

[illegible]

TABLE II

Co-crystal Former			thiourea	iodine	
Isoleucine	N-SO ₂		thiourea	iodine	
Lactobionic acid	N-SO ₂		thiourea	iodine	
Lactobionic acid					
Lactobionic acid					
Lauric acid	N-SO ₂		thiourea	iodine	
Leucine	N-SO ₂		thiourea	iodine	
Leucine	N-SO ₂		thiourea	iodine	
Lysine	N-SO ₂		thiourea	iodine	
Lysine	N-SO ₂		thiourea	iodine	
Maleic	N-SO ₂		thiourea	iodine	
Malic Acid	N-SO ₂		thiourea	iodine	epoxide
Malic Acid	N-SO ₂		thiourea	iodine	
Malonic	N-SO ₂		thiourea	iodine	
Mandelic Acid	N-SO ₂		thiourea	iodine	epoxide
Mandelic Acid	N-SO ₂		thiourea	iodine	
Methionine	N-SO ₂		thiourea	iodine	
Methionine	N-SO ₂		thiourea	iodine	
Methionine					
Nicotinamide	dithiadiazocyclopentadienyl				
Nicotinamide	N-SO ₂		thiourea	iodine	epoxide peroxide
Nicotinic Acid	N-SO ₂		thiourea	iodine	
Nicotinic Acid	dithiadiazocyclopentadienyl				
Orotic acid	N-SO ₂		thiourea	iodine	
Orotic acid	N-SO ₂		thiourea	iodine	epoxide peroxide
Oxalic acid	N-SO ₂		thiourea	iodine	
Palmitic acid	N-SO ₂		thiourea	iodine	
Pamolic acid	N-SO ₂		thiourea	iodine	
Pamolic acid					
Pamolic acid					
Phenylalanine	N-SO ₂		thiourea	iodine	
Phenylalanine	N-SO ₂		thiourea	iodine	
Piperazine	N-SO ₂		thiourea	iodine	
Procaine	N-SO ₂		thiourea	iodine	

TABLE II

Co-crystal Former		Interacting Group					
Co-crystal Former	Functional Group	alcohol	ketone	thiol	amide	amine	aniline
Proline	Ketone	alcohol			amide	amine	aniline
Proline	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Proline	Amine	alcohol	ketone	thiol	amide	amine	aniline
p-Toluenesulfonic acid	Sulfonic Acid	pyridine	ketone	aldehyde	ether	ester	amide
	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
	Amine	alcohol	ketone	thiol	amide	amine	aniline
Pyridoxamine	Pyridine	*alcohol		*	*amide	nitro	*amine
Pyridoxine (4-Pyridoxic Acid)	Pyridine	*alcohol	pyridinium	*	*amide	nitro	*amine
Pyridoxine (4-Pyridoxic Acid)	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Pyroglutamic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Pyroglutamic acid	Lactam	alcohol	ketone	thiol	amide	amine	aniline
Quercetin	Ketone	alcohol		thiol	amide	amine	aniline
Quercetin	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Quercetin	Ether	aromatic-N	amide	amine	aromatic_s	Sp2 amine	sulfoxide
Resveratrol	Ketone	alcohol		thiol	amide	amine	aniline
Resveratrol	Phenol	amine	amide	sulfoxide	n	pyridine	cyano
Saccharin	Amide	alcohol	ketone	thiol	amide	amine	aniline
Saccharin	Ketone	alcohol		thiol	amide	amine	aniline
Saccharin	Sulfoxide	pyridine	ketone	aldehyde	ether	ester	amide
	Amine	alcohol	ketone	thiol	amide		aniline
	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Salicylic Acid	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Salicylic Acid, 4-amino	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Salicylic Acid, 4-amino	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Salicylic Acid, 4-amino	Amine	alcohol	ketone	thiol	amide	amine	aniline
Sebacic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Serine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Serine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Serine	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Stearic acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline

TABLE II

Co-crystal Former	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Procaine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Proline	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
p-Toluenesulfonic acid	Carboxylic Acid	amine	metals	thioether		sulfate	alcohol
Pyridoxamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Pyridoxamine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Pyridoxamine	*Carboxylic Acid	*sulfonamide	*ketone	ether	triazole	ammonium	oxime
Pyridoxine	*Carboxylic Acid	*sulfonamide	*ketone	ether	triazole	ammonium	oxime
Pyridoxine (4-Pyridoxic Acid)	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Pyroglutamic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Pyroglutamic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Quercetin	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Quercetin	aldehyde	alcohol	alcohol		ester	ether	chlorine
Quercetin	chlorate	chlorine		cyano	ester	amine	nitrate
Resveratrol	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Resveratrol	aldehyde		alcohol		ester	ether	chlorine
Saccharin	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Saccharin	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Saccharin	Carboxylic Acid	amine	metals	thioether		sulfate	alcohol
Saccharin	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Salicylic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Salicylic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Salicylic Acid, 4-amino	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Salicylic Acid, 4-amino	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	metals
Salicylic Acid, 4-amino	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Sebacic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Serine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Serine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Serine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Stearic acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid

TABLE II

Co-crystal Former	metals	aldehyde	ester	ether	cyano	uran	bromine
Procaine	metals	aldehyde	ester	ether	cyano	uran	bromine
Proline	metals	aldehyde	ester	ether	cyano	uran	bromine
Proline	metals	aldehyde	ester	ether	cyano	uran	bromine
p-Toluenesulfonic acid							
Pyridoxamine	metals	aldehyde	ester	ether	cyano	uran	bromine
Pyridoxamine	metals	aldehyde	ester	ether	cyano	uran	bromine
Pyridoxamine	*chlorine		thiol	n-heterocyclic ring	thionedisulfide	iodine	hydrazone
Pyridoxine (4-Pyridoxic Acid)	*chlorine		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	hydrazone
Pyridoxine (4-Pyridoxic Acid)	metals	aldehyde	ester	ether	cyano	uran	bromine
Pyroglutamic acid	metals	aldehyde	ester	ether	cyano	uran	bromine
Pyroglutamic acid	metals	aldehyde	ester	ether	cyano	uran	bromine
Quercetin	metals	aldehyde	ester	ether	cyano	uran	bromine
Quercetin	fluorine	bromine	iodine	ketone	sulfonic acid	phosphate	phosphonic acid
Quercetin	bromine	aldehyde	ketone	peroxide	epoxide		heterocyclic-S
Resveratrol	metals	aldehyde	ester	ether	cyano	uran	bromine
Resveratrol	fluorine	bromine	iodine	ketone	sulfonic acid	phosphate	phosphonic acid
Saccharin	metals	aldehyde	ester	ether	cyano	uran	bromine
Saccharin	metals	aldehyde	ester	ether	cyano	uran	bromine
Saccharin							
Saccharin	metals	aldehyde	ester	ether	cyano	uran	bromine
Salicylic Acid	metals	aldehyde	ester	ether	cyano	uran	bromine
Salicylic Acid	metals	aldehyde	ester	ether	cyano	uran	bromine
Salicylic Acid, 4-amino	metals	aldehyde	ester	ether	cyano	uran	bromine
Salicylic Acid, 4-amino	aldehyde	ester	ether	cyano		bromine	chloride
Salicylic Acid, 4-amino	metals	aldehyde	ester	ether	cyano	uran	bromine
Sebacic acid	metals	aldehyde	ester	ether	cyano	uran	bromine
Serine	metals	aldehyde	ester	ether	cyano	uran	bromine
Serine	metals	aldehyde	ester	ether	cyano	uran	bromine
Serine	metals	aldehyde	ester	ether	cyano	uran	bromine
Stearic acid	metals	aldehyde	ester	ether	cyano	uran	bromine

TABLE II

[illegible]

TABLE II

[illegible]

TABLE II

Co-crystal Former					
Procaine	N-SO ₂	thiourea	iodine		
Proline	N-SO ₂	thiourea	iodine		
Proline	N-SO ₂	thiourea	iodine		
p-Toluenesulfonic acid					
Pyridoxamine	N-SO ₂	thiourea	iodine	epoxide	
Pyridoxamine	N-SO ₂	thiourea	iodine		
Pyridoxamine	dithiadiazocyclopentadienyl				
Pyridoxine (4-Pyridoxic Acid)	dithiadiazocyclopentadienyl				
Pyridoxine (4-Pyridoxic Acid)	N-SO ₂	thiourea	iodine	epoxide	
Pyroglutamic acid	N-SO ₂	thiourea	iodine		
Pyroglutamic acid	N-SO ₂	thiourea	iodine	epoxide	peroxide
Quercetin	N-SO ₂	thiourea	iodine		
Quercetin					
Quercetin					
Resveratrol	N-SO ₂	thiourea	iodine		
Resveratrol					
Saccharin	N-SO ₂	thiourea	iodine	epoxide	peroxide
Saccharin	N-SO ₂	thiourea	iodine		
Saccharin					
Saccharin	N-SO ₂	thiourea	iodine		
Salicylic Acid	N-SO ₂	thiourea	iodine		
Salicylic Acid	N-SO ₂	thiourea	iodine		
Salicylic Acid, 4-amino	N-SO ₂	thiourea	iodine	epoxide	
Salicylic Acid, 4-amino					
Salicylic Acid, 4-amino	N-SO ₂	thiourea	iodine		
Sebacic acid	N-SO ₂	thiourea	iodine		
Serine	N-SO ₂	thiourea	iodine		
Serine	N-SO ₂	thiourea	iodine		
Serine	N-SO ₂	thiourea	iodine	epoxide	
Stearic acid	N-SO ₂	thiourea	iodine		

TABLE II

Co-crystal Former	Co-crystal Functional Group	Interacting Group					
Succinic Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Tartaric Acid	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Threonine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Threonine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Threonine	alcohol	alcohol	ketone	thiol	amide	amine	aniline
Tris	Amine	alcohol	ketone	thiol	amide	amine	aniline
Tris	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Tryptophan	Amine	alcohol	ketone	thiol	amide	amine	aniline
Tryptophan	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Tryptophan	Indole	*alcohol	pyridinium	*	*amide	nitro	*amine
Tyrosine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Tyrosine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Tyrosine	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Urea	Ketone	alcohol	ketone	thiol	amide	amine	aniline
Urea	Amine	alcohol	ketone	thiol	amide	amine	aniline
Urea	Amide	alcohol	ketone	thiol	amide	amine	aniline
Valine	Amine	alcohol	ketone	thiol	amide	amine	aniline
Valine	Carboxylic Acid	alcohol	ketone	thiol	amide	amine	aniline
Vitamin K5	Amine	alcohol	ketone	thiol	amide	amine	aniline
Vitamin K5	Alcohol	alcohol	ketone	thiol	amide	amine	aniline
Xylitol	Alcohol	alcohol	ketone	thiol	amide	amine	aniline

TABLE II

Co-crystal Former	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Succinic Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Tartaric Acid	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Threonine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Threonine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxylic acid
Threonine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Tris	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Tris	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Tryptophan	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Tryptophan	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Tryptophan	*carboxilic acid	*sulfonamide	*ketone	ether	triazole	ammonium	oxime
Tyrosine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Tyrosine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Tyrosine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Urea	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Urea	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Urea	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Valine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Valine	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Vitamin K5	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	carboxilic acid
Vitamin K5	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid
Xylitol	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	Carboxylic Acid

TABLE II

Co-crystal Former	metals	aldehyde	ester	ether	cyano	furan	bromine
Succinic Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Tartaric Acid	metals	aldehyde	ester	ether	cyano	furan	bromine
Threonine	metals	aldehyde	ester	ether	cyano	furan	bromine
Threonine	metals	aldehyde	ester	ether	cyano	furan	bromine
Threonine	metals	aldehyde	ester	ether	cyano	furan	bromine
Tris	metals	aldehyde	ester	ether	cyano	furan	bromine
Tris	metals	aldehyde	ester	ether	cyano	furan	bromine
Tryptophan	metals	aldehyde	ester	ether	cyano	furan	bromine
Tryptophan	metals	aldehyde	ester	ether	cyano	furan	bromine
Tryptophan	*chlorine		thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	hydrazone
Tyrosine	metals	aldehyde	ester	ether	cyano	furan	bromine
Tyrosine	metals	aldehyde	ester	ether	cyano	furan	bromine
Tyrosine	metals	aldehyde	ester	ether	cyano	furan	bromine
Urea	metals	aldehyde	ester	ether	cyano	furan	bromine
Urea	metals	aldehyde	ester	ether	cyano	furan	bromine
Urea	metals	aldehyde	ester	ether	cyano	furan	bromine
Valine	metals	aldehyde	ester	ether	cyano	furan	bromine
Valine	metals	aldehyde	ester	ether	cyano	furan	bromine
Vitamin K5	metals	aldehyde	ester	ether	cyano	furan	bromine
Vitamin K5	metals	aldehyde	ester	ether	cyano	furan	bromine
Xylitol	metals	aldehyde	ester	ether	cyano	furan	bromine

TABLE II

Co-crystal Former						
Succinic Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tartaric Acid	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Threonine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Threonine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Threonine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tris	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tris	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tryptophan	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tryptophan	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tryptophan	thiocyanate	*bromine		hydroxamic acid	cyano	carboxamide
Tyrosine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tyrosine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Tyrosine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Urea	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Urea	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Urea	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Valine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Valine	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Vitamin K5	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Vitamin K5	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone
Xylitol	chlorine	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone

TABLE II

Co-crystal Former							
Succinic Acid	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tartaric Acid	phosphate ester		fluorine	carbamate	imidazole	BF4	
Threonine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Threonine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Threonine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tris	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tris	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tryptophan	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tryptophan	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tryptophan	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine	acetate thione
Tyrosine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tyrosine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Tyrosine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Urea	phosphate ester		fluorine	carbamate	imidazole	BF4	
Urea	phosphate ester		fluorine	carbamate	imidazole	BF4	
Urea	phosphate ester		fluorine	carbamate	imidazole	BF4	
Valine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Valine	phosphate ester		fluorine	carbamate	imidazole	BF4	
Vitamin K5	phosphate ester		fluorine	carbamate	imidazole	BF4	
Vitamin K5	phosphate ester		fluorine	carbamate	imidazole	BF4	
Xylitol	phosphate ester		fluorine	carbamate	imidazole	BF4	

TABLE II

Co-crystal Former					
Succinic Acid	N-SO ₂	thiourea	iodine		
Tartaric Acid	N-SO ₂	thiourea	iodine		
Threonine	N-SO ₂	thiourea	iodine		
Threonine	N-SO ₂	thiourea	iodine		
Threonine	N-SO ₂	thiourea	iodine	epoxide	
Tris	N-SO ₂	thiourea	iodine		
Tris	N-SO ₂	thiourea	iodine	epoxide	
Tryptophan	N-SO ₂	thiourea	iodine		
Tryptophan	N-SO ₂	thiourea	iodine		
Tryptophan	dithiadiazocyclopentadienyl				
Tyrosine	N-SO ₂	thiourea	iodine		
Tyrosine	N-SO ₂	thiourea	iodine		
Tyrosine	N-SO ₂	thiourea	iodine	epoxide	
Urea	N-SO ₂	thiourea	iodine		
Urea	N-SO ₂	thiourea	iodine		
Urea	N-SO ₂	thiourea	iodine	epoxide	peroxide
Valine	N-SO ₂	thiourea	iodine		
Valine	N-SO ₂	thiourea	iodine		
Vitamin K5	N-SO ₂	thiourea	iodine		
Vitamin K5	N-SO ₂	thiourea	iodine	epoxide	
Xylitol	N-SO ₂	thiourea	iodine	epoxide	

TABLE III







Functional Group	Functional Group Structure	Interacting Group						
pyridine		*alcohol	pyridinium	*amide	nitro		*amine	
imidazole		imidazole	chlorine	acetamide	carboxylate		thione	
Hydroxamic acid		hydroxamic acid	alcohol	phosphinic ester	alkane		pyridine	
peroxide	$R-O-OH$	ester	peroxide	amide	ether		alkane	
epoxid		alkane	bromine	alcohol	ester		epoxide	
thioester		aromatic	thioester	alkane	sulfamide		hydroxy	
thioketon		alkane	thioketone	ketone	SULFAMIDE		AMINE	

TABLE III

Functional Group			*carboxylic acid*	*sulfonamide	*ketone	ether		triazole	alkane	ammonium	oxime	*chlorine
pyridin			*									
imidazole	nitr	cyanamide	ketone	cyno				carboxilic acid	alcohol	alkane	thiol	amine
Hydroxamic acid	amide	sulfonamide	carboxylate	phosphine	amine							
peroxide	N-heterocycle	aromatic	alcohol	pyrimidinedione				thiazole	peroxy acid	ketone		carboxilic acid
poxide	amide	alkene	hydrazone	aromatic	thioether			ketone	aldehyde		chlorine	carboxilic acid
thio st r	bromine	iodine	amide	cyno	thio ketone			amide			chlorine	nitro
thio ketone	thiol	sulfide	oxo	chlorine	cbromine			AROMATIC alkene				iodine

TABLE III

Functional Group									
pyridine	alkyne	thiol	n-heterocyclic ring	thionedisulfide	pyrrolidindione	iodine	hydrazone	thiocyanate	*bromine
imidazole	phosphinic acid hemihydrate	chlorine	sulfonyl	sulfoxide	amide	fluorine	sulfonate ester		
Hydroxamic acid									
peroxide	azide	phosphine oxide	sulfonamide						
epoxide	alkyne		ammonium	fluorine	nitro	amine	cyano		
thioester									
thio ketone	AZOXY								

TABLE III

Functional Group	aromatic	hydroxamic acid	cyano	carboxamide	*sulfonic acid	*phosphoric acid	N-oxide	ester	ether	fluorine
pyridine										
imidazole										
Hydroxamic acid										
per xld										
epoxid										
thioester										
thl keton										

TABLE III

Functional Group	acetate	thione	dithiadiazocyclopentadienyl					
pyridin								
imidazole								
Hydroxamic acid								
peroxide								
epoxide								
thioester								
thio ketone								

TABLE III








Functional Group	Functional Group Structure	Interacting Group					
nitrate ester		aromatic	amide	alkane	chlorine	nitrate ester	
Thiophosphate st r-O			imidazole	cyclic amide			
Phosphate ester		amine	alcohol	phosphate ester	aromatic N- ring	pyridine	
Thioketon		aromatic	potassium	epoxide	n-oxide	cyano	
Ketone		sulfone	ketone	thiol	amide	amine	
Aldehyde		alcohol	ketone	thiol	amide	amine	
Thiol		carboxylic acid	sodium	aldehyde	ketone	aromatic-N	

TABLE III

[illegible]

TABLE III

[illegible]

TABLE III

[illegible]

TABLE III

[illegible]

TABLE III

Functional Group	Functional Group Structure	Interacting Group						
Alcohol	$R-OH$	alcohol	ketone	thiol	amide	amine		
Thioether	$R-S-R$	aromatic-N	amide	amine	aromatic_s	Sp2 amine		
Ether	$R-O-R$	aromatic-N	amide	amine	aromatic_s	Sp2 amine		
Cyanamide	$N-C\equiv N$	cyano	amine	potassium	aromatic-N	bromine		
Thiocyanate	$-S-C\equiv N$	aromatic-S	ester	ether				
sp2 amine	$R_2C=NH$	thioether	ether	metals	MoOCl4	BF4		
Amine primary	$R-NH_2$	alcohol	ketone	thiol	amide	amine		

TABLE III

Functional Group									
Alcohol	aniline	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxylic acid
Thioether	sulfoxide	chlorate	chlorine	alkyne	cyano	ester	amine	nitro	nitrate
Ether	sulfoxide	chlorate	chlorine	alkyne	cyano	ester	amine	nitro	nitrate
Cyanamide	sodium	imidazole	ether	n-heterocyclic	alcohol	cesium	Ag		
Thiocyanate									
sp ² amine	bromine	chlorine		Sp ² amine	sulfate	Osmium			
Amine primary	aniline	phenol	phosphate	sulfate	sulfone	nitrate	pyridine	aromatic	carboxylic acid

TABLE III

Functional Group	metals	aldehyde	ester	ether	cyano	furan	bromine	chlorine
Alcohol								
Thioether	bromine	aldehyde	ketone	peroxide	epoxide	Ag	heterocyclic-S	iodine
Eth r	bromine	aldehyde	ketone	peroxide	epoxide	Ag	heterocyclic-S	iodine
Cyanamide								
Thiocyanat								
sp2 amin								
Amine primary	metals	aldehyde	ester	ether	cyano	furan	bromine	chlorine

TABLE III

Functional Group										
Alcohol	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	fluorine	carbamate	imidazole	
Thioether	ester	ether	carboxylic acid	sulfate	sulfone	alkane	alcohol	phosphate		
Ether	ester	ether	carboxylic acid	sulfate	sulfone	alkane	alcohol	phosphate	cyanamide	
Cyanamide										
Thiocyanate										
sp ² amine										
Amine primary	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	fluorine	carbamate	imidazole	

TABLE III

Functional Group	BF4	alkane	aromatic	N-SO2	thiourea	iodine	epoxide
Alcohol							
Thioether							
Ether							
Cyanamide							
Thiocyanate							
sp2 amine							
Amin primary	BF4	alkane	aromatic	N-SO2	thiourea	iodine	

TABLE III






Functional Group	Functional Group Structure	Interacting Group						
Amine secondary	R_2-NH	alcohol	ketone	thiol	amide	amine		
Amine tertiary	R_3-N	alcohol	ketone	thiol	amide	amine		
Amide		alcohol	ketone	thiol	amide	amine		
Sulfonic acid		pyridine	ketone	aldehyde	ether	ester		
Phosphinic acid		alkane	potassium	lithium	n-heterocyclic	oxime		
Phosphonic acid		alkane	potassium	lithium	n-heterocyclic	oxime		
Carboxylic acid		alcohol	ketone	thiol	amide	amine		

TABLE III

[illegible]

TABLE III

Functional Group											
Amine secondary	metals	aldehyde	ester		ether		cyano		furan	bromine	chlorine
Amine tertiary	metals	aldehyde	ester		ether		cyano		furan	bromine	chlorine
Amid	metals	aldehyde	ester		ether		cyano		furan	bromine	chlorine
Sulfonic acid											
Phosphinic acid											
Phosphonic acid	aniline	ether	phosphonic acid		aromatic-N		ketone		aldehyde	imidazole	
Carboxylic acid	metals	aldehyde	ester		ether		cyano		furan	bromine	chlorine

TABLE III

Functional Group	s-heterocyclic	pyridine	cyano	n-heterocyclic	ketone	phosphate ester	fluorine	carbamate	imidazole
Amine secondary									
Amine tertiary									
Amide									
Sulfonic acid									
Phosphinic acid									
Phosphonic acid									
Carboxylic acid									

TABLE III

Functional Group									
Amine secondary	BF ₄	alkane	aromatic	N-SO ₂	thiourea	iodine			
Amine tertiary	BF ₄	alkane	aromatic	N-SO ₂	thiourea	iodine			
Amide	BF ₄	alkane	aromatic	N-SO ₂	thiourea	iodine	epoxide	peroxide	
Sulfonic acid									
Phosphinic acid									
Phosphonic acid									
Carboxylic acid	BF ₄	alkane	aromatic	N-SO ₂	thiourea	iodine			

TABLE III




Functional Group	Functional Group Structure	Interacting Group					
Sulfate ester			pyridine	ketone	aldehyde	ether	ester
Oxime	$C=N-OH$		alcohol	alkane	amine	amide	ether
Nitrile	$-C\equiv N$		metal	ketone	phenol	alcohol	
Diazo	$RH_2C-N=N-CH_2R$		Oxime				
Nitro	NO_2		pyridine	ketone	aldehyde	ether	ester
S-het royclic ring			alcohol	thio ketone	thio ether	s-heterocyclic	ketone
Thiophen			chlorine	fluorine	amide	ketone	NO

TABLE III

[illegible]

TABLE III

Functional Group									
Sulfate ester									
Oxime									
Nitrile									
Diazo									
Nitro									
S-heterocyclic ring									
Thiophene									

TABLE III






Functional Group	Functional Group Structure	Interacting Group					
N-heterocyclic ring		alcohol	thioether	thioether	s-heterocyclic ketone	ketone	
O-het rocyclic ring		alcohol	thioether	thioether	s-heterocyclic ketone	ketone	
Pyrrole		chlorine	fluorine	amide	ketone	NO	
Furan		s-heterocyclic					
Epoxide		bromine	alcohol	alkane	ester	aniline	
Peroxide	$R-O-OH$	Nitro	amide	aniline			

TABLE III

[illegible]

TABLE III

Functional Gr up										
N-heterocyclic ring	amide	iodine	carboxylic acid	sodium	cyano	chloride	aldehyde			
O-heterocyclic ring	amide	iodine	carboxylic acid	sodium	cyano	chloride	aldehyde			
Pyrrole	bromine	oxime	alcohol	phenol	ester	ether				
Furan										
Epoxid										
Peroxide										

TABLE III

[illegible]

TABLE III

Functional Group								
N-heterocyclic ring								
O-heterocyclic ring								
Pyrrol								
Furan								
Epoxide								
Peroxide								

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
(-)-amlodipine	3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, (S)- [CAS]	103129-82-4	WO 9310779	Antihypertensive, other
(-)-halofenate	(-)-Benzenecacetic acid, 4-chloro- α -(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester		US 6262118	Antidiabetic
(R)-salbutamol	1,3-Benzenedimethanol, α -(1-((1,1-dimethylethyl)amino)methyl)-4-hydroxy- [CAS]			Formulation, modified-release, ≤ 24 hr
(R)-salbutamol	1,3-Benzenedimethanol, α -(1-((1,1-dimethylethyl)amino)methyl)-4-hydroxy- [CAS]	34391-04-3	US 5547994	Antiasthma
(R,R)-formoterol	Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)- (R,R*)- [CAS]	67346-49-0	US 5795564	Antiasthma
(S)-doxazosin	(S)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-yl)carbonyl]piperazine	70918-18-2	WO 9409785	Prostate disorders
(S)-flouxetine	Benzenepropanamide, N-methyl- γ -amino-(4-(trifluoromethyl)phenoxy)- (S)			Antimigraine
(S)-oxybutynin	Benzenecacetic acid, α -(cyclohexyl)- α -(hydroxy-4-(diethylamino)-2-butynyl) ester, (S)- [CAS]	119618-22-3		Urological
1,2-Naphthoquinone		524-42-5		
17 α -Hydroxyprogesterone		68-96-2		
17-Methyltestosterone		58-18-4		
195mPt-cisplatin	Platinum-195m, diamminedichloro, (SP-4-2)-		US 6074626	Anticancer, alkylating
1 α -Hydroxycholecalciferol		41294-56-8		
1-Naphthyl Salicylate		550-97-0		

TABLE IV

Example of Indication
Hypertension, general
Diabetes, Type II
Asthma
Asthma
Asthma
Benign prostatic hyperplasia
Migraine
Incontinence
Cancer, liver

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
1-Naphthylamine-4-sulfonic Acid		84-86-6		
1-Theobromineacetic Acid		5614-56-2		
2,4,6-Tribromo-m-cresol		4619-74-3		
2,6-Diamino-2'-butyloxy-3,5'-azopyridine		617-19-6		
21-Acetoxyprogesterone		566-78-9		
2-Amino-4-picoline		695-34-1		
2-Aminothiazole		96-50-4		
2-ethoxybenzoic acid	2-Ethoxybenzoic acid		DE 5134001	Anaesthetic, NSAID
2-Naphthol		135-19-3		
2-Naphthyl Benzoate		93-44-7		
2-Naphthyl Lactate		93-43-6		
2-Naphthyl Salicylate		613-78-5		
2-p-Sulfanilylanilinoethanol		80-02-4		
2-Thiouracil		141-90-2		
3',3'',5',5''-Tetrabromophenolphthalein		76-62-0		
3-Amino-4-hydroxybutyric Acid		589-44-6		
3-Bromo-d-camphor		76-29-9		
3-Hydroxycamphor		10373-81-6		
3-O-Lauroylpyridoxol Diacetat		1562-13-6		
3-Pentadecylcatechol		492-89-7		
3-Quinuclidinol		1619-34-7		
4,4'-Oxydi-2-butanol		821-33-0		

TABLE IV

API Gen. ric Nam	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
4,4'-Sulfinyldianiline		119-59-5		
4-Amino-3-hydroxybutyric Acid		352-21-6		
4-Amino-3-phenylbutyric Acid		1078-21-3		
4-aminosalicylic acid	Benzoic acid, 4-amino-2-hydroxy- [CAS]	65-49-6		GI inflammatory/bowel disorders
4-Chlor -m-cresol		59-50-7		
4-Hexylresorcinol		136-77-6		
4-Salicyloylmorpholine		3202-84-4		
5-Nitro-2'-propoxycetanilide		553-20-8		
5-aminolevulinic acid, DUSA	Pentanoic acid, 5-amino-4-oxo- [CAS]	106-60-5		Dermatological
5-azacitidine	1,3,5-Triazin-2(1H)-one, 4-amino-1,8-D-ribofuranosyl- [CAS]	320-67-2		Anticancer, antimetabolite
5-Bromosalicylhydroxamic Acid		5798-94-7		
5F-DF-203	2-(4-Amino-3-methylphenyl)-6-hydroxybenzothiazole			Anticancer, other
5-FU	2,4(1H,3H)-Pyrimidin-5-ylidene, 5-fluoro [CAS]	51-21-8		Formulation, parenteral, targeted
5-HT3 antagonists			US 6037360	Male sexual dysfunction
6-Azauridine		54-25-1		
6-Mercaptopurine		50-44-2		
8-Hydroxyquinoline		148-24-3		
9-Aminocamptothecin		91421-43-1		
A-151892	N-[2-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl] amide			Urological
α -Antitrypsin		9041-92-3		

TABLE IV

Example of Indication
Inflammatory bowel disease
Keratosis
Myelodysplastic syndrome
Cancer, breast
Cancer, general
Premature ejaculation
Overactive bladder

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
A-5021	6H-Purin-6-one, 2-amino-9-(((1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl)methyl)-1,9-dihydro- [CAS]	145512-85-2		Antiviral, other
Abacavir	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-, sulfate (2:1) (salt) [CAS]	136470-78-5		
abacavir sulfate		136470-78-5 188062-50-2	EP 434450	Antiviral, anti-HIV
abapertone hydrochloride	7-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one hydrochloride			
abapertone hydrochloride		183849-43-6	WO 9632389	Neuroleptic
abarelix	D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylatyl)-L-lysyl-L-prolyl- [CAS]	183552-38-7	US 5843902	Anticancer, hormonal
Abciximab		143653-53-6		
Abecarnil		111841-85-1		
abelimus		169147-32-4	US 5552391	Immunosuppressant
abiraterone	Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (9S)-, [CAS]	154228-18-2	GB 2265624	Anticancer, hormonal
α -Bisabolol		515-69-5		
ABLC	Amphotericin B [CAS]	1397-89-3		Formulation, conjugate, carbohydrate
ABT-751	Benzenesulfonamide, N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy- [CAS]	30652-87-0		
		141430-65-1	EP 472053	Anticancer, other
AC-5216	N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide			
Acadesine		2627-69-2		Anxiolytic
acamprosate	1-Propanesulfonic acid, 3-(acetylamino)- [CAS]	77337-76-9	GB 2051789	Dependence treatment
Acamprosate		77337-73-6		

TABLE IV

Example of Indication
Infection, varicella zoster virus
Infection, HIV/AIDS
Schizophrenia
Cancer, prostate
Lupus erythematosus, systemic
Cancer, prostate
Infection, Candida, general
Cancer, general
Anxiety, general
Addiction, alcohol

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Acarbose	7H-Purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-compd. with trans-4-[[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol (1:1) [CAS]	56180-94-0		
acebuprophylline		96989-76-3	DE 3425007	Antiasthma
acebutolol	Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (+)-[CAS]	34381-68-5 37517-30-9	US 3726819	Antihypertensive, adrenergic
Acacetinide		32795-44-1		
Acacarbromal		77-66-7		
aceclofenac	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester [CAS]	89796-99-6	EP 119932	Anti-inflammatory
Acetadapson		77-46-3		
Acetiasulfone		80-03-5		
Acetylfin		652-37-9		
Acetylutamide		2490-97-3		
acetylutamide	Aluminum, pentakis(N2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]	12607-92-0	DE 2127176	Antitumor
acemetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester [CAS]	53164-05-9	US 3910952	Anti-inflammatory
Acemetacin		53164-05-9		
Acenocoumarol		152-72-7		
Acetal		105-57-7		
Acetamidoeugenol		305-13-5		
Acetaminophen		103-90-2		
Acetaminosalol		118-57-0		
Acetanilide		103-84-4		
Acetarsone		97-44-9		
Acetazolamide		59-86-5		
Ac tiamine		299-89-8		
Ac tohexamide		968-81-0		
Acetohydroxamic Acid		546-88-3		
Ac toph nazine		2751-68-0		

TABLE IV

Exempl of Indication
Asthma
Pain, musculoskeletal
Ulcer, GI, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Acetophenone		98-86-2		
Acetosulfone		128-12-1		
Acetoxolone		6277-14-1		
acetoxolone	Cloran-12-en-30-ole acid, 3B-hydroxy-11-oxo-acetate, aluminium salt [CAS]	28728-34-5 6277-14-1	US 3784618	Antitumor
Acetrisoate		129-63-5		
Acetyl				
Sulfamethoxypyrazine		3590-05-4		
Acetylcarnitine		14992-62-2		
Acetylcholine		66-23-9		
Acetylcholine		60-31-1		
Acetylcysteine		616-91-1		
Acetyltyrosine		149-90-6		
Monoethanolamine				
Acetylphenetidine		13402-08-9		
acetylsalicylic acid, Eurand	Benzolc acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, optimized, microencapsulate
Acetylsalicylsalicylic Acid		530-75-6		
α -Chloralose		15879-93-3		
aclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- [CAS]	59277-88-3		Formulation, dermal, topical
Acifran		72420-38-3		
acipimox	Pyrazinecarboxylic acid, 5-methyl-, 4-oxide [CAS]	51037-30-0	GB 1381967	Hypolipemic/Antiatherosclerosis
acizanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenylamino]- [CAS]	114607-46-4	EP 256507	Ophthalmological
actretin	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)- [CAS]	55079-83-9	GB 1468401	Antipsoriasis
actarubicin		57576-44-0 75443-99-1	US 3988315	Anticancer, antibiotic
Aclatonium Napadisilicate		55077-30-0		
Aconitine		302-27-2		
Acranil®		1684-42-0		
Acriflavine		8048-52-0		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Acrisorcin		7527-91-5		
acrivastine	2-Propenoic acid, 3-[6-[(1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl], (E,E)-[CAS]	87848-99-5	EP 85959	Antipruritic/inflamm, allergic
acrivastine + pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*,R*)]-, mixt with 2-Propenoic acid, 3-[6-[(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl], (E,E)-			Antiallergic, non-asthma
actagardine derivative	3,3-dimethyl-1-propylamide HCl monoxycarboxamide actagardine			Peptide antibiotic
Actarit		18699-02-0		
ACTH		9002-60-2		
Acyclovir		59277-89-3		
adapalene	2-Naphthalenecarboxylic acid; 6-(4-methoxy-3-tricyclo[3.3.1.1 ^{3,7}]dec-1-ylphenyl)-[CAS]	106685-40-9	EP 199636	Antiacne
Adapalene		106685-40-9		
ADCON-L	GL 402 [CAS]	137802-74-5		Formulation, other
Adefovir		106941-25-7		
adefovir dipivoxil	Propanoic acid, 2,2-dimethyl-, ((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxy)methylene)ester- [CAS]	142340-99-6	EP 205826	Antiviral, other
Adenoscan	6-Amino-9-β-D-ribofuranosyl-9H-purine [CAS]	58-61-7		Imaging agent
Adenosine Triphosphate		56-65-5		
ADEPT, CRT		156079-88-8		Immunoconjugate, other
Adinazolam		37115-32-5		
Adiphenine		64-95-9		
ADL-10-0101			WO 9732857	Analgesic, other
Adrafinil		63547-13-7		
Adrenalone		99-45-6		
Adrenochrome		54-06-8		

TABLE IV

Example of Indication
Rhinitis, allergic, general
Rhinitis, allergic, seasonal
Infection, general
Acne
Fibrosis, epidural
Infection, hepatitis-B virus
Diagnosis, coronary
Cancer, colorectal
Pain, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref erence	Example of Therapeutic Use
adrogolide	Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl- diacetate (ester), hydrochloride (5aR-trans) [CAS]	166591-11-3 171752-56-0	US 5597832	Dependence treatment
AEOL-10150			US 6103714	Neuroprotective
AET		56-10-0		
α -Ethylbenzyl Alcohol		93-54-9		
AF-2259	Benzeneacetic acid, Alpha-methyl-4-(2- methoxypropyl)-, 2-methoxyphenyl-ester [CAS]	66332-77-2	DE 2726435	Anti-inflammatory
Afloqualone		56287-74-2		
AG-041R	1H-Indole-3-acetamide, 1-(2,2- diethoxyethyl)-2,3-dihydro-N-(4- methylphenyl)-3-(((4- methylphenyl)amino)carbonyl)amino)-2- oxo-, (3R)- [CAS]	199800-49-2	WO 9419322	Alimentary/Metabolic, other
AG-2037	N-(5-[2-(2-amino-4(3H)-oxo-5,6,7,8- tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]- 4-methylthieno-2-yl)glutamic acid			Anticancer, antimetabolite
α -Glucose-1-phosphate		59-56-3		
AGN-194310	Benzole acid, 4-((4-(4-ethylphenyl)-2,2- dimethyl-2H-1-benzothiofuran-6-yl)ethynyl) [CAS]	229961-45-9	WO 9709297	Dermatological
agomelatine	Acetamide, N-(2-(7-methoxy-1- naphthalenyl)ethyl)- [CAS]	138112-76-2	EP 447285	Antidepressant
Ahistan		518-61-6		
AHL-157			US 5411972	Hypolipaeamic/Antiatherosclerosis
AIT-034	9H-Purine-9-propanamide, 1,6-dihydro-6- oxo-N-(3-(2-oxo-1-pyrrolidinyl)propyl)- [CAS]	138117-48-3	US 5447939	Cognition enhancer
AIT-202	N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-3-(6- oxo-6,9-dihydro-1H-purin-9- yl)propanamide		WO 9957120	Antidepressant

TABLE IV

Example of Indication
Addiction, cocaine
Unspecified
Inflammation, general
Unspecified
Cancer, general
Psoriasis
Sleep disorder, general
Atherosclerosis
Dementia, senile, general
Unspecified

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
AJ-9677	Acetic acid, ((3-(2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-Indol-7-yloxy)- [CAS]	244081-42-3		Antidiabetic
AJG-049			WO 9733985	Gastroprokinetic
Almaline		12714360		
Alac pril		74258-86-9		
albaconazole	4(3H)-Quinazolinone, 7-chloro-3-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)- [CAS]	187949-02-6	WO 9705131	Antifungal
albendazole	Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester [CAS]	54029-12-8 54965-21-8	GB 1484326	Anthelmintic
Albuterol		18559-94-9		
Albuterol				
Albutoin		830-89-7		
alclufenac	Benzeneacetic acid, 3-chloro-4-(2-propenyloxy)- [CAS]	22131-79-9	GB 1174535	Anti-inflammatory
Alclometasone		67452-97-5		
	Pregna-1,4-diene-3,20-dione, 7-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (7Alpha,11B,16Alpha)- [CAS]			
alclometasone		66734-13-2	US 4124707	Antipruritic/inflam, allergic
Alclometasone				
Alcuronium		23214-96-2		
Aldoxa		5579-81-7		
Aldol		107-89-1		
Ald sterone		52-39-1		
alendronate sodium	Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, monosodium salt- [CAS]	121268-17-5 129318-43-0	GB 2118042	Osteoporosis treatment
Alendronic Acid		66376-36-1		
Alexidine		22573-93-9		
alfacalcidol, Teva	9,10-Secocholesta-5,7,10(19)-triene-1,3-diol, (1Alpha,3B,5Z,7E)- [CAS]	41294-56-8		Osteoporosis treatment
Alfadolone Acetate		23930-37-2		
Alfaxalone		23930-19-0		

TABLE IV

Exempl of Indication
Diabetes, Type II
Motility dysfunction, GI, general
Infection, Candida, general
Infection, helminth, general
Inflammation, dermal
Osteoporosis
Osteodystrophy

TABLE IV

API Gen ric Nam	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Alfentanil		71195-58-9		
alimemprase		259074-76-5		Fibrinolytic
	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-	81403-68-1		
alfuzosin	[CAS]	81403-80-7	GB 2013679	Prostate disorders
	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-	81403-68-1		
alfuzosin, GEOMATRIX	[CAS]	81403-80-7		Formulation, modified-release, other
Algestone		595-77-7		
Algestone Acetophenide		24356-94-3		
Algin		9005-38-3		
Alglucerase		143003-46-7		
Alibendol		26750-81-2		
	(2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide	173334-57-1		Antihypertensive, renin system
aliskiren		5300-03-8		
Alitretinoin				
alitretinoin, Basilea	9-ols retinoic acid			Antipruritic/inflam, allergic
	1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl]methyl]- [CAS]	59338-93-1	GB 1475234	Antiemetic
alizapride		517-88-4		
Alkannin		7527-94-8		
Alkofanone		97-59-6		
Allantoin		52-43-7		
Allobarbitol		315-30-0		
Allopurinol				
allopurinol				
Allyl isothiocyanate		57-06-7		
Allyl strenol		432-60-0		

TABLE IV

Example of Indication
Peripheral vascular disease
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Hypertension, general
Eczema, general
Nausea and vomiting, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
almagate	Magnesium, [carbonato(2-)]heptahydroxy(aluminum)tri-, dihydrate [CAS]	66827-12-1 72526-11-5	US 4447417	Antacid/Antiflatulent
Almagate		66827-12-1		
alminoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-methyl-2-propenyl)amino]- [CAS]	39718-89-3	US 3957850	Analgesic, NSAID
Alminoprofen		39718-89-3		
almitrine	1,3,5-Triazine-2,4-diamine, 6-[4-bis(4-fluorophenyl)methyl]-1-piperazinyl-N,N'-di-2-propenyl-, dimethanesulfonate [CAS]	27469-53-0 29608-49-9	GB 1256513	Respiratory
almotriptan	Pyrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)- [CAS]	154323-57-6	WO 9402460	Antimigraine
Alo -Emodin		481-72-1		
Aloln		5133-19-7		
alosetron	2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one [CAS]	122852-42-0 122852-69-1 132414-02-9	EP 306323	GI inflammatory/bowel disorders
alovudine	Thymidine, 3'-deoxy-3'-fluoro- [CAS]	25526-93-6	EP 470355	Antiviral, anti-HIV
Aloxiprin		9014-67-9		
Alpha-1 protease Inhibitor, Nektar			US 5780014	Formulation, inhalable, topical
Alpha-dihydroergocryptine, Pol	Ergocryptine, 9,10-dihydro-methanesulfonate (salt)- [CAS]	29261-93-6		Formulation, other
Alphaprodline		77-20-3		
Alpid m		82626-01-5		
Alpiropride		81982-32-3		
alprazolam	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl- [CAS]	28981-97-7	US 3987052	Anxiolytic
aprazolam, I2R	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl- [CAS]	28981-97-7		Formulation, modified-release, immediate
Alprenolol		13655-52-2		
alsacide	Alpha 1-17-Corticotropin, 1- β -alanine-17-[N-(4-aminobutyl)-L-lysineamide]- [CAS]	34765-96-3	US 3748704	ACTH

TABLE IV

Exempl of indication
Bronchitis, chronic
Migraine
Irritable bowel syndrome
Infection, HIV/AIDS
Emphysema, alpha-1 antitrypsin deficiency
Parkinson's disease
Anxiety, general
Panic disorder
Arthritis, rheumatoid

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ALT-711	Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide [CAS]	181089-80-7	WO 9622095	Symptomatic antidiabetic
Althiazide		5588-16-9		
allicline	Pyridine, 3-ethynyl-5-(2S)-1-methyl-2-pyrolidinyl- [CAS]	179120-92-4	US 5594011	Antiparkinsonian
altretamine	1,3,5-Triazine-2,4,6-triamine, N,N,N',N'',N'''-hexamethyl- [CAS]	645-05-6	US 3424752	Anticancer, alkylating
aluminum chloride hexahydrate	Aluminum chloride, hexahydrate	7446-70-0		
Aluminon		7784-13-6		Dermatological
Aluminum Acetate Solution		569-58-4		
Aluminum Chlorate		8006-13-1		
Aluminum Hydroxychloride		15477-33-5		
Aluminum Potassium Sulfate		1327-41-9		
Aluminum Sodium Sulfate		10043-67-1		
Alusulf		10102-71-3		
Alverine	Aluminum hydroxide sulfate (Al(OH)17(SO4)2), dodecahydrate [CAS]	61115-28-4	DE 2510663	Urological
alvimopan	Glycine, N-[(2S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl- [CAS]	150-59-4		
alvocidib	4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, cis-(-)- [CAS]	156053-89-3	EP 657428	GI inflammatory/bowel disorders
ALX-0646		131740-09-5		
AM-24	2,4,6-Trifluorophenol	148426-40-6		Anticancer, other
AM-36	1-Piperazineethanol, 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-Alpha-(4-chlorophenyl)- [CAS]	609-23-4	WO 9506638	Antimigraine
		199467-52-2		GI inflammatory/bowel disorders
				Neuroprotective

TABLE IV

Example of Indication
Hypertension, general
Parkinson's disease
Cancer, ovarian
Hyperhidrosis
Hyperphosphataemia
Ileus
Cancer, renal
Migraine
Crohn's disease
Unspecified

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
AM-477	2-Methoxyoestradiol			Antiasthma
Amantadine		768-84-5		
amanitium	1-Decanaminium, N,N-dimethyl-N-[2- [[[tricyclo[3.3.1.1 ^{3,7} dec-1- ylcarbonyloxy]ethyl]-, bromide [CAS]	58158-77-3	US 4288609	Antifungal
Ambazon		539-21-9		
Amibenonium		115-79-7		
ambrisentan	(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]- 3-methoxy-3,3-diphenylpropanoic acid	177036-94-1		Vasodilator, peripheral
ambroxol	Cyclohexanol, 4-[[[2-amino-3,5- dibromophenyl)methyl]amino]-, trans- [CAS]	18683-91-5 23828-92-4	GB 1178034	COPD treatment
Ambroxol		18683-91-5		
Ambucain		119-29-9		
Ambuphylline		5634-34-4		
Ambuside		3754-19-6		
Ambutonium Bromide		115-51-5		
amcinonide	Pregna-1,4-diene-3,20-dione, 21- (acetyloxy)-16,17- [cyclopentylidenebis(oxy)]-9-fluoro-11- hydroxy-, (11 β ,16 α)- [CAS]	51022-89-6	DE 2437847	Antipsoriasis
AMD-3100	1,4,8,11-Tetraazacyclotetradecane, 1,11- (1,4-phenylenebis(methylene))bis-, octahydrochloride [CAS]	155148-31-5	US 5612478	Haematological
Amdinocillin		32887-01-7		
Amdinocillin Pivoxil		32886-97-8		
amdoxovir	1,3-Dioxolane-2-methanol, 4-(2,6-diamino- 9H-purin-9-yl)- (2R-cis)- [CAS]	145514-04-1	EP 656778	Antiviral, anti-HIV
amelubant	Carbamic acid, ((4-((3-((4-(1-(4- hydroxyphenyl)-1- methyl(ethyl)phenoxy)methyl)phenyl)metho- xy)phenyl)iminomethyl)- ethyl ester [CAS]	346735-24-8	DE 10000907	COPD treatment

TABLE IV

Example of Indication
Asthma
Infection, general
Heart failure
Bronchitis, chronic
Chemotherapy-induced injury, bone marrow, leucopenia
Infection, HIV/AIDS
Chronic obstructive pulmonary disease

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Americaine	Benzenemethanaminium, N,N-dimethyl-N-[2-[2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]-, chloride, mixt. with ethyl 4-aminobenzoate [CAS]	129128-13-8		Formulation, inhalable, other
Amezinium		30578-37-1		
Amfenac		51579-82-9		
Amidephrine		3354-67-4		
Amidinomycin		3572-60-9		
amifostine	Ethanthiol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester)- [CAS]	20537-88-6	EP 131500	Radio/chemoprotective
amiglumide	Penlanoic acid, 5-(dipentylamino)-4-(2-naphthalenylcarbonyl)amino)-5-oxo- (R)- [CAS]	63717-27-1		
amikacin		118363-62-1	WO 8805774	GI inflammatory/bowel disorders
Amiloride		37517-28-5		Formulation, optimized; microencapsulate
Aminacrine		39831-55-5		
		2609-46-3		
amineptine		90-45-9		
Aminitrozoole				
Amino Acid Preparations	Heptanoic acid, 7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]- [CAS]	30272-08-3	US 3758528	Antidepressant
Aminocaproic Acid		57574-09-1		
aminoglutethimide		140-40-9		
Aminoguanidine				
Aminohippurate Sodium	2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl- [CAS]	125-84-8	US 3944671	Anticancer, hormonal
Aminometradine		79-17-4		
Aminopentamide				
Aminophylline				
aminophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1) [CAS]	542-44-4		
Aminopromazine		60-46-8		
		317-34-0		
		317-34-0		Formulation, modified-release, other
		58-37-7		

TABLE IV

Example of Indication
Pain, general
Chemotherapy-induced injury, renal
Pancreatitis
Infection, general
Cancer, breast
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Refer nce	Example of Therapeutic Use
Aminopyrine		58-15-1		
Aminoquinuride		3811-56-1		
Aminorex		2207-50-3		
amiodarone	Methanone, (2-butyl-3-benzofuranyl)[4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl]- [CAS]	1951-25-3 18774-82-4	US 3248401	Antiarrhythmic
Amiphenazole		490-55-1		
Amiprilose		56824-20-5		
artilsulpride	Benzamide, 4-amino-N[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy- [CAS]	71675-95-9	US 4401822	Neuroleptic
Amitriptyline		50-48-6		
amitriptyline+ketamine	1-Propanamine,3-(10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-ylidene)-N,N-dimethyl + cyclohexanone,2-(2-chlorophenyl)-2-(methylamino)			
Amitriptylinoxide		4317-14-0		Formulation, fixed-dose combinations
amlexanox	5H-[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- [CAS]	68302-57-8	US 4299963	Antiasthma
amlodipine	3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester [CAS]	111470-99-6 88150-42-9 88150-47-4	EP 89167	Antianginal
Amiodipine		88150-42-9		
Ammoniacum		3779000		
Ammonium Benzoate		1863-63-4		
Ammonium Mandelate		530-31-4		
Ammonium Salicylate		528-94-9		
Ammonium Valerate		42739-38-8		
Amobarbital		57-43-2		
Amocarzin		36590-19-9		
Amodiaquin		86-42-0		
amorolfine	Morpholine, 4-[3-[4-(1,1-dimethylpropyl)phenyl]-2-methylpropyl]-2,6-dimethyl-, cis- [CAS]	78613-35-1 78613-38-4	EP 24334	Antifungal

TABLE IV.

Example of Indication
Arrhythmia, general
Schizophrenia
Pain, neuropathic
Asthma
Hypertension, general
Infection, fungal, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Amoscanate		26328-53-0		
amosulolol	Benzenesulfonamide, 5-(1'-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl)-2-methyl-, (+/-) [CAS]	70958-86-0 85320-68-9	EP 136103	Antihypertensive, adrenergic
Amotriphene		5585-64-8		
amoxapine	Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1'-piperazinyl)- [CAS]	14028-44-5	GB 1192812	Antidepressant
Amoxapine		14028-44-5		
amoxicillin, Advancis	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6S(S*)]] [CAS]	26787-78-0		Formulation, modified-release, other
amoxicillin, CSL		61336-70-7		Formulation, other
amoxicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6S(S*)]] [CAS]	26787-78-0		Formulation, other
amoxicillin+potassium clavulan		74469-00-4	GB 1508977	Formulation, fixed-dose combinations
AMPAlex	Piperidine, 1-(6-quinoxalinyloxy)- [CAS]	154235-83-3	US 5650409	Psychostimulant
Amphetaamine		300-62-9		
Amphetaminil		17590-01-1		
amphotericin B, BDSI	Amphotericin B [CAS]	1397-89-3		Formulation, optimized, microcapsulate
amphotericin B, InterMune	Amphotericin B compd. with (3B)-cholest-5-en-3-yl hydrogen sulfate (1:1) [CAS]	120895-52-5	US 4822777	Formulation, optimized, liposomes
ampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(phenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6S(S*)]] [CAS]	69-53-4 7177-48-2		Formulation, fixed-dose combinations
Amproxicam		99464-64-9		
Ampligen		38640-92-5		

TABLE IV.

Example of Indication
Hypertension, general
Depression, general
Infection, general
Infection, general
Infection, general
Infection, respiratory tract, general
Attention deficit disorder
Infection, fungal, general
Infection, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
amprenavir	Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R'-(1R',2S)))- [CAS]	161814-49-9	US 5783701	Antiviral, anti-HIV
amrinone	[3,4'-Bipyridin]-6(1H)-one, 5-amino- [CAS]	60719-84-8	US 4004012	Cardio stimulant
amrubicin	5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, hydrochloride, (7S-cis)- [CAS]	75898-90-7	EP 107486	Anticancer, antibiotic
ansacin	Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- [CAS]	51264-14-3		Anticancer, other
amtolmetin guacil	Glycine, N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrrol-2-yl]acetyl]-, 2-methoxyphenyl ester [CAS]	87344-06-7	GB 2115417	Analgesic, NSAID
Amylocaine		532-59-2		
Hydrochloride				
AN-152			WO 9719954	Anticancer, antibiotic
anabolic steroids, IC Innov			WO 9848812	Cardiovascular
Anagestone		2740-52-5		
Anagrelide		68475-42-3		
anagrelide	Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride [CAS]	58579-51-4 68475-42-3	GB 1418822	Haematological
anastrozole	1,3-Benzene diacetonitrile, Alpha, Alpha, Alpha-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	120511-73-1	EP 296749	Anticancer, hormonal
Anazolene		3861-73-2		
Ancitabine		31698-14-3		
Ancrod		9046-56-4		
andolast	N-4-[5-Tetrazolyl]-phenyl-4-(5-tetrazolyl)-benzamide			
Androisoxazole		132640-22-3	EP 460083	Antiasthma
		360-66-7		

TABLE IV

Example of Indication
Infection, HIV/AIDS
Cancer, lung, non-small cell
Cancer, leukaemia, acute lymphocytic
Arthritis, rheumatoid
Cancer, prostate
Heart failure
Thrombocytosis
Cancer, breast
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
Androstenediol	21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione	521-17-5		
anecortave acetate		7753-60-8		Ophthalmological
Anethol		4180-23-8; 104-46-1 (unspecified)		
Anethole Trithlone		532-11-6		
Angiogenix			US 6417205	Cardiovascular
Angiotensin		1407-47-2		
anhydrovinblastine	Vincalutoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	38390-45-3	US 6011041	Anticancer, other
anidulatungin	Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4''-(pentyloxy)(1,1',4',1''-terphenyl)-4''-yl)carbonyl)-L-ornithine)- [CAS]	166863-25-8	US 6384013	Antifungal
Anileridine		144-14-9		
Aniracetam		72432-10-1		
Anisindione		117-37-3		
Anisomycin		22862-76-6		
Anisotropine		80-50-2		
Methylbromide				
anistreplase	Anistreplase [CAS]	81869-57-0	EP 28489	Fibrinolytic
Antazolin		91-75-8		
Anthiolimine		305-97-5		
Anthralin		1143-38-0		
Anthramycin		4803-27-4		
Anthrabin		577-33-3		
anthrax inhibitor			US 6436933	Anti-infective, other
antiangiogenic dendrimers			US 6426067	Anticancer, other
Anticort	L-Ascorbic acid, mixt with 2-(diethylamino)ethyl 4-aminobenzoate monohydrochloride, disodium hydrogen phosphate, potassium benzoate and zinc sulfate (1:1) [CAS]	186946-39-9	WO 9640038	Anabolic
antidepressants, Nutrition			US 5998036	Antidepressant
anti-invasins, Microbia			US 6303302	Antifungal

TABLE IV

Example of Indication
Macular degeneration
Cardiomyopathy, ischaemic
Cancer, general
Infection, Candida, general
Infarction, myocardial
Infection, anthrax
Cancer, general
Cachexia
Depression, general
Infection, fungal, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Antimony Potassium Tartrate		28300-74-5		
Antimony Sodium Thioglycollate		539-54-8		
Antimony Thioglycollamide		6533-78-4		
Antiprogesterin	19-Norpregna-4,9-dien-3-one, (acetylphenyl)-20,21,21-pentafluoro-17-hydroxy- (11B,17Alpha) [CAS]	211254-73-8	DE 19706081	Anticancer, hormonal
Antipyrin		60-80-0		
Antipyrin Salicylate		520-07-0		
antithrombin III, Kabi		9000-94-6		Blood fraction
anxiolytics, Drug Discovery	Antithrombin, III [CAS]	90170-80-2	US 5758538	Anxiolytic
AP-521	N-Piperonyl-2-amino-1,2,3,4-tetrahydrobenzo(b)thieno(2,3-c)pyridine-3-carbamide	151227-08-6	WO 9321189	Anxiolytic
AP-5280			US 5965118	Anticancer, alkylating
Apalcillin		63469-19-2		
apaziquone	1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-, (E)- [CAS]	114560-48-4	WO 8706227	Anticancer, alkylating
Apazone		13539-59-8		
α -Phenylbutyramide		90-26-6		
Apocodeine		641-36-1		
apomine	Phosphonic acid, (2-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethylidene)bis- tetrakis(1-methylethyl) ester [CAS]	126411-19-0		Anticancer, other
Apomorphine		58-00-4		
apomorphine	4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride			
apraclonidine	1,4-Benzenediamine, 2,6-dichloro-N1-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	314-19-2 66711-21-5 73218-79-8	US 4517199	Formulation, transmucosal, nasal Antiglaucoma

TABLE IV

Example of Indication
Cancer, breast
Antithrombin III deficiency
Anxiety, general
Anxiety, general
Cancer, general
Cancer, breast
Cancer, prostate
Impotence
Glaucoma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
aprepitant	3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]	170729-80-3	US 5719147	Antiemetic
apripidine	1,3-Propanediamine, N-(2,3-dihydro-1H-Inden-2-yl)-N',N'-diethyl-N-phenyl-[CAS]	33237-74-0 37640-71-4	GB 1321424	Antiarrhythmic
Aprobarbital		77-02-1		
Apronalid		528-92-7		
Aprotinin		9087-70-1		
Aptiganel		137159-92-3		
AQ4N	9,10-Anthracenedione, 1,4-bis[(2-dimethyloxidoamino)ethyl]amino)-5,8-dihydroxy-[CAS]	136470-65-0	US 5132327	Anticancer, other
Aquavan			US 6204257	Anaesthetic, injectable
AR-116081			US 6107324	Neuroleptic
AR-A2	(R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide			Anxiolytic
Arachidonic Acid		506-32-1		
aranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-oxopropyl ester- [CAS]	86780-80-7	GB 2111978	Antihypertensive, other
arbekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)- [CAS]	51025-85-5 75282-65-4	US 4001208	Aminoglycoside antibiotic
Arbidol	1H-indole-3-carboxylic acid, 6-bromo-4-(((dimethylamino)methyl)-5-hydroxy-1-methyl-2-(phenylthio)methyl)-, ethylester, monohydrochloride [CAS]			
arbutamine	1,2-Benzenediol, 4-[1-hydroxy-2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-, (R)-[CAS]	131707-23-8	WO 9008135	Immunostimulant, other
Arcitumomab		128470-16-6	WO 9220324	Diagnostic
ardaparin	Heparin [CAS]	154361-48-5 9005-49-6		Anticoagulant

TABLE IV

Example of Indication
Chemotherapy-induced nausea and vomiting
Cancer, general
Anaesthesia
Unspecified
Anxiety, general
Hypertension, general
Infection, general
Infection, influenza virus
Diagnosis, coronary
Thrombosis, venous

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
arecoline, transdermal	1,2,5,6-Tetrahydro-1-methyl-3-pyridine carboxylic acid methyl ester			Formulation, transdermal, patch
argatroban	2-Piperidinecarboxylic acid, 1-[5-[(aminiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl- [CAS]	74863-84-8	EP 8746	Anticoagulant
Argatroban		74863-84-6		
Arginine		74-79-3		
Ariflo®		153259-65-5		
aripiprazole	2-(1H)-Quinolone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro- [CAS]	129722-12-9	EP 367141	Neuroleptic
arofylline	1H-Purine-2,6-dione, 3-(4-chlorophenyl)-3,7-dihydro-1-propyl- [CAS]	136145-07-8	EP 435811	COPD treatment
arotinolol	2-Thiophenecarboxamide, 5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl], (+) [CAS]	104768-23-6 68377-92-4	US 3932400	Antihypertensive, adrenergic
Arotinolol		68377-92-4		
Arsacetin		618-22-4		
arsenic trioxide	Arsenic oxide (As ₂ O ₃) [CAS]	1327-53-3		Anticancer, other
Arsphenamine		139-93-5		
Arsthinol		119-96-0		
Arteether		75887-54-6		
Arteflene		123407-36-3 (Z form)		
Artemether		71963-77-4		
Artemisinin		63968-64-9		
artemotil	3,12-Epoxy-12H-pyranol[4,3-j]-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, [3R-(3Alpha,5aB,6B,8aB,9aAlpha,10Alpha,12B,12aR)]- [CAS]	75987-54-6		Antimalarial

TABLE IV

Example of indication
Alzheimer's disease
Thrombosis, arterial
Schizophrenia
Chronic obstructive pulmonary disease
Hypertension, general
Cancer, leukaemia, acute myelogenous
Infection, malaria

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Exempl of Therapeutic Use
artesanate	Butanedioic acid mono- [(3R,6aS,6R,8aS,9R,10R,12R,12aR)- decalhydro-3,6,9-trimethyl-3,12-epoxy-12H- pyranol(4,3-J)-1,2-benzodioxepin-10-yl]ester	88495-63-0		Formulation, transmucosal, systemic
arzoifene hydrochloride	Benzo(b)thiophene-8-ol, 2-(4- methoxyphenyl)-3-(4-(2-(1- piperidinyl)ethoxy)phenoxy)-, hydrochloride [CAS]	182133-27-3	WO 9809041	Anticancer, hormonal
AS-3201	Spiro(pyrrolidine-3,4'-(1'H)-pyrrole(1,2- a)pyrazine)-1',2,3',5(2'H)-tetrone, 2'-((4- bromo-2-fluorophenyl)methyl)-, (3'R)- [CAS]	147254-64-6	EP 520320	Symptomatic antidiabetic
ASA, Benzon	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, modified-release, other
ASA, Mayne	Benzoic acid, 2-(acetyloxy)- [CAS]	56449-07-1		Formulation, modified-release, other
ASA, Micropump	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, optimized, microencapsulate
ASA, Verex	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		
α -Santonin		56449-07-1	US 4375468	Formulation, modified-release, >24hr
Ascaridol		481-06-1		
Ascorbic Acid		512-85-6		
		50-81-7		
asenapine maleate	1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole; 5- chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1) [CAS]	85650-56-2	WO 9523600	Neuroleptic
asimadoline	Benzeneacetamide, N-[2-(3-hydroxy-1- pyrrolidinyl)-1-phenylethyl]-N-methyl- α - phenyl-, [S-(R*,R*)]- [CAS]	153205-46-0	DE 4215213	GI inflammatory/bowel disorders
asoprisnil	11B-[4-(4-hydroxyiminomethyl)phenyl]-17B- methoxy-17Apha-(methoxymethyl)estra- 4,9-dien-3-one	199396-76-4	EP 0648778	Menstruation disorders
Asoxime Chloride		34433-31-3		
Aspartic Acid		56-84-8		
Aspidin		584-28-1		
Aspidinol		519-40-4		
Aspirin		50-78-2		

TABLE IV

Example of Indication
Infection, malaria
Cancer, breast
Diabetic complication, general
Pain, general
Thrombosis, general
Infarction, myocardial
Arthritis, general
Psychosis, general
Irritable bowel syndrome
Endometriosis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Aspirin, Dipyridamole				
aspirin	Glycinamide, N-methyl-D-asparaginyl-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2Alpha,5Alpha,6B)]-[CAS]	63358-49-6	GB 1539413	Penicillin, injectable
AST-120	AST 120 [CAS]	90597-58-3		Urological
Astemizol		68844-77-9		
asulacrine	4-Acridinecarboxamide, 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl- [CAS]	80841-47-0 80841-48-1	EP 39224	Anticancer, other
AT-1015	(N-[2-{4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl}-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate			Antithrombotic
atamestane	Androsta-1,4-diene-3,17-dione, 1-methyl- [CAS]	96301-34-7	DE 3338212	Anticancer, hormonal
atazanavir	2,5,6,10,13-Pentazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-(4-(2-pyridinyl)phenyl)methyl- dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt) [CAS]	229975-97-7		Antiviral, anti-HIV
atenolol	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- [CAS]	29122-68-7 73677-19-7	GB 1285038	Antihypertensive, adrenergic
atenolol + chlorthalidone	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, mixt. with 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isindol-1-yl)benzenesulfonamide [CAS]	73677-19-7	US 3836671	Formulation, fixed-dose combinations
atenolol + nifedipine	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- + 4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine			Formulation, fixed-dose combinations
α -Terpineol		98-55-5		
Atevirdine		136816-75-6		

TABLE IV

Example of Indication
Infection, respiratory tract, general
Renal failure
Cancer, general
Thrombosis, general
Cancer, breast
Infection, HIV/AIDS
Hypertension, general
Hypertension, general
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
atipamezole	1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)- [CAS]	104054-27-5	EP 183492	Reproductive/gonadal, general
atiprimod dimaleate	2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl, dimaleate	130065-61-1	US 5744495	Antiarthritic, immunological
ATL-146e			US 6232297	Imaging agent
α -Tocopherol		59-02-9		
atomoxetine	Benzenepropanamine, N-methyl-Gamma-(2-methylphenoxy)-, (R)- [CAS]	82248-59-7 83015-26-3	EP 52492	Neurological
Atorvastatin		134523-00-5		
atorvastatin calcium	1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-3,3-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt [(R*, R*)] [CAS]		EP 409281	Hypolipaeic/Antiatherosclerosis
atosiban	Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine- [CAS]	90779-69-4	EP 112809	Labour inhibitor
Atosiban		90779-69-4		
atovaquone	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans- [CAS]	95233-18-4	EP 123238	Antifungal
atovaquone + proguanil, GSK	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans + N-(4-chloro-phenyl)-N-(1-methylethyl)imidodicarbonimidic diamide			Antimalarial
atracurium besilate	Isoquinolinium, 2,2'-(1,5-pentanedyl)bis[oxy(3-oxo-3,1-propanediyl)]bis[1'-(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-dibenzenesulfonate [CAS]	64228-81-5	US 4178557	Muscle relaxant
atrasentan	3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)- [CAS]	173937-91-2	WO 9730045	Anticancer, other

TABLE IV

Example of Indication
Sexual dysfunction, female
Arthritis, rheumatoid
Unspecified
Attention deficit disorder
Hypercholesterolaemia
Labour, preterm
Infection, Pneumocystis jirovecii
Infection, malaria
Surgery adjunct
Cancer, prostate

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent R ferenc	Exempl of Therapeutic Use
Atrial Natriuretic Peptide		85637-73-6		
Atrolactamide		2019-68-3		
Atropine		51-55-8		
Augmentin XR, Glaxo		74469-00-4		Formulation, modified-release, other
auranofin	Gold, (1-thio-β-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)-[CAS]	34031-32-8	US 3708578	Antiarthritic, other
Aurothioglucose		12192-57-3		
avasimibe	Sulfamic acid, [2,4,6-tris(1-methylethyl)phenyl]acetyl-, 2,6-bis(1-methylethyl)phenyl ester [CAS]	166518-60-1	US 5491772	Hypolipaeamic/Antiatherosclerosis
Avobenzone		70356-09-1		
AWD-12-281	AWD 12-281 [CAS]	257892-33-4		Antiallergic, non-asthma
Azactidine		320-67-2		
Azacyclonol		115-46-8		
azacitadine	2-Pyrimidinamine, 4-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)ethenyl]-, (E)- [CAS]	62973-76-6	US 3882105	Antibacterial, other
azapropazone	1H-Pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione, 5-(dimethylamino)-9-methyl-2-propyl- [CAS]	13539-59-8	FR 1440629	Anti-inflammatory
Azaserine		115-02-6		
azasetron	2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride- [CAS]	123040-16-4 123040-94-8 123040-96-0	EP 313393	Antiemetic
Azasetron		123040-69-7		
Azatadine		3964-81-6		
Azathioprine		446-86-6		
azathioprine	6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine			Formulation, oral, other
azathioprine	glycine	446-86-6		Analgesic, other
AZD-4282	3,4-Difluorophenylcyclopropylamine			Antithrombotic
AZD-6140				
Azelale Acid		123-99-9		

TABLE IV

Example of Indication
Infection, respiratory tract, general
Arthritis, rheumatoid
Atherosclerosis
Rhinitis, allergic, general
Infection, trichomoniasis
Nausea and vomiting, general
Transplant rejection, bone marrow
Pain, neuropathic
Thrombosis, arterial

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent R f rence	Exmpl of Therapeutic Use
azelaic acid	Nonanedioic acid [CAS]	123-99-9		Antiacne
Az lastin		58581-89-8		
	1-(2H)-Phthalazine, 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl), monohydrochloride [CAS]	58581-89-8 79307-93-0	GB 1377231	Antlasthma
azelaic acid	3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[(1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl)ester, (+/-)- [CAS]	123524-52-7	EP 266922	Antihypertensive, other
Azidamfenicol		13838-08-9		
Azidocillin		17243-38-8		
Azimilid		149908-53-2		
Azintamide		1830-32-6		
azithromycin	9-deoxy-8a-aza-9a-methyl-9a-homoerythromycin-A	76801-85-9 83905-01-5 92395-24-9	US 4328334	Macrolide antibiotic
Azithromycin		83905-01-5		
azithromycin	9-deoxy-8a-aza-9a-methyl-9a-homoerythromycin-A			Formulation, modified-release, other
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[(2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, [2S-(2.alpha.,5.alpha.,6.alpha.,6.alpha.)]-[CAS]	37091-65-9 37091-66-0	GB 1392849	Penicillin, injectable
Azosemide		27589-33-9		
	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-(2.alpha.,3.alpha.)]-[CAS]			Beta-lactam antibiotic
aztreonam	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-(2.alpha.,3.alpha.)]-[CAS]	104184-69-2 78110-38-0	GB 2071650	
aztreonam	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-(2.alpha.,3.alpha.)]-[CAS]	104184-69-2 78110-38-0		Formulation, inhalable, topical

TABLE IV

Example of Indication
Acne
Asthma
Hypertension, general
Infection, respiratory tract, lower
Conjunctivitis
Infection, general
Infection, general
Infection, respiratory tract, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
azulene	Sodium 5-isopropyl-3,8-dimethyl-1-azulene sulfonate	6223-35-4	EP 89958	Formulation, modified-release, other
bacampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, 1-[(ethoxycarbonyloxy)ethyl ester, [2S-(2Alpha,5Alpha,6S(S'))]- [CAS]	37661-08-8 50972-17-3	GB 1363506	Penicillin, oral
Bacampicillin		50972-17-3		
Bacitracin		1405-87-4		
baclofen	β-(Aminomethyl)-4-chlorobenzenepropanoic acid [CAS]	1184-47-0		Formulation, implant
Baicalein		491-67-8		
balofoxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo- [CAS]	127294-70-6	EP 342675	Quinolone antibacterial
balsalazide	Benzoic acid, 5-[[4-[(2-carboxyethyl)amino]carbonyl]phenylazo]-2-hydroxy-, (E)- [CAS]	80573-04-2	US 4412992	GI inflammatory/bowel disorders
Bambuterol		81732-65-2		
bambuterol	Carbamic acid, dimethyl-, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-phenylene ester, monohydrochloride [CAS]	81732-46-9	EP 43807	Anticough
Bamethan		3703-79-5		
Bamifylline		2016-63-9		
Bamipine		4945-47-5		
Barbital		57-44-3		
barnidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl-1-(phenylmethyl)-3-pyrrolidinyl ester, [S-(R*, R*)]-	104713-75-9 104757-53-1 71863-56-4	US 4220649	Antihypertensive, other
Barnidipin		104713-75-9		
BAS-118	N-Methyl-3-[2-(2-naphthyl)acetyl]amino]benzamide			Antibacterial; other

TABLE IV

Example of Indication
Inflammation, general
Infection, general
Spastic paralysis
Infection, urinary tract
Colitis, ulcerative
Asthma
Hypertension, general
Infection, <i>Helicobacter pylori</i>

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Basic Aluminum Carbonate Gel		1339-92-0		
Basiliximab		179045-86-4		
Batimastat		130370-60-4		
Batroxobin		9039-61-6		
Bay-41-2272	5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-amine			Male sexual dysfunction
Bay-41-8543	2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine			Cardiovascular
BAY-43-9006	N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea			Anticancer, other
BAY-57-1293	N-[5(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide			
bazedoxifen	TSE 424 [CAS]	198481-33-3	EP 802183	Antiviral, other
β-Benzalbutyramide		7236-47-7		Osteoporosis treatment
BBR-3464	Platinum(4+), hexaaminedichlorobis(μ -(1,6-hexanediamine-N,N')tr- stereoisomer, tetranitrate [CAS]	172903-00-3	US 5744497	Anticancer, alkylating
BBR-3576			US 5519029	Anticancer, antibiotic
BBR-3610			US 6060816	Anticancer, alkylating
β-Carotene		7235-40-7		
BCH-1868	(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl)tetrahydrofuran			Anticancer, antimetabolite
Bebe rine		477-60-1		
Beclamide		501-68-8		
bedometasone	Pregna-1,4-diene-3,20-dione, 9-chloro-11 β ,17,21-trihydroxy-16 β -methyl, 17,21-dipropionate [CAS]	5534-09-8	WO 0006132	Formulation, inhalable, solution

TABLE IV

Example of Indication
Sexual dysfunction, male, general
Unspecified
Cancer, liver
Infection, herpes simplex virus
Osteoporosis
Cancer, lung, non-small cell
Cancer, prostate
Cancer, general
Cancer, general
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
becloritasone	Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-, (11B,16B)-[CAS]	4419-39-0		Formulation, inhalable, dry powder
Befloxatone		134564-82-2		
befunolol	Ethanone, 1-7-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2-benzofuran-yl-[CAS]	38543-79-8 39552-01-7		Antiglaucoma
Bemegride		64-65-3		
Benactyzine		302-40-9		
	1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-[CAS]	86541-74-4 86541-75-5 86541-78-8	EP 72352	Antihypertensive, renin system
benazepril		2179-37-5		
Bencyclane				
	1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)cycloheptyloxy]-, (E)-2-butenedioate (1:1) [CAS]	14286-84-1	WO 9829409	Vasodilator, peripheral
bencyclane		20187-55-7		
Bendazac				
	L-Lysine, mono[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]acetate [CAS]	81919-14-4	GB 2081708	Ophthalmological
bendazac		73-48-3		
Bendroflumethiazide		78718-25-9		
Benexate				
	Ethanol, 2-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]-, benzoate (ester) [CAS]	23602-78-0 23642-66-2	GB 1175518	Hypolipaeic/Antiatherosclerosis
benfluorex		22457-89-2		
Benfotiamine		3447-95-8		
Benfurodil				
H misuccinate				
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-piperidinyl ester, monohydrochloride (R*,R*)-(+/-) [CAS]	105979-17-7 91599-74-5	EP 63365	Antihypertensive, other
benidipine		5003-48-5		
Benorylat		67434-14-4		
Benoxaprofen		99-43-4		
Benoxinate		2062-84-2		
Benperidol		2156-27-6		
Benproperine				

TABLE IV

Exempl of Indication
Asthma
Hypertension, general
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Benserazide		322-35-0		
benzazepam	2H-[1]Benzothieno[2,3-e]-1,4-diazepin-2-one, 1,3,6,7,8,9-hexahydro-5-phenyl[CAS]	29462-18-8	DE 2005276	Anxiolytic
Bentiromide		37106-97-1		
B nitoquatam		1340-69-8		
Benzalkonium Chloride		8001-54-5		
Benzaron		1477-19-6		
benzbromarone	Methanone, (3,5-dibromo-4-hydroxyphenyl)[(2-ethyl-3-benzofuranyl)-[CAS]	3562-84-3	US 3012042	Antigout
Benzethonium Chloride		121-54-0		
Benzetimide		14051-33-3		
Benzilonium Bromide		1050-48-2		
Benzilodarone		68-90-6		
benznidazole	N-benzyl-2-nitroimidazole-1-acetamide	22994-85-0	GB 1138529	Protozoacide
Benzocaine		94-09-7		
Benzocaine				
benzocaine, Vinas	Benzoic acid, 4-amino-, ethyl ester	94-09-7		Formulation, fixed-dose combinations
Benzocetamine		17243-39-9		
B nzoñatate		104-31-4		
B nzoxonium Chloride		19379-90-9		
Benzoyl Peroxide		94-36-0		
benzoyl peroxide	Peroxide, dibenzoyl.[CAS]	94-36-0		Formulation, other
Benzoylpsas		13898-58-3		
Benzophetamine		156-08-1		
Benzpiperylon		53-89-4		
Benzquinamide		63-12-7		
Benzthiazide		91-33-8		
Benztropine Mesylate		132-17-2		
B nzydamine		642-72-8		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Refer nce	Example of Therapeutic Use
benzylamine flufenamate	N-(Alpha, Alpha, Alpha-trifluor-m tolyl)lantranyleate of 1-benzyl-3-(3- dimethylamine-propoxyl)-1H-imidazol			Anti-inflammatory, topical
benzylamine	1-Propanamine, N,N-dimethyl-3-[[1- (phenylmethyl)-1H-indazol-3-yl]oxy]- [CAS]	132-69-4 642-72-8		Stomatological, reproductive/gonadal, anti-inflammatory
Benzyl Benzoate		120-51-4		
Benzylhydrochlorothiazide		1824-50-6		
Benzylmorphine		14297-87-1		
B phenium		3818-50-6		
Hydroxynaphthoate				
Bepotastine		190786-43-7		
bepotastine	1-Piperidinebutanoic acid, 4-[(4- chlorophenyl)-2-pyridylmethoxy]-, (S)-, monobenzenesulfonate [CAS]	190786-44-8	WO 9829409	Antiallergic, non-asthma
bepidil	1-Pyrrolidineethanamine, 8-[(2- methylpropoxy)methyl]-N-phenyl-N- (phenylmethyl)- [CAS]	64706-54-3 74764-40-2 74764-75-3	EP 146155	Antianginal
beraprost	1H-Cyclopenta[b]benzofuran-5-butanolic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3- hydroxy-4-methyl-1-octen-6-ynyl)- [CAS]	88475-69-8	US 4474802	Prostaglandin
Beraprost		88430-50-6		
Berberine		2086-83-1		
Bergapten		484-20-8		
Bernoprofen		78499-27-1		
Besipirdine		119257-34-0		
betahistine	2-Pyridineethanamine, N-methyl-, dihydrochloride	5579-84-0 5638-76-6		Formulation, modified-release, <=24hr
betaine	Betaine- [CAS]	107-43-7		Metabolic and enzyme disorders
betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro- 11,17,21-trihydroxy-16-methyl-, (11B,16B)- [CAS]	378-44-9		Formulation, dermal, topical
Betamipron		3440-28-6		
Betasine		3734-24-5		

TABLE IV

Example of Indication
Inflammation, general
Allergy, general
Angha, general
Peripheral vascular disease
Meniere's disease
Homocystinuria
Psoriasis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
betaxolol	2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- [CAS]	63859-18-7 63859-19-8	US 4252884	Antihypertensive, adrenergic
Betazole		105-20-4		
Bethanechol Chloride		590-63-6		
Bethanidine		55-73-2		
Betoxycaine		3818-62-0		
β-Eucaine		500-34-5		
biventolol	2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(β-methylphenoxy)- [CAS]	42864-78-8 59170-23-9	US 3857891	Antihypertensive, adrenergic
B vonium Methyl Sulfate		5205-82-3		
bexarotene	Benzoic acid, 4-(1-[5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl]ethenyl)- [CAS]	153559-49-0	WO 9321146	Anticancer, other
bezafibrate	Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl- [CAS]	41859-67-0 15301-48-1	GB 1359264	Hypolipaeamic/Antiatherosclerosis
Bezitramide				
BG-9928		166374-48-7		Cardio stimulant
BIA-2-024	10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide	199997-15-4	WO 9745416	Antiepileptic
BIA-2-093	(S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide- [CAS]	236395-14-5		Antiepileptic
BIA-3-202	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone	274925-86-9	EP 1010688	Antiparkinsonian
Bialamilcol		493-75-4		
biapenem	5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6-[[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-, hydroxide, inner salt, [4R-[4α,5α,6β,6β(R*)]]- [CAS]	120410-24-4	EP 289801	Beta-lactam antibiotic

TABLE IV

Example of Indication
Hypertension, general, glaucoma
Hypertension, general
Cancer, lymphoma, T-cell
Heart failure
Epilepsy, general
Epilepsy, general
Parkinson's disease
Infection, beta-lactamase resistant

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Bibenzonium Bromide		15585-70-3		
Bibrocathol		6915-57-7		
bicalutamide	Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-) [CAS]	90357-08-5	EP 100172	Anticancer, hormonal
bicifadine	3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, (+/-) [CAS]	66504-75-4 71195-57-8	DE 2740562 US 6294585	Analgesic, other Dermatological
bicyclic monoterpene diols				
Bidisomide		116078-65-0		
Bietamiv rine		479-81-2		
Bietanautine		6888-11-5		
Bietaserpine		53-18-9		
bifemelane	1-Butanamine, N-methyl-4-[2-(phenylmethyl)phenoxy]-, hydrochloride [CAS]	62232-46-6 90293-01-9	GB 1512880	Cognition enhancer
Bifluranol		34633-34-6		
bifonazole	1H-Imidazole, 1-[(1,1'-biphenyl)-4-ylphenylmethyl]- [CAS]	60628-98-8 60629-08-5 60629-09-6	US 4118487	Antifungal
bimatoprost	5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl (1R-(1 α pha(Z)2 β (1E,3S,3 α pha,5 α pha)) [CAS]	155206-00-1	US 5688819	Prostaglandin
bimoclomol	N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-pyridinecarboximidoyl chloride, (Z)-2-butanediolate (1:1)	130493-04-8	US 5147874	Symptomatic antidiabetic
bimosiamose	(1,1'-Biphenyl)-3-acetic acid, 3',3''-(1,6-hexanediyl)bis(6'- α -D-mannopyranosyloxy)-, [CAS]	187269-40-5	US 5444050	Antiasthma
Binfibrate		69047-39-8		
binodenoson	Adenosine, 2-((cyclohexylmethylene)hydrazino)- [CAS]	144348-08-3		Vasodilator, coronary
Blomed-101			US 6423744	Anticancer, other
Biotin		58-85-5		
Biperiden		514-65-8		

TABLE IV

Example of Indication
Cancer, prostate
Pain, general
Unspecified
Attention deficit disorder
Infection, fungal, general
Glaucoma
Neuropathy, diabetic
Asthma
Diagnosis, coronary
Cancer, renal

TABLE-IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Biricodar		159997-94-1		
	2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyphenyl)acetyl)-4-(3-pyridinyl)-1-(3-(3-pyridinyl)propyl)butyl ester, (S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) [CAS]	174254-13-8		Radio/chemosensitizer
biricodar dicitrate	1-Butanone, 1-(4-fluorophenyl)-4-(3,4,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-2(1H)-yl)- [CAS]	42021-34-1	DE 2333922	Neuroleptic
Bisacodyl		603-50-9		
Bisantr ne		78186-34-2		
Bisbentamine		2667-89-2		
Bisdequalinium Chloride		52951-36-7		
Bismuth Aluminate		12284-76-3		
Bismuth		53897-25-9		
Butylthiolaurate		52951-37-8		
Bismuth Ethyl Camphorate		138-58-9		
Bismuth Iodosubgallate		53778-50-0		
Bismuth Sodium Iodide		5798-43-6		
Bismuth Sodium Triglycollamate		5892-10-4		
Bismuth Subcarbonate		22650-86-8		
Bismuth Subgallate		1304-85-4		
Bismuth Subnitrate		14882-18-9		
Bismuth Subsalicylate		5175-83-7		
Bismuth Tribromophenate				
bisoprolol	2-Propanol, 1-[4-[(2-(1-methylethoxy)ethoxy)methyl]phenoxy]-3-[(1-methylethyl)amino]- [CAS]	104344-23-2 66722-44-9	GB 1532380	Antihypertensive, adrenergic

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
bisoprolol + HCTZ	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]phenyl]-3-[(1-methylethyl)amino] mxt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide			Formulation, fixed-dose combinations
bisoprolol+trichloromethiazide	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]phenyl]-3-[(1-methylethyl)amino] mxt. with 6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide			Formulation, fixed-dose combinations
bisoprolol+trichloromethiazide		14008-48-1		
Bisoxatin Acetate		97-18-7		
Bithionol		30392-40-6		
Bitolterol		4044-65-9		
Bitoscanate			WO 0218378	Anti-inflammatory
BL-3875		11056-06-7 9041-93-4		Formulation, transdermal, enhanced
bleomycin sulfate	Bleomycin sulphate (salt) [CAS]			
bionaserin	Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro- [CAS]	132810-10-7	EP 385237	Neuroleptic
BMS-184476			EP 639577	Anticancer, other
	cis-(+/-)-2-(Ethythio)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one			Anticancer, other
BMS-387032	4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, dihydrochloride		WO 9742949	Neuroprotective
BN-82451				
	Ethanesulfonic acid, 2,2'-dithiobis-, disodium salt [CAS]	16208-51-8		Radio/chemoprotective
BNP-7787				
BO-653	5-Benzoturanol, 4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl- [CAS]	157360-23-1	WO 9408930	Hypolipaeic/Antiatherosclerosis
Bolandiol		19793-20-5		
Bolast rone		1605-89-6		
Bolderone		846-48-0		

TABLE IV

Example of Indication
Hypertension, general
Hypertension, general
Unspecified
Cancer, head and neck
Schizophrenia
Cancer, breast
Cancer, general
Unspecified
Chemotherapy-induced nausea and vomiting
Atherosclerosis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
bopindolol	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[2-methyl-1H-indol-4-yl]oxy]-, benzoate (ester), (+/-) [CAS]	62658-63-3 82857-98-3	US 4340541	Antihypertensive, adrenergic
Bornyl Chloride		464-41-5		
Bornyl Salicylate		560-88-3		
bortezomib	Boric acid, [(1R)-3-methyl-1-[(2S)-1-oxo-3-phenyl-2-[[pyrazinyl(carbonyl)amino]propyl]amino]but-1-yl] [CAS]	179324-69-7	US 6271199	Anticancer, other
bosentan	Benzenesulfonamide, 4-[(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- [CAS]	147536-97-8	EP 633259	Vasodilator, peripheral
BP2.94	Phenol, 2-[[[(1R)-2-(1H-imidazol-4-yl)-1-methylethyl]imino]phenylmethyl]- [CAS]	199191-80-3	WO 9117146	Respiratory
BP4.897	N-[4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl]naphthalene-2-carboxamide		EP 779284	Dependence treatment
β-Propiolactone		57-57-8		
Bradycor		140661-97-8		
Brain Natriuretic Peptide		114471-18-0		
Brallobarbitol		561-86-4		
brasofensine	8-Azabicyclo(3.2.1)octane-2-carboxaldehyde, 3-(3,4-dichlorophenyl)-8-methyl-, O-methylloxime, (1R-(1Alpha,2B(E),3Alpha,5Alpha))- [CAS]	171655-91-7	WO 9528401	Antiparkinsonian
Brequinar		96187-53-0		
Br tylium Tosylate		61-75-6		
Brilliant Green		633-03-4		
brimonidine	6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	59803-98-4	DE 2538620	Antiglaucoma
brinzolamide	2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)- [CAS]	138890-62-7	US 5378703	Antiglaucoma

TABLE IV

Example of indication
Hypertension, general
Cancer, myeloma
Hypertension, pulmonary
Rhinitis, general
Addiction, cocaine
Parkinson's disease
Glaucoma
Glaucoma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref r nce	Example of Therapeutic Use
brivudin	Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- [CAS]	69304-47-8		Antiviral, other
Brodinoprim		56518-41-3		
Bromazepam		1812-30-2		
Bromfenac		91714-94-2		
bromfenac	Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- [CAS]	91714-93-1 91714-94-2		Formulation, mucosal, topical
Bromhexine		3572-43-8		
Bromindione		1146-98-1		
Bromisovalium		496-67-3		
Bromocriptine		25614-03-3		
Bromodiphenhydramine		118-23-0		
Bromoform		75-25-2		
Bromopride		4093-35-0		
Bromosalicychloranilide		3679-64-9		
bromperidol	1-Butanone, 4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- [CAS]	10457-90-6	US 3438991	Neuroleptic
Brompheniramine		86-22-6		
Broparaoestrol		479-68-5		
Bropiramine		56741-95-8		
brotallicin	4-(2-Bromoacrylamido)-N ^m -(2-guanidinoethyl)-1,1',1'',1'''-tetramethyl-N 4':N',4'',N''',4'''-quater-[pyrrole-2-carboxamide] [CAS]			Anticancer, other
brotizolam	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-e][1,4]diazepine, 2-bromo-4-(2-chlorophenyl)-9-methyl- [CAS]	57801-81-7	US 4094984	Hypnotic/Sedative
Brovincamine		57475-17-9		
Broxuridin		59-14-3		
Broxyquinoline		521-74-4		
Brucine		357-57-3		
β-Sitosterol		83-46-5		
Bucetin		1083-57-4		
Bucillamine		65002-17-7		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Bucindolol		71119-11-4		
buciladine	Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate [CAS]	362-74-3	JP 51113896	Cardio stimulant
Buciladine		362-74-3		
Bucilazine		82-95-1		
Buclosamide		575-74-6		
Bucolome		841-73-6		
bucricaine	9-Acridinamine, N-butyl-1,2,3,4-tetrahydro-, monohydrochloride [CAS]	82636-28-0		Anaesthetic, local
Bucumolol		58409-59-9		
budesonide	Pregna-1,4-diene-3,20-dione, 16,17-(butyridenebis(oxy))-11,21-dihydroxy-, (11B, 16Alpha)- [CAS]	51333-22-3	GB 1428922	Antiasthma
budesonide + formoterol	Pregna-1,4-diene-3,20-dione, 16,17-(butyridenebis(oxy))-1,1,21-dihydroxy-, (11B, 16Alpha) + formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-(R*,R')-(±)			Formulation, fixed-dose combinations
budesonide	Pregna-1,4-diene-3,20-dione, 16,17-(butyridenebis(oxy))-1,1,21-dihydroxy-, (11B, 16Alpha)- [CAS]	51333-22-3		Formulation, inhalable, solution
budipine	Piperidine, 1-(1,1-dimethylethyl)-4,4-diphenyl- [CAS]	57982-78-2 63661-61-0	DE 2825322	Antiparkinsonian
Budipine		57982-78-2		
Budralazine		36798-79-5		
Bufenod		22103-14-6		
Bufetolol		53684-49-4		
bufexamac	p-butoxyacetohydroxamic acid	2438-72-4	US 3478396	Anti-inflammatory
bufloamedil	1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)- [CAS]	35543-24-9 55837-25-7	GB 1326192	Vasodilator, peripheral
Buflomedil		55837-25-7		
Buformin		692-13-7		
Bufuralol		54340-62-4		
Bumadizone		3583-64-0		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
bumetanide	Benzolic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- [CAS]	26395-03-1	US 3806534	Antihypertensive, diuretic
bumetane	1-Naphthalenecarboxamide, N-butyl-N-[2-(diethylamino)ethyl]- [CAS]	32421-46-8	DE 2009894	Antiarhythmic
Bunafine		32421-46-8		
Bunamiodyl Sodium		1923-76-8		
bunazosin	1H-1,4-Diazepine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)hexahydro-4-(1-oxobutyl)- [CAS]	52712-76-2 80755-51-7	GB 1398455	Antihypertensive, adrenergic
Bunazosin		80755-51-7		
bunitrolol	Benzonitrile, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- [CAS]	34915-68-9	US 3940489	Antihypertensive, adrenergic
Bunitrolol		34915-68-9		
Bupivacaine		2180-92-9		
bupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]	38398-39-3		Formulation, modified-release, >24hr
bupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]			Formulation, parenteral, other
Bupranolol		14556-46-8		
buprenorphine	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha(S)]- [CAS]	52485-79-7 53152-21-9	US 3433791	Analgesic, other
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2	US 4425363	Antidepressant
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2		Formulation, modified-release, <=24hr
Buramate		4663-83-6		
buserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57982-77-1 68630-75-1	GB 1523623	Releasing hormones
bupropion	8-Azaspiro[4.5]decane-7,9-dione, 8-[4-(2-pyrimidinyl)-1-piperazinyl]butyl- [CAS]	36505-84-7	EP 278536	Anxiolytic
busulfan	1,4-Butanediol, dimethanesulfonate [CAS]	55-98-1		Formulation, optimized, microparticles

TABLE IV

Example of Indication
Hypertension, general
Hypertension, general
Anaesthesia
Anaesthesia
Depression, general
Depression, general
Cancer, prostate
Anxiety, general
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
busulfan	1,4-Butanediol, dimethanesulfonate- [CAS]	55-98-1		Formulation, parenteral, other
Butabarbital Sodium		143-81-7		
Butacaine		149-16-6		
Butacetyl		2109-73-1		
Butalamine		22131-35-7		
Butalbital		77-26-9		
Butallylonal		1142-70-7		
Butamben		94-25-7		
butamben	4-Aminobenzoic acid butyl ester [CAS]	94-25-7		Formulation, modified-release, other
Butamirate		18109-80-3		
	Benzeneacetic acid, Alpha-ethyl-, 2-[2-(diethylamino)ethoxy]ethylester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	18109-80-3 18109-81-4		Antitussive
butamirate citrate		3785-21-5		
Butanillicaine		653-03-2		
Butaperazine		55837-14-4		
Butaverine		16790-49-1		
Butazolamide		51395-42-7		
But dronic Acid				
	1-Naphthalenemethanamine, N-((4-(1,1-dimethyl(ethyl)phenyl)methyl)-N-methyl-[CAS]	101827-46-7 101828-21-1	EP 164697	Antifungal
butenafine		101828-21-1		
Butenafine		77-28-1		
Butethal		14007-64-8		
Butethamate		2090-89-3		
Butethamine		510-90-7		
Buthalital Sodium		2043-38-1		
Buthiazid		55837-18-8		
Butibufen		1506-12-3		
Butidrine Hydrochloride				
	benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediybis[(methylimino)(2-ethyl-2,1-ethanediy)] ester, [S-(R*, R*)]- [CAS]	55769-64-7 55769-65-8	US 4021473	Antiarrhythmic
butobendine		55769-65-8		
Butobendine		55769-65-8		

TABLE IV

Example of Indication
Cancer, leukaemia, acute myelogenous
Pain, cancer
Cough
Infection, dermatological
Arrhythmia, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
butoconazole	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (+/-)-[CAS]	64872-76-0 64872-77-1	GB 1567431	Antifungal
butoconazole, KV	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (+/-)-[CAS]	64872-76-0		Formulation, mucosal, topical
Butocetamide		32838-26-9		
Butoflitolol		64552-17-6		
	Morphinan-3,14-diol, 17-(cyclobutylmethyl)-, [S-(R*, R*)]-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	42408-82-2 58786-99-5	GB 1412129	Analgescic, other
butorphanol		3772-43-8		
Butoxycaine		35941-65-2		
Butriptyline		29025-14-7		
Butroplum Bromide		3691-21-2		
Buzeptide			WO 0208178	Anorectic/Antiobesity
BVT-5182				
BXT-51072	2H-1,2-Benzoselenazine, 3,4-dihydro-4,4-dimethyl- [CAS]	173026-17-0		GI inflammatory/bowel disorders
	6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-, 2HCl, 2H2O			Anticancer, other
C-1311				
	Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8S)- [CAS]	81409-90-7 85329-89-1	GB 2103603	Antiprolactin
cabergoline		81409-90-7		
Cabergoline		75-60-5		
Cacodylic Acid		8052-16-2		
Cactinomycin		84820-09-4		Anti-infective, other
cadexomer iodine	Cadexomer iodine [CAS]			
Cadmium Salicylate		19010-79-8		
Cadralazine		64241-34-5		
Cafaminal		30924-31-3		
Caffeine		58-08-2		
caffeine citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione [CAS]	69-22-7		Respiratory

TABLE IV

Example of Indication
Infection, Candida, general
Infection, gynaecological
Obesity
Colitis, ulcerative
Cancer, general
Galactorrhoea
Ulcer, venostasis
Apnoea

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Calcifediol		19356-17-3		
Calcipotriene		112965-21-6		
calcipotriol	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1 α ,3 β ,5 β ,7 α ,22 α)- [CAS]	112965-21-6	WO 8700834	Antipsoriasis
calcipotriol+betametasone	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1 α ,3 β ,5 β ,7 α ,22 α)- + Pregna-1,4-diene-3,20-dione, 9-chloro-1,18,17,21-trihydroxy-16 β -methyl-, 17,21-dipropionate			Formulation, fixed-dose combinations
calcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1 α ,3 β ,5 β ,7 α)- [CAS]	32222-06-3		Antipsoriasis
Calcium 3-Aurothio-2-propanol-1-sulfonate		5743-29-3		
Calcium Acetylsalicylate		69-46-5		
Calcium		33659-28-8		
Bromolactobionate		471-34-1		
Calcium Carbonate		299-28-5		
Calcium Gluconate		27214-00-2		
Calcium				
Glycerophosphate	Calcium D-(+)-4-(2,4-dihydroxy-3,3-dimethylbutyramido)butyrate (hemihydrate) [CAS]	17097-76-6	EP 117260	Neurological
calcium hopantothénate		1319-91-1		
Calcium Iodobehenate		1301-16-2		
Calcium Iodostearate		814-80-2		
Calcium Lactate		591-64-0		
Calcium Levulinate		21085-60-9		
Calcium Mesoxalate		16649-79-9		
Calcium N-Carbamoylaspartate				
Calcium Polycarbophil		9003-97-8		
calcium polycarbophil, Fujisawa	Polycarbophil, calcium salt [CAS]	126040-58-2		GI inflammatory/bowel disorders

TABLE IV

Example of Indication
Psoriasis
Psoriasis
Psoriasis
Attention deficit disorder
Irritable bowel syndrome

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent R ferenc	Example of Th rapeutic Use
Calcium Propionate		4075-81-4		
Calcium Succinate		140-99-8		
calcaret	5-methyl-2-(1-piperazinyl)-benzenesulfonic acid monohydrate	133804-44-1		Cardio stimulant
Calusterone		17021-26-0		
Camazepam		36104-80-0		
camostat	Benzeneacetic acid, 4-[[4-[(aminomino methyl)amino]benzoyloxy]-2-(dimethylamino)-2-oxoethyl ester, monomethanesulfonate [CAS]	59721-28-7 59721-29-8 71079-09-9	US 4021472	GI inflammatory/bowel disorders
Camphor		76-22-2		
Camphotamide		4876-45-3		
camptothecin, Sonus	4-Ethyl-4-hydroxy-1H-pyrano-[[3':4':6',7']indolizinol[1,2-b:]quinoline-3,14(4H,12H)-dione			Formulation, optimized, microemulsion
Candesartan		139481-59-7		
candesartan cilexetil	1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[[cyclohexyloxy]carbonyloxy]ethyl ester, (+/-)- [CAS]	145040-37-5 123122-55-4	EP 520423	Antihypertensive, renin system
Candoxatril				
canertinib dihydrochloride	N-[4-(3-(Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl)-acrylamide dihydrochloride	289489-45-2 976-71-6 56-25-7		Anticancer, other
Canrenone				
Cantharidin	Maytansine, N2-deacetyl-N2-(3-mercaptopropyl)-, conjugated humanized C242 monoclonal antibody			Immunotoxin
cantuzumab mertansine		139504-50-0		
capcitabine	Cytidine, 5-deoxy-5-fluoro-N-[[pentyl]oxy]carbonyl]- [CAS]	154361-50-9	EP 602454	Anticancer, antimetabolite
Capobenic Acid		21434-91-3		

TABLE IV

Example of Indication
Heart failure
Pancreatitis
Cancer, general
Hypertension, general
Cancer, lung, non-small cell
Cancer, colorectal
Cancer, breast

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
capravirine	1H-imidazole-2-methanol, 5-(3,5-dichlorophenyl)thio-4-(1-methylethyl)-1-(4-pyridyl)methyl carbamate (ester) [CAS]	178979-85-6		Antiviral, anti-HIV
Capromab		151763-64-3		
capsaicin cream, Maruishi	N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)- [CAS]	404-86-4		Formulation, dermal, topical
Captodiamine		486-17-9		
captopril	L-Proline, 1-(3-mercaptopropan-2-yl)-1-oxopropan-2-yl-, (S)- [CAS]	62571-86-2	US 4105776	Antihypertensive, renin system
captopril + HCTZ	L-Proline, 1-(3-mercaptopropan-2-yl)-1-oxopropan-2-yl-, (S)-, mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide [CAS]	110075-07-5	US 4217347	Antihypertensive, renin system
Capuride		5579-13-5		
carabersat	Benzamide, N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluoro, (3R-trans)- [CAS]	184653-84-7	WO 9811890	Antiepileptic
Caramiphen		77-22-5		
carazolol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[(1-methylethyl)amino]- [CAS]	57775-29-8	DE 2240599	Antihypertensive, adrenergic
Carazolol		57775-29-8		
Carbachol		51-83-2		
Carbamazepine		298-46-4		
carbamazepine, Microtol	5H-Dibenz[b,f]azepine-5-carboxamide [CAS]	298-46-4		Formulation, modified-release, other
Carbamide Peroxide		124-43-6		
Carbarsone		121-59-5		
Carbaryl		63-25-2		
Carbazochrome		13051-01-9		
Salicylate				
Carbazochrome Sodium Sulfonate		51460-26-5		
carbendazim	Methyl-2-benzimidazolecarbamate			Anticancer, other
Carbenicillin		4697-36-3		
Carbenoxolone		5697-56-3		

TABLE IV

Example of Indication
Infection, HIV/AIDS
Pain, post-herpetic
Hypertension, general
Epilepsy, general
Epilepsy, general
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Carbetapentane	Carbonic acid disodium salt, mixt. with monosodium salt-[CAS]	77-23-6		
Carbicarb		72227-05-5		Alimentary/Metabolic, other
Carbidopa	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate +3-hydroxy-L-tyrosine	28860-95-9		
carbidopa+levodopa-1,Nouvel				Formulation, fixed-dose combinations
carbidopa+levodopa-2,NeoPharma	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate+3-hydroxy-L-tyrosine			Formulation, fixed-dose combinations
Carbimazole		22232-54-8		
Carbinoxamine		486-16-8		
Carbocloral		541-79-7		
Carbocysteine		638-23-3		
carbocysteine lysine salt; Dom		151756-26-2	EP 546272	Cystic fibrosis treatment
Carbon Tetrachloride		56-23-5		
carboplatin	Platinum, diammine[1,1'-cyclobutanedicarboxylato(2-)]-, (SP-4-2)-[CAS]	41575-94-4		Anticancer, alkylating
Carboprost		35700-23-3		
carboprost trometamol	Prosta-5,13-dien-1-olc acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9.alpha.,11Alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol(1:1) [CAS]	58551-69-2 74849-93-7	US 3728382	Prostaglandin
Carboquone	2,5-Cyclohexadiene-1,4-dione, 2-[2-[(aminocarbonyloxy)-1-methoxyethyl]-3,6-bis(1-aziridinyl)-5-methyl- [CAS]	24279-91-2	DE 1905224	Anticancer, antibiotic
Carbomal		24279-91-2		
Carbubarb		77-65-6		
Carbutamide		960-05-4		
Carbuterol		339-43-5		
Carfimate		34866-47-2		
		3567-38-2		

TABLE IV

Example of indication
Acidosis
Parkinson's disease
Parkinson's disease
Cystic fibrosis
Cancer, ovarian
Abortion

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
carglumic acid, Orphan Europe	N-Carbamoyl-L-glutamic acid	1188-38-1		Metabolic and enzyme disorders
Cargutocin		33605-67-3		
Carindacillin		35531-88-5		
cariporide	Benzamide, N-(aminoininomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)- [CAS]	159138-80-4 159138-81-5	EP 589336	Antianginal
Cariporide		159138-80-4		
Carisoprodol		78-44-4		
carimofur	1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo- [CAS]	61422-45-5	US 4071519	Anticancer, antimetabolite
Carmofur		61422-45-5		
Carmoxirole		98323-83-2		
carmustine, Guilford	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, Implant
carmustine, Sanchundang	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, Implant
carmustine, Direct Therapeutics	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, parenteral, other
Carnitine		461-06-3		
Caroverine		23465-76-1		
Caroxazone		18464-39-6		
Carphenazine		2622-30-2		
Caripramine		5942-95-0		
carprofen	9H-Carbazole-2-acetic acid, 6-chloro-Alpha-methyl-, (+/-)- [CAS]	53716-49-7	US 3896145	Anti-inflammatory
Carsalam		2037-95-8		
carteolol	2(1H)-Quinolone, 5-[3-{(1,1'-dimethylethyl)amino}-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride [CAS]	51781-06-7 51781-21-6	US 3910924	Antihypertensive, adrenergic
carteolol, ophthalmic	2(1H)-Quinolone, 5-[3-{(1,1'-dimethylethyl)amino}-2-hydroxypropoxy]-3,4-dihydro- [CAS]	51781-06-7 51781-21-6		Formulation, mucosal, topical
Carticaine		23964-58-1		
Carubicin		50935-04-1		
Carumonam		87638-04-8		
Carvacrol		499-75-2		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
carvedilol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-[CAS]	72956-09-3	EP 4920	Antihypertensive, adrenergic
Carvon		99-49-0		
Cascarin		10118-56-6		
caspofungin	Pneumocandin B0, 1-[(4R,5S)-5-(2-aminooethyl)amino)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-(threo-3-hydroxy-L-ornithine)-, diacetate (salt) [CAS]	162808-62-0 178483-17-3	WO 9421677	Antifungal
Catechin		154-23-4		
cathepsin K inhibitors, Celera			WO 9613523	Osteoporosis treatment
cathepsin K inhibitors, NAEJA	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide			Osteoporosis treatment
cathepsin S inhibitors, NAEJA	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide			Anticancer
CC-401			US 6342595	Immunosuppressant
CCI-779	Rapamycin 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) [CAS]	162635-04-3		Anticancer, antibiotic
CCR5 antagonists, Euroscreen			WO 9732019	Antiviral, anti-HIV
CDC-394			US 634061	Anticancer, other
CDC-801			US 5605914	GI inflammatory/bowel disorders
CEE-03-310	1H-3-Benzazepin-7-ol, 5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-8-nitro-, (5S)-, [CAS]	128022-68-4	EP 347672	Dependence treatment
cefaclor	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[aminophenylacetyl]amino]-3-chloro-8-oxo-, [6R-[6Alpha,7B(R')]]-, [CAS]	53994-73-3 70356-03-5	GB 1461323	Cephalosporin, oral
Cefaclor		70356-03-5		

TABLE IV

Example of Indication
Hypertension, general
Infection, Aspergillus
Osteoporosis
Osteoporosis
Asthma
Arthritis, rheumatoid
Cancer, renal
Infection, HIV/AIDS
Cancer, myeloma
Crohn's disease
Addiction, alcohol
Infection, Haemophilus influenzae prophylaxis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefadroxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	50370-12-2	GB 1240687	Cephalosporin, oral
Cefadroxil		66592-87-8		
cefalexin HCl monohydrate	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[aminophenyl]acetyl]amino]-3-methyl-8-oxo-, monohydrochloride, monohydrate, [6R-[6Alpha,7B(R*)]]- [CAS]	105879-42-3	US 4775751	Cephalosporin, oral
cefalexin pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[aminophenyl]acetyl]amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7B(R*)]]- [CAS]	27726-31-4		Cephalosporin, oral
cefalexin, Shionogi	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[aminophenyl]acetyl]amino]-3-methyl-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	15686-71-2		Formulation, modified-release, other
cefamandole	7-D-mandelamido-3[(1-methyl-1H-tetrazol-5-yl)thio]methyl-3-cephem-4-carboxylic acid	34444-01-4	US 3641021	Cephalosporin, injectable
cefatrizine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-, [6R-[6Alpha,7B(R*)]]- [CAS]	51627-14-6	GB 1460914	Cephalosporin, oral
cefatrizine, Ausonia	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-, [6R-[6Alpha,7B(R*)]]- [CAS]	51627-14-6		Cephalosporin, oral
Cefazedone		56187-47-4		
Cefazolin		25953-19-9		
Cefbuperazone		76610-84-9		

TABLE IV

Example of Indication
Infection, general
Infection, respiratory tract, upper
Infection, general
Infection, general
Infection, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref. rence	Example of Therapeutic Use
cefcapepene pivoxil	7-[2-(2-amino-4-thiazolyl)-2-penteno-1-yl]-3-carbamoyloxymethyl-3-oxo-4-oxo-1,4-dihydro-2H-pyridine-2-carboxylic acid, pivaloyloxymethyl ester HCl, [CAS]	105889-45-0 105889-46-1	GB 2173194	Cephalexin, oral
		105889-45-0		
		105239-91-6		
Cefaclor	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl(methoxymethyl)acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7B(Z)]]-, [CAS]	91832-40-5	EP 105459	Cephalexin, oral
cefprozil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl(methoxymethyl)acetyl]amino]-3-[(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [6R-[3Z], 6Alpha, 7B(Z)]]-, [CAS]	104145-95-1 104146-53-4 117467-28-4	JP 61178991	Cephalexin, oral
cefprozil	Pyrolidinium, 1-[7-[[2-amino-4-thiazolyl(methoxymethyl)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl-1-methyl-, hydroxide, inner salt, [6R-[6Alpha,7B(Z)]]-, [CAS]	107648-80-6 123171-59-5 98040-23-7	EP 531981	Cephalexin, injectable
		88040-23-7		
		65052-63-3		
Cefepime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl(methoxymethyl)acetyl]amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7B(Z)]]-, [CAS]	111896-23-2	GB 1581854	Cephalexin, oral
Cefepime pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-amino-4-thiazolyl(methoxymethyl)acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7B(Z)]]-, [CAS]	79350-37-1	EP 30630	Cephalexin, oral
Cefixime				

TABLE IV

Example of Indication
Infection, respiratory tract, general
Infection, dermatological
Infection, general
Infection, respiratory tract, lower
Infection, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefmenoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	65085-01-0 75738-58-8	GB 1536281	Cephalosporin, injectable
cefmetazole	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-cis]- [CAS]	56796-20-4 56796-39-5	GB 1449420	Cephalosporin, injectable
cefminox	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7A]alpha,7(S')]]- [CAS]	84305-41-9	EP 24879	Cephalosporin, injectable
cefodizime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[[[(5-(carboxymethyl)-4-methyl-2-thiazolyl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	69739-16-8 86329-79-5 61270-58-4	US 4590267	Cephalosporin, injectable
Cefonicid sodium	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[(1-(sulfomethyl)-1H-tetrazol-5-yl)thio]methyl]]-, disodium salt, [6R-[6Alpha,7B(R')]]- [CAS]	61270-78-8	GB 1547473	Cephalosporin, injectable
cefoperazone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-4-hydroxyphenyl]acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(R')]]- [CAS]	62883-19-0 92739-15-6 60925-61-3	GB 1508071 US 4234579	Cephalosporin, injectable Antibiotic, other
Ceforanide				

TABLE IV

Example of Indication
Infection, ocular
Infection, general
Infection, urinary tract
Infection, respiratory tract, lower
Infection, general
Infection, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefoselis	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-, [6R-[6Alpha,7B(2)]]	122841-12-7	EP 307804	Cephalosporin, injectable.
Cefoselis		122841-10-5		
Cefotaxime		63527-52-6		
cefotaxime sodium	(6R,7R)-7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]cephalosporanic acid sodium salt	64485-93-4	GB 1580621	Cephalosporin, injectable
Cefotetan		69712-56-7		
cefotiam	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R-trans)-[CAS]	61622-34-2 66309-69-1	US 4080498	Cephalosporin, injectable
cefotiam hexetil	1-(cyclohexyloxy)carbonyloxyethyl 7B-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate 2HCl [CAS]	95789-30-3	EP 128029	Cephalosporin, oral
Cefoxitin		35607-66-0		
cefoxitin sodium	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyloxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-monosodium salt, (6R-cis)- [CAS]	33564-30-6	GB 1348984	Cephalosporin, oral
cefprozan	Imidazo[1,2-b]pyridazinium; 1-[[7-[[[(5-amino-1,2,4-thiadiazol-3-yl)(methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-hydroxide, inner salt, [6R-[6Alpha,7B(2)]]- [CAS]	113359-04-9	EP 203271	Cephalosporin, injectable

TABLE IV

Example of Indication
Infection, general
Infection, general
Infection, general
Infection, respiratory tract, lower
Infection, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefprozil	Pyridinium, 1-[[[2-carboxy-7-[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenyl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, hydroxide, inner salt, [6R-[6Alpha,7B(R*)]]- [CAS]	84880-03-5 85287-61-2	EP 60028	Cephalosporin, injectable
Cefpimizole		84880-03-5		
cefpiramide	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	70797-11-4	US 4156724	Cephalosporin, injectable
cefpirome	5H-1-Pyridinium, 1-[[7-[[[2-amino-4-thiazolyl](methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-, hydroxide, inner salt, [6R-[6Alpha,7B(Z)]]- [CAS]	84957-29-9 98753-19-6	EP 64740	Cephalosporin, injectable
Cefpodoxime Proxetil		87239-81-4		
cefprozil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7B(R*)]]- [CAS]	92665-29-7	GB 2173798	Cephalosporin, oral
Cefprozil		92665-29-7 (anhydrous); 121123-17-9 (monohydrate)		
cefroxadine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[amino-1,4-cyclohexadien-1-yl]acetyl]amino]-3-methoxy-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	51762-05-1	GB 1435111	Cephalosporin, oral

TABLE IV

Example of Indication
Infection, respiratory tract, general
Infection, general
Infection, respiratory tract, lower
Infection, dermatological
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefalulodin	Pyridinium, 4-(aminocarbonyl)-1-[[2-carboxy-8-oxo-7-[(phenylsulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, hydroxide, inner salt, [6R-[6Alpha,7B(R*)]]- [CAS]	52152-93-9 62567-73-9	GB 1387656	Cephalosporin, injectable
ceftazidime	Pyridinium, 1-[[7-[[[(2-amino-4-thiazolyl)](1S)-carboxy-1-methylethoxy]imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, hydroxide, inner salt, [6R-[6Alpha,7B(Z)]]- [CAS]	72558-82-8 82547-58-8 26973-24-0	GB 2025398	Cephalosporin, injectable
Ceftferam				
Cefthezole				
ceftibuten	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl]amino]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	97519-39-6	EP 136721	Cephalosporin, oral
ceftizoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	68401-81-0 68401-82-1	GB 1600735	Cephalosporin, injectable
ceftizoxime alapivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-1-oxopropyl)amino]-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7B(Z(S*))]]- [CAS]	113812-94-5 135767-36-1	JP 62209112	Cephalosporin, oral
ceftioxone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl]thio]methyl]-, [6R-[6Alpha,7B(Z)]]- [CAS]	73384-59-5 74578-69-1 55268-75-2	GB 2022090	Cephalosporin, injectable
Cefuroxime				

TABLE IV

Example of Indication
Infection, pseudomonal
Infection, respiratory tract, upper
Infection, respiratory tract, lower
Infection, general
Infection, general
Infection, respiratory tract, lower

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cefuroxime axetil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[amino]carbonyloxy)methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-1-(acetoxy)ethyl ester, [6R]-[6Alpha, 7B(Z)]- [CAS]	15888-71-2 64544-07-6	GB 1571683	Cephalosporin, oral
cefuroxime sodium	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[amino]carbonyloxy)methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-1-(acetoxy)ethyl ester, [6R]-[6Alpha, 7B(Z)]- [CAS]	55268-75-2 56238-63-2	GB 1453049	Cephalosporin, injectable
Cefuzonam		82219-78-1		
celecoxib	Benzene-sulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)- [CAS]	169590-42-5	US 5760068	Antiarthritic, other
celastrol	Butanoic acid, octahydro-1,7,8-trihydroxy-6-indoliziny ester, [1S]-[1Alpha, 6B, 7Alpha, 8B, 8aB]- [CAS]	121104-96-9	US 5017563	Antiviral, other
celliprolol	Urea, N'-[3-acetyl-4-[[3-[(1,1'-dimethylethyl)amino]-2-hydroxypropoxy]phenyl]-N,N-diethyl- [CAS]	56980-93-9 57470-78-7 9004-58-4	GB 1441359	Antihypertensive, adrenergic
Cellulose Ethyl Hydroxyethyl Ether				
Centchroman		31477-60-8		
CEP-1347	9,12-Epoxy-1H-dindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethythio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10S,12R)-[CAS]	156177-65-0	WO 9731002	Antiparkinsonian
CEP-701	9,12-Epoxy-1H-dindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-[CAS]	111358-88-4		Anticancer, antimetabolite
Cephacetrile Sodium		23239-41-0		
Cephalexine		483-17-0		
Cephalexin		15886-71-2		

TABLE IV

Exempl of Indication
Infection, respiratory tract, upper
Infection, general
Arthritis, rheumatoid
Infection, hepatitis virus, general
Angina, unstable
Parkinson's disease
Cancer, prostate

TABLE IV

API Generic Name	API Chemical Name	CAS.No.	Patent Reference	Example of Therapeutic Use
Cephaloglycin		3577-1-3		
Cephaloridine		50-59-9		
Cephalosporin C		61-24-5		
Cephalothin		153-61-7		
Cephapirin Sodium		24356-60-3		
Cephadrine		38821-53-3		
Cerivastatin		145599-86-6		
Ceronapril		111223-26-8		
certoparin	Heparin [CAS]	9005-49-6		Anticoagulant
Ceruletide		17650-98-5		
Cerviprost	Prosta-5,13-dien-1-olc acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,-15S)-[CAS]	363-24-6		Formulation, dermal, topical
Cetalkonium Chloride		122-18-9		
Cetamolol		34919-98-7		
Cethexonium Bromide		1794-74-7		
cethromycin	2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetraone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinoliny)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexapyranosyl)oxy)-(3a S,4R,7R,9R,10R,11R,13R,15R,15aR)-[CAS]	205110-48-1	EP 929563	Macrolide antibiotic
Cetiedil		14176-10-4		
Cetirizine		83881-51-0		
cetirizine dihydrochloride	Acetic acid, [2-[4-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-, dihydrochloride [CAS]	83881-51-0 83881-52-1	EP 58146	Antiallergic, non-asthma
cetirizine+pseudoephedrine,UC B	Acetic acid, [2-[4-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-, dihydrochloride, Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*)]-	83881-52-1 90-82-4		Formulation, optimized, microencapsulate
Cetotiamine		137-76-8		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
C tolime		25394-78-9		
cetrazate	Benzenepropanoic acid, 4-[[4-(aminomethyl)cyclohexyl]carbonyloxy]-, trans-[CAS]	27724-98-5 34675-84-8	JP 48075547	Antiulcer
Cetraxate		34675-84-8		
Cetrimonium Bromide		57-09-0		
Cetorelix		120287-85-6		
Cetyl dimethylethylammonium Bromide		124-03-8		
Cetylpyridinium Chloride		123-03-5		
cevimeline	Spiro[1-azabicyclo[2.2.2]octane-3,5'-(1,3)oxathiolane], 2'-methyl-, cis-[CAS]	107220-27-9 107233-08-9	EP 205247	Stomatological
CG-1521	7-phenyl-2,4,6-heptatrienylhydroxamic acid			Anticancer, other
Chaulmoogric Acid		29106-32-9		
Chenodiol		474-25-9	EP 951465	Analgesic, other
CHF-3381				
Chlophedianol		791-35-5		
Chloracizine		800-22-6		
Chloral Betaine		2218-68-0		
Chloral Formamide		515-82-2		
chloral hydrate, SSP	1,1-Ethanediol, 2,2,2-trichloro- [CAS]	302-17-0		Formulation, transmucosal, systemic
Chlorambucil		305-03-3		
Chloramine-B		127-52-6		
Chloramine-T		127-65-1		
Chloraminophenamide		121-30-2		
Chloramphenicol		56-75-7		
Chlorazaniil		500-42-5		
Chlorbenzoxamine		522-18-9		
Chlorbetamide		97-27-8		
Chlorcyclizine		82-93-9		
Chlordantoin		5588-20-5		
Chlordiazepoxide		58-25-3		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Chlorguanide		500-92-5		
Chlorhexadol		3563-58-4		
chlorhexidine, Knowell	2,4,11,13-Tetraazatetradecanedimidamide, N,N"-bis(4-chlorophenyl)-3,12-dilino- [CAS]	55-56-1		Formulation, other
chlorhexidine, Perio	2,4,11,13-Tetraazatetradecanedimidamide, N,N"-bis(4-chlorophenyl)-3,12-dilino- [CAS]	55-56-1		Formulation, modified-release, >24hr
Chlorisondamine Chloride		69-27-2		
Chlormadinone Acetate		302-22-7		
Chlormerodrin		62-37-3		
Chlormezanone		80-77-3		
Chlormidazole		3689-76-7		
Chlornaphazine		494-03-1		
Chlorazodol		502-98-7		
Chlorophyll		1406-65-1		
Chloroprednisone		52080-57-6		
Chloroprocaine		3858-89-7		
Hydrochloride				
Chloropyramine		59-32-5		
Chloroquine		54-05-7		
Chibrothen		148-65-2		
Chlorothiazide		58-94-6		
Chlorotrianisene		569-57-3		
Chloroxine		773-76-2		
Chloroxylenol		88-04-0		
Chlorozotocin		54749-90-5		
chlorphenamine	2-Pyridinepropanamine, Gamma-(4-chlorophenyl)-N,N-dimethyl- [CAS]	132-22-9		Formulation, modified-release, other
Chlorphenesin		104-29-0		
Chlorphenesin Carbamate		886-74-8		
Chlorpheniramine		132-22-9		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Chlorphenoxamide		3576-64-5		
Chlorphenoxamine		77-38-3		
Chlorphentermine		461-78-9		
Chlorproethazine		84-01-5		
Chlorproguanil		537-21-3		
chlorproguanil + dapsons, GSK	4,4'-Sulfonyldianiline + 1-(3,4-Dichlorophenyl)5-isopropylbiguanide	537-21-3 80-08-0		Antimalarial
Chlorpromazine		50-53-3		
Chlorpropamide		94-20-2		
Chlorprothixene		113-59-7		
Chlorquinadol		72-80-0		
Chlortetracycline		57-62-5		
Chlorthalidone		77-36-1		
Chlorthenoxazin(e)		132-89-8		
Chlorzoxazone		95-25-0		
Cholic Acid		81-25-4		
Choline Alfoscerate		28319-77-9		
Choline Chloride		67-48-1		
Choline Salicylate		2016-36-6		
choline theophyllinate, Amarin	Ethanaminium, 2-hydroxy-N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1) [CAS]	4499-40-5		Formulation, modified-release, other
choline-L-alfoscerate	Ethanaminium, 2-[[[2,3-dihydroxypropoxy]hydroxyphosphinyloxy]-N,N,N-trimethyl-, hydroxide, inner salt, (R)-] [CAS]	28319-77-9	JP	Cognition enhancer
Chromocarb		4940-39-0		
Chromonar		804-10-4		
Chrysoidine		532-82-1		
CHS-828	Guanidine, N-[6-(4-chlorophenoxy)hexyl]-N'-cyano-N"-4-pyridinyl- [CAS]	200484-11-3	US	Anticancer, other

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
CI-1031	Glycine, N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methyl- [CAS]	183305-24-0	WO 9638421	Antianginal
CI-1040	Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- [CAS]	212631-79-3	WO 9837881	Anticancer, other
cibenzoline	1H-imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro- [CAS]	53267-01-9	GB 1417174	Antiarrhythmic
ciclesonide	Pregna-1,4-diene-3,20-dione 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy) (11B, 16Alpha). [CAS]	126544-47-6	DE 4129535	Asthma
ciclatanine	Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (+/-)- [CAS]	82747-58-6 89943-82-8	US 4383998	Antihypertensive, other
Cicletanine	3-Pyridinecarboxylic acid, 3,3,5-trimethylcyclohexyl ester, trans- [CAS]	89943-82-8		
ciclonicate		53449-58-4	DE 1910481	Vasodilator, peripheral
Ciclonicate		53449-58-4		
Ciclopirox		29342-05-0		
ciclopirox olamine	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd. with 2-aminoethanol (1:1) [CAS]	41621-49-2	US 3883545	Antifungal
Ciclosidomine		66564-16-7		
ciclosporin A, Chong Kun Dang	Cyclosporin A- [CAS]	59865-13-3		Formulation, optimized, microemulsion
cidofovir	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)- [CAS]	113852-37-2	EP 253412	Antiviral, other
cidofovir gel	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)- [CAS]			Antiviral, other
Cifenline		53267-01-9		

TABLE IV

Example of Indication
Angina, unstable
Cancer, general
Arrhythmia, general
Asthma
Cancer, lung, small cell
Infection, fungal, general
Transplant rejection, general
Infection, cytomegalovirus
Infection, herpes simplex virus

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cilastetron	4H-Pyrido[3,2,1-k]carbazol-11(8H)-one, 5,6,9,10-tetrahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-, (R)-, [CAS]	120635-74-7	EP 297651	GI inflammatory/bowel disorders
Cilastatin		82009-34-5		
	6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[(1-ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, [(1S,8S,9S,10S)-], (R)-, [CAS]	88768-40-5	GB 2128984	Antihypertensive, renin system
cilazapril	[1Alpha,9Alpha(R*)]-[CAS]	90139-06-3		
cilengitide	Cyclo(L-arginylglycyl-L-Alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl) [CAS]	188968-51-6	EP 770622	Anticancer, other
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester- [CAS]	102106-21-8	EP 161877	Antihypertensive, other
clindipine		132203-70-4		
Clindipine				
	Cis-4-cyano-4-[3-(cyclopentyl)-4-methoxyphenyl]cyclohexane-1-carboxylic acid	153259-65-5	US 5602157	COPD treatment
cilornilast				
cilostazol	2(1H)-Quinolone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-[CAS]	73963-72-1	GB 2033893	Antithrombotic
Cimetidine		51481-61-9		
	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,4} .0 ^{3,6} .0 ^{4,5}]nonane, 9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [(S)-(1Alpha,2B,4B,5Alpha,7B)]-[CAS]	51598-60-8	US 3853886	Antispasmodic
cimetropium bromide				
	1-naphthalenemethanamine, Alpha-methyl-N-[(3-{3-(trifluoromethyl)phenylpropyl}, (AlphaR)-, hydrochloride	384782-34-3		Hormone
cinacalcet hydrochloride		485-71-2		
Cinchonidine		118-10-5		
Cinchonine		132-60-5		
Cinchophen		23887-41-4		
Cinepazet		23887-46-9		
Cinepazide				

TABLE IV

Example of Indication
Irritable bowel syndrome
Hypertension, general
Cancer, lung, non-small cell
Hypertension, general
Chronic obstructive pulmonary disease
Peripheral vascular disease
Muscle spasm, general
Hyperparathyroidism

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cinepazide maleate	Piperazine, 1-[2-oxo-2-(1-pyrrolidinylethyl)-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-, (Z)-2-butenedioate (1:1)] [CAS]	26328-04-1	GB 1218581	Vasodilator, peripheral
Cinitapride		66564-14-5		
Cinmetacin		20168-99-4		
Cinnamedrine		90-86-8		
Cinnarizine		298-57-7		
cindolazepam	1H-1,4-Benzodiazepine-1-propanenitrile, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo- [CAS]	75696-02-5	DE 2950235	Hypnotic/Sedative
cinoxacin	[1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo- [CAS]	26657-80-9	GB 1296753	Quinolone antibacterial
Cinoxate		104-28-9		
Cinromide		58473-74-8		
Closteronel		89672-11-7		
cipamylline	1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- [CAS]	132210-43-6	EP 389282	Antipruritic/inflamm, allergic
cipralisant	1H-Imidazole, 4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]- [CAS]	213027-19-1	US 6008240	Psychostimulant
ciprolibrate	Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl- [CAS]	52214-84-3	GB 1365828	Hypolipaeamic/Antiatherosclerosis
ciprofloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	85721-33-1	US 4670444	Quinolone antibacterial
ciprofloxacin+fluocinolone, SAL	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- + (6Alpha, 11B, 16Alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-pregna-1,4-diene-3,20-dione			
Ciramadol		63269-31-8		Formulation, fixed-dose combinations

TABLE IV

Example of Indication
Peripheral vascular disease
Insomnia
Infection, urinary tract
Eczema, atopic
Attention deficit disorder
Hyperlipidaemia, general
Infection, general
Otitis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
cisapride	Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- [CAS]	81098-60-4	EP 76530	Gastroprokinetic
cisatracurium besylate	Isoquinolinium, 2,2'-[1,5-pentanediyldiisox(3-oxo-3,1-propanediyl)]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, [1R-[1'Alpha,2'Alpha(1'R',2'R')]], dibenzenesulfonate [CAS]	98946-42-8	US 5453510	Muscle relaxant
cisplatin	Platinum, diamminedichloro-, (SP-4-2)- [CAS]	15663-27-1	US 4177263	Anticancer, alkylating
Citalopram		59729-33-8		
citalopram hydrobromide	5-Isobenzofurancarboxonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-monohydrobromide [CAS]	59729-32-7	GB 1526331	Antidepressant
citicoline	Cytidine 5'-(trihydrogen diphosphate), P-[2-(trimethylammonio)ethyl]ester, hydroxide, inner salt [CAS]	987-78-0	JP 39006541	Cognition enhancer
Citlone		1195-16-0		
Citric Acid		77-92-9		
Citrulline		372-75-8		
cizolitrine citrate	Ethanamine, N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate [CAS]	142155-44-0		Urological
CJ-13610	4-(3-[4-(2-Methylimidazol-1-yl)-phenylsulfonyl]-phenyl)-tetrahydro-pyran-4-carboxylic acid amide			COPD treatment
CKD-602	1H-Pyran[3,4':8,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-1-[2-[(1-methylethyl)amino]ethyl]-, monohydrochloride, (4S)- [CAS]	213819-48-8	WO 9902530	Anticancer, other
cladribine	Adenosine, 2-chloro-2'-deoxy- [CAS]	4291-63-8	EP 173059	Anticancer, antimetabolite
Clanobutin		30544-61-7		

TABLE IV

Example of Indication
Surgery adjunct
Depression, general
Infarction, cerebral
Incontinence
Chronic obstructive pulmonary disease
Cancer, ovarian
Cancer, leukaemia, hairy cell

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
clarithromycin	Erythromycin, 6-O-methyl- [CAS]	81103-11-9	EP 41355	Macrolide antibiotic
Clavulanate Potassium, ticarcillin Disodium				
Clavulanic Acid		58001-44-8		
Clebopride		55905-53-8		
Clemastine		15686-51-8		
Clemizole		442-52-4		
Clenbuterol		37148-27-9		
Clenfazem		96125-53-0		
clevudipine	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester (±) [CAS]	167221-71-8	WO 9512578	Antihypertensive, other
clevudine	2,4-(1H,3H)-Pyrimidinedione, 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)-5-methyl- [CAS]	163252-36-6		Antiviral, other
Clidanac		28968-07-2		
Cfidinium Bromide		3485-62-9		
Clinafloxacin		105956-97-6		
Clindamycin		18323-44-9		
clindamycin + tretinoin, Yaman	L-threo-Alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[(1-methyl-4-propyl-2-pyrrolidinyl)carbonylamino]-1-thio-, (2S-trans)- + retinoic acid			Formulation, fixed-dose combinations
clindamycin	L-Threo-Alpha-D-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[(1-methyl-4-propyl-2-pyrrolidinyl)carbonylamino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-	18323-44-9 24729-96-2		Formulation, parenteral, other
Clinofibrate		30299-08-2		
Clinprost		88931-51-5		

TABLE IV

Example of Indication
Infection, respiratory tract, lower
Hypertension, general
Infection, hepatitis-B virus
Acne
Infection, gynaecological

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
clobazam	1H-1,5-Benzodiazepine-2,4-(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl- [CAS]	22316-47-8	GB 1214682	Anxiolytic
Clobenfurol		3611-72-1		
Clobenoside		29899-95-4		
Clobenzepam		1159-93-9		
Clobenzorex		13364-32-4		
Clobenztropine		5627-46-3		
Clobetasol		25122-41-2		
	Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11B,16B)- [CAS]	25122-41-2		Formulation, dermal, topical
clobetasol, Solitec		54063-32-0		
Clobetasone				
	Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16B)- [CAS]	25122-57-0	GB 1253631	Antipruritic/inflam, allergic
clobetasone butyrate		14860-49-2		
Clobutinol		47739-98-0		
Clocapramine		298-55-5		
Clocinlazine		77175-51-0		
Cloconazole		4828-27-7		
Clocortolone				
	Phosphonic acid, (dichloromethylene)bis-, disodium salt- [CAS]	22560-50-5		Osteoporosis treatment
clodronate disodium, Abiogen				
	Phosphonic acid, (dichloromethylene)bis-, disodium salt- [CAS]	22560-50-5		Anticancer, hormonal
Clodronic Acid		10596-23-3		
	2-chloro-9-(2-deoxy-2-fluoro-8-D-arabinofurasonyl)adenine			Anticancer, antimetabolite
clotarabine				
	3-(p-chloroanilo)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine	2030-63-9		Formulation, optimized, microencapsulate
clotazimine		671-95-4		
Clofenamide		637-07-0		
Clofibrate		882-09-7		
Clofibric Acid				

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Cloflucarban		369-77-7		
Clofoctol		37693-01-9		
Cloforex		14261-75-7		
Clomacran		5310-55-4		
Clomestrone		4091-75-2		
Clom tacin		25803-14-9		
Clomethiazole		533-45-9		
Clometocillin		1926-49-4		
Clomiphene		911-45-5		
Clomipramine		303-49-1		
Clomocyclin		1181-54-0		
clonazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- [CAS]	1622-61-3	US 4316897	Antiepileptic
clonidine, Alza	1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [CAS]	4205-90-7	US 4060084	Formulation, transdermal, patch
Clonitazene		3861-76-5		
Clonitrat		2612-33-1		
Clonixin		17737-65-4		
Clopamide		636-54-4		
Clopenthixol		982-24-1		
Cloperastine		3703-76-2		
Clopidogrel		113665-84-2		
clopidogrel hydrogen sulfate	Thieno[3,2-c]pyridine-5(4H)-acetic acid, Alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)-, sulfate (1:1) [CAS]	120202-48-4 90055-48-4	EP 99802	Antithrombotic
Clopirac		42779-82-8		
Cloprednol		5251-34-3		
cloranolol	2-Propanol, 1-(2,5-dichlorophenoxy)-3-[[1,1-dimethylethyl]amino]- [CAS]	39563-28-5 54247-25-5	US 4310549	Antihypertensive, adrenergic
Cloranolol		39563-28-5		
Clorazepic Acid		23887-31-2		
Clorexolone		2127-1-7		
cloricromene	Acetic acid, [[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]-, ethyl ester [CAS]	68206-94-0	US 4349566	Vasodilator, coronary

TABLE IV

Example of Indication
Epilepsy, general
Hypertension, general
Infarction, myocardial
Peripheral vascular disease

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Clorindione		1146-99-2		
Clorprenaline		3811-25-4		
Clortermine		10389-73-8		
Clospirazin		24527-27-3		
Clostebol		1093-58-9		
Clothiapine		2058-52-8		
	2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-[CAS]	33671-46-4	US 3849405	Anxiolytic
clotiazepam	1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole	23593-75-1	US 3705172	Antifungal
clotrimazole	Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11R,16R)-, mixt. with 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole [CAS]	92522-91-3		Formulation, fixed-dose combinations
clotrimazole + betamethasone	1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole			
clotrimazole, Bentley		61-72-3		Formulation, dermal, topical
Cloxacillin				
	Oxazolol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro- [CAS]	24166-13-0	US 3772371	Anxiolytic
cloxazolam		24166-13-0		
Cloazolam		53608-96-1		
Cloxotestosterone		130-16-5		
Cloxyguin	5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)- [CAS]	5786-21-0	US 3539573	Neuroleptic
clozapine	Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran			
CMI-392	2-Naphthacene-carboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- [CAS]	193739-23-0	US 5648486	Antipsoriasis
CMT-3		15866-90-7	US 5637696	Anticancer, other

TABLE IV

Example of Indication
Anxiety, general
Infection, fungal, general
Infection, onychomycosis
Schizophrenia
Psoriasis
Cancer, sarcoma, Kaposi's

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
CNI-1493	Decanediamide, N,N'-bis[3,5-bis(1-[(aminolinomethyl)hydrazono]ethyl)phenyl]-, tetrahydrochloride [CAS]	164301-51-3	US 5750573	Anti-inflammatory
CNS-5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine [CAS]	150754-76-7	WO 9427591	Analgesic, other
Cobamamide		13870-90-1		
Cocacethylene		529-38-4		
Cocaine		50-36-2		
Codeine		76-57-3		
Codeine Phosphate		52-28-8		
CoFactor	5,10 methylene - tetrahydrofolate			Anticancer, antimetabolite
Colchicine		64-86-8		
	1-Hexanaminium, N,N,N-trimethyl-5-(2-propenylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS]	182815-44-7	US 5807669	Hypolipaeic/Antiatherosclerosis
colesevelam	1H-imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS]	95522-45-5	JP 59155421	Hypolipaeic/Antiatherosclerosis
Colectilan		26658-42-4		
Colestipol	6-(3-dimethylaminopropyl)forskolin-[CAS]	138605-00-2	EP 222413	Cardio stimulant
colforsin daropate				
	3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, inner salt, 4-oxide, (R)- [CAS]	63-89-8 99732-49-7	US 4826821	Lung Surfactant
colfosceril		138331-02-9		Formulation, implant
Collagraft		1398-78-3		
Colocynthin		1247-71-8		
Colpormon				
	1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)- [CAS]			
coltracetam		135463-81-9	EP 427636	Cognition enhancer
combretastatin A-4 prodrug	disodium combretastatin-A-4-3-O-phosphate			Anticancer, other

TABLE IV

Example of Indication
Psoriasis
Pain, neuropathic
Cancer, colorectal
Hyperlipidaemia, general
Hypercholesterolaemia
Heart failure
Respiratory distress syndrome, infant
Regeneration, bone
Alzheimer's disease
Cancer, thyroid

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
compound B, Pharmacor	[1,1'-Biphenyl]-2-carboxamide, N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1-benzazepin-6(1H)-yl)carbonyl]phenyl]-monohydrochloride [CAS]		US 6362165	Antiviral; anti-HIV
conivaptan hydrochloride	Hyaluronic acid [CAS]	168626-94-6	WO 9503305	GI inflammatory/bowel disorders
Connetivina		9004-61-9		Vulnerary
Convallatoxin		508-75-8		
Coparaffinate		8001-60-3		
Corticorelin Ovine Trifluorate				
Corticosterone		50-22-6		
Cortisone		53-06-5		
Cortivazol		1110-40-3		
Cosyntropin		16960-16-0		
Cotarnine		82-54-2		
Cotinine		486-56-6		
co-trimazine	Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	39474-58-3		Trimethoprim and analogues
Coumetarol		4366-18-1		
CP-248	1H-Indene-3-acetamide; 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene], (1Z)- [CAS]	200803-37-8	WO 9747303	Anticancer, other
CP-461			US 5948779	Anticancer, other
CPC-211	Acetic acid, dichloro-, sodium salt [CAS]	2156-56-1		Neuroprotective
CPI-1189	CPI 1189 [CAS]	210475-67-5	WO 9631462	Cognition enhancer
CRA-0450			WO 0202549	Anxiolytic
creatinal-O-phosphate	Guanidine, N-methyl-N-[2-(phosphonoxy)ethyl]- [CAS]	6803-79-3		Antianginal
CRL-5661	Oxirane, methyl-, polymer with oxirane, block [CAS]	106392-12-5	US 4837014	Antisticking

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
crobeneline	(2R,6S)-3-[2-(S)-Benzoyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ol		WO 9914199	Neuroprotective
croconazole	1H-Imidazole, 1-[1-[2-(3-chlorophenyl)methoxy]phenyl]ethenyl]-[CAS]	77175-51-0	DE 3021467	Antifungal
cromoglicic acid, Transphyto	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxy)]bis(4-oxo- [CAS]	53736-52-0		Formulation, mucosal, topical
Cromolyn		16110-51-3		
cromolyn sodium, Durect	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxy)]bis(4-oxo-, disodium salt [CAS]			Formulation, modified-release, other
cromolyn sodium, Emisphere	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxy)]bis(4-oxo-, disodium salt [CAS]			Formulation, oral, other
cromolyn sodium, Premaire	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[[2-hydroxy-1,3-propanediyl]bis(oxy)]bis(4-oxo-, disodium salt [CAS]	15826-37-6		Formulation, inhalable, solution
Cropropamide		633-47-6		
Crotamiton		483-63-6		
Crotethamide		6168-76-9		
Crystacide			US 4557935	Formulation, dermal, topical
CS-502	D		EP 799823	Analgesic, other
CS-758	4-[(1E,3E)-4-(trans-5-[[1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]-1,3-butadienyl-3-fluorobenzonitrile			Antifungal

TABLE IV

Example of Indication
Ischaemia, cerebral
Infection, fungal, general
Conjunctivitis
Asthma
Asthma
Infection, dermatological
Pain, general
Infection, fungal, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
CS-894	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3R)-5-oxo-3-pyrrolidinylthio)- (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)- [CAS]	157542-49-9	EP 599512	Beta-lactam antibiotic
CT-052923	[(2H-benzo[d][1,3-dioxolan-5-methylamino][4-(6,7-dimethoxyquinazolin-4-yl)piperazinyl)methane-1-thione			Cardiovascular
CT-32228	N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-1,3,5-triazine-2,4-diamine			Anticancer, other
Cupric Citrate		866-82-0		
Cuproxoline		13007-93-7		
GVT-2584	Ethanol, 2,2'-[[6-[[[(4-methoxyphenyl)methylamino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bis-[CAS]	19986-75-9	WO 9805335	Cardiovascular
CX-659S	[(S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-methyl-1-phenyl-2,4-(1H,3H)-pyrimidinone			Dermatological
Cyacetacide		140-87-4		
Cyamemazine		3546-03-0		
Cyanidin Chloride		528-58-5		
CYC400			WO 00172745	Anticancer, other
Cyclacillin		3485-14-1		
Cyclandelate		456-59-7		
Cyclazocine		3572-80-3		
Cyclexanone		15301-52-7		
Cyclexedrine		532-52-5		
cyclidrol, Convi	3-Cyclohexene-1-methanol, 5-hydroxy-Alpha,Alpha,4-trimethyl- [CAS]	498-71-5		COPD treatment, Respiratory
cyclin D1 inhibitors, Topo			US 6033943	Anticancer, hormonal

TABLE IV

Example of Indication
Infection, general
Restenosis
Cancer, general
Restenosis
Eczema, general
Cancer, general
Bronchitis, chronic
Cancer, breast

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Cyclizine		82-92-8		
Cyclobarbitol		52-31-3		
Cyclobendazole		31431-43-3		
cyclobenzaprine, Alza	1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS]	303-53-7		Formulation, modified-release, other
cyclobenzaprine, I2R	3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propamide			Formulation, modified-release, immediate
cyclobenzaprine, Vela	1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS]	303-53-7		Formulation, oral, other
Cyclobutylol		512-16-3		
Cyclocumaryl		518-20-7		
Cyclodrine		52109-93-0		
Cyclofenil		2624-43-3		
Cycloguanil		516-21-2		
Cyclomethycaine		139-62-8		
Cyclonium Iodide		6577-41-9		
Cyclopentamine		102-45-4		
Cyclopenthiiazide		742-20-1		
Cyclopentobarbital		76-68-6		
Cyclopentolate		512-15-2		
cyclophosphamide, Pro-Pharm	N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate	50-18-0 6055-19-2		Formulation, parenteral, targeted
cyclopiroxalamine, FOAM-SYS	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd with 2-aminoethanol(1:1) [CAS]	41621-49-2		Formulation, transdermal, other
Cycloserine		68-41-7		
Cyclothiazide		2259-96-3		
Cyclovalone		579-23-7		
Cymarol		508-77-0		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
cymsertine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrol[2,3-b]indol-5-yl ester [CAS]	145209-39-8	WO 9902154	Cognition enhancer
Cynarin(e)		30964-13-7		
CYP26 inhibitors, derm			US 6063606	Dermatological
Cyproheptadine		129-03-3		
cyproterone	(18,28)-6-Chloro-1,2-dihydro-17-hydroxy-3H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]	2098-66-0		Radio/chemoprotective
Cysteamine		60-23-1		
cystic fibrosis ther, BI	[[4-[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl ester			Cystic fibrosis treatment
cytarabine octofate	2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphiny]-β-D-arabinofuranosyl]-, monosodium salt [CAS]	65093-40-5	EP 239015	Anticancer, antimetabolite
cytarabine, DepoFoam	2(1H)-Pyrimidinone, 4-amino-1-β-D-arabino furanosyl- [CAS]	147-94-4		Formulation, modified-release, other
D-24851	N-(Pyridin-4-yl)-1-(4-chlorobenzyl)-indol-3-yl)-glyoxyl- amide)			Anticancer, other
D-4418	8-Methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide			Antiasthma
DA-5018	Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride [CAS]	174661-97-3	US 5242944	Analgesic, other
DA-6034			US 6025387	GI inflammatory/bowel disorders
DA-7867			KR 9957803	Antibacterial, other
DA-7911			KR 56034	Antiarthritic, other

TABLE IV

Example of Indication
Alzheimer's disease
Unspecified
Chemotherapy-induced injury, general
Cystic fibrosis
Myelodysplastic syndrome
Cancer, brain
Cancer, general
Asthma
Pain, musculoskeletal
Crohn's disease
Infection, general
Arthritis, rheumatoid

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
DA-8159	3-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo-[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide		KR 353014	Male sexual dysfunction
Dacarbazine		4342-3-4		
Dacilzumab		152923-56-3		
Dactinomycin		50-76-0		
dalbavancin	5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-58-O-[2-deoxy-2-(10-methylundecanamido)-8-D-glucopyranosyl]-38-[N-[3-(dimethylamino)propyl]carbamoyl]-42-O-Alpha-D-mannopyranosyl-N15-methylristomycin A aglycone	171500-79-1		Peptide antibiotic
Dalifopristin		112362-50-2		
dalifopristin + quinupristin	Virginiamycin M1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26R,27S)-, mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid) virginiamycin, S1- [CAS]	126602-89-9	EP 248703	Antibiotic, other
dalteparin sodium	Heparin-, sodium salt [CAS]	9041-08-1	US 4303651	Anticoagulant
Daltroban		79094-20-5		
delta-Aminolevulinic Acid		106-60-5		
danaparoid sodium			EP 66908	Anticoagulant
danazol	Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17Alpha)- [CAS]	17230-88-5	GB 905844	Menstruation disorders
Danthron		117-10-2		
Dantrolen		7261-97-4		
dapiprazole, ophthalmic	1,2,4-Triazolo[4,3-a]pyridine, 5,6,7,8-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- [CAS]	72822-12-9 72822-13-0	US 4252721	Ophthalmological

TABLE IV

Example of Indication
Sexual dysfunction, male, general
Infection, dermatological
Infection, respiratory tract, general
Thromboprophylaxis
Thrombosis, venous
Glaucoma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
capivirine	4-[[4-(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl]amino]benzonitrile	244767-67-7		Antiviral, anti-HIV
dapoxetine	(+)-(S)-N,N-dimethyl-Alpha-[2-(1-naphthyl-oxy)ethyl]benzylamine HCl	119356-77-3	EP 288188	Male sexual dysfunction
dapsone	4,4'-Sulfonyldianiline	80-08-0		Formulation, dermal, topical
daptomycin	Daptomycin [CAS]	103060-53-3	EP 178152	Peptide antibiotic
Darbepoetin Alfa				
darifenacin	3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzotriazinyl)ethyl]-Alpha, Alpha-diphenyl-, (S)- [CAS]	133099-04-4	EP 388054	Urological
daunorubicin	5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-[CAS]	20830-81-3	US 5441745	Formulation, optimized, liposomes
DAX, SolClone	3-diallyl-8-cyclohexylxanthine			Cystic fibrosis treatment
DB-67	7-tert-Butyldimethylsilyl-10-hydroxycamptothecin			Anticancer, other
d-Camphocarboxylic Acid		18530-30-8		
DCF-987	Dextran		US 5514665	Formulation, other
DDT		50-29-3		
Deaminooxytocin		113-78-0		
Deanol		108-01-0		
Debrisoquin		1131-64-2		
Decamethonium Bromide		541-22-0		
Decimemide		14817-09-5		
decitabine	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-[CAS]	23339-46-0 2353-33-5		Anticancer, antimetabolite
decipramide	Benzamide, 4-amino-3-chloro-N-(2-diethylamino)ethyl- [CAS]	891-60-1	WO 9732582	Anticancer, other

TABLE IV

Example of Indication
Infection, HIV/AIDS
Premature-ejaculation
Acne
Infection, dermatological
Overactive bladder
Cancer, sarcoma, Kaposi's
Cystic fibrosis
Cancer, general
Cystic fibrosis
Myelodysplastic syndrome
Cancer, colorectal

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Deferiprone		30652-11-0		
Deferoxamine		70-51-9		
dellazacort	5H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2-methyl-, (11R,16R)- [CAS]	14484-47-0 74712-90-6	GB 1077393	Hormone
Deflazacort		14484-47-0		
Defosfamide		3733-81-1		
degarelix	N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-[[[(4S)-2,6-dioxohexahydro-2H-pyrimidin-4-yl]carbamoyl]amino]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	214766-78-6		Anticancer, hormonal
dehydroascorbic acid, Progenics	L-threo-2,3-Hexodiolosonic acid gamma-lactone	490-83-5		Cognition enhancer
Dehydrocholic Acid		81-23-2		
Dehydroemetine		4914-30-1		
delapril	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-{1-(ethoxycarbonyl)-3-phenylpropyl}-L-alanyl]-, (S)- [CAS]	83435-66-9 83435-67-0	EP 51391	Antihypertensive, renin system
delapril+mandipine, Chiesi	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-{1-(ethoxycarbonyl)-3-phenylpropyl}-L-alanyl]-, (S)-3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]		FR 2733911	Formulation, fixed-dose combinations
delavirdine	Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl- [CAS]	136817-59-9	WO 9109849	Antiviral, anti-HIV
Delavirdine Mesylate				
Delmadinone Acetate		13698-49-2		
Delmopinol		79874-76-3		

TABLE IV

Example of Indication
Asthma
Cancer, prostate
Alzheimer's disease
Hypertension, general
Hypertension, general
Infection, HIV/AIDS

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
delorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro- [CAS]	2894-87-9	CH 408029	Anxiolytic
delucemine hydrochloride	3,3-Bis-(m-fluorophenyl)-N-methylpropylamine hydrochloride- [CAS]	186495-99-8		Neuroprotective
Demanyl Phosphate		6909-62-2		
Demecarium Bromide		56-94-0		
demeclocycline, Elan	2-Naphthacene-carboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-, [4S-(4 α),4a α],5 α Alpha,6 β ,12aAlpha)-[CAS]	127-33-3		Formulation, modified-release, <=24hr
Dem colcine		477-30-5		
Demegestone		10116-22-0		
Demexiptiline		24701-51-7		
denaverine hydrochloride	Benzeneacetic acid, Alpha-(2-ethylbutoxy)-Alpha-phenyl-, 2-(dimethylamino)ethyl ester, hydrochloride [CAS]	3321-06-0	DE 4133785	Analgesic, NSAID
Denileukin Diffitox		173146-27-5		
Denopamine		71771-90-9		
Denopterlin		22006-84-4		
Deoxycholic Acid		83-44-3		
Deoxycorticosterone		64-85-7		
Deoxycorticosterone		56-47-3		
Ac tate				
Deoxydihydrostreptomycin		26086-49-7		
Deoxyepinephrine		501-15-5		
D preotide		161982-62-3		
depsipeptide	L-Valine, N-[(3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-, (4-1)-lactone, cyclic (1-2)-disulfide [CAS]	128517-07-7	EP 352846	Anticancer, antibiotic
Deptropine		604-51-3		
Dequalinium Chloride		522-51-0		

TABLE IV

Example of Indication
Ischaemia, cerebral
Infection, general
Pain, musculoskeletal
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
deslazaine	Benzoic acid, 2-hydroxy-5-[[4-[3-(4-(2-methyl-1H-imidazol[4,5-c]pyridin-1-yl)methyl]-1-piperidinyl)-3-oxo-1-phenyl-1-propenyl]phenyl]azo] (Z) [CAS]	188913-57-7 188913-58-8	US 5747477	Anti-inflammatory
Deserpidine		131-01-1		
desferrioxamine mesylate	Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy- [CAS]	70-51-9		Antidote
Desflurane		57041-67-5		
Desipramine		50-47-5		
Deslanoside		17598-65-1		
desloratadine	5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- [CAS]	100643-71-8	US 5595997	Antiallergic, non-asthma
deslorelin	Luteinizing hormone-releasing factor (p1g), 6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57773-65-6	US 4034082	Releasing hormones
desmopressin	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]	16679-58-6	DE 2948345	Hormone
desmopressin, Columbia	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]			Formulation, transdermal, other
Desogestrel		54024-22-5		
desogestrel + estradiol, Akzo	Estra-1,3,5(10)-triene-3,17-diol (17 β), mixt. with (17 α)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol [CAS]	122364-17-4		Menopausal disorders
desogestrel, Akzo Nobel	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)- [CAS]	54024-55-5		Formulation, oral, other
desogestrel+ethinylestrad (1)	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)- [CAS]	54024-22-5 71198-35-7	US 3927046	Formulation, oral, other
desogestrel+ethinylestrad (2)	18-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17 α)-, mixt. with (17 α)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol- [CAS]	71198-35-7		Formulation, modified-release, multi
Desomorphine		427-00-9		
Desonide		638-94-8		
Desoximetasone		382-67-2		

TABLE IV

Example of Indication
Colitis, ulcerative
Poisoning, metal
Rhinitis, allergic, perennial
Cancer, prostate
Enuresis
Unspecified
Hormone replacement therapy
Contraceptive, female
Contraceptive, female

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Detaxtran		9015-73-0		
Devacade			WO 9308176	Analgescic, other
Dexamethasone		50-02-2		
dexamethasone sodium phosphate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonoxy)-, disodium salt, (11B,16Alpha)- [CAS]	2392-39-4 312-93-6		Formulation, mucosal, topical
dexamethasone, Oculex	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11B,16Alpha)- [CAS]	50-02-2		Formulation, other
dexanabinol	6H-Dibenz[a,b]pyran-9-methanol, 3-(1,1-dimethyl-2-propyl)-5a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)- [CAS]	112924-45-5	EP 427518	Neuroprotective
dexcedotril	Glycine, N-[2-(acetylthio)methyl]-1-oxo-3-phenylpropyl-, phenylmethyl ester, (R)-, [CAS]	112573-72-5	EP 318377	Alimentary/Metabolic, other
dexelaxan	1H-imidazole, 2-(2-ethyl-2,3-dihydro-2-benzotriazinyl)-4,5-dihydro- [CAS]	89197-00-2 89197-32-0	EP 71368	Cognition enhancer
Dextimidine		21888-98-2		
dexibuprofen	Benzenecarboxylic acid, Alpha-methyl-4-(2-methylpropyl)-, (AlphaS)- [CAS]	51146-56-6		Analgescic, NSAID
dexketoprofen, Menarini	Benzenecarboxylic acid, 3-benzoyl-Alpha-methyl-, (S)- [CAS]	22161-81-5		Anti-inflammatory
dexloxiglumide	Penicilic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (R)- [CAS]	119817-90-2	EP 0344184	GI inflammatory/bowel disorders
dexmedetomidine	1H-imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, (R)- [CAS]	113775-47-6 86347-15-1	EP 187471	Hypnotic/Sedative
Dexm detomidine		113775-47-6		
dexmethylphenidate HCl/Celgene	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester, hydrochloride, (AlphaR,2R)-	19282-68-1 81-13-0		Psychostimulant
Dexpanthenol				
dexrazoxane	2,6-Piperazine-dione, 4,4'-(1-methyl-1,2-ethanediyldi)-, (S)- [CAS]	24584-09-6	DE 1910283	Radio/chemoprotective
Dextran-1	Dextran [CAS]	9004-54-0		Plasma substitute

TABLE IV

Example of Indication
Pain, general
Inflammation, ocular
Inflammation, ocular
Head trauma
Unspecified
Alzheimer's disease
Pain, general
Inflammation, general
Irritable bowel syndrome
Anaesthesia
Attention deficit disorder
Chemotherapy-induced injury, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Dextranomer		56087-11-7		
Dextroamphetamine		51-64-9		
dextromethorphan HBr, Pennkine	Morphinan, 3-methoxy-17-methyl-, (9 α), 13 α), 14 α), hydrobromide, monohydrate			
dextromethorphan, IriSys	Morphinan, 3-methoxy-17-methyl-, (9 α), 13 α), 14 α), [CAS]	6700-34-1	US 4221788	Formulation, oral, other
Dextromoramide		125-71-3		Formulation, fixed-dose combinations
		357-56-2		
	Benzeneethanol, Alpha-[2-(dimethylamino)-1-methyl-ethyl]-Alpha-phenyl-, propanoate (ester), [S-(R*, S*)], [CAS]	469-62-5		Formulation, modified-release, other
Dezocine		53648-55-8		
DF-1012	N-Tropyl 7-azaindol-3-ylcarboxamide	163220-65-3	WO 9504742	Respiratory
DFA-IV	di-D-fructofuranose 2,6':6,2' dianhydride		US 5700832	Antianemic
d-F nchone		4695-62-9		
D-Glucuronolactone		32449-92-6		
Diab II	Diab II	309959-85-2	US 6153632	Antidiabetic
diacerein	2-Anthracenecarboxylic acid, 4,5-bis(acyloxy)-9,10-dihydro-9,10-dioxo-[CAS]	13739-02-1	US 4244968	Antiathritic, other
Diampromide		552-25-0		
Diamthazole		136-96-9		
Dihydrochloride		5964-62-5		
Diathymosulfone		737-31-5		
Diatrizoate Sodium		439-14-5		Formulation, parenteral, other
diazepam emulsion, Pharmacia	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-, [CAS]			
diazepam, Dumex-Alpha	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-, [CAS]	439-14-5		Formulation, transmucosal, systemic
diazepam, Elan	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-, [CAS]	439-14-5		Formulation, transmucosal, systemic
Diaziquone		57998-68-2		
Diazoxide		364-98-7		

TABLE IV

Example of Indication
Cough
Emotional lability
Pain, general
Respiratory disease, general
Anaemia, aplastic
Diabetes, Type II
Arthritis, rheumatoid
Anxiety, general
Anxiety, general
Epilepsy, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Dibekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt) [CAS]	34493-98-6		
dibekacin sulfate		34493-98-6 58980-55-5	GB 1349302	Aminoglycoside antibiotic
Dibenzepin		4498-32-2		
Dibromopropamide		496-00-4		
Dibucaine Hydrochloride		61-12-1		
Dichloralphenazone		480-30-8		
Dichloramine T		473-34-7		
Dichlorisone		7008-26-6		
Dichlorobenzyl Alcohol		177-82-8		
Dichlorophen		97-23-4		
Dichlorophenarsine		536-29-8		
Hydrochloride				
Dichlorophenamide		120-97-8		
diclofenac + HA, SkyePharma	Hyaluronic acid + benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]- [CAS]			Formulation, transdermal, systemic
diclofenac gel, SkyePharma	Benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]- [CAS]	15307-86-5		Formulation, mucosal, topical
diclofenac once-daily, SSP	Benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt [CAS]	15307-79-6 15307-86-5		Formulation, modified-release, <=24hr
diclofenac potassium	Benzenecarboxylic acid, 2-[(2,6-dichlorophenyl)amino]-, monopotassium salt- [CAS]	15307-81-0		Anti-inflammatory
Dicloxacillin		3116-76-5		
Dicumamol		66-76-2		
Dicyclomine		77-19-0		
didanosine	Inosine, 2',3'-dideoxy- [CAS]	69655-05-6	US 4861759	Antiviral, anti-HIV
Dideoxyadenosine		4097-22-7		
didox	Benzamide, N,3,4-trihydroxy- [CAS]	69839-89-4	US 4263322	Anticancer, antimetabolite
Dienestrol		84-17-3		

TABLE IV

Example of Indication
Infection, general
Keratosis
Pain, general
Pain, general
Pain, general
Infection, HIV/AIDS
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dienogest	19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)-(CAS)	65928-58-7	GB 1524917	Menstruation disorders
dienogest+estradiol, sequentia	19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)-(CAS) + Estra-1,3,5(10)-triene-3,17-diol(17 β)			Formulation, fixed-dose combinations
Diethadione		702-54-5		
Diethazine		60-91-3		
Diethylbromacetamide		511-70-6		
Diethylcarbamazine		90-89-1		
diethylpropion, Biovail	1-Propanone, 2-(diethylamino)-1-phenyl- [CAS]	90-84-6		Formulation, modified-release, <=24hr
Diethylstilbestrol		56-53-1		
Difemrine		80387-96-8		
Difenamizole		20170-20-1		
Difenoxin		28782-42-5		
Difenpiramide		51484-40-3		
difenotecan	(5R)-5-Ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino[3',4':6,indolizino[1,2-b]quinoline-3,15-dione			
Diflorasone		220997-97-7		Anticancer, other
diflorasone diacetate		2557-49-5		
Difloxacin	Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6 α), (11 β), (16 β)-, [CAS]	33564-31-7	US 3980778	Antipsoriasis
Diflucortolone		98106-17-3		
diflunisal		6/9/2607		
Diflunisal	2,4'-difluoro-4'-hydroxy[1,1'-biphenyl]-3-carboxylic acid	23674-86-4	GB 1175212	Analgesic, NSAID
Difluprednate		22494-42-4		
Digitalin		23674-86-4		
Digitoxin		752-61-4		
Digoxin		71-63-6		
		20830-75-5		

TABLE IV

Example of Indication
Endometriosis
Contraceptive, female
Obesity
Cancer, general
Pain, post-operative

TABLE IV

API Generic Name	API Chemical Nam	CAS No.	Patent Reference	Example of Therapeutic Use
digoxin, Beiersdorf	Card-20(22)-enolide, 3-[(O-2,6-dideoxy-8-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-8-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-8-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (9S,5S,12S)-, [CAS]	20830-75-5	US 4088750	Formulation, oral, enteric-coated
Dihexyverine		561-77-3		
Dihydralazine		484-23-1		
Dihydrocodeine		125-28-0		
Dihydrocodeinone Enol Acetate		466-90-0		
dihydroergocryptine, Poli	Ergocryptine, dihydro-, [CAS]	25447-66-9		Formulation, other
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)-, [CAS]	511-12-6	6495535	Formulation, modified-release, other
dihydroergotamine SR, Elthypha				
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)-, [CAS]	511-12-6		Formulation, modified-release, other
dihydroergotamine, bioMerieux				
	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)-, [CAS]	511-12-6		Formulation, modified-release, other
dihydroergotamine, Tempo				
Dihydromorphone		509-60-4		
Dihydrostreptomycin		128-46-1		
Dihydrotachysterol		67-96-9		
Dihydroxyaluminum		13682-92-3		
Aminoacetate				
Dihydroxyaluminum		539-68-4		
Sodium Carbonate				
Disopromine		5966-41-6		
Disopropyl Paraonon		3254-66-8		
Disopropylamine		660-27-5		
Dichloroacetate				

TABLE IV

Example of Indication
Heart failure
Depression, general
Migraine
Migraine
Migraine

TABLE IV

API Generic Nam	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dilazep	Benzoic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)di-3,1-propanediyl ester [CAS]	35698-87-4	JP 51095086	Vasodilator, coronary
Difevalol		75659-07-3		
Diloxanide		579-38-4		
diloxanide furoate	2-Furan-carboxylic acid, 4-[(dichloroacetyl)methylamino]phenyl ester [CAS]	3736-81-0		Amoebicide
diltiazem	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7	US 4721619 US 5529791 EP 322277	Antianginal
Diltiazem		42399-41-7		
Diltiazem Hydrochloride				
Diltiazem Hydrochloride				
diltiazem once-daily, Bago	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem once-daily, Biov	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7	US 5529791	Formulation, modified-release, <=24hr
diltiazem once-daily, Elan	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem once-daily, Biovall-2	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]			Formulation, modified-release, <=24hr
diltiazem SR, Ethypharm	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7		Formulation, modified-release, other

TABLE IV

Example of Indication
Angina, general
Hypertension, general
Angina, general
Hypertension, general
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
diltiazem twice-daily, Elan	(1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Alza	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Amarin	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Andrx, PPDS	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, other
diltiazem, Andrx, SMHS	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, oral, solubility-enhanced
diltiazem, Diffutab	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, Douglas	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7		Formulation, modified-release, other
diltiazem, Dov Pharmaceutical	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7		Formulation, modified-release, multi
diltiazem, GEOMATRIX	((1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7		Formulation, modified-release, multi

TABLE IV

Example of Indication
Angina, general
Hypertension, general
Angina, general
Angina, general
Angina, general
Angina, general
Angina, general
Angina, general
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Exmpl of Th rapautic Use
diltiazem, once-daily, Mundipharma	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
diltiazem, once-daily, Synthe	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis) [CAS]	42399-41-7	EP 322277	Formulation, modified-release, <=24hr
diltiazem, SURECAPS	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	42399-41-7		Formulation, modified-release, <=24hr
Dimecrotic Acid		7706-67-4		
Dimeflin		1165-48-6		
Dimemorfan		36309-01-0		
Dimenhydrinate		523-87-5		
Dimenoxadol		509-78-4		
Dimepheptanol		545-90-4		
Dimercaprol		59-52-9		
Dimetacrine		4757-55-5		
Dimethadione		695-53-4		
Dimethazan		519-30-2		
Dimethindene		5636-83-9		
Dimethisoquin		86-80-6		
Dimethisterone		79-64-1		
Dimethocaine		94-15-5		
Dimethoxanate		477-93-0		
Dimethyl Sulfoxide		67-68-5		
Dimethylthiambutene		524-84-5		
Dimetofrine		22950-29-4		
Dimorpholamine		119-48-2		
di-noprostone, Controlled Ther	Prosta-5,13-dien-1-olc acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,15S)- [CAS]			Formulation, modified-release, <=24hr
diosmectite	Smecta- [CAS]	363-24-6	FR 2770778	Antidiarrhoeal
		110070-78-5		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
diostmin	4H-1-Benzopyran-4-one, 7-[(6-O-(6-deoxy-Alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)- [CAS]	526-27-4	DE 2602314	Vasoprotective, systemic
Diosmin		520-27-4		
Dioxadrol		6495-46-1		
Dioxaphetyl Butyrate		467-86-7		
Dioxethedrine		497-75-6		
Dioxybenzone		131-53-3		
Diphemanil		62-97-5		
Methylsulfate				
Diphenadione		82-66-6		
Diphencyprone		886-38-4		
Diphenhydramine		58-73-1		
Diphenidol		972-02-1		
Diphenoxylate		915-30-0		
Diphenylpyraline		147-20-6		
Diphetarsons		515-76-4		
Diphtheria & Tetanus Toxoids And Acellular Pertussis Vaccine Adsorbed				
Dipipanone		467-83-4		
dipivetrin	Propanoic acid, 2,2-dimethyl-, 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester, (+/-)- [CAS]	52365-63-6	US 3809714	Antiglaucoma
Dipivefrin		52365-63-6		
Dipyridamole		58-32-2		
Dipyroc tyl		486-79-3		
Dipyrone		5907-38-0		
diquafosol tetrasodium	Uridine 5'-(pentahydrogen tetraphosphate)-5'-ester with uridine, tetrasodium salt [CAS]	211427-08-6		Ophthalmological

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dirithromycin	Erythromycin, 9-deoxy-11-deoxy-9,11-bis[2-(2-methoxyethoxy)ethylidene]oxy]-, (9S(R))- [CAS]	62013-04-1	DE 2515075	Macrolide antibiotic
Dirithromycin		62013-04-1		
disodium pamidronate	Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt [CAS]	57248-88-1	EP 177443	Osteoporosis treatment
disodium pamidronate, Gadoi	Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt [CAS]	57248-88-1	AR 200473	Formulation, oral, enteric-coated
Disofenil		65717-97-7		
Disopyramide		9/5/3737		
disopyramide SR, Ethypharm	2-Pyridineacetamide, Alpha-[2-bis(1-methylethyl)amino]ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, other
disopyramide, AstraZeneca	2-Pyridineacetamide, Alpha-[2-bis(1-methylethyl)amino]ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, <=24hr
disopyramide, Biocell	2-Pyridineacetamide, Alpha-[2-bis(1-methylethyl)amino]ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, <=24hr
Distigmine Bromide		15876-67-2		
Disulfamide		671-88-5		
Disulfiram		97-77-8		
<i>Disulfiram</i>				
Ditazol		18471-20-0		
Dithiazanine Iodide		514-73-8		
dithranol, Bioglan	9(10H)-Anthracenone, 1,8-dihydroxy- [CAS]	1143-38-0		Formulation, dermal, topical
Diltiocard Sodium		148-18-5		
Dixanthogen		502-55-6		
Dixyrazine		2470-73-7		
DJ-927			WO 01027115	Anticancer, other

TABLE IV

Example of Indication
Tonsillitis
Hypercalcaemia of malignancy
Paget's disease
Arrhythmia, general
Arrhythmia, general
Arrhythmia, general
Psoriasis
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Exempl of Therapeutic Use
DK-507k	(-)-7-[(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate			Quinolone antibacterial
DL-Lactic Acid		598-82-3		
DMDC	Cytidine, 2'-deoxy-2'-methylene-, monohydrochloride [CAS]	113848-25-2	WO 8807049	Anticancer, antimetabolite
DMXAA	5,6-dimethylkhantherone-4-acetic acid			Anticancer, other
DNA Stealth Nucleosides, Koron			US 6132776	Antiviral, anti-HIV
Dobesilate Calcium		20123-80-2		
dobutamine	1,2-Benzenediol, 4-[2-[(3-(4-hydroxyphenyl)-1-methylpropyl)amino]ethyl]-, (+/-) [CAS]	34368-04-2 49745-95-1	US 3987200	Cardio stimulant
Dobutamine		34368-04-2		
Docarpamine		74639-40-0		
docetaxel	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2Alpha,4,7β,10β,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate [CAS]	114977-28-5 148408-66-6	EP 253738	Anticancer, other
Docetaxel		114977-28-5		
docetaxel formulation, Aventis	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2Alpha,4,7β,10β,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate [CAS]	114977-28-5 148408-66-6		Formulation, other
docosahexaenoic acid, Martek			EP 707487	Hypolipaeamic/Antiatherosclerosis
docosanol	1-Docosanol [CAS]	661-19-8	EP 469064	Antiviral, other
docusate			US 4752617	Formulation, dermal, topical
Docusate Calcium		128-49-4		
Docusate Sodium		577-11-7		

TABLE IV

Example of Indication
Infection, general
Cancer, general
Cancer, lung, general
Infection, HIV/AIDS
Cancer, breast
Cancer, general
Hyperlipidaemia, general
Infection, herpes simplex virus
Infection, herpes simplex virus prophylaxis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dofetilide	Methanesulfonamide, N-[4-{2-[methoxy-((methylsulfonyl)amino)phenoxy]ethyl]aminophenyl]- [CAS]	115256-11-6	EP 245997	Antiarrhythmic
Dofetilide		115256-11-6		
<i>Dofetilide</i>				
Dolasetron		115956-12-2		
	1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2Alpha,6Alpha,8Alpha,9Alpha)-, monomethanesulfonate- [CAS]	115956-13-3	EP 266730	Antiemetic
dolasetron mesilate				
Dolasetron Mesylate				
<i>Dolasetron Mesylate</i>				
Domiodol		61869-07-6		
Domiphen Bromide		538-71-6		
Domitroban		112966-96-8		
	2H-Benzimidazol-2-one, 5-chloro-1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro- [CAS]	57808-68-9	US 4066772	Antiemetic
domperidone		57808-66-9		
Domperidone		57808-66-9		
Donepezil		120014-06-4		
	1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, hydrochloride- [CAS]	120011-70-3 120014-06-4	EP 296560	Cognition enhancer
donepezil hydrochloride				
	Piperazine, 1-(((3-(2-aminoethyl)-1H-indol-5-yl)oxy)acetyl)-4-(4-cyanophenyl)- [CAS]	170912-52-4		Antimigraine
donitriptan mesylate		51-61-6		
Dopamine		86197-47-9		
Dopexamine				
	urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-(2-(4-morpholinyl)ethoxy)-1-naphthalenyl]-			
doramiprid		265983-48-4		Antiarrhythmic, immunological

TABLE IV

Example of Indication
Fibrillation, atrial
Chemotherapy-induced nausea and vomiting
Alzheimer's disease
Migraine
Arthritis, rheumatoid

TABLE IV

API/Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dorazolidone	(±)-1,2,4-Butanetriol, 3-(2-nitro-1H-imidazol-1-yl)methoxy- [CAS]	137339-64-1	WO 9414778	Radio/chemosensitizer
doripenem	(1R,5S,6S)-2-[(3S,5S)-5-(sulfamoylaminoethyl)pyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methylcarbamoyl-2-am-3-carboxylic acid	148016-81-3	EP 528678	Beta-lactam antibiotic
dorzolamide	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans)- [CAS]	120279-96-1	EP 296879	Antiglaucoma
Dorzolamide		120279-96-1		
dorzolamide + timolol	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[[[1,1-dimethylamino]-3-[(4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy]-1, (S), (Z)-2-butenedicate (1:1) (salt) [CAS]	120279-96-1 26839-75-8 26921-17-5		Formulation, fixed-dose combinations
dosmaltate	Aluminium, μ 7-(7-[(6-O-(6-deoxy-2,3,4-tri-O-sulfo-Alpha-L-mannosylpyranosyl)-2,3,4-tri-O-sulfo- β -D-glucopyranosyl)oxy]-5-hydroxy-2-(4-methoxy-3-(sulfoxy)phenyl)-4H-1-benzopyran-4-onato(7-))tetradeca- μ -hydroxyphenicosahydroxytetradeca- [CAS]	122312-55-4		Antituber
dosulepine	1-Propanamine, 3-dibenzolb, ethlepin-11(6H)-ylidene-N,N-dimethyl- [CAS]	113-53-1		Antidepressant
Dotarizine		84625-59-2		
Dothiepin		113-53-1		
Doxacurium Chloride		106819-53-8		
Doxapram		309-29-5		
doxazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8	GB 2007656	Antihypertensive, adrenergic
Doxazosin		74191-85-8		

TABLE IV

Example of Indication
Surgery adjunct
Infection, urinary tract
Glaucoma
Glaucoma
Ulcer, gastric
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
doxazosin-GITS	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8		Formulation, modified-release, <=24hr
Doxefazepam		40762-15-0		
Doxenitoin		3254-93-1		
Doxepin		1668-19-5		
doxepin, GenDerm	1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-	1668-19-5		Formulation, dermal, topical
doxercalciferol	9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol (1Alpha, 3B, 5Z, 7E, 22E) [CAS]	54573-75-0	US 5104854	Hormone
Doxercalciferol		54573-75-0		
doxifluridine	Uridine, 5'-deoxy-5-fluoro- [CAS]	3094-09-5	US 4071680	Anticancer, antimetabolite
Doxifluridine		9/5/3094		
doxofylline	1H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl- [CAS]	99975-86-6	US 4187308	Antiasthma
Doxofylline		69975-86-6		
Doxorubicin		23214-92-8		
doxorubicin citrate, TLC	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8	EP 191824	Formulation, optimized, liposomes
doxorubicin Extra		23214-92-8		
Doxorubicin Hydrochloride	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]			Formulation, parenteral, other
Doxorubicin Hydrochloride				

TABLE IV

Examp ^l of Indication
Hypertension, general
Pruritus
Hyperparathyroidism
Cancer, colorectal
Asthma
Cancer, breast
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
doxorubicin, Advectus	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, optimized, nanoparticles
doxorubicin, BioAlliance	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, optimized, nanoparticles
doxorubicin, FeRx	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, parenteral, targeted
doxorubicin, Inhaled		23214-92-8		Formulation, inhalable, solution
doxorubicin, Mitsubishi	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]			Formulation, optimized, liposomes
doxorubicin, NeoPharm	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]	23214-92-8		Formulation, optimized, liposomes
doxorubicin, Nippon Kayaku	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S)-cis- [CAS]			Formulation, optimized, nanoparticles

TABLE IV

Example of Indication
Cancer, brain
Cancer, liver
Cancer, liver
Cancer, lung, non-small cell
Cancer, stomach
Cancer, prostate
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
doxorubicin, Pro-Pharm	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, parenteral, targeted
doxorubicin, Regulon	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, optimized, liposomes
doxorubicin, SIRTex	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, optimized, microencapsulate
doxorubicin, Stealth	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8	US 5213804	Formulation, optimized, liposomes
doxorubicin, Supratek	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8		Formulation, other
doxorubicin, Targesome	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]			Formulation, optimized, liposomes

TABLE IV

Example of Indication
Cancer, general
Cancer, general
Cancer, liver
Cancer, sarcoma, Kaposi's
Cancer, oesophageal
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Doxycycline		17086-28-1 (monohydrate); 564-25-0 (anhydrous)		
	2-Naphthacene-1-carboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,5,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-[4S- (4 α),4 α],5 α],5 α],5 α],6 α],6 α],1 2a α], [CAS]	564-25-0		Formulation, modified-release, immediate
doxycycline, Atrix				
	2-Naphthacene-1-carboxamide, 4- (dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,5,10,12,12a-pentahydroxy-6- methyl-1,11-dioxo-[4S- (4 α),4 α],5 α],5 α],5 α],6 α],6 α],1 2a α], [CAS]	564-25-0		Formulation, oral, other
doxycycline, CollaGenex				
Doxylamine		469-21-6		
	N,N-Dimethyl-2-[1-phenyl-1-(2- pyridinyl)ethoxy]ethanamine			Formulation, transmucosal, systemic
doxylamine, I2R				
	β -D-2',3'-didehydro-2',3'-dideoxy-5- fluorocytidine			Antiviral, anti-HIV
DPC-817			US 5681830	Analgesic, other
DPI-3290				
	5-Amino-7-[(3S,4R)-(1-aminocyclopropyl)- 3-fluoropyrrolidin-1-yl]-1-[(1R,2S)-2-fluoro- 1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxo- 3-quinolinecarboxylic acid			Quinolone antibacterial
DQ-113				
Drofenine		1679-76-1		
Droloxifene		82413-20-5		
Drometrizole		2440-22-4		
Dromostanolone		58-19-5		
dronabinol, Pars	6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a- tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR- trans)-, [CAS]	1972-08-3		Antiemetic

TABLE IV

Example of Indication
Periodontitis
Periodontitis
Rhinitis, allergic, general
Infection, HIV/AIDS
Pain, general
Infection, general
Chemotherapy-induced nausea and vomiting

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
dronedrone hydrochloride	2-n-Butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]-5-methylsulfonamidobenzofuran hydrochloride			Antiarrhythmic
Droperidol		548-73-2		
Drophenilamine		57653-27-7		
Dropropizine		17692-31-8		
Drosiprenone		67392-87-4		
Drotaverine		14009-24-6		
Drotebanol		3/2/3176		
dioxlicam	2H,5H-1,3-Oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione, 5-methyl-3-(2-pyridinyl), 6,6-dioxide [CAS]	90101-16-9	EP 99770	Anti-inflammatory
Droxicam		90101-16-9		
droxidopa	L-Tyrosine, 6,3-dihydroxy-, threo- [CAS]	23651-95-8	EP 128684	Antiparkinsonian
Droxidopa		23651-95-8		
DU-12530	1,2-Benzisothiazol-3(2H)-one, 2-[4-{4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl}butyl]-, 1,1-dioxide [CAS]	161811-99-0	EP 639260	Anxiolytic
Duloxetine		116539-59-4		
duloxetine hydrochloride	2-Thiophenepropanamine, N-methyl-Gamma-(1-naphthalenyl)oxy-, hydrochloride, (S)- [CAS]	136434-34-9	US 5362886	Antidepressant
duramycin, MoliChem			WO 9428726	Formulation, inhalable, solution
Durapatite		1306-06-5		
dutasteride	4-Azaandrosta-1-ene-17-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5Alpha, 17B)- [CAS]	164656-23-9	US 5565467	Prostate disorders
Dutasteride		164656-23-9		
DW-1141	N,N-disopropyl-4-[4-(3-aminobenzodioxazol-6-yloxy)butoxy]-3-methoxybenzamide			Osteoporosis treatment

TABLE IV

Example of Indication
Arrhythmia, general
Inflammation, general
Parkinson's disease
Anxiety, general
Depression, general
Cystic fibrosis
Benign prostatic hyperplasia
Osteoporosis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Refer nce	Example of Therapeutic Use
DW-286a	(R)-(-)-7-(4-aminomethyl-4-methyl-3-(Z)-methyloxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid			Quinolone antibacterial
DW-471			US 5922871	Antiviral, other
DX-8085a	2-Naphthalenepropanoic acid, 7-(aminoiminomethyl)-Alpha-[4-[[1-(1-iminoethyl)-3-pyrrolidinyl]oxy]phenyl]-monohydrochloride, pentahydrate, [S-(R*, R*)]- [CAS]	155204-81-2		Antithrombotic
DY-9760e	1H-Indazole, 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy- [CAS]	160522-00-9	US 5681854	Neuroprotective
Dyclonine		586-60-7		
Dydrogesterone		152-62-5		
Dymanthine		124-28-7		
Dyphylline		479-18-5		
E-1010	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-monohydrochloride, (4R,5S,6S)- [CAS]	186319-97-1		Beta-lactam antibiotic
E-2101	N-Ethyl-1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide			Muscle relaxant
E2F antagonists, TopoTarget			WO 9606943	Anticancer, other
E-3620	Benzamide, 4-amino-5-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-[(1-methyl-2-butynyl)oxy]-; monohydrochloride, [3(S)-endo]- [CAS]	151213-86-4	EP 554794	Antacid/Antiflatulent

TABLE IV

Example of Indication
Infection, general
Infection, hepatitis-B virus
Thrombosis, general
Ischaemia, cerebral
Infection, general
Muscle spasm, general
Cancer, general
Dyspepsia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
E-5564	Alpha-D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-(2-deoxy-3-O-((3R)-3-methoxydecyl)-6-O-methyl-2-(((11Z)-1-oxo-11-octadecenyl)amino)-4-O-phosphono-8-D-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)-1-(dihydrogen phosphate), tetrasodium salt [CAS]	185954-98-7	EP 536969	Septic shock treatment
E-5842	Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	220120-14-9		Neuroleptic
E-6259	1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole			Antiarthritic, other
EAA-90	[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid	57-08-9		Anaesthetic, other
s-Acetamidocaproic Acid				
s-Amin caproic Acid		60-32-2		
ebastine	1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-(4-(diphenylmethoxy)-1-piperidinyl) [CAS]	90729-43-4	EP 134124	Antiallergic, non-asthma
Ebastine		90729-43-4		
eberconazole	1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzof[a,d]cyclohepten-5-yl)- [CAS]	128326-82-9 130104-32-4	ES 2012297	Antifungal
ebrotidine	Benzenesulfonamide, N-[[[2-[[[2-((aminomino)methyl)amino]-4-thiazolyl)methyl]thio]ethyl]amino]methyl]ene]-4-bromo- [CAS]	100981-43-9	EP 159012	Anticancer
ebesen	1,2-Benzisoxalenazol-3(2H)-one, 2-phenyl- [CAS]	60940-34-3	EP 44971	Neuroprotective
Eburnamonine		474-00-0		
Ecabapide		104775-36-2		

TABLE IV

Example of Indication
Sepsis
Schizophrenia
Unspecified
Pain, neuropathic
Rhinitis, allergic, seasonal
Infection, dermatological
Ulcer, duodenal
Haemorrhage, subarachnoid

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ecabet	1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, [1R-(1Alpha,4aB,10aAlpha)]-, [CAS]	33159-27-2 86408-72-2	DE 3239172	Antilcer
ecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (S)-[CAS]	112573-73-6	EP 318377	Antihypertensive, other
Ecgonidine		484-93-5		
Ecgonine		481-37-8		
Echothiophosphate iodide		513-10-0		
Econazole		27220-47-9		
ecopipam	5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, (6aS-trans)- [CAS]	112108-01-7	EP 230270	Anorectic/Antiobesity
ecraprost	Prosta-8,13-dien-1-olc acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11Alpha,13E,15S)- [CAS]	136892-84-3	EP 423697	Vasodilator, peripheral
Ectylurea		95-04-5		
ED-71	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1Alpha,28,38,5Z,7E)- [CAS]	104121-92-8	EP 184206	Osteoporosis treatment
edaravone	3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- [CAS]	89-25-8	JP 62108814	Neuroprotective
Edatrexate		80576-83-6		
Edetate Calcium Disodium		62-33-9		
Edetat Disodium		139-33-3		
Edetat Sodium		64-02-8		
Edetate Trisodium		150-38-9		
edonentan	Butanamide, N-[2-[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl[methyl]-N,3,3-trimethyl-, monohydrate	210891-04-6		Cardiostimulant

TABLE IV

Example of Indication
Ulcer, gastric
Hypertension, general
Obesity
Peripheral vascular disease
Osteoporosis
Infarction, cerebral
Heart failure

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
edotreotide	[N-[2-[4,7-Bis[(carboxy-kappaO)methyl]-10-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfidato(3-yl)]trium	204318-14-9	US 6183721	Anticancer, hormonal
edoxudine	Uridine, 2'-deoxy-5-ethyl- [CAS]	15176-29-1	GB 1170565	Antiviral, other
Edrecolomab		156586-89-9		
Edrophonium		116-38-1		
Efalith	Butanedioic acid, lithium salt [CAS]	16090-08-8		Antipruritic/inflam, allergic
efaproxiral sodium	Propanoic acid, 2-[4-[2-(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxyl-2-methyl- [CAS]	131179-95-8	US 5705521	Radio/chemosensitizer
efavirenz	2H-3,1-Benzoxazin-2-one, 8-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)- [CAS]	154598-52-4	WO 9403440	Antiviral, anti-HIV
efetirizine	[2-[4-[Bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid	150758-35-7	GB 2311940	Antiallergic, non-asthma
Eflornithine		67037-37-0		
eflornithine	DL-Ornithine, 2-(difluoromethyl)- [CAS]	70052-12-9	US 4413141	Protozoacide, dermal, topical
Efloxat		119-41-5		
eflucimibe	Benzeneacetamide, Alpha-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)- (S)- [CAS]	202340-45-2		Hypolipaeamic/Antiatherosclerosis
efonidipine	3-pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)- 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide [CAS]	111011-53-1 111011-63-3 111011-76-8	EP 230944	Antihypertensive, other
EGIS-7229	5-Chloro-4-[3-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]propylamino]- 3(2H)-pyridazinone fumarate [CAS]	150800-12-7 190933-92-7	DE 4243361	Antiarrhythmic

TABLE IV

Example of indication
Cancer, lung, small-cell
Infection, herpes virus, general
Eczema, seborrhoeic
Cancer, brain
Infection, HIV/AIDS
Allergy, general
Infection, trypanosomiasis, African, Hirsutism
Hyperlipidaemia, general
Hypertension, general
Arrhythmia, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
eglumegad	Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S)- [CAS]	178199-48-7 209216-09-1		Anxiolytic
egualen	1-Azulenecarboxylic acid, 3-ethyl-7-(1-methylethyl)-	97683-31-3 99287-30-6	EP 147915	Antitumor
Eicosapentaenoic Acid		10417-94-4		
elarofiban	3-Pyridinepropanoic acid, B-(((3R)-1-[(1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl)carbonyl)amino)-, (8S)- [CAS]	198958-88-2	WO 9741102	Antithrombotic
Elcatonin		60731-46-6		
Eledoisin		69-25-0		
elotriptan	1H-Indole, 3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)- (R)- [CAS]	143322-58-1	US 5607951	Antimigraine
Elgodipine		119413-55-7		
Ellagic Acid		476-66-4		
Elliptinium		58337-35-2		
Eltoprazine		98224-03-4		
elvucitabine	(β-L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine	181785-84-2		Antiviral, other
elzasonan	(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one monohydrochloride- [CAS]	220322-05-4 361343-20-6		Antidepressant
Embellin		550-24-3		
Embramine		3565-72-8		
emadastine	1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, (E)-2-butenedioate (1:2) [CAS]	87233-61-2 87233-62-3	EP 79545	Antiallergic, non-asthma
Emeprolum Bromide		3614-30-0		
Emetine		483-18-1		
Emitofur		110690-43-2		
EMM-210525	17Alpha-Acetoxy-6Alpha-methyl-18-nor-18,23-dihydrocyclopropa[1,2]pregn-4-ene-3,20-dione+Esra-1,3,5(10)-triene-3,17-diol(17β)			Formulation, fixed-dose combinations

TABLE IV

Example of Indication
Anxiety, general
Ulcer, gastric
Thrombosis, general
Migraine
Infection, hepatitis-B virus
Depression, general
Rhinitis, allergic, general
Hormone replacement therapy

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Emodin		518-82-1		
emofezone	3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-(4-morpholinyl)- [CAS]	38957-41-4	JP 7224030	Anti-inflammatory
EMR-62203			WO 9806722	Male sexual dysfunction
emtricitabine	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R, cis)- [CAS]	143491-57-0	WO 9214743	Antiviral, anti-HIV
Emylcamate		78-28-4		
enalapril	L-Proline, 1-[N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl]-, (S)-, (Z)-2-butenedioate [CAS]	76095-16-4	US 4374829	Antihypertensive, renin system
Enalaprilat		76420-72-9		
Enallypropymal		1861-21-8		
Encalinide		66778-36-7		
Enciprazine		68576-86-3		
Endralazine		39715-02-1		
enfenamic acid	Benzoic acid, 2-[(2-phenylethyl)amino]- [CAS]	23049-93-6	IN 103066	Anti-inflammatory
enflurane	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro- [CAS]	13838-16-9	US 3489011	Anaesthetic, inhalation
Enliconazole		35554-44-0		
Enluracil		59989-18-3		
ENMD-0995	S-3-amino-phthalidoglutarimide		US 5712291	Anticancer, other
Enocitabine		55726-47-1		
Enol-3-IPA	1H-Indole-3-propanoic acid, Alpha-oxo- [CAS]	392-12-1	EP 106813	Hypnotic/Sedative
enoxacin	1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	74011-58-8	US 4359578	Quinolone antibacterial
enoxaparin sodium	Heparin, sodium salt-[CAS]	9005-49-6		
enoximone	2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]- [CAS]	9041-08-1	EP 40144	Antithrombotic
Enoxolone		77671-31-9	EP 59948	Cardio stimulant
		471-53-4		

TABLE IV

Example of indication
Impotence
Infection, HIV/AIDS
Anaesthesia
Cancer, myeloma
Insomnia
Infection, general
Thrombosis, venous
Heart failure

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
enprostil	4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, methyl ester, [(1 α ,2 β)(1 E ,3 R),3 α]-[CAS]	73121-56-9	GB 2025431	Prostaglandin
enrasentan	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5-propoxy-, (1S-(1 α ,2 β ,3 α))- [CAS]	167256-08-8	US 5817693	Antihypertensive; other
entacapone	2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N,N-diethyl- [CAS]	130929-57-6	EP 428468	Antiparkinsonian
entecavir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)- [CAS]	142217-69-4	EP 481754	Antiviral, other
Enviomycin		33103-22-9		
epalrestat	3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)- [CAS]	82159-09-9	EP 47109	Symptomatic antidiabetic
Epavir	L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate			Antiviral, other
EPC-K1	L-ascorbic acid 2-(3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl)-hydrogen phosphate/potassium- [CAS]	127061-56-7	EP 127471	Neuroprotective
eperisone	1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS]	64840-90-0	US 3995047	Muscle relaxant
epervudine, Biogal	Uridine, 2'-deoxy-5-(1-methylethyl)- [CAS]	60136-25-6	DE 2918260	Antiviral, other
Ephedrine		299-42-3		
Epicillin		26774-90-3		
Epimestrol		7004-98-0		
epinastine, oral, Bi	1H-Dibenz[<i>c,f</i>]imidazo[1,5- <i>a</i>]azepin-3-amine, 9,13b-dihydro- [CAS]	80012-43-7	DE 3008944	Antialsthma
epinephrine	(R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol	51-43-4		Formulation, inhalable, dry powder

TABLE IV

Example of Indication
Ulcer, duodenal
Hypertension, pulmonary
Parkinson's disease
Infection, hepatitis-B virus
Neuropathy, diabetic
Infection, herpes simplex virus
Infarction, cerebral
Spastic paralysis
Infection, herpes simplex virus
Asthma
Anaphylaxis

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Epirizol		18694-40-1		
	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	56390-09-1 56420-45-2	GB 1457632	Anticancer, antibiotic
Epitiostanol		2363-58-8		
	Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, Gamma-lactone, methyl ester (7Alpha,11Alpha,17Alpha)-[CAS]			
epiprenone		107724-20-9	EP 122232	Antihypertensive, diuretic
	1-Propanone, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z)-, (E)-2-butenedioate (2:1) (salt) [CAS]	130580-02-8	EP 373988	Anxiolytic
epivanserin		35121-78-9 61849-14-7		
	Prosta-5,13-dien-1-olc acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9Alpha,11Alpha,13E,15S)-[CAS]		DE 2720999	Prostaglandin
epoprostenol		80471-63-2		
Epostan		10402-90-1		
Eprazinone		119169-78-7		
Epristeride				
	3-[2-Butyl-1-(4-carboxybenzyl)-1H-imidazol-5-yl]-2-(2-thienylmethyl)-2-(E)-propenoic acid			
eprosartan		133040-01-4	EP 403159	Antihypertensive, renin system
Eprozinol		32665-36-4		
	4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5-dione	179756-85-5		Antidepressant
eptapirone				
	Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]	146665-77-2	WO 9216539	Anticancer, alkylating
Eptastigmine		101246-68-8		
	1,6-Methano-1H-4-benzazolin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1S)-[CAS]			
epiazocine		72522-13-5	US 4082744	Analgesic, other
Eptifibatide		188627-80-7		

PI 1141167

RECEIVED

10 MAR 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 05, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/487,064

FILING DATE: July 11, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/41273

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



W. Montgomery
W. MONTGOMERY
Certifying Officer

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 171 (a) OR (b)

PART (2) OF (2) PART(S)

TABLE IV

Example of Indication
Hypertension, general
Schizophrenia
Hypertension, pulmonary
Hypertension, general
Depression, general
Cancer, lung, small-cell

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Equilenin		517-09-9		
Equilin		474-86-2		
ERA-923	ERA 923 [CAS]	352233-89-7	EP 802183	Female contraceptive
erdosteine	Acetic acid, [[2-oxo-2-(tetrahydro-2-oxo-3-thienyl)amino]ethylthio]- [CAS]	84611-23-4	EP 61386	Respiratory
Ergocornine		564-36-3		
Ergocorninine		564-37-4		
Ergoloid Mesylates		8067-24-1		
Ergonovine		60-79-7		
Ergosterol		57-87-4		
ergotamine tartrate, TEMPO	(5 α)-12'-Hydroxy-2-methyl-(phenylmethyl)ergotaman-3',6',18-trione	113-15-5		Formulation, inhalable, systemic
Eritadenine		23918-98-1		
erlotinib	4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-monohydrochloride [CAS]	183319-69-9	WO 9630347	Anticancer, other
Ertapenem		153832-46-3		
ertapenem sodium	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[[(3S,5S)-5-[[[(3-carboxyphenyl)amino]carbonyl]-3-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, monosodium salt, (4R,5S,6S)- [CAS]	153773-82-1	WO 9315078	Beta-lactam antibiotic
Erythrityl Tetranitrate		7297-25-8		
Erythrocentaurin		50276-98-7		
erythromycin acistrate	Erythromycin, 2'-acetate, octadecanoate (salt) [CAS]	96128-89-1	US 4599326	Macrolide antibiotic
Erythromycin Acistrate		96128-89-1		
Erythr mycin Estolate		3521-62-8		
Erythromycin		23067-13-2		
Glucoseptonate				
Erythromycin		3847-29-8		
Lactobionate				
Erythromycin Propionate		134-36-1		

TABLE IV

Example of Indication
Contraceptive, female
Respiratory disease, general
Migraine
Cancer, lung, non-small cell
Infection, GI tract
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Erythromycin Stearate		643-22-1		
erythromycin stearate	Erythromycin, 2'-propanoate, compd. with N-acetyl-L-cysteine (1:1) [CAS]	84252-03-9	EP 57489	Macrolide antibiotic
erythromycin	Erythromycin [CAS]	114-07-8		Formulation, dermal, topical
Erythrophleine		36150-73-9		
Esaprazole		64204-55-3		
escitalopram oxalate	5-Isobenzofuran carbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (S)- [CAS]	128196-01-0	EP 347066	Antidepressant
Esculin		531-75-9		
Eseridine		25573-43-7		
esmolol	Benzenepropanoic acid, 4-[2-hydroxy-3-((1-methylethyl)amino)propoxy]-, methyl ester, (+/-) [CAS]	81147-92-4	US 4387103	Antihypertensive, adrenergic
esomeprazole magnesium	Magnesium, bis (5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazolato)	161973-10-0	US 5877192	Antispasmodic
estazolam	4H-1,2,4-Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl- [CAS]	29975-16-4	US 3987052	Hypnotic/Sedative
estradiol	Androst-4-en-3-one, 17-hydroxy-, (17β)- [CAS]	58-22-0	US 5460820	Formulation, transdermal, patch
estradiol	Estra-1,3,5(10)-triene-3,17-diol (17β)- [CAS]	50-28-2	EP 430491	Formulation, transdermal, systemic
Estramustine		2998-57-4		
estramustine phosphate	Estra-1,3,5(10)-triene-3,17-diol (17β), 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate) [CAS]	2998-57-4 4891-15-0 52205-73-9		Anticancer, alkylating
Estriol		50-27-1		
estrogen			WO 9924041	Menopausal disorders
Estrone		53-16-7		
eszopiclone	1-Piperazinecarboxylic acid, 4-methyl- 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester (S)- [CAS]	138729-47-2	US 5786357	Hypnotic/Sedative

TABLE IV

Example of Indication
Infection, respiratory tract, lower
Acne
Depression, general
Tachycardia, supraventricular
Gastro-oesophageal reflux
Sexual dysfunction, female
Menopausal symptoms, general
Cancer, prostate
Menopausal symptoms, general
Insomnia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref reince	Example of Therapeutic Use
Etafedrine		7681-79-0		
Etafenone		90-54-0		
Etamiphyllin		314-35-2		
Etanercept		185243-69-0		
Etanidazole		22668-01-5		
Etaqualone		7432-25-9		
Eterobarb		27511-99-5		
Ethacridine		442-16-0		
Ethacrynic Acid		58-54-8		
Ethadione		520-77-4		
Ethambutol		74-55-5		
Ethamivan		304-84-7		
Ethamsylate		2624-44-4		
Ethanolamine		141-43-5		
Ethaverine		486-47-5		
Ethchlorvynol		113-18-8		
Ethenzamide		938-73-8		
Ethiazide		1824-58-4		
Ethinamate		126-52-3		
Ethinyl Estradiol		57-63-6		
ethinyl estradiol sulfonate	19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17Alpha)-[CAS]	28913-23-7	DE 1949095	Formulation, modified-release, >24hr
Ethionamide		536-33-4		
Ethisterone		434-03-7		
Ethioheptazine		77-15-6		
Ethiopropazine		522-00-9		
Ethosuximide		77-67-8		
Ethotoin		86-35-1		
Ethoxzolamide		452-35-7		
Ethybenztropine		524-83-4		
Ethyl Alcohol		64-17-5		
Ethyl Biscoumacetate		548-00-5		
Ethyl Chloride		75-00-3		
Ethyl Dibunate		5560-69-0		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ethyl Ether	5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- [CAS]	60-29-7		
ethyl icosapentate		86227-47-6	JP 61043143	Antithrombotic
ethyl loflazepate	1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester [CAS]	29177-84-2	US 3657223	Anxiolytic
Ethyl Loflazepate		29177-84-2		
Ethylamine		75-04-7		
Ethylene		74-85-1		
Ethyl stireol		965-90-2		
Ethylidene Dicummarol		1821-16-5		
Ethylmethylthiambutene		441-61-2		
Ethylmorphine		76-58-4		
Ethylnorepinephrine		536-24-3		
Ethynodiol		1231-93-2		
ethynylcytidine	Uridine, 3'-C-ethynyl- [CAS]	180300-49-6	WO 9618636	Anticancer, antimetabolite
Etidocaine		36637-18-0		
etidronate disodium	Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt- [CAS]	2809-21-4 7414-83-7	US 4137309	Osteoporosis treatment
Etidronic Acid		2809-21-4		
Etifelmin		341-00-4		
etifoxine	4H-3,1-Benzoxazin-2-amine, 6-chloro-N-ethyl-4-methyl-4-phenyl- [CAS]	21715-46-8	US 3725404	Anxiolytic
Etilefrin		709-55-7		
etillevodopa	L-Tyrosine, 3-hydroxy-, ethyl ester [CAS]	37178-37-3	US 5354885	Antiparkinsonian
etiprednol dicloacetate	androsta-1,4-diene-17-carboxylic acid, 17-[(dichloroacetyl)oxyl]-11-hydroxy-3-oxo-, ethyl ester, (11B,17Alpha)-	198331-40-3		GI inflammatory/bowel disorders
Etiroxate		17365-01-4		
Etizolam		40054-69-1		
etodolac	Pyranol[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- [CAS]	41340-25-4	US 3939178	Antiarthritic, other
Etidroxizine		17692-34-1		

TABLE IV

Example of Indication
Peripheral vascular disease
Anxiety, general
Cancer, general
Osteoporosis
Parkinson's disease
Crohn's disease
Arthritis, osteo

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
etofenamate	Benzoic acid, 2-[(3-(trifluoromethyl)phenyl)amino]-, 2-(2-hydroxyethyl)ethyl ester [CAS]	30544-47-9	GB 1285400	Anti-inflammatory, topical
etofibrate	3-Pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl ester [CAS]	31637-97-5	US 3723446	Hypolipaeamic/Antiatherosclerosis
Etofylline		519-37-9		
etofylline clofibrate	Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)ethyl ester [CAS]	54504-70-0	DE 2308626	Hypolipaeamic/Antiatherosclerosis
Etofylline Nicotinate		13425-39-3		
Etoglucid		1954-28-5		
Etomidate		33125-97-2		
Etomidoline		21590-92-1		
Etonitazene		911-65-9		
etonogestrel	18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene, (17 α)-[CAS]	54048-10-1		Formulation, implant
Etooperidone		52942-31-1		
etoposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[(4,6-O-ethylidene- β -D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-[5 α],5 α ,8 α ,9 α]-[CAS]	33419-42-0	GB 1205966	Anticancer, other
etoposide phosphate	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[(4,6-O-ethylidene- β -D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-, [5R-[5 α],5 α ,8 α ,9 α]-[CAS]	117091-64-2	EP 302473	Anticancer, other
etoricoxib	2,3-Bipyridine, 5-chloro-6-methyl-3-(4-methylsulfonyl)phenyl [CAS]	202409-33-4	WO 9803484	Antiarthritic, other
Etosadrol		28189-85-7		
Etosozolin		73-09-6		
etretinate	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)- [CAS]	54350-48-0	US 4215215	Antipsoriasis

TABLE IV.

Example of Indication
Inflammation, general
Contraceptive, female
Cancer, testicular
Cancer, testicular
Arthritis, osteo

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Eryptamine		2235-90-7		
Etymemazine		523-54-6		
Eucatropine		100-91-4		
Eugenol		97-53-0		
EUK-134	Manganese, chloro[[2,2'-(1,2-ethanediyldi)bis(nitrilo-kappaN)methylidene]]bis(6-methoxyphenolato-kappaO)]], (SP-5-13)-[CAS]	81065-76-1	US 6046188	Cardiovascular
EUK-189			US 6046188	Radio/chemoprotective
Evan's Blue		314-13-6		
everolimus	Rapamycin, 42-O-(2-hydroxyethyl)-[CAS]	159351-69-6	WO 9409010	Immunosuppressant
exalamide	Benzamide, 2-(hexyloxy)-[CAS]	53370-90-4	GB 726786	Antifungal
Exalamid		53370-90-4		
Exametazime		105613-48-7		
exatecan mesylate	10H, 13H-Benzo[de]pyrano[3',4':8,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, monomethanesulfonate (salt) [CAS]	171335-80-1		Anticancer, other
exemeslane	Androsta-1,4-diene-3,17-dione, 6-methylene-[CAS]	107868-30-4	DE 3622841	Anticancer, hormonal
Exifone		52479-85-3		
exisulind	1H-Indene-3-acetic acid 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene), (Z)-[CAS]			
Exosurf®		59973-80-7		Anticancer, other
		99732-49-7		
ezetimibe	2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-[CAS]	163222-33-1	US 5846966	Hypolipemic/Antiatherosclerosis
Ezetimibe		163222-33-1		
Factor IX		9001-28-9		
Factor VIII		9001-27-8		

TABLE IV

Example of Indication
Unspecified
Chemotherapy-induced injury, general
Transplant rejection, general
Infection, fungal, general
Cancer, pancreatic
Cancer, breast
Polyp
Hypercholesterolaemia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Factor XIII		9013-56-3		
fadolimide	1H-Inden-5-yl, 2,3-dihydro-3-(1H-imidazol-4-ylmethyl)-, monohydrochloride [CAS]	189353-32-0	WO 9712874	Analgescic, other
Fadrozole		102676-47-1		
falecalcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 26,26,27,27,27-hexafluoro-, (1Alpha,3S,5Z,7E)- [CAS]	83805-11-2	JP 03099022	Osteoporosis treatment
famciclovir	1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester)-, [CAS]	104227-87-4	JP 61085388	Antiviral, other
famotidine	Propanimidamide, 3-[[[2-[(aminiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)- [CAS]	76824-35-6	US 4283408	Antitumor
fampridine	4-pyridinamine	504-24-5		Neuroprotective
fandofloxacin hydrochloride	3-Quinolonecarboxylic acid, 6-fluoro-1-(5-fluoro-2-pyridinyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo, monohydrochloride [CAS]	164150-85-0 164150-99-6	US 5496947	Quinolone antibacterial
Fantofarone		114432-13-2		
faropenem daloxate	(5R,6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)-tetrahydrofuryl]-2-penam-3-carboxylic acid-5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester			Beta-lactam antibiotic
faropenem sodium	4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, monosodium salt, [5R-[3(R'),5Alpha,6Alpha(R')]]-[CAS]	122547-49-3	EP 410727	Beta-lactam antibiotic
fasidotril	L-Alanine, N-[(2S)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl]-, phenylmethyl ester [CAS]	135038-57-2	EP 419327	Antihypertensive, renin system
fasudil	1H-1,4-Diazepine, hexahydro-1-(5-isquinolinylsulfonyl)- [CAS]	103745-39-7 105628-07-7	EP 187371	Neuroprotective
Fazadinium Bromide		49564-56-9		
febarbamate	2,4,6-(1H,3H,5H)-Pyrimidinone, 1-[2-[(aminocarbonyloxy]-3-butoxypropyl]-5-ethyl-5-phenyl- [CAS]	13246-02-1	US 3075983	Psychostimulant
Febuprol		3102-00-9		

TABLE IV

Example of Indication
Pain, general
Hyperparathyroidism
Infection, gynaecological
Ulcer, duodenal
Spinal cord injury
Infection, urinary tract
Infection, general
Infection, ocular
Hypertension, general
Vasospasm, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
febuxostat	5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl- [CAS]	144060-53-7	WO 9209279	Antigout
Fedotozine		123618-00-8		
felbamate	1,3-Propanediol, 2-phenyl-, dicarbamate [CAS]	25451-15-4	US 4868327	Antiepileptic
felbinac	[1,1'-Biphenyl]-4-acetic acid [CAS]	5728-52-9	EP 127840	Anti-inflammatory, topical
felodipine	3,5-Pyridinedicarboxylic acid, 4-[(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-ethyl methyl ester] [CAS]	72509-76-3	US 4264811	Antihypertensive, other
Felypressin		56-59-7		
Femoxetine		59859-58-4		
Fenb nicillin		1926-48-3		
fenbuten	[1,1'-Biphenyl]-4-butanolic acid, Gamma-oxo- [CAS]	36330-85-5	US 3784701	Anti-inflammatory
F nbutrazate		4378-36-3		
Fencamfamine		1209-98-9		
Fencamine		28947-50-4		
Fenclozic Acid		17969-20-9		
Fendiline		13042-18-7		
Fendosal		53597-27-6		
Fenethyliline		3736081		
F nfluramine		458-24-2		
Fenipentol		583-03-9		
fenofibrate, Pan Medica	Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS]	26129-32-8 49562-28-9		Formulation, modified-release, <=24hr
fenoldopam	1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)- [CAS]	67227-56-9 67227-57-0	EP 22330	Antihypertensive, other
Fenoprofen		31879-05-7		
Fenoterol		13392-18-2		
fenoverine	10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl]-[CAS]	37561-27-6 4846-91-7	FR 2092639	Antispasmodic
Fenoxazoline		54063-40-0		
Fenoxedil				

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
F nozolone		15302-16-6		
Fenpentadiol		15687-18-0		
Fenpiprane		3540-95-2		
Fenpiverinium Bromide		125-60-0		
Fenproporex		15686-61-0		
Fenquizone		20287-37-0		
fenretinide	Retinamide, N-(4-hydroxyphenyl)- [CAS]	65648-68-6	BE 847942	Anticancer, other
Fenspiride		5053066		
Fentanyl		437-38-7		
fentanyl citrate	Propanamide, N-phenyl-N-1-(2-phenylethyl)-4-piperidinyl- [CAS]	437-38-7		Formulation, transmucosal, systemic
Fentiazac		18046-21-4		
F ntictor		97-24-5		
fenticonazole	1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]- [CAS]	72479-26-6 73151-29-8	US 4221803	Antifungal
Fentonium Bromide		5868064		
fepradinol	Benzenemethanol, Alpha-[[[2-hydroxy-1,1-dimethylethyl]amino]methyl]-, (+)-, [CAS]	36981-91-6 67704-50-1		Anti-inflammatory, topical
Fepradinol		63075-47-8		
Feprazone		30748-29-9		
Ferric Sodium Edetate		15708-41-5		
ferrioxamine B			WO 9426263	Septic shock treatment
Ferrochollinate		1336-80-7		
Ferrous Gluconate		299-29-6		
ferumoxylol	Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite			Imaging agent
fesoterodine	2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)Phenyl ester, (2E)-2-butenedioate (1:1) (Salt), [CAS]	266930-03-8		Urological

TABLE IV

Example of Indication
Cancer, breast
Anaesthesia, adjunct
Infection, gynaecological
Respiratory distress syndrome, adult
Diagnosis, cancer
Incontinence

TABLE IV

API Generic Nam	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Fexofenadine		83799-24-0		
	Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxycyclophenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, hydrochloride [CAS]			
fexofenadine HCl		153439-40-8	US 5375693	Antiallergic, non-asthma
	Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxycyclophenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, hydrochloride [CAS]	138452-21-8 153439-40-8		Formulation, modified-release, <=24hr
Fibrostat			CA 2132416	Vulnerary
fidaresat	Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]	136087-85-9	EP 418834	Symptomatic antidiabetic
	8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione	208993-54-8		Prostate disorders
fiduxosin	4-Azaandroster-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5Alpha,17b)-[CAS]	98319-26-7	EP 155096	Prostate disorders
finasteride	Benzonitrile, 4'-(3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)-propyl)-[CAS]	160146-16-7	EP 476944	Urological
finrozole		34161-24-5		
Flipexide	N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide monohydrate- [CAS]	133920-70-4	WO 9101979	Cognition enhancer
FK-960		146426-40-6		
Flavopiridol	4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester [CAS]	15301-69-6 3717-88-2	US 2921070	Urological
flavoxate		15301-69-6		
Flavoxate		54143-55-4		
Flecalinide	Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate [CAS]	54143-55-4 54143-56-5		Formulation, modified-release, <=24hr
flecainide acetate, CR				

TABLE IV

Example of Indication
Rhinitis, allergic, seasonal
Rhinitis, allergic, seasonal
Wound healing
Neuropathy, diabetic
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Urinary retention
Alzheimer's disease
Fibrillation, atrial

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
floroxacin	3-Quinolincarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	79660-53-0 79660-72-3	US 4398029	Quinolone antibacterial
Flesinoxan	2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)- [CAS]	98206-10-1 167933-07-5		Reproductive/gonadal, general
flibanserin	Benzole acid, 2-[[8-(trifluoromethyl)-4-quinolinyl]amino]-, 2,3-dihydroxypropyl ester [CAS]	23779-99-9	US 3644368	Analgesic, NSAID
floctafenine	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(difluoromethyl)thio]acetyl]amino]-3-[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-, (8R-cis)- [CAS]	92823-03-5 99665-00-6	EP 128536	Cephalosporin, injectable
flomoxef		99665-00-6		
Flomoxef				
Fluopropione		2295-58-1		
Florantyrone		519-95-9		
Flosequinan		76568-02-0		
Floxacin		5250-39-5		
Floxuridine		50-91-9		
Fluacizine		30223-48-4		
Fluanisone		1480-19-9		
fluasterone	Androst-5-en-17-one, 18-fluoro-, (16 α)- [CAS]	112859-71-9	EP 246650	Cardiovascular
fluzacort	5H-Pregna-1,4-dienol[17,16-dioxazole-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-2-methyl-, (11 β ,16 β)- [CAS]	19888-56-3 3693-39-8	US 3461119	Antipruritic/inflamm, non-allergic
Flucloronide		1847-24-1 34214-51-2		Formulation, other
flucloxacillin, CSL	1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difluorophenyl)-Alpha-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	86386-73-4 2022-85-7	EP 96569	Antifungal
fluconazole		21679-14-1		
Flucytosine				
Fludarabine				

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fludarabine phosphate	9H-Purin-6-amine, 2-fluoro-9-(5'-O-phosphono-8-D-arabino-furanosyl)- [CAS]	75607-67-9	US 4357324	Anticancer, antimetabolite
Fludeoxyglucose F18		105851-17-0		
Fludiaz pam		3900-31-0		
Fludrocortisone		127-31-1		
Flufenamic Acid		530-78-9		
Fluindione		957-56-2		
	4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-fluoro-5,8-dihydro-5-methyl-6-oxo-, ethyl ester [CAS]			
flumazenil		78755-81-4	EP 27214	Neurological
Flumecinol		56430-99-0		
Flumequin		42835-25-6		
Flumethasone		2135-17-3		
Flumethiazide		148-56-1		
flunarizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)- (E)- [CAS]	30484-77-8 52468-60-7	GB 1268710	Antimigraine
flunarizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)- (E)- [CAS]	27848-84-8 52468-60-7		Formulation, fixed-dose combinations
flunisolide	Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[1-methylethylidene)bis(oxy)]-, (6Alpha,11beta,16Alpha)- [CAS]	3385-03-3	US 3124571	Antiasthma
flunitrazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro- [CAS]	1622-62-4	US 3116203	Hypnotic/Sedative
Flun xaprofen		66934-18-7		
Fluocinolone Acetonide		67-73-2		
Fluocinonide		356-12-7		
Fluocortin Butyl		41767-29-7		
Fluocortolone		152-97-6		
Fluorescein		2321075		
<i>Fluorescein Sodium</i>				

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Fluoresone		2924-67-6		
Fluorometholone		426-13-1		
Fluorosalan		4776061		
fluorouracil, microsphere	2,4-(1H,3H)-Pyrimidinone, 5-fluoro- [CAS]	51-21-8		Formulation, transdermal, enhanced
fluoxetine	Benzenepropanamine, N-methyl-Gamma-[4-(trifluoromethyl)phenoxy]-, (+)- [CAS]	54910-89-3 56296-78-7	US 4314081	Antidepressant
Fluoxymesterone		76-43-7		
Flup nixol		2709-56-0		
Fluperolone Acetate		2119-75-7		
Fluphenazine		69-23-8		
flupirtine	Carbamic acid, [2-amino-6-[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-ethyl ester [CAS]	33400-45-2 56895-20-1 75507-68-5	US 4481205	Analgasic, other
Fluprednidene Acetate		1255-35-2		
Fluprednisolone		53-34-9		
Fluproquazone		40507-23-1		
Flurandrenolide		1524-88-5		
Flurazepam		17617-23-1		
flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]	5104-49-4	US 3793457	Anti-inflammatory
flurbiprofen transdermal, Lead	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]	5104-49-4		Formulation, transdermal, patch
flurthromycin ethylsuccinate	Erythromycin, 8-fluoro-mono(ethyl butanedioate) (ester)- [CAS]	82730-23-2	EP 56291	Macrolide antibiotic
Fluogestone Acetate		2529-45-5		
Flurothyl		333-36-8		
Fluoxetine		406-90-6		
Fluspirilene		1841-19-6		
flutamide	Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- [CAS]	13311-64-7	US 4329364	Anticancer, hormonal
flutazolam	Oxazol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]	27060-91-9	US 3905956	Anxiolytic

TABLE IV

Exempl of indication
Keratoses
Depression, general
Pain, post-operative
Pain, general
Infection, respiratory tract,
lower

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Fluticasone Propionate		80474-14-2		
	Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6Alpha, 11B, 16Alpha, 17Alpha)- [CAS]	80474-14-2 90566-53-3		Formulation, inhalable, solution
fluticasone propionate	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro- [CAS]	25967-29-7	GB 1253368	Anxiolytic
flutoprazepam	1H-Imidazole, 1-[(2-fluorophenyl)(4-fluorophenyl)phenylmethyl]- [CAS]	119006-77-8	EP 352352	Antifungal
flutrimazole		63516-07-4		
Flutropium Bromide				
	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (R*, S*(E))- (±)- [CAS]	93957-55-2	EP 114027	Hypolipaeic/Antiatherosclerosis
fluvastatin		93957-54-1		
Fluvastatin				
	1-Pentatone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-O-(2-aminoethyl)oxime, (E)- [CAS]	54739-18-3 61718-82-9	GB 1535226	Antidepressant
fluvoxamine				
	1-Pentatone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-O-(2-aminoethyl)oxime, (E)- [CAS]	59-30-3 58-05-9 7554-65-6		Formulation, modified-release, other
fluvoxamine				
Folic Acid				
Folinic Acid				
F mepizole				
	Benzamide, N-[3-chloro-2-[(methyl(2-(4-morpholinyl)-2-oxoethyl)amino]methyl]phenyl]- [CAS]	18053-31-1 24600-36-0	US 3661903	Respiratory stimulant
fomiroben		144245-52-3		
F mivirsen		17692-39-6		
Fomocaine		7456-24-8		
Fonazine				
Fondaparinux		114870-03-0		

TABLE IV

Example of Indication
Asthma
Psychosis, general
Infection, dermatological
Hypercholesterolaemia
Depression, general
Obsessive-compulsive disorder
Eczema, general

TABLE IV

API Gen ric Name	API Ch mical Name	CAS No.	Patent Refer nce	Example of Therapeutic Use
fondaparinux sodium	Alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-β-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-O-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate) [CAS]	104993-28-4 2454117		Anticoagulant
Formebolone				
formestane	Androst-4-ene-3,17-dione, 4-hydroxy- [CAS]	566-48-3 2825-60-7	EP 346953	Anticancer, hormonal
Formocortol				
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*, R*)-, (+/-)- [CAS]	43229-80-7 73573-87-2	GB 1415256	Antiasthma
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*, R*)-, (±)- [CAS]	43229-80-7 73573-87-2		Formulation, inhalable, dry powder
fosamprenavir calcium	Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)- C-((3S)-tetrahydro-3-furanyl ester, calcium salt (1:1) [CAS]	226700-81-8 34156-56-4 4428-95-9 63585-09-1		Antiviral, anti-HIV
fosarnet	Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt [CAS]	522-40-7	US 4839445	Antiviral, other
Fosfestrol				
fosfluconazole	2,4-difluoro-Alpha,Alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)	194788-83-9 23155-02-4 26016-98-8		Antifungal
fosfomycin	Phosphonic acid, (3-methoxyoxiranyl)-, (2R-cis)- [CAS]	23155-02-4	GB 1223923	Antibiotic, other
Fosfomycin				

TABLE IV

Example of Indication
Thrombosis, venous
Cancer, breast
Asthma
Asthma
Infection, HIV/AIDS
Infection, cytomegalovirus
Infection, fungal, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
fosfomycin trometamol	Phosphonic acid, (3-methoxytrany)-, (2R-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)- [CAS]	78964-85-9	EP 27597	Antibiotic, other
Fosfosal		6064-83-1		
	L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphinyl]acetyl]-, (2Apha,4R)- [CAS]	88889-14-9 99048-97-6	EP 63896	Antihypertensive, renin-system
fosinopril	2,4-Imidazolidinedione, 5,5-diphenyl-3-[[phosphonoxy)methyl]- [CAS]	92134-98-0 93390-81-9	US 4260769	Antiepileptic
fosphenytoin	Phosphonic acid, 1-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]ethyl]-, diethyl ester [CAS]	92118-27-9	EP 117959	Anticancer, alkylating
foleustine		106560-14-9		
Fropenem				
fravatrilpan	1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)- [CAS]	158747-02-5	WO 9922730	Antimigraine
Fructose		57-48-7		
Fructose-1,6-diphosphate		488-69-7		
FTC	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- (4R)			Antiviral, anti-HIV
FTY-720	1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride [CAS]	162359-56-0	WO 9408943	Immunosuppressant
fudosteine	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-5	US 5047428	Antitussive
fulvestrant	Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[[[4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7Apha,17B)- [CAS]	129453-61-8	EP 346014	Anticancer, hormonal
fumagiline	2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiran-1-yl]-1-oxaspiro[2.5]oct-6-yl] ester, [3R-[3Apha,4Apha(2R*,3R*),5B,6B(all-E)]]- [CAS]	23110-15-8		Protozoacide
Fumagillin		23110-15-8		

TABLE IV

Exempl of Indication
Infection, urinary tract
Hypertension, general
Epilepsy, generalized, tonic-clonic
Cancer, melanoma
Migraine
Infection, HIV/AIDS
Transplant rejection, general
Cough
Cancer, breast
Infection, GI tract

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Furaltadone		139-91-3		
Furazabol		1239-29-8		
Furazolidone		67-45-8		
Furazolum Chloride		5118-17-2		
Furonazide		3460-67-1		
furosemide	Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[[2-furanylmethyl]amino]- [CAS]	54-31-9		Formulation, modified-release, other
Fursultiamine		804-30-8		
Furtrethonium		7618-86-2		
Fusidic Acid		613/6990		
G1, YM BioSciences	1-(5-bromofur-2-yl)-2-bromo-2-nitroethene			Antifungal
G25			WO 9804252	Antimalarial
GABA-A Alpha5 inverse agonist, Mer			WO 0206285	Cognition enhancer
gabapentin	Cyclohexanecarboxylic acid, 1-(aminomethyl)- [CAS]	60142-86-3	US 4152326	Antiepileptic
gabexate	Benzoic acid, 4-[[6-[(aminomethyl)amino]-1-oxohexyl]oxy]-, ethyl ester, monomethanesulfonate [CAS]	39492-01-8 56974-61-9	US 3751447	GI inflammatory/bowel disorders
gaboxadol	Isosaxolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7-tetrahydro- [CAS]	64603-91-4	CA 1125288	Hypnotic/Sedative
Gadobenate		127000-20-8		
Dimeglumine		138071-82-6		
Gadobutrol		131410-48-5		
Gadodiamide		80529-93-7		
Gadopentetic Acid		120066-54-8		
Gadoteridol		131069-91-5		
Gadoversetamide		135326-11-3		
Gadoxetic Acid	(4aS,6R,8aS)-6-Hydroxy-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-benzofuro[3a,3,2-e][2]benzazepine			Formulation, modified-release, other
galantamine				
Galanthamine		357-70-0		

TABLE IV

Exempl of Indication
Hypertension, general
Infection, gynaecological
Infection, malaria
Alzheimer's disease
Epilepsy, general
Pancreatitis
Sleep disorder, general
Alzheimer's disease

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
galarubicin hydrochloride	D-Alanine, 2-[4-[(2,6-dideoxy-2-fluoro- Alpha-L-falopyranosyl)oxy]-1,2,3,4,6,11- hexahydro-2,5,12-trihydroxy-7-methoxy- 6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester, hydrochloride, (2S-cis)- [CAS]	140637-82-7 140637-86-1	EP 424899	Anticancer, antibiotic
Gallamine Triethiodide		65-29-2		
Gallic Acid		149-91-7		
gallium maltolate	4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex			Anticancer, other
gallium nitrate	Nitric acid, gallium salt [CAS]	13494-90-1	US 4529593	Osteoporosis treatment
gallopamil	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4- dimethoxyphenyl)ethyl(methylamino)propyl]- 3,4,5-trimethoxy-Alpha-(1-methylethyl)- [CAS]	16662-47-8	GB 1367677	Antianginal
Gallopamil		16662-47-8		
γ-Aminobutyric Acid		56-12-2		
Ganax lone		38398-32-2		
ganciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2- hydroxy-1-(hydroxymethyl)ethoxy]methyl]- [CAS]	107910-75-8 82410-32-0	EP 49072	Antiviral, other
ganirelix	[N-Ac-D-Nal,D-pCl-Phe,D-Pal,D- hArg(Et)2,hArg(Et)2,D-Ala]GnRH- [CAS]	124904-93-4	EP 312052	Releasing hormones
ganstigmine hydrochloride	Carbamic acid, (2-ethylphenyl)-, (3aS,8aS)- 1,2,3,3a,8,8a-hexahydro-1,3a,8- trimethylpyrrolo[2,3-b]indol-5-yl ester, hydrochloride			
		223585-99-7	EP 1023297	Cognition enhancer
gantofiban	1-Piperazineacetic acid, 4-[[[(5R)-3-[4- [imino(methoxycarbonyl)amino]methyl]phe- nyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester [CAS]	183547-57-1	EP 741133	Antithrombotic

TABLE IV

Example of indication
Cancer, breast
Cancer, myeloma
Hypercalcaemia of malignancy
Angina, general
Infection, cytomegalovirus
Infertility, female
Alzheimer's disease
Thrombosis, general

TABLE IV

API Generic Nam	API Chemical Name	CAS No.	Patent Reference	Example of Th rapeutic Use
garenoxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1R)-2,3-dihydro-1-methyl-1H-isindol-5-yl)-1,4-dihydro-4-oxo-6H-methanesulfonate [CAS]	223652-82-2		Quinolone antibacterial
garnocastim	5-73-macrophage inflammatory protein 2Alpha (human gene gro2)- [CAS]	246861-96-1		Radio/chemoprotective
gatifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-6-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)- [CAS]	112811-59-3	EP 230295	Quinolone antibacterial
Gatifloxacin		112811-59-3		
Gefarnat		51-77-4		
gefitinib	4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy) [CAS]	184475-35-2	WO 9633980	Anticancer, other
gemcabene calcium	calcium 6,6'-oxybis(2,2-dimethylhexanoate)	209789-08-2		Hypolipaeamic/Antiatherosclerosis
Gemcitabine		95058-81-4		
gemcitabine hydrochloride	Cytidine, 2'-deoxy-2', 2'-difluoro-, monohydrochloride [CAS]	122111-03-9 95058-81-4	GB 2136425	Anticancer, antimetabolite
gemeprost	Prosta-2,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, methyl ester, (2E,11Alpha,13E,15R)- [CAS]	64318-79-2	GB 1540427	Prostaglandin
Gemeprost		64318-79-2		
gemfibrozil	Penantoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- [CAS]	25812-30-0	US 3674836	Hypolipaeamic/Antiatherosclerosis
Gemfibrozil		25812-30-0		
gemifloxacin	1,6-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxymino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- [CAS]	175463-14-6	US 5869670	Quinolone antibacterial
gentamicin	Gentamicin [CAS]	1403-66-3		Formulation, Implant
Gentian Violet		548-62-9		
Gentiopicroin		20831-76-9		

TABLE IV

Example of Indication
Infection, respiratory tract, lower
Chemotherapy-induced injury, bone marrow, neutropenia
Infection, respiratory tract, general
Cancer, lung, non-small cell
Hyperlipidaemia, general
Cancer, pancreatic
Hyperlipidaemia, general
Infection, respiratory tract, general
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Genitistic Acid		490-79-9		
Gepefrine		18840-47-6		
geprone-ER	2,6-Piperidinedione, 4,4-dimethyl-1-[4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl]- [CAS]			Formulation, modified-release, other
gestodene	18,19-Dinopregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- [CAS]	109852-02-0 60282-87-3	GB 1569135	Formulation, fixed-dose combinations
gestodene + ethinyltest, Scherl	18,19-Dinopregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-mixt with 19-Norpregna-1,3,5(10)-trien-20-yn-13,17-diol (17 α)- [CAS]			Formulation, modified-release, >24hr
Gestonorone Caproate		1253-28-7		
Gestrinone		16320-04-0		
γ -Hydroxybutyrate		591-81-1		
gimatecan	(4S)-11-[(E)-[(1,1-dimethylethoxy)imino]methyl]-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyranol[3,4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione	292618-32-7		Anticancer, other
Giractid		24870-04-0		
Gitoxin		4562-36-1		
GL-406349	N,N'-Bis[2-[N-(2-(N2,N5-dimethyl-DL-lysylamino)-ethyl]carbamoyl]1H-indol-6-yl]-1H-indole-2,5-dicarboxamide			Antifungal
Glafenine		3920-67-5		
Glatramer		28704-27-0		
glatramer acetate	L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt) [CAS]	147245-92-9	WO 580808	Multiple sclerosis treatment
Glibornuride		26944-48-9		
gliclazide	Benzenesulfonamide, N-[[[hexahydrocyclopenta[c]pyrrol-2'(1H)-yl]amino]carbonyl]-4-methyl- [CAS]	21187-98-4	GB 1153982	Antidiabetic

TABLE IV

Example of Indication
Depression, general
Contraceptive, female
Contraceptive, female
Cancer, brain
Infection, fungal, general
Multiple sclerosis, relapsing- remitting
Diabetes, Type II

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Gliflazide		21187-98-4		
	1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-{4-[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonylphenyl}ethyl]-2-oxo- [CAS]	93479-97-1	WO 9303724	Antidiabetic
glimepiride		506-26-3		
γ-Linolenic Acid				
	Pyrazinecarboxamide, N-[2-{4-[[[(cyclohexylamino)carbonyl]amino]sulfonylphenyl}ethyl]-5-methyl- [CAS]	29094-61-9	US 3669966	Antidiabetic
glipizide				
	Benzenesulfonamide, N-[[cyclohexylamino]carbonyl]-4-[2-{3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isouquinoliny]ethyl]- [CAS]	93342-05-1	GB 1277847	Antidiabetic
gliquidone				
	3-Isoxazolecarboxamide, N-[2-{4-[[[(cyclohexylamino)carbonyl]amino]sulfonylphenyl}ethyl]-5-methyl- [CAS]	24477-37-0		Antidiabetic
glisolanide		25046-79-1		
Glisocepid		52443-21-7		
Glucametacin		87-74-1		
Glucosulfonic Acid		526-95-4		
Glucosamine		3416-24-8		
	D-Glucose, 2-amino-2-deoxy-, sulfate (salt) [CAS]	29031-19-4	DE 1953689	Antiarthritic, other
Glucosulfone Sodium		554-18-7		
	β-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamide)- [CAS]	132682-98-5	DE 3835772	Anticancer, alkylating
glutofamide		56-86-0		
Glutamic Acid		111-30-8		
Glutaraldehyde		77-21-4		
Glutethimide		10238-21-8		
Glyburide		535-65-9		
Glybuthiazole(e)		1492-02-0		
Glybuzole		56-81-5		
Glycerol		352-97-6		
Glycocycamine		87-28-5		
Glycol Salicylate				

TABLE IV

API Generic Name	API Chemical Nam	CAS No.	Patent Refer nce	Example of Therapeutic Use
Glyconlazide		3691-74-5		
Glycopyrrolate		596-51-0		
Glyhexamide		451-71-8		
Glymidine		339-44-6		
Glypinamide		1228-19-9		
GMDP	N-acetylglucosaminyl-N-acetylmuramyl dipeptide.			Anti-infective, other
Gold Sodium Thiomalate		12244-57-4		
G Id Sodium Thiosulfate		10233-88-2		
goserelin	Luteinizing hormone-releasing factor (p1g), 6-[O-(1,1-dimethylethyl)-D-serine]-10-deglycinamide-, 2-(aminocarbonyl)hydrazide [CAS]	65807-02-5	US 4100274	Releasing hormones
Gosarelin Acetate				
GPI-1485	L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester [CAS]	186452-09-5		Antiparkinsonian
GPI-5693	2-(Phosphononemethyl)pentanedioic acid		US 5672592	Analgesic, other
Graftskin				
granisetron	1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo- [CAS]	107007-99-8 109889-09-0	EP 200444	Antiemetic
Grepafloxacin		119914-60-2		
griseofulvin	Spiro[benzofuran-2(3H),1'-[2(cyclohexane)-3,4'-dione, 7-chloro-2',4,6-trimethoxy-6methyl-, (1'S-trans)-] [CAS]	126-07-8		Formulation, dermal, topical
Gualacol		90-05-1		
Gualapat		852-42-6		
Gualazulene		489-84-9		
Gualifen sin		93-14-1		
gualinesal	4H-1,3-Benzodioxin-4-one, 2-(2-methoxyphenoxy)-2-methyl- [CAS]	81674-79-5	GB 2098201	Anti-inflammatory

TABLE IV

Example of Indication
Infection, general
Cancer, prostate
Parkinson's disease
Pain, neuropathic
Chemotherapy-induced nausea and vomiting
Infection, dermatological

TABLE IV

API Generic Name	API Chemical Nam	CAS No.	Patent Reference	Example of Th rapeutic Use
Guamecycline		16545-11-2		
Guanabenz		5051-62-7		
Guanadrel		40580-59-4		
Guanethidine		55-65-2		
Guanfacine		29110-47-2		
Guanoxabenz		24047-25-4		
Guanoxan		2165-19-7		
gugulipid	Pregna-4,17(20)-diene-3,16-dione [CAS]	95975-55-6	EP 447706	Hypolipaeamic/Antiatherosclerosis
Gusperimus		104317-84-2		
	(Z)-2-Chlorofumaric acid 1-[3-{[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinum-2-yl]propyl}]			Muscle relaxant
GW-280430A	[2S,3S,5R]-2-[3,5-difluorophenyl]-3,5-dimethyl-2-morpholinol			Anorectic/Antiobesity
GW-320659				Prostate disorders
GYKI-16084	(+)-R-2-[3-{N-(2-Benzo[1,4]dioxanylmethyl)amino}-1-propyl]-3(2H)-pyridazinone hydrochloride		US 6194411	
Hachimycin		1394-02-1		
Halazepam		23092-17-3		
Halcinonide		3093-35-4		
halobetasol propionate	Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6Alpha,11B,16B)- [CAS]	66852-54-8	US 4619921	Antipsoriasis
halofantine	9-Phenanthrenemethanol, 1,3-dichloro-Alpha-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)- [CAS]	36167-63-2 69756-53-2	EP 138374	Antimalarial
halometasone	Pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6Alpha,11B,16Alpha)- [CAS]	50629-82-8	US 4076737	Antipruritic/inflamm; allergic
Haloperidol		52-86-8		

TABLE IV

Example of Indication
Anaesthesia, adjunct
Obesity
Benign prostatic hyperplasia
Psoriasis
Infection, malaria

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Haloperidol Decanoate				
Halopredone Acetate		57781-14-3		
Halopr gin		777-11-7		
Halopropane		679-84-5		
Halothane		151-67-7		
Haloxazolam		59128-97-1		
harkoseride	2(R)-Acetamido-N-benzyl-3-methoxypropionamide		WO 9733861	Antiepileptic
HE-2000	16Alpha-Bromo-38-hydroxy-5Alpha-androstane-17-one			Antiviral, anti-HIV
Healos			WO 9714376	Musculoskeletal
Hematoporphyrin		14459-29-1		
Hepronicate		7237-81-2		
Heptabarbital		509-86-4		
Heptaminol		372-66-7		
Hetacillin		3511-16-8		
Hetastarch		9004-62-0		
Hexachlorophene		70-30-4		
Hexadimethrine Bromide		28728-55-4		
Hexafluorenum Bromide		317-52-2		
Hexamethonium		60-26-4		
Hexamidine		3811-75-4		
Hexapropymate		358-52-1		
Hexedine		5980-31-4		
Hexestrol		84-16-2		
H xestrol Bis(β -diethylaminoethyl ether)		2691-45-4		
Hexethal Sodium		144-00-3		

580

[illegible]

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Hexetidine		141-94-6		
Hexobarbital		56-29-1		
Hexobendine		54-03-5		
Hexocyclium Methyl Sulfate		115-63-9		
Hexoprenaline		3215-70-1		
Hexend	Hexend [CAS]	235746-51-7	US 5407428	Plasma substitute
Hexylcaline Hydrochloride		532-76-3		
HF-0289	11b-hydroxy androstenedione			Osteoporosis treatment
HGP-2	Benzeneacetic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 2-tricyclo[3.3.1.1 ^{3,7} dec-1-yl]ethyl ester, (2Z)-2-butenedioate (1:1) (salt) [CAS]	121009-31-2		Antiglaucoma
HGP-6a	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)-, methyl sulfate [CAS]	113932-41-5		Antiepileptic
Hydrosmiln	Hydrosmiln- [CAS]	120250-44-4		Vasoprotective, systemic
Histamine		51-45-6		
Histamine dihydrochloride	histamine dihydrochloride		EP 0493468	Anticancer, immunological
Histapyrrodine		493-80-1		
Histrelin	Luteinizing hormone-releasing factor (pig), 8-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	76712-82-8	EP 217659	Releasing hormones
HM-101	HM 101 [CAS]	217311-70-1		Osteoporosis treatment
HMN-214	(E)-4-[2-(p-methoxybenzenesulfonamide)-phenyl]ethenylpyridine-1-oxide			Anticancer, other
Homatropine		87-00-3		
Homocamfin		535-86-4		
Homochlorcyclizine		848-53-3		
Hopantenic Acid		18679-90-8		

TABLE IV

Example of Indication
Surgery adjunct
Osteoporosis
Glaucoma
Epilepsy, general
Cancer, melanoma
Precocious puberty
Osteoporosis
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
HP-228	Glycinamide, N-acetyl-L-norleucyl-L-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl- [CAS]	172617-89-9	EP 759770	Analgescic, other
Huperzine A		102518-79-6		
hyaluronan	Hyaluronic acid [CAS]	9004-61-9		Formulation, other
Hycanhone		3105-97-3		
Hydnocarpic Acid		459-67-6		
Hydralazine		86-54-4		
Hydrastine		118-08-1		
Hydrastinine		6592-85-4		
Hydrochlorothiazide		58-93-5		
Hydrocodone		125-29-1		
hydrocodone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5 α)- [CAS]	466-99-9		Formulation, modified-release, other
Hydrocortamate		76-47-1		
Hydrocortisone		50-23-7		
hydrocortisone aceponate	Pregn-4-ene-3,20-dione, 21-(acetoxy)-11-hydroxy-17-(1-oxopropoxy)-, (11 β)- [CAS]	74050-20-7	DE 2828257	Dermatological
hydrocortisone butyrate propio	Pregn-4-ene-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (11 β)- [CAS]	72590-77-3	DE 2910899	Antipruritic/inflam, allergic
hydrocortisone-17-butyrate	Pregn-4-ene-3,20-dione, 11,21-dihydroxy-17-(1-oxobutoxy)-, (11 β)- [CAS]	13609-67-1		Formulation, optimized, microemulsion
Hydroflumethiazide		135-09-1		
hydromorphone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5 α)-, mixt with acetamide, N-(4-hydroxyphenyl)-, mixt with morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 α)-	103-90-2 16590-41-3 466-99-9		Formulation, fixed-dose combinations
Hydroquinidine		1435-55-8		
Hydroquinine		522-66-7		
Hydroquinone		123-31-9		

TABLE IV

Example of Indication
Pain, post-operative
Restenosis
Pain, general
Unspecified
Eczema, atopic
Pain, general

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Hydroxocobalamin		13422-51-0		
Hydroxyamphetamine		1518-86-1		
Hydroxychloroquine		118-42-3		
Hydroxydione Sodium		53-10-1		
Hydroxypethidine		468-56-4		
Hydroxyphenamate		50-19-1		
Hydroxypropyl Cellulose		9004-64-2		
Hydroxystilbamidine		495-99-8		
Hydroxytetracaine		490-98-2		
Hydroxyzine		68-88-2		
Hylan G-F 20				
Hym cr mone		90-33-5		
	benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1]oct-3-yl ester, [3(S)-endo], sulfate (2:1), dihydrate	101-31-5		Formulation, oral/orally-disintegrating
hyoscyamine sulfate				
	Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9		Anticancer, other
hypericin		180468-34-2		
IACFT				
	Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene] bis- [CAS]	114084-78-5	EP 252504	Osteoporosis treatment
ibandronic acid				
	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1	GB 1551661	Cardio stimulant
ibopamine				
	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1		Formulation, mucosal, topical
ibritumomab Tiuxetan		206181-63-7		
	Phosphonic acid, [[4-[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl[methyl]-],-, diethyl ester [CAS]			
ibrolipim		133208-93-2	EP 402033	Hypolipaeic/Antiatherosclerosis

TABLE IV.

Example of Indication
.
.
.
.
.
.
.
.
.
.
Ulcer, GI, general
.
Cancer; brain
.
Hypertalcaemia of malignancy
.
Heart failure
.
Surgery adjunct
.
Hypertiglyceridaemia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ibudilast	1-Propanone, 2-methyl-1-[2-(1-methyl-1H-pyrazol-5-yl)pyridin-3-yl]-[CAS]	50847-11-5	EP 215438	Antiasthma
ibufenac	Benzenecarboxylic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridinylmethyl ester [CAS]	1553-60-2		
ibuprofen piconol	Benzenecarboxylic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	64622-45-3	DE 2658610	Antipruritic/inflam, non-allergic
ibuprofen	Benzenecarboxylic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	15687-27-1		Formulation, modified-release, other
ibuproxam		53648-05-8		
ibutilide		122647-31-8		
ibutilide fumarate	Methanesulfonamide, N-[4-[(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (+-), (E)-2-butenedioate (2:1) (salt) [CAS]	122647-31-8 122647-32-9	JP 60239458	Antiarrhythmic
ICA-17043			US 6288122	Antisickling
icodextrin, CAPD, ML Labs	Dextrin- [CAS]	9004-53-9		Urological
idarubicin	5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- [CAS]	58957-92-9 86189-66-4	US 4471052	Anticancer, antibiotic
idazoxan	2-(2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	79944-58-4		
IdB-1016	2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-[CAS]	134499-06-2	EP 209038	Anticancer, hormonal
idebenone		58186-27-9	EP 58057	Neuroprotective

TABLE IV

Example of Indication
Asthma
Eczema, contact
Inflammation, general
Fibrillation, atrial
Anaemia, sickle cell
Renal failure
Cancer, leukaemia, acute lymphocytic
Cancer, ovarian
Ischaemia, cerebral

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref	Example of Therapeutic Use
IDN-5109	4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy)carbonylamino]-2-hydroxy-5-methyl- (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetyloxy)-13-(benzoyloxy)- 3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methanocyclodeca [1,2-d] dioxyl-4-yl ester, 2R,3S] [CAS]	186348-05-0 116057-75-1	US 5264591	Anticancer, other
Idoxifene	Alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-3-D-glucopyranuronosyl-(1-4)-O-2,3,6-tri-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-idopyranuronosyl-(1-4)-tris(hydrogen sulfate) nonasodium salt [CAS]	149920-56-9	AU 698456	Antithrombotic
Idraparinux sodium	2-Propenamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6961-46-2	US 3659014	Anti-inflammatory, topical
Idroclamide	(7)-2-(4-benzyl piperidino)-1-p-hydroxyphenylpropanol tartrate	23210-56-2		
Ifenprodil		23210-56-4	US 3509164	Neuroprotective
Ifenprodil tartrate				
Ifosfamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-2-oxide [CAS]	3778-73-2	US 3732340	Anticancer, alkylating
Iguratimod	N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-chromen-7-yl] methanesulfonamide	123663-49-0	DE 3634204	Antiarthritic, other
Ilaprazole	1H-Benzimidazole, 2-(((4-methoxy-3-methyl-2-pyridinyl) methyl)sulfinyl)-5-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US 5703097	Antilulcer

TABLE IV

Example of Indication
Cancer, colorectal
Thrombosis, venous
Cancer, lung, general
Arthritis, rheumatoid
Ulcer, GI, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tiomastat	Butanediamide, N4-hydroxy-N1-(1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*, S*))-[CAS]	142880-36-2	US 5692112	COPD treatment
tioperidone	Ethanone, 1-(4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy)-3-methoxyphenyl)- [CAS]	133454-47-4	US 5776963	Neuroleptic
tioprost trometamol	Pentanoic acid, 5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]- [CAS]	78919-13-8	DE 3417638	Prostaglandin
tiLX23-7553	1Alpha,25-Hydroxy-16-yne vitamin D3			Anticancer, other
tiatinib	4-((Methyl-1-piperazinyl)methyl)-N-(4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]-phenyl)benzamide methanesulfonate	152459-95-5	US 5521184	Anticancer, other
tiadapril	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3(R*(R*)), 4R*]]- [CAS]	89371-37-9 89396-94-1	EP 95163	Antihypertensive, renin system
tiadapril hydrochloride, Ark	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3(R*(R*)), 4R*]]-, monohydrochloride			Musculoskeletal
tiadazole salicylate	Benzolic acid, 2-hydroxy-, compd. with 1H-imidazole (1:1) [CAS]	36364-49-5	US 4329340	Anti-inflammatory
tiipenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[2-[[[(linomethyl)amino]ethyl]thio]-7-oxo-, [5R-[5Alpha, 6Alpha(R*)]]- [CAS]	64221-86-9 74431-23-5 81129-83-1	GB 1570990	Beta-lactam antibiotic
tiipramine		50-49-7		
tiipramine N-Oxide		6829-98-7		
tiiquimod	1H-imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- [CAS]	99011-02-6	EP 145340	Antiviral, other

TABLE IV

Example of indication
Emphysema, smoking-related
Schizophrenia
Peripheral vascular disease
Cancer, general
Cancer, leukaemia, chronic myelogenous
Hypertension, general
Cachexia
Pain, general
Infection, general
Infection, human papilloma virus

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Imolamine		318-23-0		
implipapide	Benzeneacetamide, Alpha-cyclopentyl-4-((2,4-dimethyl-9H-pyrido(2,3-b)indol-9-yl)methyl)-N-((1R)-2-hydroxy-1-phenylethyl)- (AlphaS)- [CAS]	177469-96-4	EP 705831	Hypolipaeic/Antiatherosclerosis
Improsulfan		13425-98-4		
Inaperisone		99323-21-4		
Inadronate disodium	Phosphonic acid, ((cycloheptylamino)methylene)bis-, disodium salt [CAS]	138330-18-4		Musculoskeletal
Incadronic Acid		124351-85-5		
Indalpine		63758-79-2		
Indanazoline		40507-78-6		
Indapamide	4-chloro-N-(2-methylindol-1-yl)-3-sulfamoylbenzamide	26807-65-8	GB 1203691	Antihypertensive, diuretic
Indecalnide		74517-78-5		
Indeloxazine	Morpholine, 2-((1H-inden-7-yloxy)methyl)- [CAS]	80829-23-9 85043-22-3	JP 52083773	Cognition enhancer
Ind loxazine Hydrochloride		65043-22-3		
Indenolol		30190-87-5 60807-88-3 68906-88-7	GB 1290343	Antihypertensive, adrenergic
Indinavir		150378-17-9		
Indinavir sulfate	D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-(1Alpha(R),2Alpha)]-, sulfate (1:1) (salt) [CAS]	150378-17-9 157810-81-6	EP 0541168	Antiviral, anti-HIV
indiplon	Acetamide, N-methyl-N-(3-(2-(thienylcarbonyl)pyrazole(1,5-a) pyrimidin-7-yl)phenyl)- [CAS]	925715-02-4	US 6398621	Hypnotic/Sedative

TABLE IV

Example of Indication
Atherosclerosis
Hypercalcaemia of malignancy
Hypertension, general
Alzheimer's disease
Infection, HIV/AIDS
Insomnia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Indisetron	1H-Indazole-3-carboxamide, N-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, diendo- [CAS]	160472-97-9		Antiemetic
Indisulam	1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]	165668-41-7		Anticancer, other
Indobufen		63610-08-2		
Indocyanine Green		3599-32-4		
Indometacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- [CAS]	53-86-1		Formulation, modified-release, other
Indoprofen		31842-01-0		
Indoramin	Benzamide, N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]- [CAS]	28844-12-2 36821-52-2	GB 1218570	Antihypertensive, adrenergic
Inducterm			US 5993810	Labour Inducer
Infliximab		170277-31-3		
Inosine Pranobex		36703-88-5		
Inositol		87-89-8		
Inositol Niacinate		6556112		
Iobenguane		80663-95-2		
Iobenzamic Acid		3115057		
Iobitridol		136949-58-1		
Iocarmic Acid		10397-75-8		
Iocetamic Acid		16034-77-8		
Iodamide		440-58-4		
Iodine, Symbolon	Iodine [CAS]	7553-56-2		Formulation, oral, other
Iodipamide		606-17-7		
Iodixanol		92339-11-2		
Iodoalphonic Acid		577-91-3		
Iodochlorhydroxyquin	5-Chloro-7-iodo-8-quinolinol	130-26-7		Cognition enhancer
Iodoform		75-47-8		
Iodopyracet		300-37-8		
Iodopyrrole		87-58-1		
Iodoquinol		83-73-8		
Iofetamine 123I		75917-92-9		

TABLE IV

Example of Indication
Nausea and vomiting, general
Cancer, lung, non-small cell
Inflammation, general
Labour, induction
Fibrocystic breast disorder
Alzheimer's disease

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Iloglycamic Acid		2618-25-9		
Iohexol		66108-95-0		
Iomeglamic Acid		25827-76-3		
Iomeprol		78649-41-9		
Iopamidol		60166-93-0		
Iopanoic Acid		96-83-3		
Iopentol		89797-00-2		
Iophendylate		99-79-6		
Iophenoxic Acid		96-84-4		
Iopromide		73334-07-3		
Iopr nic Acid		41473-08-9		
Iopydol		5579-92-0		
Iopydone		5579-93-1		
Iothalamic Acid		2276-90-6		
Iotrolan		79770-24-4		
Iov r sol		87771-40-2		
Ioxaglic Acid		59017-64-0		
Ioxilan		107793-72-6		
Ioxilan [P-751]	(3R,4R)-(delta6)-THC-DMH-11-olic acid		WO 9401429	Analgesic, other
Ipidacrine		62732-44-9		
	Stigmaster-15-one, 22,29-epoxy- 3,4,6,7,29-pentahydroxy-, (3Alpha,4B,5Alpha,6Alpha,7B,14B,22S)- [CAS]	137571-30-3	US 6046185	Antisthma
IPL-576092		5587-89-3		
Ipodate		22254-24-6		
Ipratropium Bromide				
Ipratropium bromide		86985-17-9		Formulation, inhalable; solution
Ipratropium, AeroDose	(endo, syn)-(+)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane			Formulation, inhalable; topical

TABLE IV

Example of Indication
Pain, neuropathic
Asthma
Chronic obstructive pulmonary disease
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Iprazochrome	Hydrazinecarboxamide, 2-[1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5H-indol-5-ylidene]- [CAS]	7248-21-7		Haemostatic
Ipriflavone	4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- [CAS]	35212-22-7	EP 214647	Osteoporosis treatment
Iprindole		5560-72-5		
Iproclozide		3544-35-2		
Iproniazid		54-92-2		
Ipsapirone		95847-70-4		
Iribesartan	2-n-butyl-4-spirocyclopentane-1-(((2-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-imidazolyl-5-one	138402-11-6	WO 9114679	Antihypertensive, renin system
IRFI-042	Butanedioic acid, mono[2-[2-(acetylthio)ethyl]-2,3-dihydro-4,6,7-trimethyl-5-benzofuranyl] ester, (+/-) [CAS]	134867-62-2	US 5114966	Cardiovascular
IRFI-165	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine	191349-26-5	EP 865442	Antidepressant
Iridomyrmecin		485-43-8		
Iridalone	Imidazolidinone, 1-[2-[4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-piperazinyl]ethyl]-, (1R-trans)- [CAS]	104113-57-7 96478-43-2	EP 183349	Antidepressant
Irinotecan		97682-44-5		
Irofulven	Spiro[cyclopropane-1,5'-[5H]inden]-7'(6H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]	125392-76-9	US 5563176	Anticancer, other
Iron Sorbitex		1338-16-5		
Irsoglazine	1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- [CAS]	57381-26-7 57381-28-9 57381-33-6	US 4657807	Antihypertensive, diuretic
IS-741	Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]- [CAS]	141283-87-6	EP 465913	GI inflammatory/bowel disorders
isaglitazone	2,4-Thiazolidinedione, 5-[[6-(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-[CAS]	161600-01-7	US 5594016	Antidiabetic

TABLE IV

Example of Indication
Osteoporosis
Hypertension, general
Atherosclerosis
Depression, general
Depression, general
Cancer, prostate
Hypertension, general
Pancreatitis
Diabetes, Type II

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ISABx-247			NZ 502362	Immunosuppressant
Isbogrel		89667-40-3		
	D-Sireptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]	58152-01-5 58152-03-7	US 4029882	Aminoglycoside antibiotic
Isepamicin		77-51-0		
Isoaminile		94-14-4		
Isobutyl p-Aminobenzoate				
Isocarboxazid		59-63-2		
Isoconazole	1-[2-(2,6-dichlorobenzoyloxy)-2-(2,4-dichlorophenyl)ethyl]	24168-96-5	GB 1244530	Antifungal
Isoconazole		27523-40-6		
Isoetharine		530-08-5		
	1-Piperazineethanol, 4-[3-fluoro-10,11-dihydro-8-(1-methylethyl)dibenzolb,5[thiepin-10-yl]-[CAS]	106819-39-0 106819-41-4 70931-18-9	GB 2010843	Neuroleptic
Isoflonythepin				
Isoflurane	Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro- [CAS]	26675-46-7	US 3535388	Anaesthetic, inhalation
Isoflurophate		55-91-4		
Isoladol		530-34-7		
Isomethadone		466-40-0		
Isomethheptene		503-01-5		
Isoniazid		54-85-3		
Isonixin		57021-61-1		
Isopromethazine		303-14-0		
Isopropamide Iodide		71-81-8		
Isopropyl Alcohol		67-63-0		
	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-, 1-methylethylester, (1R-(1Alpha(Z), 2S,3Alpha,5Alpha))- [CAS]		EP 289349	Prostaglandin
Isopropyl unoprostane		120373-24-2		
Isoproterenol		7683-59-2		

TABLE IV

[illegible]

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Isosorbide		652-67-5		
Isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-93-2		Formulation, modified-release, other
Isosorbide mononitrate	D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate [CAS]	16051-77-7		Formulation, modified-release, other
Isothip ndyl		482-15-5		
Isotretinoin	Retinoic acid, 13-cis- [CAS]	4759-48-2	US 4843096	Antiacne
Is valeryl Diethylamide		533-32-4		
Isoxepac		55453-87-7		
Isoxicam		34552-84-6		
Is xsuprine		395-28-8		
	3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester [CAS]	75695-93-1	GB 2037766	Antihypertensive, other
Isradipine	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-(4-(2-methylpropyl)phenyl)ethyl]-[CAS]	117279-73-9	EP 268242	Antihypertensive
Israpafant			US 5447926	Formulation, mucosal, topical
ISV-403				
Itasetron		123258-84-4		
ITF-282	ITF 282 [CAS]	93615-44-2	GB 2115821	Antianaemic
	Benzamide, N-[[4-(2-(dimethylamino)ethoxy]phenyl)methyl]-3,4-dimethoxy-, monohydrochloride [CAS]			
Itopride		122892-31-3	EP 308827	Gastroprokinetic
	3H-1,2,4-Triazol-3-one, 4-[4-(4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl)methoxy]phenyl]-1-piperazinylphenyl]-2,4-dihydro-2-(1-methylpropyl)- [CAS]	84625-61-6	EP 6711	Antifungal
Ittramin Tosylate		13445-63-1		

TABLE IV

Example of Indication
Angina, general
Angina, general
Acne
Hypertension, general
Asthma
Conjunctivitis
Anaemia, general
Gastritis
Infection, fungal, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
litriglumide	1-Naphthalenepropanoic acid, 8-[2-[(2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-dimethylphenyl]amino]-2-oxoethyl]-, (8R)-[CAS]	201605-51-8	WO 9800404	Anxiolytic
litrelis	D-Alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	112568-12-4	WO 8901944	Fertility enhancer
ivabradine hydrochloride	7,8-dimethoxy-3-[[[1S](4S)-dimethoxybenzocyclobutan-1-yl)methyl]methylamino]propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one hydrochloride			Antianginal
ixabepilone	17-Oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl, (1R,3S,7S,10R,11S,12S,16R) [CAS]	219989-84-1		Anticancer, other
J-104132	5H-Cyclopenta[b]pyridine-6-carboxylic acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7-[(2[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-, (5S,6R,7R)- [CAS]	198279-45-7	WO 9737665	Antihypertensive, other
J-107088	5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12-B-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-[(2-hydroxy-1-(hydroxymethyl)ethyl)amino]-[CAS]	174402-32-5		Anticancer, other
J-113397	1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one			Analgesic, other
Janex-1	Phenol, 4-[(6,7-dimethoxy-4-quinazolinyl)amino]-[CAS]	202475-60-3		Anticancer, other

TABLE IV

Example of Indication
Anxiety, general
Infertility, female
Angina, general
Cancer, breast
Heart failure
Cancer, bladder
Pain, general
Cancer, leukaemia, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
losamycin	Leucomycin V, 3-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	JP 41021759	Macrolide antibiotic
JTV-519	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- [CAS]	145903-06-6	WO 9212148	Cardiovascular
K-777			US 6287840	Protozoicide
Kainic Acid		487-79-6		
Kalimate	Kalimate- [CAS]	92354-70-6		Urological
Kallidin		342-10-9		
KB-130015	Acetic acid (2,6-dichloro-4-[(2-methyl-3-benzotriazinyl)methyl]phenox)- [CAS]	147030-48-6		Antiarrhythmic
KCB-328	Methanesulfonamide, N-[3-amino-4-{2-[(2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]	177596-55-3	WO 9604231	Antiarrhythmic
K buzone		853-34-9		
ketamine	2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride	6740-88-1		Formulation, transmucosal, nasal
ketanserin	2,4-(1H,3H)-Quinazolinedione, 3-[2-{4-(4-fluorobenzoyl)-1-piperidinyl}ethyl]-[CAS]	74050-98-9 83846-83-7	EP 13612	Antihypertensive, other
ketazolam	4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- [CAS]	27223-35-4	GB 1222294	Anxiolytic
Kethoxal		27762-78-3		
Ketobemidone		469-79-4		
ketoconazole	Piperazine, 1-acetyl-4-[4-[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis- [CAS]	65277-42-1	US 4335125	Antifungal
ketoprofen lysine salt	DL-Lysine, mono(3-benzoyl)-Alpha-methylbenzeneacetate) [CAS]	173011-11-5	EP 502502	Formulation, transdermal, systemic
ketorolac	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, (+)- [CAS]	74103-06-3 74103-07-4	EP 53021	Analgesic, NSAID

TABLE IV

Example of Indication
Infection, general
Infarction, myocardial
Infection, trypanosomiasis, American
Arrhythmia, general
Arrhythmia, general
Pain, post-operative
Hypertension, general
Infection, fungal, general
Pain, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ketorolac Tromethamine				
Ketotifen	10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1)-[CAS]	34580-13-7		
Ketotifen fumarate	10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1)-[CAS]	34580-14-8		Formulation, modified-release, <=24hr
Ketotifen hydrogen fumarate		34580-13-7 34580-14-8	GB 1355539	Antiasthma
Khellin		82-02-0		
kinetin		9001-29-0		Dermatological
	4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[2-hydroxy-3-[[2-[[5-isquinolinyl(oxy)acetyl]amino]-3-[(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl], [4R-[3(2S*,3S*(R*))],4R*]]-[CAS]	147318-81-8	US 5644028	Antiviral, anti-HIV
KNI-272	(R,R)-2-(2,4-Difluorophenyl)-3-(4-methylepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)-2-butanol			Antifungal
KP-103			US 6110961	Antidepressant
KP-157			WO 9919305	Cognition enhancer
KP-544				
	L-glycero-β-L-manno-Heptopyranosylamine, 4-deoxy-4-[[[(2E,4E)-1-oxo-2,4-tetradecadienyl]amino]acetyl]amino]-N-1H-purin-6-yl- [CAS]			
KRN-5500	Alpha-D-Glucopyranoside, β-D-fructofuranosyl, mixt. with 1-ethenyl-2-pyrrolidinone homopolymer compd. with iodine [CAS]	151276-95-8	WO 9015811	Anticancer, antibiotic
KT-136		121602-88-8		Formulation, dermal, topical

TABLE IV

Example of Indication
Asthma
Asthma
Photodamage
Infection, HIV/AIDS
Infection, general
Depression, general
Unspecified
Cancer, colorectal
Ulcer, decubitus

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
KUL-7211	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[(2R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate			Urological
KW-2170	6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[(2-hydroxyethyl)amino]methyl-, dihydrochloride [CAS]	207862-44-0		Anticancer, alkylating
KW-6002	1H-Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-, (E)- [CAS]	155270-99-8		Antiparkinsonian
KW-7158	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-oxo-4,10-dihydrothieno[3,2-C][1]benzothiepin-9-yl)propanamide 5,5 dioxide			Urological
L-365260	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)- [CAS]	118101-09-0	EP 284256	Anticancer, other
L-5-hydroxytryptophan	L-Tryptophan, 5-hydroxy- [CAS]	4350-09-8		Metabolic and enzyme disorders
L-745337	Methanesulfonamide, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]- [CAS]	158205-05-1	WO 9413635	Analgesic, NSAID
L-758298	Phosphonic acid, [3-[[[(2R,3S)-2-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- [CAS]	172673-20-0	WO 9523788	Antiemetic
L-826141			WO 9722585	Antiasthma
labetalol	5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]salicylamide HCl	32780-84-6 36894-69-6	US 4012444	Antihypertensive, adrenergic
lacidipine	3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E)- [CAS]	103890-78-4	GB 2164336	Antihypertensive, other

TABLE IV

Example of Indication
Urinary calculus
Cancer, lung, non-small cell
Parkinson's disease
Incontinence
Cancer, general
Unspecified
Pain, general
Chemotherapy-induced nausea and vomiting
Unspecified
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
<i>Lactic Acid</i>				
lactitol	D-Glucitol, 4-O-β-D-galactopyranosyl- [CAS]	585-86-4		Hepatoprotective
Lactitol		585-86-4		
Lactulose		4618-18-2		
lafutidine	Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N- [4-[(4-(1-piperidinylmethyl)-2-pyridinyl)oxy]- 2-butenyl]-, (Z)- [CAS]	118288-08-7	EP 282077	Anticancer
Lafutidine		118288-08-7; 169899-19-8		
Lamifiban		144412-49-7		
lamivudine	2(1H)-Pyrimidinone, 4-amino-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl]-, (2R- cis)- [CAS]	134678-17-4	EP 513917	Antiviral, anti-HIV
lamotrigine	1,2,4-Triazine-3,5-diamine, 6-(2,3- dichlorophenyl)- [CAS]	84057-84-1	EP 21121	Antiepileptic
landiolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[[2- [(4-morpholinylcarbonyl)amino]ethyl]amino]pro- poxyl-, (2,2-dimethyl-1,3-dioxolan-4- yl)methyl ester, (S-(R*, R*))· HCL	133242-30-5	EP 397031	Antiarrhythmic
lanicemine	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	153322-05-5		Neurological
laniquidar	Methyl 6,11-dihydro-11-[1-[2-[4-(2- quinolylmethoxy)phenylethyl]-4- piperidinylidene]-5H-imidazo[2,1- b][3]benzazepine-3-carboxylate	197509-46-9	WO 9734897	Radio/chemosensitizer
lanocnazole	1H-Imidazole-1-acetonitrile, Alpha-[4-(2- chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)- (±) [CAS]	101530-10-3	US 4738976	Antifungal
Lanoteplase		171870-23-8		
Lanreotide		108736-35-2		
lansoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2- trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]- [CAS]	103577-45-3	EP 174726	Anticancer

TABLE IV

Example of Indication
Infection, neurological
Ulcer, gastric
Infection, HIV/AIDS
Epilepsy, partial (focal, local)
Tachycardia, general
Unspecified
Cancer, general
Infection, fungal, general
Ulcer, duodenal

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lanthanum carbonate	Carbonic acid, lanthanum(3+) salt (3:2) [CAS]	587-26-8	US 5968976	Urological
lapatinib ditosylate	4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy phenyl]-6-[5-[[2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl] bis (4-methylbenzenesulfonate) monohydrate	388082-78-8		Anticancer, other
laquinimod		248281-84-7		Multiple sclerosis treatment
lasofoxiene	2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl) (5R-cis)-, (S-(R*, R*))-2,3-dihydroxybutanedioate [CAS]	190791-29-8	WO 9716434	Menopausal disorders
latamoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo- [CAS]	64952-97-2 64953-12-4	GB 1547351	Beta-lactam antibiotic
latanoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1'Alpha(Z),2'beta(R'),3'Alpha,5'Alpha))- [CAS]	130209-82-4	WO 9002553	Prostaglandin
Lauroguadine		135-43-3		
Laurolinium Acetate		146-37-2		
Lawson		83-72-7		
LAX-111	1-(Z,Z,Z,Z-icos-5,8,11,14,17-pentaenoyloxy)-3-(Z,Z,Z,Z-icos-5,8,11,14,17-pentaenoyloxy)-propane			Neuroleptic
Lazabemide		103878-84-8		
LB-30057	Benzenecarboximide acid, 4-[(2S)-3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-hydrazide [CAS]		WO 9749673	Antithrombotic

TABLE IV

Example of Indication
Hyperphosphataemia
Cancer, breast
Multiple sclerosis, general
Hormone replacement therapy
Infection, general
Glaucoma
Schizophrenia
Thrombosis, venous

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
L-Cystine, Inositol, Methionine, Sodium Propionate, Urea				
L-fetamine	4-Isosazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	7262-75-1		
leflunomide	4-Isosazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	75706-12-6	EP 13376	Antiartritic, immunological
leflunomide		104981-93-3	US 5610173	Anticancer, other
Lelopyrrole		75706-12-6		
		5633-16-9		
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[amino(phenylacetyl)amino]-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [2S-[2 α ,5 α],6 β (S*)]]- [CAS]	80734-02-7	EP 61206	Penicillin, oral
lenampicillin		86273-18-9		Anticancer, immunological
lentian, Ajinomoto	Lentian [CAS]	37339-90-5		
Lepirudin				
	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester, hydrochloride [CAS]	100427-26-7	US 4705797	Antihypertensive, other
lercanidipine		132866-11-6		
lerisetron	1H-Benzimidazole, 1-(phenylmethyl)-2-(1-piperazinyl)- [CAS]	149257-98-1	US 5256665	Antiemetic
Lesopitron		132449-46-8		
leptatinim	Benzoic acid, 4-[(3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino]-, monopotassium salt [CAS]	138117-50-7	US 6338963	Antiparkinsonian
letosteine	4-Thiazolidinecarboxylic acid, 2-[2-(2-ethoxy-2-oxoethyl)thioethyl]- [CAS]	53943-88-7	US 4032534	COPD treatment
letrozole	Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis- [CAS]	112809-51-5	EP 236940	Anticancer, hormonal
Leuc cyanidin		480-17-1		
Leuprolide		53714-56-0		

TABLE IV

Example of Indication
Arthritis, rheumatoid
Cancer, ovarian
Infection, general
Cancer, stomach
Hypertension, general
Nausea and vomiting, general
Parkinson's disease
Bronchitis, chronic
Cancer, breast

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
leuprolide acetate	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide, monoacetate (salt) [CAS]	53714-56-0 74381-53-6		Formulation, implant
leuporelin	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide [CAS]	53714-56-0		Formulation, implant
Levallorphan	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]	152-02-3 14789-73-4 16595-80-5	US 4584305	Anthelmintic
levamisole		14769-73-4		
Levamisole		94535-50-9		
Levcromakalim	1-Pyrrolidineacetamide; Alpha-ethyl-2-oxo-, (S)- [CAS]	102767-28-2	EP 162036	Antiepileptic
levetiracetam				
levobunolol	2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methyl-2-ethoxy)amino)-2-hydroxypropoxy)-3,4-dihydro-, (S)- [CAS]	116209-55-3		Formulation, mucosal, topical
levobunolol	1-(2H)-Naphthalene, 5-[3-((1,1-dimethyl-2-ethoxy)amino)-2-hydroxypropoxy)-3,4-dihydro-, (S)- [CAS]	27912-14-7 47141-42-4	US 3941152	Formulation, mucosal, topical
levobupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]	27262-47-1	WO 9510276	Anaesthetic, injectable
levocabastine	4-Piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, [3S-[1(cis),3Alpha,4B]]- [CAS]	79449-98-2 79516-68-0 79547-78-7	US 4369184	Antiallergic, non-asthma
levocetirizine	Acetic acid, (2-(4-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, (R)- [CAS]	130018-77-8	WO 9406429	Antiallergic, non-asthma
Levodopa	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]	59-92-7 99291-25-5	EP 147847	Antitussive
levodropropizine	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]	100986-85-4 138199-71-0	EP 206283	Quinolone antibacterial
levofloxacin				

TABLE IV

Example of Indication
Cancer, prostate
Cancer, prostate
Infection, helminth, general
Epilepsy, general
Glaucoma
Glaucoma
Anaesthesia
Rhinitis, allergic, general
Allergy, general
Cough
Infection, respiratory tract, lower

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Levomethadyl Acetate		1477-40-3		
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]	27058-84-0 5741-22-0 77164-20-6	EP 15418	Antihypertensive, adrenergic
levonorgestrel, Leiras	18,19-Dinorgestrel-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α) [CAS]	797-63-7		Formulation, implant
Levophacetoperane		24558-01-8		
Lev pr poxyphene		2338-37-6		
Levorphanol		77-07-6		
levosimendan	Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]	131741-08-7 141505-33-1	EP 383449	Cardio stimulant
Levosimendan		141505-33-1		
levosulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB 2014990	Antiemetic
Levothyroxine Sodium				
levovirin	1- β -L-ribofuranosyl-1,2,4-triazole-3-carboxamide			Antiviral, other
lexipafant	L-Leucine, N-methyl-N-[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-, ethyl ester, [CAS]	139133-26-9	WO 9203423	Neurological
LF-15-0195			WO 9624579	Immunosuppressant
LF-16-0687	2-Pyrrolidinecarboxamide, N-[3-[(4-(aminoliminomethyl)benzoyl)amino]propyl]-1-[[2,4-dichloro-3-[[2,4-dimethyl-8-quinolinyloxy]methyl]phenyl]sulfonyl]-, (2S), [CAS]	209733-45-9	FR 2756562	Neuroprotective
LGD-1550	2,4,6-Octatrienoic acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl-, (2E,4E,6E), [CAS]	178600-20-9		Anticancer, other

TABLE IV

Example of Indication
Contraceptive, female
Heart failure
Dyspepsia
Infection, hepatitis-C virus
Dementia, AIDS-related
Lupus erythematosus, general
Head trauma
Cancer, cervical

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
LH		9002-67-9		
LH-RH		9034-40-6		
liarazole	1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- [CAS]	115575-11-6		Formulation, other
licofelone	1H-Pyrrolizine-5-acetic acid, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl- [CAS]	158897-06-2		Antiarthritic, other
Licostinel		153504-81-5		
lidacronate	Phosphonic acid, {1-amino-3-(dimethylamino)propylidene}bis- [CAS]	63132-38-7	WO 9702827	Urological
Lidamide		66871-56-5		
lidocaine	Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- [CAS]	137-58-6		Formulation, transdermal, patch
Lidofenin		59160-29-1		
Lidoflazine		3416-26-0		
linaprost	Prosta-2,13-dien-1-olic acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-, (2E,11Alpha,13E,15S,17S)-, [CAS]	74397-12-9	GB 2041368	Prostaglandin
Lincomycin		154-21-2		
Lindane		58-89-9		
linezolid	Acetamide, N-[(3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl]-, (S)- [CAS]	165800-03-3	WO 9507271	Antibiotic, other
Linoleic Acid		60-33-3		
Linolenic Acid		463-40-1		
Liothyronine		6893023		
Lipase		9001-62-1		
Lipo-dexamethasone palmitate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxohexadecyl)oxy]-, (11B,16Alpha)- [CAS]	14899-36-6		Formulation, optimized, microemulsion
lipo-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-, 1-(acetoxy)ethyl ester [CAS]	91503-79-6	JP 60208910	Formulation, optimized, microemulsion
Lipogel HA			EP 525655	Formulation, optimized, liposomes
LiquiVent	perfluorooctylbromide	423-55-2	US 5437272	Lung Surfactant

TABLE/IV

Example of indication.
Psoriasis
Arthritis, osteo
Unspecified
Pain, post-herpetic
Buerger's syndrome
Infection, dermatological
Arthritis, rheumatoid
Pain, cancer
Unspecified
Respiratory distress syndrome, adult

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
iranafate	Carbamothioic acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) ester [CAS]	88678-31-3	GB 2124617	Antifungal
lisinopril	L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, (S)- [CAS]	76547-98-3 83915-83-7	EP 12401	Antihypertensive, renin system
Lisofylline		100324-81-0		
Lisuride		18016-80-3		
lisuride hydrogen maleate	Urea, N'-[(8Alpha)-9,10-didehydro-6-methylergolin-8-yl]-N,N-diethyl-, (Z)-2-butenedioate (1:1) [CAS]	19875-60-6 305-13-5		Antiprolactin
Lithium Citrate		919-16-4		
lithium	Carbonic acid, dilithium salt [CAS]	554-13-2		Formulation, modified-release, <=24hr
livivaptan	Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl- [CAS]	168079-32-1	US 5736540	Cardiovascular
LJP-1082			US 6207160	Immunosuppressant
LLUAlpha	S-2,7,8-Trimethyl-6-(8-carboxyethyl)-6-hydroxychroman			Antihypertensive, other
LMP-160			US 5643893	Antiasthma
LMP-420			US 5643893	Antiarthritic, other
lobaplatin	Platinum, (1,2-cyclobutanedimethanamine-N,N')[2-hydroxypropanoate(2-)-O1,O2]-, [SP-4-3(S), (trans)]- [CAS]	195558-11-1	DE 4115559	Anticancer, alkylating
Lob line		90-69-7		
Lobenzarit		63329-53-3		
Lodoxamide		53882-12-5		
lodoxamide tromethamine	2,2'-(2-chloro-5-cyano-1,3-phenylene)dilimino bis(2-oxoacetate)-2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)	63610-09-3	US 4439445	Antiasthma
Lof ntanil		61380-40-3		

TABLE IV

Example of Indication
Infection, dermatological
Hypertension, general
Acromegaly
Depression, bipolar
Heart failure
Thrombosis, venous
Hypertension, general
Asthma
Arthritis, rheumatoid
Cancer, lung, small cell
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lofepramine	Ethanone, 1-(4-chlorophenyl)-2-[(3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl)methylamino]- [CAS]	23047-25-8 26786-32-3	GB 1177525	Antidepressant
lofexidine	1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]	31036-80-3 790-69-2	GB 1181356	Antihypertensive, adrenergic
Loflucarban	3-Quinolincarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- [CAS]	98079-51-7 98079-52-8	EP 140116	Quinolone antibacterial
Lomerizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-, dihydrochloride- [CAS]	101477-55-8		
lomerizine hydrochloride	7-(5-oxohexyl)theophylline	101477-54-7 10226-54-7	EP 159566 DE 2207860	Antimigraine Neurological
lometylline	Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso- [CAS]	13010-47-4 13010-47-4	JP 48075526	Anticancer, alkylating
Lomustine	1-Piperidinecarboxamide, 4-[2-(4-[(1R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl)-2-oxoethyl]- [CAS]	193275-84-2 91431-42-4 53808-88-1	US 5874442	Anticancer, other
lonalarnib	1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- [CAS]	50264-69-2	DE 2310031	Radio/chemosensitizer
Lonapalene	4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	US 3714159	Antidiarrhoeal
Lonazolac	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-, 1-oxide, trans- [CAS]	106900-12-3	EP 219898	Antidiarrhoeal
loperamide	4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidinebutyramide HCl	34552-83-5 53179-11-6		Formulation, dermal, topical

TABLE IV

Example of Indication
Hypertension, general
Infection, respiratory tract, lower
Migraine
Cancer, lung, non-small cell
Cancer, breast
Diarrhoea, general
Diarrhoea, general
Pain, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lopinavir + ritonavir	1-(2H)-Pyrimidineacetamide, N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl)-1-(phenylmethyl)-peryl)(tetrahydro-Alpha-(1-methylethyl)-2-oxo-, (1S-(1R*(R*),3R*,4R*)) + 2,4,7,12-Tetraazatridecan-13-olc acid, 10-hydroxy-2-methyl-5-(1-methylethyl))	155213-67-5 192725-17-0		Antiviral, anti-HIV
lorazepam	1H-imidazo[1,2-a][1,4]benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4-methyl-1-piperazinyl)methylene]-8-nitro- [CAS]	61197-73-7 61197-93-1 70111-54-5	GB 1496426	Hypnotic/Sedative
Lopinone		106730-54-5		
loracarbef	1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7B(R*)]]- [CAS]	76470-66-1	EP 14475	Cephalosporin, oral
Loracarbef		121961-22-6		
Lorajmine		47562-08-3		
loratadine	1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-1H-benzo[5,6]cyclohepta[1,2-b]pyridin-1'-ylidene)-, ethyl ester- [CAS]	79794-75-5	EP 42544	Antiallergic, non-asthma
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-	846-49-1		Formulation, oral, orally-disintegrating
lorazepam	Benzeneacetamide, N-(4-chlorophenyl)-N-[(1-methylethyl)-4-piperidinyl]-[CAS]	58934-46-6 59729-31-6	DE 2642856	Antiarrhythmic
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl- [CAS]	848-75-9	US 3296249	Hypnotic/Sedative

TABLE IV

Example of Indication
Infection, HIV/AIDS
Infection, respiratory tract, lower
Rhinitis, allergic, general
Epilepsy, general
Insomnia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ibuprofen	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide- [CAS]	70374-39-9	EP 313935	Anaesthetic, NSAID
Losartan		114798-26-4		
Losartan potassium	1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[(2-[(1H-tetrazol-5-yl)(1'-biphenyl)-4-yl]methyl)-, monopotassium salt [CAS]	124750-99-8	EP 253310	Antihypertensive, renin system
Lofeprednol etabonate	Androsta-1,4-diene-17-carboxylic acid, 17-[[ethoxycarbonyloxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11B, 17Alpha)- [CAS]	82034-46-6	GB 2079755	Anti-inflammatory, topical
Lotrafiban		171049-14-2		
Lovastatin		75330-75-5		
Loxapine		1021977		
Loxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoylamino)-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (±)- [CAS]	107097-80-3	WO 8703869	GI inflammatory/bowel disorders
Loxoprofen	Benzenoacetic acid, Alpha-methyl-4-[(2-oxocyclopentyl)methyl]-, [CAS]	68767-14-6 80382-23-6 87828-36-2	EP 55588	Antiarthritic, other
Lu-35-138	1-[3]2-[5-chloro-1-(4-fluorophenyl)-3-1H-indolyl]ethyl[methylamino]propyl-2-imidazolidinone hydrochloride		WO 9516684	Neuroleptic
Lubeluzole		144665-07-6		
Lubiprostone	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid	136790-76-6		Laxative
Lucanthone	Thioxanthene-9-one, 1-[(2-(diethylamino)ethyl)amino-4-methyl- [CAS]	479-50-5		Radio/chemosensitizer
Lucanthone Hydrochloride		548-57-2		
Lumefantrine		82186-77-4		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lumiracoxib	Benzenecarboxylic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- [CAS]	220991-20-8		Analgescic, NSAID
luteotecan hydrochloride, OSI	11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1-piperazinyl]methyl] dihydrochloride, [S]- [CAS]	155773-58-3		Formulation, optimized, liposomes
lutetium texaphyrin	Lutetium, bis(acetato-O)(9,10-diethyl-20,21-bis-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6,16,19-dinitrilo-1,18-benzodiazacycloicosine-5,14-dipropionato-N1,N18,N23,N24,N25)-, (PB-7-11-233'2'4)- [CAS]	156436-90-7	WO 9906411	Radio/chemosensitizer
LV-216	Zinc[2-(2,6-dichloroanilino)phenyl]acetate			Anti-inflammatory
	Hexadecanamide, N-{4-[2-[2-[2-[O-(N-acetyl-Alpha-neuraminosyl)-(2-3)-O-β-D-galactopyranosyl-(1-4)-O-(6-deoxy-Alpha-L-galactopyranosyl-(1-3))-β-D-glucopyranosyl]oxy]ethoxy]ethoxy]ethoxy]methyl]phenyl}-2-tetradecyl- [CAS]	158792-45-1		Cognition enhancer
LX-104	β-methyl-6-chloromelatonin		EP 656243	Hypnotic/Sedative
LY-156735	Benzolic acid, 2-[3-[3-[(5-ethyl-4-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propyl]phenoxyl- [CAS]	161172-51-6		Anticancer, other
LY-293558	3-Isosquinolinecarboxylic acid, decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-, [3S-(3Alpha.,4aAlpha.,6S.,8aAlpha.)]- [CAS]	154652-83-2		Analgescic, other
	1,4-Dioxo-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrono, 10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2S,3R)-3-phenylloxiranyl]ethyl]-, (3S,10R,13E,16S)- [CAS]			
LY-355703		18256-67-7	WO 9707798	Anticancer, other
Lyapolate Sodium		25053-27-4		

TABLE IV

Example of Indication
Pain, general
Cancer, ovarian
Atherosclerosis
Arthritis, rheumatoid
Dementia, senile, general
Sleep disorder, general
Cancer, melanoma
Pain, neuropathic
Cancer, lung, non-small cell

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Lymecycline		992-21-2		
Lynestrenol		52-76-6		
Lypressin		50-57-7		
Lysin Acetylsalicylate		62952-06-1		
lysine salicylate	L-Lysine, 2-hydroxybenzoate [CAS]	59535-08-9	WO 9624331	Analgesic, NSAID
lysophospholipids, Atargin			WO 9843093	Diagnostic
M-40403	Dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahydro-1,7-nitro-7H-dibenzo[b,h][1,4,7,10]tetraazacycloheptadecine-kappaN5,kappaN13,kappaN16,kappaN21,kappaN22]manganese		US 6180620	Anticancer, other
mabuprofen	Benzeneacetamide, N-(2-hydroxyethyl)-Alpha-methyl-4-(2-methylpropyl)-, (+-)-[CAS]	82821-47-4	DE 3121595	Anti-inflammatory
Mabuterol		56341-08-3		
Macrophage Colony-Stimulating Factor		81627-83-0		
MADU		840-50-6		
Mafenide		138-39-6		
mafenide acetate	Benzenesulfonamide, 4-(aminomethyl)-monoacetate [CAS]	13009-99-9		Vulnératy
mafostamide	Ethanesulfonic acid, 2-[2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl[thio]-, P-oxide, cis-(±)-[CAS]	88859-04-5 98845-64-8	EP 393575	Anticancer; alkylating
magaldrate	Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2, hydrate [CAS]	74978-16-8	US 2923660	Antacid/Antiflatulent
magaldrate, FDS	Aluminum magnesium hydroxide sulfate, hydrate [CAS]	74978-16-8		Formulation, modified-release, other
Mag nta l		632-99-5		
Magnesium Ac tyalsalicylate		132-49-0		

TABLE IV

Example of Indication
Diagnosis, cancer
Unspecified
Burns
Cancer, renal
Gastro-oesophageal reflux

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Magnesium Carbonate Hydroxide	Magnesium chloride (MgCl ₂) [CAS]	39409-82-0		
	Magnesium chloride, Glentair	7786-30-3		Formulation, oral, enteric-coated
Magnesium Citrate	D-Gluconic acid; magnesium salt (2:1) [CAS]	3344-18-1		
	magnesium gluconate, Sopar	3632-91-5		Formulation, other
Magnesium Lactate		18917-93-6		
Magnesium Salicylate		18917-89-0		
Malathion		121-75-5		
Malotilate		59937-28-9		
Mandellic Acid		90-64-2		
Mandellic Acid Isoamyl Ester		5421045		
Mangafodipir		118248-94-5 (free acid); 155319-91-8 (hexahydrogen)		
manidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(4-(diphenylmethyl)-1-piperazinyl)ethyl] methyl ester [CAS]	89226-50-6 89226-75-5	EP 94159	Antihypertensive, other
Maninomustine	mannose-6-phosphate	551-74-6		
mannose-6-phosphate, BTG				Vulnerary
Maprotiline		10262-69-8		
maribavir	1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methyl-ethyl)-1-β-L-ribofuranosyl- [CAS]	176161-24-3		Antiviral, other
marimastat	N-[2,2-Dimethyl-1(S)-(N-methylcarbamoyl)propyl]-N,3(S)-dihydroxy-2(R)-isobutylsuccinamide	154039-60-8	WO 9402447	Anticancer, other

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
maxacalcitol	1,3-Cyclohexanediol, 4-methylene-5-(2-octahydro-1-(1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene), (1S-(1Alpha(R*),3aB,4E(1S*,3R*,5Z),7aAlpha))-[CAS]	103909-75-7	US 4891364	Hormone
mazindol	3H-Imidazo[2,1-a]isindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Antiobesity
Mazipredone		13085-08-0		
MC-5723			US 6043259	Cardiovascular
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)			Antiviral, other
MCi-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Cardio stimulant
m-Cresyl Acetate		122-46-3		
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite
MDI-101			US 4885311	Antiacne
MDI-403		403849-94-5	US 4677120	Antiacne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)-[CAS]	139290-65-6		Hypnotic/Sedative
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB 1307308	Anthelmintic
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl(2-(4-methoxyphenyl)-1-methylethylamino)butyl ester] [CAS]	3625-06-7		Antispasmodic
Mebhydroline		524-81-2		
Mebrofenin		78266-06-5		
Mebutamate		64-55-1		
mecamylamine HCl, Targacept	Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological
Mechlorethamine		51-75-2		

TABLE IV

Example of Indication
Hyperparathyroidism
Obesity
Unspecified
Infection, hepatitis-B virus
Heart failure
Cancer, general
Acne
Acne
Sleep disorder, general
Irritable bowel syndrome
Unspecified

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Mechlorethamine Oxide Hydrochloride		302-70-5		
meclizine	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6Beta,7-)]-[CAS]	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable
Mecizine		569-65-3		
Meclocycline		2013-58-3		
meclofenamate	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, monosodium salt [CAS]	6385-02-0 644-62-2		Antiarthritic, other
Meclofenamic Acid		644-62-2		
Meclof noxate		51-68-3		
Mecloqualone		340-57-8		
Mecysteine		18598-63-5		
Hydrochloride				
Medazepam		12/6/2898		
medifoxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy-[CAS]	32359-34-5	FR M5498	Antidepressant
Medrogestone		977-79-7		
Medronic Acid		1984-15-2		
Medroxyprogesterone		520-85-4		
medroxyprogesterone acetate	Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6Alpha)			Formulation, fixed-dose combinations
Medrysone		71-58-9		
Mefenamic Acid		2668-66-8		
Mefenorex		61-68-7		
Mefexamide		17243-57-1		
mefloquine		1227-61-8		
Mefloquine Hydrochloride	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(±)-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB 1594282	Antimalarial
Mefruside		51773-92-3		
		7195-27-9		

TABLE IV

Example of indication
Infection, general
Arthritis, osteo
Contraceptive, female

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Megestrol Acetate		595-33-5		
Meglumin Acetizoate		22154-43-4		
Meglumine Diatrizoate		131-49-7		
meglutol	2-hydroxy-2-methyl-1,3-propanedicarboxylic acid	503-49-1	US 3629449	Hypolipemic/Antiatherosclerosis
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[4-(aminolinomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]- [CAS]	159776-70-2	WO 9616671	Antithrombotic
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)pyridin-1-yl]-2-oxoethylamine (1)			Anorectic/Antiobesity
Melarsoprol		494-79-1		
Melengestrol		5633-18-1		
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian
Mellinamide		14417-88-0		
Mellitrac n		5118-29-6		
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1822-79-3 3575-80-2	BE 1651144	Neuroleptic
Melphalan		148-82-3		
Melphalan Hydrochloride				
meludrine	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (R)-, (R*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	134865-37-5	EP 420120	Labour inhibitor
Memantine		19982-08-2		

TABLE IV

Example of indication
Hyperlipidaemia, general
Thrombosis, general
Obesity
Parkinson's disease
Arthritis, rheumatoid
Labour, preterm

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
mefenamic acid hydrochloride	Tricyclo[3.3.1.1 ^{3,7}]decan-1-amine, 3,5-dimethyl, hydrochloride [CAS]	41100-52-1	EP 392059	Cognition enhancer
MEN-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]- [CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic
Menadiol		481-85-6		
Menadione		58-27-5		
Menadoxime		573-01-3		
Menbutone		3562-99-0		
Menogaril		71628-96-1		
MENT	7-Alpha-Methyl-19-nortestosterone			Formulation, transdermal, systemic
Menthofol		89-78-1		
menthol	Cyclohexanol, 5-methyl-2-(1-methylethyl)- [CAS]	1490-04-6		Formulation, dermal, topical
Menthyl Valerate		89-47-4		
Meobentine		46464-11-3		
Meparfynol		77-75-8		
meparticin	Particin, methyl ester [CAS]	11121-32-7	US 3780173	Antifungal
Meparticin		11121-32-7		
Mepazine		60-89-9		
M benzolate Bromide		76-90-4		
Meperidine		57-42-1		
Mephenesin		59-47-2		
Mephenoalane		70-07-5		
Mephentermine		100-92-5		
Mephénytoin		50-12-4		
Mephobarbital		115-38-8		

TABLE IV

Example of Indication
Dementia, AIDS-related
Infection, general
Cancer, breast
Contraceptive, male
Pruritus
Infection, Candida, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
Mepindolol		23694-81-7		
Mepitostane		21362-69-6		
Mepivacaine				
mepivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8		Formulation, modified-release, >24hr
Mepixanox		17854-59-0		
Meprednisone		1247-42-3		
Meprobamate		57-53-4		
meprosicillin	Bula-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl-Alpha-L-mannopyranosyloxy]-14-hydroxy-, (3B)- [CAS]	33396-37-1	DE 1910207	Cardio stimulant
mepizadol	Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	53340-58-8	GB 1285025	Analgesic, other
mequitazine	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	59263-76-2	GB 1250534	Antiallergic, non-asthma
Meralein Sodium		29216-28-2		
M ralluride		4386-35-0		
Merbromin		8069-64-5		
Mercaptopimerin Sodium		129-16-8		
		21259-76-7		
Mercumallylic Acid		86-36-2		
Mercuric Chloride, Ammoniated		10124-48-8		
Mercuric Oleate		1191-80-6		
Mercuric Oxycyanide		1335-31-5		
merimepodib	Carbamic acid, ((3-(((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl-, (3S)-tetrahydro-3-furanyl ester [CAS]	198821-22-8	US 5807876	Antiviral, other

TABLE IV

Example of Indication
Pain, post-operative
Heart failure
Pain, general
Infection, hepatitis-C virus

TABLE IV

API Generic Nam	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinylthio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4Alpha,5S,6S(R*)]]-, [CAS]	96036-03-2	EP 126587	Beta-lactam antibiotic
Mersalyl		492-18-2		
Mesalazine		89-57-6		
Mesalazine	Benzic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other
Mesna		19767-45-4		
Mesoridazine Besylate		5588-33-0		
M stanolone		521-11-9		
M st rolone		1424-00-6		
Mestranol		72-33-3		
M sulfen		135-58-0		
Metaciazepam		84031-17-4		
Metampicillin		6489-97-0		
Metapramine		21730-16-5		
M tapr t renol		586-06-1		
Metaproterenol Sulfate				
Metaraminol		54-49-9		
Metazocine		3734-52-9		
metergoline	Carbamic acid, [(8B)-1,6-dimethylergolin-8-yl]methyl-, phenylmethyl ester [CAS]	17692-51-2 21631-37-8 2706-42-5	GB 1401935	Antiprolactin
metformin	Imidodicarbonimidic diamide, N,N-dimethyl- [CAS]	657-24-9		Formulation, modified-release, <=24hr
Methacholine		62-51-1		
Methacycline		914-00-1		
Methadone		76-99-3		
Methafurylene		531-06-6		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref erence	Example of Therapeutic Use
Methamphetamine		537-46-2		
Methandriol		521-10-8		
Methandrostenolone		72-63-9		
Methanth line		53-46-3		
Methapyrilene		91-80-5		
Methaqualone		72-44-6		
Metharbital		50-11-3		
M thazolamide		554-57-4		
Methdilazine		1982-37-2		
Methenamine		100-97-0		
Methenolone		153-00-4		Anticancer; antimetabolite
M th strol		130-73-4		
Methetoin		5696-06-0		
Methicillin		132-92-3		
Methimazole		60-56-0		
Methiodal		126-31-8		
Methionie Acid		503-40-2		
Methionine		63-68-3		
Methisazone		1910-68-5		
Methitural		467-43-6		
Methixene		2/2/4969		
Methocarbamol		532-03-6		
Methohexital		22151-68-4		
methotrexate	L-Glutamic acid, N-[4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-[CAS]	59-05-2	US 2512572	Anticancer; antimetabolite
Methotrexate Sodium				
Methotrimeprazine		60-99-1		
Meth xamine		390-28-3		
Methoxsalen		298-81-7		
Methoxyflurane		76-38-0		
M thoxyphenamine		93-30-1		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
M thoxypromazine		61-01-8		
Methscopolamine		155-41-9		
Methscopolamine Nitrate				
Methsuximide		77-41-8		
Methyclothiazide		135-07-9		
Methyl Blue		28983-56-4		
Methyl Nicotinate		93-60-7		
Methyl Propyl Ether		557-17-5		
Methyl Salicylate		119-36-8		
Methyl tert-Butyl Ether		1634-04-4		
Methylbenzethonium Chloride		25155-18-4		
Methylcobalamin		13422-55-4		
methyldopa	L-Tyrosine, 3-hydroxy-Alpha-methyl- [CAS]	555-30-6		Formulation, modified-release, <=24hr
Methylene Blue		61-73-4		
Methylergonovine		113-42-8		
Methylhexaneamine		105-41-9		
methyphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	113-45-1 298-59-9		Formulation, modified-release, multi
Methylprednisolone		83-43-2		
methyprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha, 11B)- [CAS]	88401-95-8	EP 72547	Antipruritic/inflamm, allergic
methyprednisolone suleptanate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[(8-[methyl(2-sulfoethyl)amino]-1,8-dioxoctyl)oxy]-, monosodium salt, (6Alpha, 11B)- [CAS]	90350-40-6	JP 59137500	Antiasthma
M thyliouracil		56-04-2		
Methyltrienolone		965-93-5		
Methypyrion		125-64-4		
Methysergide		361-37-5		
Metiazinic Acid		13993-65-2		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
metipranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate [CAS]	22664-55-7	GB 1206148	Antihypertensive, adrenergic
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-62-5		Formulation, modified-release, <=24hr
Metocurline iodide		7601-55-0		
Metofenazate		388-51-2		
metolazone	6-Quinazolinonesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US 4517179	Antihypertensive, diuretic
Metopimazine		14008-44-7		
Metopon		143-52-2		
Metoprolol		37350-58-6		
metoprolol	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (+)- [CAS]	51384-51-1 56392-17-7		Formulation, modified-release, other
Metralindole		54188-38-4		
Metrizamide		31112-62-6		
Metrizoic Acid		1949-45-7		
Metr n S		13946-02-6		
Metyrapone		54-36-4		
Metyrosine		672-87-7		
Mexazolam		31868-18-5		
Mexenone		1641-17-4		
Mexiletin		31828-71-4		
mezlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3,3-dimethyl-6-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]-42057-22-7; 51481-65-3 amino]-7-oxo-, [2S-[2Alpha,5Alpha,6S(S*)]]- [CAS]	42057-22-7 51481-65-3 72539-76-5	GB 1301961	Penicillin, injectable
MFH-244	Benzenecarboximidic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	95933-76-9	US 4623659	Cardiovascular
mianserin	Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, [CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Mibefradil		116644-53-2		
Miboplatin		103775-75-3		
Micafungin		235114-32-6		
miconazole	1H-Imidazole, 1-(2,4-dichlorophenyl)-2(2,4-dichlorophenyl)methoxy[ethyl]	22916-47-8		Formulation, modified-release, other
Micronomicin		52093-21-7		
midaxifylline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-[CAS]		US 5378844	Cardiovascular
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-[CAS]	151159-23-8 59487-70-8 59487-94-6	US 4280957	Anaesthetic, injectable
midecamycin	Leucomycin V, 3,4B-dipropionate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropionate [CAS]	55881-07-7	JP 49124087	Macrolide antibiotic
midestelne	2-Thiophenecarboxylic acid, S-[1-methyl-2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl] ester [CAS]	94149-41-4	EP 120534	COPD treatment
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]-[CAS]	42318-56-0 42794-76-3	EP 164571	Urological
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-dindolo[1,2,3-g:3',2',1'-im]pyrrolo[3,4-j][1,7]benzodiazolin-11-yl)-N-methyl-, (9Alpha,10B,11B,13Alpha)-[CAS]	120685-11-2	EP 296110	Anticancer, other
mifepristone	Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11B,17B)-[CAS]	84371-65-3	EP 57115	Abortifacient
Mifepristone		84371-65-3		
miglitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2Alpha,3B,4Alpha,5B)]-[CAS]	72432-03-2	EP 55431	Antidiabetic

TABLE IV

Example of Indication
Infection, Candida, general
Unspecified
Infection, general
Infection, general
Emphysema, general
Incontinence
Cancer, leukaemia, acute myelogenous
Abortion
Diabetes, Type I

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Ref.ence	Example of Therapeutic Use
milgustat	3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-(2R-(2Alpha, 3E, 4Alpha, 5E)) [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders
midronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1-trimethyl-, inner salt-[CAS]	76144-81-5	WO 8001068	Cardio stimulant
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(±)-[CAS]	101152-94-7 92623-85-3	US 4478836	Antidepressant
Miloxacin		37065-29-5		
milrinone	[3,4'-Bipyridine]-5-carbonitrile, 1,5-dihydro-2-methyl-6-oxo- [CAS]	78415-72-2	US 4313951	Cardio stimulant
miltefosine	Ethanaminium, 2-[[[(hexadecyloxy)hydroxyphosphinyloxy]-N,N,N-trimethyl-, hydroxide, inner salt [CAS]	53949-20-5 58066-85-6	EP 225608	Anticancer, other
minaprine	4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	25905-77-5 25953-17-7	GB 1345880	Antidepressant
minocycline	2-Naphthacene carboxamide, 4,7-bis[(dimethylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,1-dioxo-, (4S)-(4Alpha, 4aAlpha, 5a.alpha., 12aAlpha)]-[CAS]	10118-90-8		Formulation, optimized, microparticles
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethylidene)bis-, [CAS]	180064-38-4	EP 354806	Anticancer, other
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US 4139619	Vasodilator, peripheral
Milokamycin		55881-07-7		
mirtazapine	Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8	GB 1543171	Antidepressant
Mirtazapine		61337-67-5		
misoprostol	Prost-13-en-1-olic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11Alpha, 13E)(±)- [CAS]	59122-46-2 59122-48-4	US 4301146	Prostaglandin

TABLE IV

Example of Indication
Gaucher's disease
Heart failure
Depression, general
Heart failure
Cancer, skin, general
Depression, general
Infection, oral
Cancer, myeloma
Hypertension, general
Depression, general
Ulcer, gastric

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Pat nt Reference	Example of Therapeutic Use
mitomycin	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxy-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO 9324509	Gastropokinetic
mitiglinide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isindolylcarbonyl)propionate, dihydrate- [CAS]	145525-41-3	EP 507534	Antidiabetic
Mitobronitol		488-41-5		
Mitoguanzone		459-86-9		
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-28-0	US 3993781	Anticancer, alkylating
mitomycin	Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[(aminocarbonyloxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8i3,8aAlpha,8bAlpha)]- [CAS]	50-07-7		Formulation, parenteral, other
Mitotane		53-19-0		
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-3	US 4197249	Anticancer, other
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-9		Formulation, optimized, liposomes
MIV-210	(3'-Fluoro-2'-3'-dideoxy guanosine)			Antiviral, other
mivacurium	Isoquinolinium, 2,2'-[(1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R(R', R''-(E))]- [CAS]	108861-44-3	EP 181055	Muscle relaxant
Mivazerol		125472-02-8		
imizolastine	4(1H)-Pyrimidinone, 2-[[1-{(4-fluorophenyl)methyl}-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9	EP 217700	Antiallergic, non-asthma
Mizoribine		50924-49-7		

TABLE IV

Example of Indication
Gastro-oesophageal reflux
Diabetes, Type II
Cancer, cervical
Cancer, stomach
Cancer, breast
Cancer, general
Infection, hepatitis-B virus
Anaesthesia, adjunct
Rhinitis, allergic, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
MKG-733	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	194093-42-0	JP 08216888	Gastroprokinetic
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO 9915183	Neuroprotective
MLN-576	4-Methoxy-benzol[a]phenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methyl-ethyl)-amide			Anticancer, other
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	68893-11-8	DE 2809625	Psychostimulant
moxipril	3-Isosquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropylamino)-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (3S-(2(R*(R*),3R*)))- [CAS]	103775-10-6 103775-14-0	US 4344949	Antihypertensive, renin system
Mofarotene		125533-88-2		
Mofebutazone		2210-63-1		
Mofegiline		119386-96-8		
mofezolac	5-Isosazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP 26928	Analgesic, NSAID
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-1-[4-[2-(4-aminophenyl)-acetamido]butyl]piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antiasthma
Molindon		7416-34-4		
Molindone Hydrochloride				
molisidine	Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	25717-80-0	US 3769283	Vasodilator, coronary

TABLE IV

Example of Indication
Gastro-oesophageal reflux
Ischaemia, cerebral
Cancer, general
Depression, general
Narcolepsy
Hypertension, general
Pain, post-operative
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
monetasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11 β ,16 α)- [CAS]	105102-22-5 83919-23-7	EP 57401	Antipruritic/inflamm, allergic
Monatepil		103377-41-9		
Monobenzene		103-16-2		
monolaurin	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological
Montelukast		158966-92-8		
montelukast sodium	Cyclopropaneacetic acid, 1-[[[1-(3-{2-(7-chloro-2-quinolinyl)ethenyl}phenyl)-3-{2-(1-hydroxy-1-methylethyl)phenyl}propyl]thio]methyl]-, mono sodium salt, [R-(E)]- [CAS]	151767-02-1		Antiasthma
Mont plase		122007-85-6		
Moperone		1050-79-9		
Mopidamol		13665-88-8		
Moprolol		5741-22-0		
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US 3884487	Antiarrhythmic
Morazon		6536-18-1		
Moricizine		31883-05-3		
Moroxycine		3731-59-7		
Morphazinamide		952-54-5		
Morphine		57-27-2		
morphine sulfate	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5 α ,6 α)-, sulfate	64-31-3		Formulation, modified-release, immediate
morphine, Takeda	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5 α ,6 α)-, hydrochloride, trihydrate- [CAS]	57-27-2 6055-06-7		Formulation, parenteral, other
morphine-6-glucuronide, UFC	morphine-6-glucuronide			Formulation, inhalable, systemic
mosapramine	Spiro[imidazo[1,2-a]pyridine-3(2H), 4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (+)- [CAS]	89419-40-9 98043-60-8	US 4337260	Neuroleptic

TABLE IV

Example of indication
Psoriasis
Ichthyosis
Asthma
Tachycardia, ventricular
Pain, general
Pain, cancer
Pain, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-(((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)- [CAS]	112885-41-3 112885-42-4	EP 243959	GI Inflammatory/bowel disorders
motexalin gadolinium	Gadolinium, bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16,18,13-dinitrilo-1,18-benzodiazacycloicosine-5,14-dipropanolato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-2332'4) [CAS]	246252-08-2		Radio/chemosensitizer
Motretinide		56281-36-8		
Movelipril		85856-54-8		
Moxalactam		64952-97-2		
Moxastine		3572-74-5		
Moxaverine		10539-19-2		
Moxestrol		34816-55-2		
moxifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cis)- [CAS]	186826-86-8	DE 19548249	Quinolone antibacterial
Moxifloxacin		151096-09-2		
Moxisylyte		54-32-0		
moxisylyte hydrochloride	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester), hydrochloride [CAS]	964-52-3		Male sexual dysfunction
moxonidine	5-Pyrimidinamine; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- [CAS]	75438-57-2	DE 2849537	Antihypertensive, other
M-PGA	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 5712291	Anticancer, other
MPI-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol		US 6224883	Formulation, parenteral, other

TABLE IV

Example of Indication
Gastritis
Cancer, brain
Infection, respiratory tract, general
Impotence
Hypertension, general
Cancer, general
Cancer, head and neck

TABLE IV

API Generic Name	API Chemical Nam	CAS No.	Patent Reference	Example of Therapeutic Use
MPI-5020	2,4-(1H,3H)-Pyrimidin-5-ylidene-5-fluoro- [CAS]	51-21-8	US 5750146	Formulation, parenteral, other
MPL, Cortia		198076-81-2		Immunostimulant, other
MRS-1754			US 6060481	Antiasthma
MS-209	1-Piperazineethanol, 4-(diphenylacetyl)- Alpha-[(5-quinolinyl)oxy)methyl]-, (2E)-2- butenedioate (2:3) (salt) [CAS]	158681-49-3		Radio/chemosensitizer
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl- methoxycarbonyl)aminomethyl]benzamide			Anticancer, antimetabolite
MS-325		201688-00-8		
MS-377			EP 839805	Neuroleptic
Mupirocin		12650-69-0		
Muscarine		300-54-9		
Muzolimine		55294-15-0		
MX-1013			US 6153591	Hepatoprotective
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy- 6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, 2-(4- morpholinyl)ethyl ester, (E)- [CAS]	116680-01-4 128794-94-5	WO 9119498	Immunosuppressant
Mycophenolic Acid		24280-93-1		
mycophenolic acid sodium	4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy- 6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, monosodium salt, (4E)-	37415-82-6		Formulation, oral, enteric-coated
Myrophin		467-18-5		
N- (Hydroxymethyl)nicotina imide		3569-99-1		
N,N,N',N'- Tetraethylphthalamide		83-81-8		
N ₂ -Formylsulfisomidine		795-13-1		

TABLE IV

Example of Indication
Cancer, breast
Vaccine adjunct
Asthma
Cancer, breast
Cancer, lung, general
Schizophrenia
Unspecified
Transplant rejection, general
Transplant rejection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
N-β-D-Glucosylsulfanilamide		53274-53-6		
N-Sulfanilylsulfanilamide		547-52-4		
Nabilone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)-[CAS]	51022-71-0		
nabumetone	L-Cysteine, N-acetyl- [CAS]	42924-53-8	GB 1476721	Anti-inflammatory
N-Acetylmethionine		616-91-1		Anticancer, other
nadifloxacin	1H,5H-Benzof[5,4-b]quinoline-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	65-82-7		Quinolone antibacterial
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42209-33-9	US 4346106	Antihypertensive, adrenergic
Nadexolol		54063-51-3		
nafamostat	Benzoic acid, 4-[(aminolinomethyl)amino]-6-(aminolinomethyl)-2-naphthalenyl ester- [CAS]	80251-32-7 81525-10-2 82956-11-4	EP 450232	GI inflammatory/bowel disorders
nafarelin	Luteinizing hormone-releasing factor (pig), 8-[3-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones
Nafcilin		147-52-4		
Nafronyl	2-Furanpropanoic acid, tetrahydro-Alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4		
naftidrofuryl		31329-57-4		Formulation, modified-release, other
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 65473-14-5	US 4282251	Antifungal
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)-Alpha-[(1-naphthalenyloxy)methyl]- [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic

TABLE IV

Example of Indication
Arthritis, osteo
Cancer, general
Acne
Pancreatitis
Endometriosis
Unspecified
Infection, dermatological
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
nalbuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5 α)-[CAS]	20594-83-6 23277-43-2	US 3393197	Analgescic, other
Nalidixic Acid		389-08-2		
nalmeferene	Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5 α)-[CAS]	55086-26-9	JP 56167687	Dependence treatment
Nalorphine		62-67-9		
Naloxone		465-65-6		
naloxone	Morphinan-6-one, 17-allyl-4,5 α -epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4		Septic shock treatment
naltrexone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5 α)-[CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrachlororuthenate (III)			Anticancer, other
nemindil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N''-[(1R)-1,2,2-trimethylpropyl]-[CAS]	220641-11-2		Dermatological
Nandrolone		434-22-0		
Naphazoline		835-31-4		
Naphazoline Hydrochloride				
Naphthalen		91-20-3		
naproxen betaine	Methanaminium, 1-carboxy-N, N, N-trimethyl-, salt with (R)-6-methoxy- α -methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other
naproxen sodium	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, sodium salt, (S)-[CAS]	26159-34-2	GB 1211134	Analgescic, NSAID
naproxen sodium	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, sodium salt, (S)-[CAS]	26159-34-2		Formulation, modified-release, other
naproxen	2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, (S)-[CAS]	22204-53-1		Formulation, modified-release, multi

TABLE IV

Example of Indication
Pain, general
Poisoning, drug
Addiction, narcotic/opiate
Cancer, general
Alopecia, general
Arthritis, rheumatoid
Arthritis, general
Pain, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent R ference	Example of Therapeutic Use
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121678-13-8	EP 303507	Antimigraine
Naratriptan Hydrochloride				
Narc in		131-28-2		
Narcobarbital		125-55-3		
Natamycin		7681-93-8		
nateglinide	D-phenylalanine, N-(4-(1-methylethyl)cyclohexyl)carbonyl)-, trans- [CAS]	105816-04-4	EP 196222	Antidiabetic
N-Butyldoxynojirimycin		72599-27-0		
N-Butylscopolammonium Bromide		149-64-4		
NC-503			US 5643562	Anti-inflammatory
NC-531			US 5643562	Cognition enhancer
NCX-1000			WO 0061604	Hepatoprotective
NCX-4016	Benzoic acid, 2-(acetyloxy)-, 2-((nitrooxy)methyl)phenyl ester [CAS]	175033-36-0	WO 9718405	Symptomatic antidiabetic
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	256499-26-0		GI inflammatory/bowel disorders
NCX-950	Alpha-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol nitrate]			
n-Docosanol		661-19-8		Antiasthma
NE-100	Benzenesethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	WO 9507113	Neuroleptic
Nealbarbital		561-83-1		
nebirolol	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-, (2R*(R*(S')))-(1+)- [CAS]	118457-14-0	EP 145067	Antihypertensive, adrenergic

TABLE IV

Example of Indication
Migraine
Diabetes, Type II
Amyloidosis
Alzheimer's disease
Cirrhosis, hepatic
Insulin-related metabolic syndrome
Inflammatory bowel disease
Asthma
Schizophrenia
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Nebivolol		99200-09-6		
nebostinel	N1-(4,4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP 0688312	Cognition enhancer
Nebracetam		97205-34-0		
nedaplatin	Platinum, diammine[hydroxyacetato(2-O1,O2)-, (SP-4-3)-, [CAS]	95734-82-0	EP 216362	Anticancer, alkylating
nedocromil	4H-Pyranol[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP 555718	Antiasthma
nedocromil sodium, Allergan	4H-Pyranol[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7		Ophthalmological
Nefazodone		83366-66-9		
nefazodone hydrochloride	3H-1,2,4-Triazol-3-one, 2-[3-(4-(3-chlorophenyl)-1-piperazinyl)propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, monohydrochloride [CAS]	82752-99-6 83366-66-9	US 4338317	Antidepressant
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	US 4341790	Cognition enhancer.
nefopam	1H-2,5-Benzoxazocine, 9,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13689-70-0 23327-57-3	US 3487153	Analgesic, NSAID
Negamycin		33404-78-3		
Nelfinavir		159989-64-7		
nelfinavir mesylate	3-Isosquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2S',3S'),3Alpha,4aB,8aB))-, monomethanesulfonate (salt)-, [CAS]	159989-65-8		Antiviral, anti-HIV.
Nemonapride		75272-39-8		
N ostigmine		59-99-4		
nepadulant	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetyl amino)-2-deoxy-9-D-glucopyranosyl] L-asparaginy]L-Alpha-aspartyl-L-tryptophyl L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5	WO 9628467	Antiasthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0		Dependence treatment

TABLE IV

Example of Indication
Unspecified
Rhinitis, allergic, general
Ocular disorder, general
Depression, general
Dementia, senile, general
Infection, HIV/AIDS
Asthma
Addiction, alcohol

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9		Musculoskeletal
Nerifolin		466-07-9		
N-Ethylamphetamine		457-87-4		
neticonazole	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3	EP 445540	Antifungal
Neticonazole		130726-68-0		
netilmicin	D-Streptamine, O-3-deoxy-4-C-methyl-3-[(methylamino)-6-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB 1473733	Aminoglycoside antibiotic
nevirapine	6H-Dipyrrolo[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	129618-40-2	EP 429987	Antiviral, anti-HIV
NGD-98-2			WO 9635689	Anxiolytic
Nialamide		51-12-7		
Niaprazine		27367-90-4		
Nicametate		3099-52-3		
nicaraven	3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediy)bis- [CAS]	79455-30-4	EP 29602	Neuroprotective
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	US 3985758	Neuroprotective
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5		Formulation, modified-release, other
nicergoline	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6		Formulation, modified-release, other
Niceritrol		5868053		

TABLE IV

Example of Indication
Osteogenesis imperfecta
Infection, Candida, general
Infection, general
Infection, HIV/AIDS
Anxiety, general
Haemorrhage, subarachnoid
Hypertension, general
Unspecified
Unspecified

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Niclosamide		50-65-7		
Nicoclonate		10571-59-2		
Nicofuranose		15351-13-0		
Nicomol		27959-26-8		
Nicomorphine		639-48-5		
nicorandil	3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]- [CAS]	65141-46-0	US 4792564	Vasodilator, coronary
Nicotinamide		98-92-0		
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5		Formulation, inhalable, other
Nicotinic Acid		59-67-6		
Nicotinic Acid Benzyl Ester		94-44-0		
Nicotinyl Alcohol		100-55-0		
nifedipine	4-(2-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary
nifekalanil hydrochloride	2,4-(1H,3H)-Pyrimidinedione, 6-[[2-[(2-hydroxyethyl)]3-(4-nitrophenyl)propylamino]ethylamino]-1,3-dimethyl-, monohydrochloride- [CAS]	130636-43-0 130656-51-8	EP 369827	Antiarrhythmic
Nifenalol		7413-36-7		
Niflumic Acid		4394-00-7		
Nifuratel		4936-47-4		
Nifurfoline		3363-58-4		
Nifuroxazide		965-52-6		
Nifuroxime		6236051		
Nifurpirinol		13411-16-0		
Nifurprazine		1614-20-6		
Nifurtimox		23256-30-6		
Nifurtinol		1088-92-2		
nifurzide	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2-furanyl)-2-propenylidene]hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other
Nikethamid		59-26-7		
niltamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-[CAS]	63612-50-0	US 4472362	Anticancer, hormonal
niltvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-66-6	US 4338322	Antihypertensive, other
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	US 3640597	Anti-inflammatory
Nimetaz pam		2011-67-8		
nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66065-59-4	EP 533014	Neuroprotective
Nimorazole		6506-37-2		
nimustine	Urea, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	103745-00-2 42471-28-3 55661-38-6	GB 1374344	Anticancer, alkylating
Ninopterin		2179-16-0		
NIP-142	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-yl]-4-methoxybenzeneacetamide		WO 9604542	Antiarrhythmic
NIP-531	N'-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-[N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-amino]propyl-N-methylurea hydrochloride			Antipruritic/inflamm, allergic
niperotidine	N-[2-[5-[(dimethylamino)methyl]furfurylthio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine	84845-75-0	GB 2104071	Anticancer
nipradilol, ophthalmic	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42299	Formulation, mucosal, topical
Niridazole		61-57-4		

TABLE IV

Example of Indication
Infection, general
Cancer, prostate
Hypertension, general
Pain, general
Cancer, brain
Fibrillation, atrial
Eczema, atopic
Ulcer, GI, general
Glaucoma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
nisoldipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	63675-72-9	GB 1516793	Antihypertensive, other
nitazoxanide	Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- [CAS]	55981-09-4	US 5387598	Protozoacide
nitisone	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	104206-65-7	EP 186118	Metabolic and enzyme disorders
nitracrine	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	4533-39-5 6514-85-8	FR 1458183	Anticancer, other
Nitrazepam		146-22-5		
nitrendipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	GB 1358951	Antihypertensive, other
nitroflurbiprofen	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	159836-71-6	EP 670825	Urological
Nitrofurantoin		67-20-9		
Nitrofurazone		59-87-0		
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		Formulation, transdermal, patch
Nitromersol		133-58-4		
nitronaproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	WO 9509831	Analgesic, NSAID
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	16398-39-3	NL 6608671	Antidepressant
Nitroxoline		4008-48-4		
nizatidine	1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-(thiazolyl)methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	76963-41-2	EP 49618	Antituber
Nizofenone		54533-85-6		
NM-3	3-(2-methoxycarbonylmethyl)-6-methoxy-8-hydroxy-isocoumarin		JP 08176138	Anticancer, other

TABLE IV

Example of Indication
Hypertension, general
Infection, GI tract
Cirrhosis, hepatic
Cancer, ovarian
Hypertension, general
Incontinence
Angina, general
Pain, post-operative
Ulcer, duodenal
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
NM-702	4-Bromo-5-(3-pyridyl)methylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride			Antithrombotic
N-Methylephedrine		552-79-4		
N-Methylepinephrine		554-99-4		
N-Methylglucamine		6284-40-8		
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e]-[1,2,4]thiadiazine-1,1-dioxide			Antidiabetic
NNC-05-1869	(R)-1-(3-{10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl}-3-piperidine carboxylic acid			Symptomatic antidiabetic
Nogalamycin		1404-15-5		
Nolatrexed		147149-76-6		
nolatrexed dihydrochloride	4(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio), dihydrochloride [CAS]	152946-68-4	WO 9320055	Anticancer, antimetabolite
nolomirole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/-)-[CAS]	138531-51-8	WO 9529147	Cardio stimulant
nolpitanium	1-Azoniabicyclo[2.2.2]octane, 1-[2-[3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-, chloride, (S)-[CAS]	153050-21-6	EP 591040	GI inflammatory/bowel disorders
nomegestrol	19-Norpregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- [CAS]	58652-20-3	DE 2522533	Menstruation disorders
Nomifensine		24526-64-5		
Noprylsulfamide		576-97-6		
Norbolethone		1235-15-0		
Nordazepam		1088-11-5		

TABLE IV

Example of Indication
Peripheral vascular disease
Diabetes, Type II
Neuropathy, diabetic
Cancer, liver
Heart failure
Inflammatory bowel disease
Menstrual disorder, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (R*,S*)-(±)- form		
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)		
Norelgestromin, Ethinyl Estradiol				
Norepinephrine		51-41-2		
Norethandrolone		52-78-8		
Norethindrone		68-22-4		
Norethynodrel		68-23-5		
Norfenefrine		536-21-0		
norfloxacin	3-Quinolincarboxylic acid, 1-ethyl-6-fluoro- 1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	68077-27-0 70458-96-7	US 4146719	Quinolone antibacterial
Norgesterone		13563-60-5		
Norgestimate		35189-28-7		
Norgestrel		6533-00-2		
Norgestrienone		848-21-5		
Norlevorphanol		1531-12-0		
Normethadone		467-85-6		
Normethandrone		514-61-4		
Normorphine		466-97-7		
Norphenazone		89-25-8		
Norpipanone		561-48-8		
Norpseudoephedrine		492-39-7		
Nortriptyline		72-69-5		
Norvinisterone		6795-60-4		
Noscapine		128-62-1		
Novembichin		1936-40-9		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Novobiocin		303-81-1		
Noxiptilin		3362-45-6		
Noxythiolin		15599-39-0		
NS-1209	Butanoic acid, 2-[[[5-[4-((dimethylamino)sulfonyl)phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy-[CAS]	254751-28-5	WO 9426747	Antiepileptic
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-(3,2-h)naphthalene-2,3-dione-3-oxime			Neuroprotective
NS-126			US 5083222	Antiallergic, non-asthma
NS-220	2-Methyl-5-(4-[5-methyl-2-(4-methylphenyl)-4-oxazoyl]butyl)-1,3-dioxane-1,2-carboxylic acid			Hypolipemic/Antiatherosclerosis
NS-2330	NS 2330 [CAS]	402856-42-2		Cognition enhancer
NSA inhibitors, Questor			US 6030785	Antiviral, other
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[[5-(1-piperidinyl)pentyl]oxy]-1-methoxy]monohydrochloride [CAS]	178429-67-9	WO 9607641	Neuroprotective
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile			Urological
NSC-330507	17-Allylaminogeldanamycin			Anticancer, antibiotic
NSC-619534	2-chloroethyl phenyl selenone			Anticancer, alkylating
NSC-697726	2,5-diazolidinyl-3-[hydroxymethyl]6-methyl-1,4-benzoquinone			Anticancer, antibiotic
N-Sulfanilyl-3,4-xylamide		120-34-3		
NU-6027	2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8		Anticancer, other
NV-07	2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	53745-16-7	US 6455032	Antipruritic/inflam, non-allergic

TABLE IV

Example of Indication
Epilepsy, general
Ischaemia, cerebral
Rhinitis, allergic, general
Atherosclerosis
Alzheimer's disease
Infection, hepatitis-C virus
Ischaemia, cerebral
Incontinence
Cancer, general
Cancer, general
Cancer, general
Cancer, general
Keratosi

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
NVP-SRA880	[(3R,4aR,10aR)-1,2,3,4,4a,5,10,10a-octahydro-6-methoxy-1-methyl-6-benz[<i>g</i>]quinoline-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate			Neurological
NW-1029	(S)-(+)-2-[4-(2-fluorobenzoyloxy)benzylamino]propanamide methanesulfonate			Analgesic, other
NYX-059	CPI 22 [CAS]	168021-79-2	US 5780510	Neuroprotective
Nylidrin		447-41-6		
NZ-314	1-imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	EP 353188	Symptomatic antidiabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP 412940	Urological
Obidoxim Chloride		114-90-9		
OC-108	OC 108 [CAS]	162602-62-2		Vasoprotective, topical
ocinaplon	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]	96604-21-6	EP 129847	Anxiolytic
Octabenzene		1843-05-6		
Octacaine		13912-77-1		
Octamin		4684-87-1		
Octavrin		549-68-8		
octenidine	1-Octanamine, N,N'-(1,10-decanediyl)di-1(4H)-pyridinyl-4-ylidene)bis- [CAS]	70715-75-6 71251-02-0 86767-75-1	WO 8705501	Stomatological
Octadrin		543-82-8		
Octopamine		104-14-3		
Oct tiamine		137-86-0		
octreotide, Atrigel	L-Cysteineamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophanyl-L-tyrosyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, [R-(R*, R*)]- [CAS]	83150-76-9		Formulation, fixed-dose combinations

Example f Indication
Unspecified
Pain, general
Ischaemia, cerebral
Neuropathy, diabetic
Renal failure
Venous Insufficiency
Generalized anxiety disorder
Periodontitis
Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Octyl Methoxycinnamate		5466-77-3		
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (4S)- [CAS]	82419-36-1	EP 47005	Quinolone antibacterial
-lod hippurat Sodium		133-17-5		
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-08-1	EP 454436	Neuroleptic
Oleandrin		465-16-7		
Oleic Acid		112-80-1		
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system
olopatadine hydrochloride	11-[(2)-3-(Dimethylamino)propylidene]-8,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 9619998	Osteoporosis treatment
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2 53200-51-4	US 4559330	GI inflammatory/bowel disorders
olipiraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- [CAS]	64224-21-1	DE 2705641	Anticancer, other
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-[4-[3(R)-hydroxytetradecanamido]-5-(phosphonoxy)pentyl]-4-(phosphonoxy)butyramide			Anticancer, immunological

Exemplification of Indication
Schizophrenia
Hypertension, general
Conjunctivitis
Osteoporosis
Colitis, ulcerative
Cancer, general
Unspecified

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-elcosa-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6		Hypolipaeic/Antiatherosclerosis
omapatrilat	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10ab))- [CAS]	167305-00-2	US 5508272	Antihypertensive, renin system
omeprazole	1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- [CAS]	73590-68-6	US 4255431	Antilulcer
omiloxetine	Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rat- [CAS]	176894-09-0		Antidepressant
omoconazole	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	EP 8804	Antifungal
Onapristone	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	96346-61-1		
ondansetron	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenylamino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminomethyl)phenyl ester, monomethanesulfonate [CAS]	99614-01-4 99614-02-5	US 4847281	Antiemetic
ONO-3403	1,4,9-Triazapirrolidino(5,5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]- [CAS]	181586-07-2		GI Inflammatory/bowel disorders
ONO-4128	L-lysine (Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-(S)-4-(1-ethylcyclobutyl)-4-hydroxy-1-butenyl]cyclopentyl]-5-heptenoate	342394-93-8		Antiviral, anti-HIV
ONO-8815 Ly				Labour inhibitor

Example of Indication
Hypertiglyceridaemia
Hypertension, general
Ulcer, GI, general
Depression, general
Infection, dermatological
Chemotherapy-induced nausea and vomiting
Unspecified
Infection, HIV/AIDS
Labour, preterm

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ONT-093			US 5756527	Radio/chemosensitizer
OPC-14523	2-[1-(4-Quinolone, 1-[3-(4-chlorophenyl)-1-piperazinyl]propyl)-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Antidepressant
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-	137975-06-5	WO 9105549	Urological
OPC-51803	(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Antidiabetic
OPC-6535	2-Pyridinecarboxylic acid, 6-[2-(3,4-dihydroxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	GI inflammatory/bowel disorders
Opinlazid		2779-55-7		
opioid analgesics, Adolor	2-(4-(trifluoromethyl)phenyl)-N-methyl-1-phenyl-2-(1-pyrolidinyl)ethylacetamide			
Opipramol		315-72-0		Analgesic, other
Orazamide		2574-78-9		
orazipone	2,4-Paritanedione, 3-[(4-methylsulfonyl)phenyl]methylene)- [CAS]	137109-78-5	EP 440324	Antiasthma
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9		Antidepressant
Org-24448			US 6166008	Neuroleptic
oritavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabino-hexopyranosyl)-N3"-[(4'-chloro)1,1'-biphenyl-4-yl]methyl]-, (4"R)- [CAS]	171099-57-3	US 5840684	Peptide antibiotic
orlistat	[L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2Alpha(R*),3a)]- [CAS]	96829-58-2	EP 129748	Anorectic/Antiobesity
orneloxifene	Pyridoline, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans- [CAS]	31477-60-8	DE 2329201	Female contraceptive
Ornidazole		16773-42-5		

Exempl of Indication
Cancer, general
Depression, general
Unspecified
Diabetes, insipidus
Inflammatory bowel disease
Pain, general
Unspecified
Depression, general
Schizophrenia
Infection, dermatological
Obesity
Contraceptive, female

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ornibressin		3397-23-7		
Ornithine		70-26-8		
ornoprostil	Prost-13-en-1-olc acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70867-28-4	US 4278688	Prostaglandin
Orotic Acid		65-86-1		
Orphenadrine		83-98-7		
Ortho cain		536-25-4		
Osalmid		526-18-1		
osametant	Acetamide, N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-N-methyl- [CAS]	160492-58-8	EP 673928	Neuroleptic
osaterone acetate	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-8-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3Alpha,4B,5Alpha))- [CAS]	186618-13-0	WO 9626933	Antiviral, other
OSI-7636	4'-Thio-8-D-arabinothiuranylcytosine			Anticancer, antimetabolite
	Penitanedibic acid, 2-[5-[(1,2-dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl], (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes
ospemifene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy], bromide [CAS]	26095-59-0	GB 1181406	Antispasmodic
Quabain		630-60-4		
Oxaceprol		33996-33-7		
Oxacillin		66-79-5		
Oxaflozane		26629-87-8		

Example of Indication
Ulcer, gastric
Schizophrenia
Benign prostatic hyperplasia
Infection, influenza virus
Cancer, general
Cancer, general
Osteoporosis
Irritable bowel syndrome

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N')ethanedioato(2-)-O,O', [SP-4-2-(1R-trans)]- [CAS]	61825-94-3	EP 393575	Anticancer, alkylating
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE 2249274	Urological
Oxamarlin		15301-80-1		
Oxametacine		27035-30-9		
Oxamniquin		21738-42-1		
oxandrolone	2-Oxaandrost-3-one, 17-hydroxy-17-methyl-, (5Alpha,17B)- [CAS]	53-39-4	US 3128283	Reproductive/gonadal, general
Oxantol		36531-26-7		
Oxapranium chloride		541-66-2		
oxaprozin	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB 1206403	Antiarthritic, other
oxatamide	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinylpropyl]-1,3-dihydro- [CAS]	60607-34-3	GB 1579365	Antiallergic, non-asthma
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating
oxazolam	Oxazol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US 3772371	Anxiolytic
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE 2011087	Antiepileptic
Oxeladin		468-61-1		
Oxendolone		33765-68-3		
Oxethazain		126-27-2		
Oxetorone		26020-55-3		
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB 1514870	Antifungal
Oxidrinic Acid		15468-10-7		
Oxiniaclic Acid		2398-81-4		
Oxiracetam		62613-82-5		

Exempl of Indication
Cancer, colorectal
Sex-chromosome abnormality, Turner's syndrome
Arthritis, osteo
Rhinitis, allergic, general
Anxiety, general
Epilepsy, general
Infection, fungal, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
oxitropium	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1 α ,2 β ,4 β ,5 α)-] [CAS]	30286-75-0	GB 1178305	Antiasthma
Oxolamin		959-14-8		
Oxolinic Acid		14698-29-4		
Oxphenarsine		538-03-4		
Oxprenolol		6452-71-7		
Oxybenzone		131-57-7		
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester [CAS]	5633-20-5		Formulation, modified-release, other
Oxycinchophen		485-89-2		
oxycodone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5 α)-	76-42-6		Formulation, transmucosal, nasal
Oxyfedrin		15687-41-9		
Oxygent	Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro- [CAS]	423-55-2		Haematological
Oxymestrol		145-12-0		
Oxymetazoline		1491-59-4		
oxymetholone, Unimed	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 α)-, (17 β)- [CAS]	434-07-1		Hormone
Oxymethurea		140-95-4		
oxymorphone	(5 α)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	76-41-5		Formulation, modified-release, immediate
Oxypindyl		5585-93-3		
Oxypirtine		153-87-7		
Oxyphenbutazone		129-20-4		
Oxyphencyclimine		125-53-1		
Oxyphenisatin		115-33-3		

Examp f Indication
Incontinence
Pain, general
Surgery adjunct
Anaemia, general
Pain, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Oxyph nonium		50-10-2		
Oxypinocamphone		10136-65-9		
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0		Antigout
Oxyl tracycline		79-57-2		
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (E)- [CAS]	78712-43-3 82571-53-7	GB 2025946	Antithrombotic
P- (B nzylsulfonamido)ben zoic Acid P-100, Pharmacor		536-95-8		
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	US 6313177	Antiviral, anti-HIV
P32/98	Di-(3N-(2S,3S)-2-amino-3-methylpentanoyl)-1,3-thiazolidine)fumarate			Antidiabetic
PA-824			WO 9701562	Antimycobacterial
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128608-20-2	US 5128242	Neuroprotective
pacitaxel	5β,20-Epoxy-1,2Alpha,4,7B,10B,13Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenyl)hippurate)	33069-62-4		Formulation, optimized, nanoparticles
PADRE			US 6413935	Immunostimulant, other
pagoclone	1H-isoindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)- (R)- [CAS]	133737-32-3	US 4960779	Anxiolytic
PAI Inhibs, thrombosis, Xenova			WO 9404512	Antithrombotic
palindore fumarate	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)amino]methyl-, 2(S)-, (2E)-2-butendicate (1:1)			
Palivizumab		189881-71-8 188039-54-5		Neuroleptic

Example of Indication
Hyperuricaemia
Vasospasm, cerebral
Infection, HIV/AIDS
Keratosis
Diabetes, Type II
Infection, tuberculosis
Nerve injury, general
Cancer, breast
Vaccine adjunct
Panic disorder
Thrombosis, venous
Schizophrenia

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	135729-62-3	US 5202333	Antiemetic
Pamabrom		606-04-2		
Pamaquine		491-92-9		
pamicoxetil	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic
pamidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid- [CAS]	40391-99-9		Formulation, Implant
Pamidr nic Acid		40391-99-9		
p-Amin benzoic Acid		150-13-0		
p-Aminohippuric Acid		61-78-9		
p-Amin proplophenone		70-69-9		
p-Amin salicylic Acid		65-49-6		
Panavir	4,4'-isopropylidenedithiobis-2,6-di-t-butylphenol			Neuroprotective
Pancur nium		15500-66-0		
Panipenem		87726-17-8		
Pantethine		16816-67-4		
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[3,4-dimethoxy-2-pyridinyl]methyl]sulfinyl]- [CAS]	102625-70-7	EP 166287	Antulcer
Pant th nic Acid		79-83-4		
Papain, Urea				
Papaverine		58-74-2		
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release
Parafutizide		1580-83-2		
Paraldehyde		123-63-7		
Paramethadione		115-67-3		
Param thasone		53-33-8		
Paranyline		1729-61-9		

Exempl of Indication
Chemotherapy-induced nausea and vomiting
Thrombosis, cerebral
Hypercalcaemia of malignancy
Vasospasm, cerebral
Ulcer, duodenal
Pain, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Parathyroid hormone	Propanamide, N-[(4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl]-, sodium salt [CAS]	9002-64-6		
parecoxib		198470-85-8	WO 9738986	Analgesic, NSAID
Parethoxycain		94-23-5		
Pargyline		555-57-7		
paricalcitol	19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1 α ,3 β ,7 β ,22 β)- [CAS]	131918-61-1	EP 387077	Hormone
paromomycin	O-2-Amino-2-deoxy-Alpha-D-glucopyranosyl-(1 \rightarrow 4)-O-[O-2,6-diamino-2,6-dideoxy-8-L-idopyranosyl-(1 \rightarrow 3)-8-D-ribofuranosyl-(1 \rightarrow 5)]-2-deoxy-D-streptamine	7542-37-2		Protozoacide
paroxetine	Piperidine, 3-[(1,3-benzodioxol-5-yl)oxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)- [CAS]	61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating
Paroxypropion		70-70-2		
Parsalimid		30653-83-9		
Patrin-2	4-Bromomethylguanidine			Radio/chemosensitizer
Pazinaclofen		103255-66-9		
	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- [CAS]	127045-41-4 127046-45-1 136905-87-8	DE 3913245	Quinolone antibacterial
pazufloxacin		103-88-8		
p-Bromoacetanilide			US 4918063	Formulation, other
PC-NSAIDs, GrassRoots	6-(2,6-Dichlorophenyl)-2-[4-(diethylaminoethoxy)-phenylamino]-8-pyrido[2,3-D]pyrimidine-7-one			Anticancer, other
PD-0166285		19504-77-9		
Pecillocin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70458-92-3	GB 1598915	Quinolone antibacterial
pelloxacin				

Examp ^l of Indication
Pain, post-operative
Hyperparathyroidism
Infection, leishmaniasis
Depression, general
Cancer, melanoma
Infection, general
Arthritis, general
Cancer, general
Infection, urinary tract

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pegvisomant	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 178-threonine (human), pegylated [CAS])	218620-50-9		Somatostatin
Pelletierin		4396-1-4		
Pemetrexid		137281-23-3		
Pemilolast	L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrido[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt [CAS]	137281-23-3	US 5248775	Anticancer, antimetabolite
Pemilolast	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	150399-23-8		
Pemilolast		100299-08-9	US 4457932	Antiasthma
Pemilolast		69372-19-6		
Pemilolast		2152-34-3		
Pemilolast		79-55-0		
Pemilolast				
Pemilolast			US 5955446	Antiviral, other
Pemilolast		983-85-7		
Pemilolast	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[[[1,1-dimethylethyl]amino]-, (S)-, sulfate (2:1) (salt) [CAS]	38363-32-5		
Pemilolast		38363-40-5	GB 1215751	Antihypertensive, adrenergic
Pemilolast		38363-40-5		
Pemilolast	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP 60058982	Antiviral, other
Pemilolast		808-71-9		
Pemilolast	4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	26864-56-2	DE 2040231	Neuroleptic
Pemilolast		52-67-5		
Pemilolast		61-33-6		
Pemilolast		1538-09-6		
Pemilolast		6130-64-9		
Pemilolast		525-94-0		
Pemilolast		87-09-2		

Exempl of Indication
Acromegaly
Cancer, mesothelioma
Asthma
Infection, human papilloma virus
Infection, herpes simplex virus

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Penicillin V		87-08-1		
P nimepicycline		4599-60-4		
Pentuss			US 4221778	Formulation, modified-release, other
P ntaerythritol Chloral		78-12-6		
Penta r ythritol		2209-86-1		
Dichl r hydrin		597-71-7		
Pentaerythritol		5534-95-2		
P ntagestrin		7001-56-1		
P ntagestrone		9005-27-0		
Pentalyte	Starch, 2-hydroxyethyl ether [CAS]		US 5407428	Plasma substitute
P ntameth nilum		541-20-8		
pentamidine	Benzenecarboximidamide, 4,4'-(1,5-pentanediyldis(ox))bis- [CAS]	100-33-4		Formulation, inhalable, systemic
P ntaz cin		359-83-1		
Pentetate		12111-24-9		
Pentetic Acid		67-43-6		
Pent tr otide		138661-02-6		
P nthi nate		60-44-6		
Pentifylin		1028-33-7		
P ntlig tid		62087-72-3		
P ntisomid		78833-03-1		
Pent barbital		76-74-4		
P nt linium		52-62-0		
P ntor x		434-43-5		
pentosan polysulfate	Xylan, hydrogen sulfate, sodium salt [CAS]	37319-17-8	US 5180715	Urological
pentostatin	imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]			Neuroprotective
P nt xy]		147-61-5		
Pentritritol		1607-17-6		
Pentylen tetrazole		54-95-5		

Exempl of Indication
Rhinitis, allergic, general
Surgery adjunct
Infection, Pneumocystis jirovecii prophylaxis
Inflammation, urinary tract
Cancer, leukaemia, hairy cell
Amniotrophic lateral sclerosis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
peplomycin	Bleomycinamide, N1-[3-[(1-phenylethyl)amino]propyl]-, (S)- [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic
Perazine		84-97-9		
P rfiubron		423-55-2		
Perf sfamide		62435-42-1; 39800-16-3 (unspecified)		
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (8β)-, monomethanesulfonate- [CAS]	86104-22-1 66104-23-2	US 4797405	Antiparkinsonian
Perhexilin		6621-47-2		
P ricvazin		2622-26-6		
peritrosine	Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyloxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP 594999	Anticancer, other
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- [CAS]	536-59-4	US 5110832	Anticancer, other
Permethazine		13093-88-4		
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1(R*(R*))], 2Alpha,3aB,7aB]], compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 82834-16-0 95153-31-4	EP 49658	Antihypertensive, renin system
Peri dyl		53586-99-5		
P risoxal		2055-44-9		
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	2139-25-5	JP 04217925	Anti-inflammatory
Perlapiine		1977-11-3		
Permethrin		52645-53-1		
perospirone	1H-Indole-1,3(2H)-dione, 2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic
Perphenazine		58-39-9		
Petroleum Benzin		8030-30-6		

Example of Indication
Parkinson's disease
Cancer, prostate
Cancer, breast
Hypertension, general
Schizophrenia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
PH-10			US 6331286	Antipsoriasis
Phanquinone		84-12-8		
Pharmaprojects No. 4994			WO 9638482	Immunological
Pharmaprojects No. 5325			WO 9703986	Neuroleptic
Pharmaprojects No. 5972			WO 0204426	Antiasthma
Pharmaprojects No. 6362			US 6057346	Antiviral, anti-HIV
	(R)-N-[4-{2-[2-Hydroxy-2-(3-pyridyl)ethyl]amino}ethyl]phenyl]-4-{4-(trifluoromethyl)phenyl}thiazol-2-yl]benzenesulfonamide			
Pharmaprojects No. 6446				Anorectic/Antiobesity
Pharmaprojects No. 6590			WO 0206223	Psychostimulant
Pharmaprojects No. 6656			US 6455026	Genomics-based drug discovery
Pharmaprojects No. 6691			US 6299900	Formulation, other
	3-(6-Aminopyridin-3-yl)-N-methyl-N-((1-methyl-1H-indol-2-yl)methyl)acrylamide			
Pharmaprojects No. 6743				Antibacterial, other
	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylidibenzofc, [pyrazinc]1,2-ajazepin			Antidepressant
Pharmaprojects No. 6748		620-99-5		
Ph nacain				
Hydrochloride				
Phenacetamide		63-98-9		
Phenacetin		62-44-2		
Phenadoxon		467-84-5		
Phenallymal		115-43-5		
Phenamet		3819-34-9		
Phenaz cin		127-35-5		
Phenazopyridin		136-40-3		
Hydrochloride				
Phenbutamide		3149-00-6		
Phencyclidine		77-10-1		
Phendimetrazine		634-03-7		
Phenelzine		51-71-8		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Phenacetin		3546-10-9		
Phenethbarbital		357-67-5		
Phenethicillin Potassium		132-93-4		
Phenethicillin		90-49-3		
Phenformin		114-86-3		
Phenylglutaramide		1156-05-4		
Phenindamine		82-88-2		
Phenindione		83-12-5		
Pheniprazin		55-52-7		
Pheniramine		86-21-5		
Phenmetrazin		134-49-6		
Phenobarbital		50-06-6		
Phenobutiodiol		554-24-5		
Phenocillin		103-97-9		
Phenocidine		78-05-7		
Phenolphthalein		77-09-8		
Phenolphthalol		81-92-5		
Phenolsulfonphthalein		143-74-8		
Phenoltrichlorophthalin		639-44-1		
Phenpropidin		562-26-5		
Phenosulfazole		515-54-8		
Phenoxymethamine		59-96-1		
Phenoxypipazine		3818-37-9		
Phenprobamate		673-31-4		
Phenprocoumon		435-97-2		
phenylephrine	Pyrrolidino(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, (3aS-cis)- [CAS]	101246-66-6		Cognition enhancer
Phenylsulfonamide		86-34-0		
Phentermine		122-09-8		
Phentermine				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Phentoltholal in Sodium		18265-54-8		
Ph nt lamin		50-60-2		
phenoltamine mesylate, Zonagen	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1		Formulation, oral, other
phenoltamine mesylate, Novartis	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1		Formulation, oral, other
Ph nyl Acetylsalicylate		134-55-4		
Phenyl Amin salicylate		133-11-9		
Ph nyl Salicylat		118-55-8		
Ph nylbutazone		50-33-9		
Phenylephrine		61-76-7		
Hydr chlorid				
Phenylethanalamine		7568-93-6		
Phenylm rcury Borate		102-98-7		
Phenylm thylbarbituric Acid		76-94-8		
Phenylpropanolamine		14838-15-4		
phenylpropanolamine, Alza	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Anorectic/Antiobesity
phenylpropanolamine, Difitucap	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Formulation, optimized, microparticles
phenylpropanolamine, KV	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Formulation, other
phenylpropanolamine, Verex	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-) [CAS]	14838-15-4		Formulation, modified-release, other
Ph nylpropylmethylaniline		93-88-9		
Phenylt loxamine		92-12-6		
Phenylramidol		553-69-5		
Ph nytoin		57-41-0		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
phenytoin, Sirus	2,4-Imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0		Formulation, oral, other
Phethenylat Sodium		510-34-9		
Phlor glucinol		108-73-6		
Ph Icodin		509-67-1		
Ph Iedrin		370-14-9		
Phosphocreatine		67-07-2		
Phosphocysteamine		5746-40-7		
Ph sphorylch line		107-73-3		
Phthalylsulfacetamide		131-69-1		
Phthalylsulfathiazole		85-73-4		
p-Hydroxyeph drine		365-26-4		
Phylloquinone		84-80-0		
Physostigmine		57-47-6		
Phytic Acid		83-86-3		
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	185077-23-0		Anticancer, other
Piberaline		39640-15-8		
piboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO 9318036	Antiarrhythmic
Pib serod		152811-62-6		
Picil r x		62510-56-9		
Picloxydine		5636-92-0		
Picoperine		21755-66-8		
Picosulfat Sodium		10040-45-6		
Picotamid		32828-81-2		
Picumast		39577-19-0		
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonyl]- [CAS]	121808-62-6	EP 276752	Immunomodulator, anti-infective
Pidotimod		121808-62-6		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pifarmin		56208-01-6		
piketopofen	Benzeneacetamide, 3-benzoyl-Alpha-methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB 1436502	Anti-inflammatory, topical
Pik toprofen		60576-13-8		
Pildralazine		64000-73-3		
Pil carpin		92-13-7		
pilocarpine, Alza	2(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Formulation, Implant
pilocarpine, MGI	2(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Stomatological
Piloplex	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoic acid, compd. with (3S-cis)-3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical
Pilsicainide		88069-67-4		
pilsicainide hydrochloride	1H-Pyrrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US 4564624	Antiarrhythmic
Pimeclonone		534-84-9		
pimecrolimus	15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxazacyclicosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,28,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R'E(1S',3S',4R'))), 4S',5R',8S',9E',12R',14R',5S',16R',18S,8,19S',26aR'))- [CAS]	137071-32-0	EP 626385	Antipruritic/inflam, allergic
Pim crollimus		137071-32-0		
Pimefyllin		10001-43-1		

Example of Indication
Xerostomia
Glaucoma
Arrhythmia, general
Eczema, atopic

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pimilprost	Acetic acid, [2-(octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl)ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha,4Alpha(1E,3S*,5S*),5B,6aAlpha]]- [CAS]	139403-31-9		Dermatological
Pimin din		13495-09-5		
Pimobendan		74150-27-9		
pimozide	2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- [CAS]	2062-78-4	FR 13695	Neuroleptic
Pim zide		2062-78-4		
Pimozide				
Pinacidil		85371-64-8		
pinaverium bromide	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, bromide- [CAS]	53251-94-8 59995-65-2	EP 406743	Antispasmodic
Pinaverium Bromide		53251-94-8		
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic
Pinaz pam		52463-83-9		
Pindolol		13523-86-9		
Pliglitazone		111025-46-8		
pioglitazone hydrochloride	2,4-Thiazolidinedione, 5-[(4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochloride (+/-)- [CAS]	111025-46-8 112529-15-4	EP 193256	Antidiabetic
Pioglitazone Hydrochloride				
Pipacycline		1110-80-1		
Pipamazine		84-04-8		
Pipamper n		1893-33-0		
Pipazethate		2167-85-3		
Pipebuz n		27315-91-9		
Pipecurium Bromide		52212-02-9		

Example of Indication
Ulcer, general
Irritable bowel syndrome
Diabetes, Type II

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pilocarpine hydrobromide	Pilocarpine, 4,4'-bis[(2S,3R,5R,6R,7R)-3,17-bis(acetyloxy)androstane-2,16-diol]bis[1,1'-dimethyl-, dibromide [CAS]	5212-02-9 68399-57-5	GB 1398050	Muscle relaxant
pilocarpine	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)-[CAS]	51940-44-4	GB 1451911	Antibacterial, other
Pipemidic Acid		51940-44-4		
Pipenzolate Bromide		125-51-9		
Piperacetazin		3819-00-9		
piperacillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-, [2Alpha,5Alpha,6S(S')]- [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable
Pip racillin		61477-96-1		
piperacillin, KRKA	4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-, [2Alpha,5Alpha,6S(S')]]	59703-84-3 61477-96-1		Penicillin, injectable
Piperazine Adipate		142-88-1		
Piperidone		77-03-2		
Piperidolol		82-98-4		
Piperilate		4546-39-8		
piperine analogues, BTG			WO 002544	Dermatological
Pip rocaline		136-82-3		
Piperonal		120-57-0		
Pip roxan		59-39-2		
Piperylone		4/6/2531		
Pipobroman		54-91-1		
Pip sulfan		2608-24-4		
Pip tiazine		39860-99-6		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pipotiazine palmitate	Hexadecanoic acid, 2-[1-[3-(2-((dimethylamino)sulfonyl)-10H-phenothiazin-10-yl)propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39860-99-6	US 4782077	Neuroleptic
Pipoxolan Hydrochloride		18174-58-8		
Pipradr I		467-60-7		
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene], ethyl ester [CAS]	17243-64-0	US 3971794	GI inflammatory/bowel disorders
Pipr z lin		17243-64-0		
Piracetam		7491-74-9		
pirarubicin	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8Alpha,10Alpha(S')]]- [CAS]	72496-41-4	US 4303785	Anticancer, antibiotic
Pirarubicin		72496-41-4		
Pirazac		71002-09-0		
pirbuterol	2,6-Pyridinedimethanol, Alpha-[[1,1-dimethyl(ethyl)amino]methyl]-3-hydroxy-, monoacetate (salt) [CAS]	38029-10-6 38677-81-5 65652-44-0	US 3786160	Antiasthma
Pirbut r I		38677-81-5		
Pirenexine		1043-21-6		
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1	FR 1505795	Antitumor
Pir nz pine		28797-61-7		
pirenzepine, Valley Forge	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29868-97-1		Formulation, mucosal, topical
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic
Piretanid		55837-27-9		

Example of Indication
Motility dysfunction, GI, general
Cancer, breast
Asthma
Myopia
Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
pirfenidone	2-(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	US 3299067	Vasodilator, peripheral
Piribedil		1/4/3605		
Piridocaine		87-21-8		
Pirifibrate		55285-45-5		
Piriramide		302-41-0		
Piritr xlm		72732-56-0		
pirindole	1H-Pyrazino[3,2,1-k]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant
pirmenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-, Alpha,phenyl, cis-(+)- [CAS]	61477-94-9 68252-19-7	US 4112103	Antiarrhythmic
Pirmenol		68252-19-7		
Piracetam		50650-76-5		
Piroheptine		16378-21-5		
Piridolic Acid		19562-30-2		
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-inflammatory
Piroxicam		36322-90-4		
piroxicam betadex	β-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121698-62-6 96684-39-8	EP 153998	Formulation, other
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarthritic, other
piroxicam suppositories	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, transmucosal, systemic
piroxicam, Douglas	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, oral, other

Exemplar Indication
Fibrosis, pulmonary
Parkinson's disease
Depression, general
Tachycardia, supraventricular
Pain, musculoskeletal
Inflammation, general
Inflammation, general
Inflammation, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
piroxicam, KIRKA	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, other
piroxicam, Zydis	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4		Formulation, oral, orally-disintegrating
Pir z adil		54110-25-7		
Pirpr fen		31793-07-4		
pivastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-(R', S'-(E))]- [CAS]	147526-32-7	EP 304063	Hypolipemic/Antiatherosclerosis
pivagabine	N-trimethylacetyl-4-aminobutyric acid	69542-93-4		Neurological
pivaloxyoxymethyl butyrate	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other
Pivalylbenzhydrazine		306-19-4		
Pivampicillin		33817-20-8		
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral
Pivcefalexin		63836-75-9		
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6S)]- [CAS]	32886-97-8	GB 1293590	Penicillin, oral
pixantrone	Benz[gl]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate(1:2) [CAS]	144675-97-8	EP 503537	Anticancer, other
pizotifen	4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine	15574-96-6	DE 2346747	Antimigraine
Pizotyline		15574-96-6		
PKI-166	Phenol, 4-(4-((1R)-1-phenylethylamino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl)- [CAS]	187724-61-4		Anticancer, other
p-Lactoph netide		539-08-2		

Examp ^l of Indication
Arthritis, rheumatoid
Arthritis, osteo
Hyperlipidaemia, general
Anxiety, general
Cancer, lung, non-small cell
Infection, general
Infection, general
Cancer, lymphoma, non-Hodgkin's
Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Plafibril		63394-05-8		
Plasminogen activator, Asahi	Plasminogen activator [CAS]	105913-11-9	EP 151998	Fibrinolytic
Plasmocid		551-01-9		
Plat nil		3571-88-8		
Plaun tol		64218-02-6		
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	EP 805145	Antifungal
PLD-147	(OC-6-43)-Bis(acetate)(1'-adamantylamine)amine-dichloro-platinum (IV)			Anticancer, alkylating
pleconaril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9	US 5464848	Antiviral, other
Pleconaril		153168-05-9		
Plicamycin		18378-89-7		
p-Methyldip nhydramine		19804-27-4		
PMS-601			WO 0001677	Antiviral, anti-HIV
Pneumococcal Vaccine, Diphtheria Conjugate				
Pneumococcal Vaccine, Polyvalent				
PNU-288034	N-[(5s)-3{4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl}acetamide]			Antibiotic, other
Podophyllotoxin		518-28-5		
polaprezinc	Zinc, bis(N-6-alanyl-L-histidinato-N3,OAlpha-), (T-4)- [CAS]	107667-60-7	EP 303380	Antitumor
Polapr zinc		107667-60-7		

Example 1 Indication
Infection, myocardial
Infection, Candida, general
Cancer, general
Infection, respiratory tract, general
Infection, HIV/AIDS
Infection, general
Ulcer, duodenal

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Polidine Methylsulfate		545-80-2		
Policresulen		2/3/9011		
Polid xide		9064-92-0		
Polid canol		9002-92-0		
polidocanol, BTG	Polyethylene glycol monododecyl ether	3055-99-0		Vasoprotective, systemic
Poliovirus Vaccine Inactivated				
poly-ADPRT inhibitors, Isotech			WO 9845253	Anticancer, other
Poly stradi l Phosphate		28014-46-2		
Polyphenon E	Polyphenon E [CAS]	188265-33-0		Antiviral, other
Polythiazide		346-18-9		
porfimer sodium	Photofrin [CAS]	87806-31-3	US 4882234	Anticancer, other
Porfiromycin		801-52-5		
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(1(S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US 5714490	Antifungal
Posaconazole		171228-49-2		
Posatrelin		78664-73-0		Formulation, oral, enteric-coated
potassium chloride, Amarin	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, oral, other
potassium chloride, Liquifard	Potassium chloride (KCl) [CAS]	7447-40-7	US 4259315	Formulation, optimized, microencapsulate
potassium chloride, Microcap	Potassium chloride (KCl) [CAS]	7447-40-7		
Potassium Gluconate		299-27-4		
Potassium		1321-14-8		
Guaiac Isulfonate				

Example of Indication
Venous Insufficiency
Cancer, general
Infection, human papilloma virus
Cancer, lung, non-small cell
Infection, fungal, general
Nutrition
Nutrition

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Potassium p-aminobenzoate		138-84-1		
Potassium permanganate		7722-64-7		
Povidone-iodine		9003-39-8		
		25655-41-8		
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	62756-44-9	DE 2633028	Formulation, oral, other
PR-2699	(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetone			Antifungal
PR-608	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride			Antiparkinsonian
Practolol		6673-35-4		
Praimaline		35080-11-6		
Pralidoxim Chloride		51-15-0		
pralnacasan	6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-, (1S,9S)- [CAS]	192755-52-5		Antiarthritic, immunological
pramipexole	2,6-Benzothiazolodiamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP 186087	Antiparkinsonian
Pramipexol		104632-26-0		
pramiracetam	1-Pyrrolidineacetamide, N-[2-[bis(1-methylethyl)aminoethyl]-2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-50-5	US 4145347	Cognition enhancer
Pramiracetam		68497-62-1		
Pramiverin		14334-40-8		
pramlintide	1,2-Dithia-5,8,11,14,17-pentaazacyclopentacosane, cyclic peptide deriv. [CAS]	151126-32-8	US 5124314	Antidiabetic
Pramlintide		151126-32-8		

Example of Indication
Unspecified
Infection, fungal, general
Parkinson's disease
Arthritis, rheumatoid
Parkinson's disease
Amnesia
Diabetes, Type I

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pramoxin		140-65-8		
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP 173126	Antihypertensive, other
Pranlukast		103177-37-3		
Pranprafen		52549-17-4		
pranoprofen, Senju	5H-[1]Benzopyran[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	52549-17-4		Formulation, mucosal, topical
Prasterone		53-43-0		
prasterone, Nippon Organon	Androst-5-en-17-one, 3-hydroxy-, (3 β)- [CAS]	53-43-0		Labour inducer
prazosin	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)]1,1'-biphenyl]-4-ylmethyl]- [CAS]	153804-05-8	US 5409947	Antihypertensive, renin system
pravastatin	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8, delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1Alpha(8S*, deltaS*), 2Alpha, 6Alpha, 8B(R*), 8aAlpha)]- [CAS]	81093-37-0 81131-70-6	US 4346227	Hypolipemic/Antiatherosclerosis
Pravastatin Sodium		81131-70-6		
	Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8, delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1Alpha(8S*, deltaS*), 2Alpha, 6Alpha, 8B(R*), 8aAlpha)]- [CAS]	81093-37-0 81131-70-6		Formulation, oral, other
Praxepam		2955-38-6		
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	55268-74-1	US 4001411	Schistosomicide
Praziquantel		55268-74-1		
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- [CAS]	19216-56-9 19237-84-4	US 4092315	Antihypertensive, adrenergic
Prazosin		19216-56-9		

Exempl of Indication
Hypertension, general
Ocular disorder, general
Hypertension, general
Atherosclerosis
Atherosclerosis
Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
prazosin, Alza	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9		Formulation, modified-release, other
Prednicarbat		73771-04-7		
prednimustine	Pregna-1,4-diene-3,20-dione, 21-[4-{4-[bis(2-chloroethyl)amino]phenyl}-1-oxobutoxy]-11,17-dihydroxy-, (11B)-, [CAS]	29069-24-7	GB 1272841	Anticancer, alkylating
Prednimustine		29069-24-7		
Prednisolone		50-24-8		
Prednisolone 21-Diethylamin acetate		5626-34-6		
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyloxy)-, [11B,21(2E,8E)]-, [CAS]	118244-44-3	EP 332143	Antiarrhythmic, other
Pr dnisolon Sodium Phosphat		125-02-0		
Pr dnis n		53-03-2		
Prednival		15180-00-4		
Pr dnyliden		599-33-7		
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-, [CAS]	148553-50-8		Antiepileptic
Pr gabalin		148553-50-8		
Pregnan-3 α -ol-20-one		128-20-1		
Premarin + trimegestone	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17B (S)]: [CAS]	74513-62-5		Menopausal disorders
prenalaterol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470039	Cardiostimulant
Prenalter I		57526-81-5		
Prenoxdiazine Hydr chloride		982-43-4		
Pr nylamine		390-64-7		

Example f Indication
Hypertension, general
Arthritis, rheumatoid
Epilepsy, general
Hormone replacement therapy

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
prezate copper acetate, gel	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinate)(N2-(N-glycyl-L-histidyl)-L-lysinate(2-))-, hydrogen, diacetate- [CAS]	130120-57-9		Vulnerary
Pridlin I		511-45-5		
Prifinium Br milde		4630-95-9		
Prilocaine		721-50-6		
Primaquine		90-34-6		
Primid n		125-33-7		
Prin mastat		192329-42-3		
PRO-2000			US 5614599	Antiviral, anti-HIV
Probenecid		57-66-9		
ProbucoI		23288-49-5		
Pr cainamid		614-39-1		
Hydr chloride				
procainamide, Pfizer	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]- [CAS]	51-08-9		Formulation, other
Procaine		59-46-1		
Procarbazine		671-16-9		
procatrol	2(1H)-Quinolione, 8-hydroxy-5-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-, monohydrochloride [CAS]	59828-07-8 60443-17-6	GB 1496766	Antiasthma
Procatrol		72332-33-3		
procatrol, ML Labs		59828-07-8 60443-17-6		Formulation, inhalable, dry powder
Pr chl rperazine		58-38-8		
Prochlorperazine Maleate				
prochlorperazine maleate, IVAX	10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate	58-38-8 84-02-6		Formulation, oral, other
procidazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES 407882	Anticancer, immunological
Procodazole		23249-97-0		
Procyclidine		77-37-2		

Example of Indication
Wound healing
Infection, HIV prophylaxis
Arrhythmia, general
Asthma
Nausea and vomiting, general
Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pr cymat		13931-64-1		
Proclipine		31314-38-2		
Proflavine		92-62-6		
Pr gabide		62666-20-0		
Progest rone		57-83-0		
progesterone, Dekk-Tec	Pregn-4-ene-3,20-dione [CAS]	57-83-0		Formulation, transmucosal, systemic
progesterone, Eflik	Pregn-4-ene-3,20-dione [CAS]	57-83-0	US 5776495	Formulation, oral, solubility-enhanced
progesterone, I2R	Pregn-4-ene-3, 20-dione [CAS]	57-83-0		Formulation, modified-release, immediate
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (+/-) [CAS]	57132-53-3 59209-40-4	GB 1467568	Anti-inflammatory
Pr glumetacin		57132-53-3		
proglumide	Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-) [CAS]	6620-60-6	DE 1518125	Anticancer
Proglumide		6620-60-6		
Proheptazine		77-14-5		
Pr lactin		9002-62-4		
Prolintan		493-92-5		
Prolonium iodide		123-47-7		
Promazine		58-40-2		
Promedol		64-39-1		
Pr m g st ne		34184-77-5		
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 β)- [CAS]	39219-28-8	GB 1337198	Reproductive/gonadal, general
Pr methazine		60-87-7		
Pronethal I		54-80-8		
propacetamol	Glycine, N,N-diethyl-, 4-(acetylamino)phenyl ester [CAS]	66532-85-2 66532-86-3	US 4127671	Formulation, parenteral, other
Propac tam I		66532-85-2		

Exempl f Indication
Amenorrhoea
Hormone replacement therapy
Amenorrhoea
Inflammation, general
Ulcer, gastric
Acne

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
propafenone	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- [CAS]	54083-53-5	GB 1307455	Antiarrhythmic
Pr pafenone		54083-53-5		
Propagermanium		12758-40-6		
Propallylonal		545-93-7		
Pr pamidline		104-32-5		
propane-1,2-diol, Vinas	1,2-propanediol	57-55-6		Formulation, dermal, topical
Propanidid		1421-14-3		
Propantheline Bromide		50-34-0		
Proparacaine		499-67-2		
Propatyl Nitrate		2921-92-8		
propenidazole	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2		Antifungal
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB 1470220	Neuroprotective
Propentofylline		55242-55-2		
Propicillin		551-27-9		
Propiomazine		362-29-8		
Pr pini nic Acid		79-09-4		
propionyl L-carnitine, Sigma	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB 2008578	Vasodilator, peripheral
Propipocaine		3670-68-6		
Propiram		15686-91-6		
Propiverin		60569-19-9		
propiverine hydrochloride	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54558-98-8 60569-19-9		Urological
Pr piz pine		10321-12-7		
propofol	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	US 4056635	Anaesthetic, injectable
Pr p fol		2078-54-8		
Propofol				

Example f Indication
Fibrillation, ventricular
Infection, fungal, general
Infection, trichomoniasis
Ischaemia, cerebral
Peripheral vascular disease
Incontinence
Anaesthesia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
propofol phosphate, Vyrex	Phenol, 2,6-bis(1-methylethyl)- phosphate		US 6254853	Anaesthetic, injectable
propofol, Maelor	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	GB 2359747	Formulation, optimized, microencapsulate
propofol, SioyePharma	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8		Formulation, optimized, microparticles
Prop xycalin		550-83-4		
Hydr chl ride		469-62-5		
Pr poxyphene		525-66-6		
Propranolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, <=24hr
propranolol, Biovail	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	318-98-9		Formulation, modified-release, <=24hr
propranolol, Elian	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, other
propranolol, EUCAPS	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	525-66-6		Formulation, modified-release, other
propranolol, Forest		101-40-6		
Pr pylhexedrin		587-61-1		
Propylidone		51-52-5		
Pr pylthiouracil		479-92-5		
Pr pyphenaz ne		22760-18-5		
Pr quazon		466-06-8		
Proscillaridin		35121-78-9		
Prostacyclin		745-65-3		
Pr staglandin E ₁		363-24-6		
Pr staglandin E ₂		551-11-1		
Pr staglandin F _{2α}		59-58-5		
Prostutiamine		60202-16-6		
Protein C		50-39-5		
Pr theobr min		303-69-5		
Prothipendyl		58416-00-5		
Pr ti fat		14222-60-7		
Protonamide				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
protiznic acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha, 10-dimethyl-, (+/-)- [CAS]	13799-03-6	US 3450698	Anti-inflammatory
Protiznic Acid		54323-85-2		
Protoanemonin		108-28-1		
Prot kyl I		136-70-9		
Prot porphyrin IX		553-12-8		
Pr triptylin		438-60-8		
Pr -Urokinas		82657-92-9		
Pr xazole		9/3/5696		
Proxibarbal		2537-29-3		
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediy)bis- [CAS]	12758-40-8	FR 2005110	Antiviral, other
Pr xyphylin		603-00-9		
Pr zapine		8/2/3426		
Prucal pride		179474-81-8		
prulifloxacin	1H,4H-[1,3]Thiazolo[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial
Pseudococaine		478-73-9		
Pseud ephedrine		90-82-4		
pseudoephedrine + triprolidine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*, R*)]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]	8054-27-1		Formulation, modified-release, other
pseudoephedrine, Alza	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4		Formulation, oral, other
pseudoephedrine, Difiucap	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4		Formulation, optimized, microparticles
pseudoephedrine, KV	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	345-78-8 90-82-4		Formulation, modified-release, other
pseudoephedrine, Phoenix	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*, R*)]- [CAS]	90-82-4		Formulation, fixed-dose combinations

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Psil cybin	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	520-52-5		
PSK-3841		154992-24-2		Dermatological
p-Sulfanilylbenzylamine		4393-19-5		
PT-141			US 8051555	Male sexual dysfunction
Pter pt rin		89-38-3		
Puromycin		53-79-2		
PX-12	1-Methylpropyl 2-mercaptimidazolyl disulfide			Anticancer, other
Pyrant l		15686-83-6		
Pyrazinamid		98-96-4		
Pyridinol Carbamate		1882-26-4		
Pyrid stigmin Bromide		101-26-8		
Pyridoxal 5-Phosphate		54-47-7		
Pyridoxine		58-56-0		
Hydrochl ride		91-84-9		
Pyrilamin		58-14-0		
Pyrimethamine		1740-22-3		
Pyrin lin		33605-94-6		
Pyrisuccid an l		1121-30-8		
Pyritition		77-04-3		
Pyritnyldione		1098-97-1		
Pyritinol		120-80-9		
Pyrocatechol		87-66-1		
Pyrogallol		74847-35-1		
Pyr naridin		3563-49-3		
Pyrovalerone		9004-70-0		
Pyroxylin		91-82-7		
Pyrobutamine		2210-77-7		
Pyrocaine				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Pyrolnitrin		1018-71-9		
Pyvinium Pamoate		3546-41-6		
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US 3845039	Hypnotic/Sedative
Quazepam		36735-22-5		
Qu rc tin		117-39-5		
Quetiapine		111974-69-7		
quetiapine fumarate	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP 240228	Neuroleptic
quetiapine fumarate, SR	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2		Formulation, modified-release, <=24hr
Quinacillin		1596-63-0		
Quinacrine		83-89-6		
quinacrine, CJD treatment	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl			Neurological
quinagolide	Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-, (3Alpha,4aAlpha,10aB)- (+/-)- [CAS]	87056-78-8 94424-50-7 97805-49-7	EP 77754	Antiprolactin
Quinagolide		87056-78-8		
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropylamino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2(R'(R'),3R')]- [CAS]	82588-55-8 85441-61-8 90243-99-5	EP 49805	Antihypertensive, renin system
Quinapril		85441-61-8		
Quinapril Hydrochloride				

Example of Indication
Insomnia
Schizophrenia
Schizophrenia
Creutzfeldt-Jakob disease
Hyperprolactinaemia
Hypertension, general

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
quinaprilat	3-Isouquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2(R*(R*))],3R*]-, [CAS]	82768-85-2	EP 46953	Antihypertensive, renin system
Quinapryramine		20493-41-8		
Quinbolone		2487-63-0		
Quinestradiol		1169-79-5		
Quinestril		152-43-2		
Quinethazone		73-49-4		
quinfolide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-88-3	US 3997542	Anticoagulant
Quinfolide		62265-88-3		
Quinidin		56-54-2		
quinidine bisulfate, Eurand	Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5		Formulation, modified-release, other
Quinine		130-95-0		
Quinidol		525-61-1		
Quinupramin		31721-17-2		
Quinupristin		120138-50-3		
R-107500	cis-2,3,3a,8-tetrahydro-N,N-dimethylidibenz[c,f]isoxazole[2,3-a]azepine-2-methanamine		WO 9614320	Anxiolytic
R-667			WO 0204439	COPD treatment
Rabeprazole		117976-89-3		
rabeprazole sodium	1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinylmethyl]sulfinyl]-, sodium salt- [CAS]	117976-89-3 117976-90-6	EP 268956	Anticancer
Rabeprazole Sodium				
Rabeprazole Sodium				
racecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)- [CAS]	112573-72-5 81110-73-8	EP 38758	Antidiarrhoeal

Example of Indication
Hypertension, general
Arrhythmia, general
Anxiety, general
Emphysema, general
Ulcer, gastric
Diarrhoea, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Rac cadotril		81110-73-8		
Racem thiorphan		510-53-2		
Raloxif n		84449-90-1		
raloxifene hydrochloride	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]-, hydrochloride [CAS]	82840-04-8 84449-90-1	EP 62503	Osteoporosis treatment
ralitrexed	L-glutamic acid, N-[[5-[[1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]- [CAS]	112887-68-0	EP 239362	Anticancer, antimetabolite
Raltitr xed		112887-68-0		
ramatroban	9H-Carbazole-9-propanoic acid, 3-[[4-(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	EP 242518	Antiallergic, non-asthma
Ramatr ban		116649-85-5		
Ramifenazone		3615-24-5		
ramipril	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1,2,5-triazol-4-yl], [2S-[1R*(R*),2A]alpha,3aB,6aB]]-[CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system
Ramipril		87333-19-5		
Ramipril				
Ram setr n		132036-88-5		
ramosetron hydrochloride	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3	EP 381422	Antiemetic
ramosetron, WOWTAB	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3	EP 381422	Formulation, oral, orally-disintegrating
Ramot project No. 1097			US 5730992	Dermatological
Ranimustin		58994-96-0		
ranitidine	1,1-Ethenediamine, N-[2-[[5-[[[dimethylamino)methyl]-2-turanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]	66357-35-5	US 4128658	Antilucer

Exemplification of Indication
Osteoporosis
Cancer, colorectal
Rhinitis, allergic, perennial
Heart failure
Nausea and vomiting, general
Chemotherapy-induced nausea and vomiting
Unspecified
Ulcer, duodenal

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ranitidine	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-(2-(((5-(dimethylamino)methyl)-2-furanyl)methylthio)ethyl)-N-methyl-2-nitroethenediamine (1:1)- [CAS]	68357-35-5		
ranitidine bismuth citrate	1,1-Ethenediamine, N-[2-(((5-(dimethylamino)methyl)-2-furanyl)methylthio)ethyl]-N-methyl-2-nitro [CAS]	128345-62-0	EP 533281	Antitumor
ranitidine, Phoenix		68357-35-5		Formulation, modified-release, other
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+)- [CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal
Ran lazine		95635-55-5		
Ranplmase		133737-96-9		
Rapacur nium Bromide		156137-99-4		
rasagiline mesylate	1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, methanesulfonate [CAS]	161735-79-1	US 5457133	Antiparkinsonian
Raubasine		483-04-5		
ravuconazole	Benzonitrile, 4-[2-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-4-thiazolyl]- [CAS]	182760-06-1		Antifungal
raxofelast	2-Benzofuranacetic acid, 5-(acetoxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4999350	Symptomatic antidiabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediy)bis- [CAS]	21416-67-1	GB 1234935	Anticancer, other
Razoxane		21416-87-5		
RC-529	Tetradecanoic acid (1R)-1-(2-((2-deoxy-3-O-((3R)-1-oxo-3-(1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-β-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethylethanamine (1:1) [CAS]	216014-46-9		Immunostimulant, other

Example of Indication
Ulcer, duodenal
Ulcer, GI, general
Angina, general
Parkinson's disease
Infection, meningitis, general
Nephropathy, diabetic
Cancer, general
Vaccine adjunct

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
rebamipide	4-Quinolonepropanoic acid, Alpha-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS]	90098-04-7	DE 3324034	Antitumor
Rebamipid		90098-04-7		
rebinastat	L-Valinamide, N-[(2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl]-L-leucyl-N,3-dimethyl- [CAS]	259188-38-0		Anticancer, other
reboxetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R* S*)- [CAS]	71620-89-8	US 4229449	Antidepressant
Rebox tine		98769-81-4		
Remac mide		128298-28-2		
remifentanil	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-methyl ester- [CAS]	132539-07-2	EP 383579	Analgescic, other
Remifentanil		132875-61-7		
remindertant	Tricyclo[3.3.1.1 ^{3,7}]decane-2-carboxylic acid, 2-[[1-(7-chloro-4-quinoliny)]-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1	EP 699438	Neuroleptic
Rem xiprid		80125-14-0		
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	109872-41-5 88721-77-1	JP 58188885	Gastroprokinetic
repaglinide	Benzoic acid, 2-ethoxy-4-[2-[(3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]	135062-02-1	WO 9300337	Antidiabetic
Repaglinide		135062-02-1		
repertaxin L-lysine salt	2(R)-4-isobutylphenylpropionyl methanesulfonamide L-lysine salt		WO 0024710	Cardiovascular
Repin tan		144980-29-0		

Example f Indication
Cancer, lung, non-small cell
Depression, general
Pain, general
Schizophrenia
Irritable bowel syndrome
Diabetes, Type II
Reperfusion injury

API G n rlc Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
reprotran hydrochloride	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]	144980-77-8	US 5137901	Neuroprotective
repirinast	4H-Pyran[3,2-c]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73080-51-0	US 4298610	Antialsthma
Repirinast		73080-51-0		
R posal		3625-25-0		
reproterol	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR M5969	Antialsthma
R proterol		54063-54-6		
Resclm t l		73573-42-9		
R scinnamin		24815-24-5		
R serpillin		131-02-2		
Reserpine		50-55-5		
R sibuf g nin		465-39-4		
resiquimod	1H-imidazo[4,5-o]quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US 5389640	Antiviral, other
Resorcin l		108-46-3		
Reteplax		133652-38-7		
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic
retinoic acid, Antigenics	Retinoic acid [CAS]	302-79-4		Formulation, parenteral, other
Revimid			US 6261230	Anticancer, other
R-flutridiprotein	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4		Anticancer, other
Rho (D) Immune Globulin (Human)				
Rho-kinase inhibitors, Kirin			WO 0156988	Antialsthma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-B-D-ribofuranosyl- [CAS]	36791-04-5	US 4211771	Antiviral, other
Ribavirin		36791-04-5		
Ribavirin				
Ribavirin				
ribavirin + Alpha-interferon, SP			US 6172046	Antiviral, other
Riboflavin		146-17-8		
M n ph sphate				
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic
Ribostamycin		25546-65-0		
Ricin leic Acid		141-22-0		
Rid gr I		110140-89-1		
ribabutin	Ritamyacin XIV, 1',4'-didehydro-1'-deoxy-1,4'-dihydro-5'-(2-methylpropyl)-1'-oxo- [CAS]	72559-06-9	US 4219478	Antimycobacterial
Ritabutin		72559-06-9		
	Ritamyacin VIII, 1',4'-didehydro-1'-deoxy-1,4'-dihydro-3'-hydroxy-5'-14-(2-methylpropyl)-1'-piperazinyl-1'-oxo- [CAS]	129791-92-0 129781-94-2 133633-12-2	EP 366914	Antimycobacterial
Ritalazil		129791-92-0		
	Ritamyacin, 3-[[[1-(diethylamino)ethylidene]hydrazono]methyl]- [CAS]	94168-98-6	EP 119571	Antimycobacterial
ritametine		2750-76-7		
Ritamide				
	Ritamyacin, 3-[[[4-methyl-1-piperazinyl]imino]methyl]-, mixt. with 5-pyrimidinethiolamine [CAS]	61498-94-0		Formulation, fixed-dose combinations
ritampicin + trimethoprim		13292-46-1		
Ritampin		6998-60-3		
Ritamyacin SV				
ritaperitine	Ritamyacin, 3-[[[4-cyclopentyl-1-piperazinyl]imino]methyl]- [CAS]	61379-65-5	DE 2608218	Antibiotic, other

Example 1 Indication
Infection, haemorrhagic fever
Infection, hepatitis-C virus
Infection, general
Infection, Mycobacterium avium complex
Infection, tuberculosis
Infection, general
Infection, general
Infection, tuberculosis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Rifapentine		61379-65-5		
Rifaximin	Epoxy-pentadeca[1,11,13]trienino]benzo[uro[4,5-e]-pyrro[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16E,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other
Rifampin	4-deoxy-4'-methylpyrro[1',2'-1,2]imidazo[5,4-c]rifamycin SV	80621-81-4		
Rifaximine cream		80621-81-4	BE 888895	Formulation, dermal, topical
Rilmazafin		99593-25-6		
Rilmenidine	2-Oxazolinamine, N-(dicyclopropylmethyl)-4,5-dihydro- [CAS]	54187-04-1 54249-57-9	DE 2362754	Antihypertensive, adrenergic
Rilmenidin		54187-04-1		
riluzole	2-Benzothiazolinamine, 8-(trifluoromethoxy)- [CAS]	1744-22-5	EP 50551	Neuroprotective
Riluzole		1744-22-5		
Rimantadin		13392-28-4		
	4H-Pyrido[1,2-a]pyrimidinium, 3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, methyl sulfate [CAS]	28610-84-6 35615-72-6	DE 2461349	Analgesic, NSAID
Rimazolium Methylsulfate		28610-84-6		
	Androst-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11R,16Alpha,17R)- [CAS]	49697-38-3	DE 2301317	Ophthalmological
Rimexolone		49697-38-3		
Rimitecor		32953-89-2		
	1H-Pyrazole-3-carboxanide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]			
rimonabant		158681-13-1	US 5624941	Anorectic/Antiobesity

Example of Indication
Infection, GI tract
Infection, dermatological
Hypertension, general
Amyotrophic lateral sclerosis
Inflammation, ocular
Obesity

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ritonavir	1,3-Benzene-diol, 2,4,6-tri-ortho- [CAS]	19403-92-0	US 3755251	Antiviral, other
Riopir stil		77287-05-9		
risedronate sodium	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115436-72-1	EP 304961	Osteoporosis treatment
Risedronate Sodium				
Risedr nic Acid		105462-24-6		
risperidone	4H-Pyrida[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinylethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2	EP 196132	Neuroleptic
Risperidone		106266-06-2		
risperidone, Mediscorb	4H-Pyrida[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinylethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2		Formulation, optimized, microencapsulate
risperidone, Quicklets	4H-Pyrida[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidinylethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]			Formulation, oral, orally-disintegrating
Ritanserlin		87051-43-2		
Ritipenem		84845-57-8		
ritodrine	Benzenemethanol, 4-hydroxy-Alpha-1-[12-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R,S)- [CAS]	23239-51-2 26652-09-5	US 3410944	Labour inhibitor.
Ritodrin		26652-09-5		
ritonavir	2,4,7,12-Tetraazatridecan-13-olic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))-[CAS]	155213-67-5	WO 9414436	Antiviral, anti-HIV
Ritonavir		155213-67-5		
Ritonavir				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ritonavir, soft gel	2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,6R*,10R*,11R*))-[CAS]	155213-67-5		Formulation, other
Rituximab		174722-31-7		
Rivastigmin		123441-03-2		
Rivastigmine tartrate	Carbamic acid, ethylmethyl-, 3,1'-(dimethylamino)ethylphenyl ester, (S)-[CAS]	123441-03-2 129101-54-8	DE 3805744	Cognition enhancer
Rivastigmine Tartrate				
Rivastigmine Tartrate				
Rizatriptan		144034-80-0		
Rizatriptan benzoate	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, monobenzoate-[CAS]	145202-66-0 159776-67-7	EP 497512	Antimigraine
Rizatriptan benzoate, Zydus	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, monobenzoate-[CAS]			Formulation, oral, orally-disintegrating
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	163286-99-5		Cognition enhancer
RNA Splein Nucleosides, Koron	5-Formyluridine			Antiviral, other
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine			Anticancer, antimetabolite
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl]-5-methyl-[CAS]	180384-56-9	WO 8618459	Cardiovascular
Rociv rin		53716-44-2		
Rocuronium		143558-00-3		

Exemplar Indication
Infection, HIV/AIDS
Alzheimer's disease
Migraine
Migraine
Alzheimer's disease
Infection, hepatitis-C virus
Cancer, general
Haemorrhage, subarachnoid

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
	Pyrolicidinum, 1- [(2S,3A)alpha,5Alpha,16b,17B)-17-(leceyloxy)-3-hydroxy-2-(4- morpholinyl)androstane-16-yl]-1-(2- propenyl)-, bromide- [CAS]	104855-17-6 104884-91-5 119802-91-9	EP 287150	Muscle relaxant
rofecoxib	2(5H)-Furanone, 4-(4- (methylsulfonyl)phenyl)-3-phenyl- [CAS]	162011-90-7	US 5474995	Analgesic, NSAID
R fecoxib		162011-90-7		
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5- dichloro-4-pyridinyl)-4-(difluoromethoxy)- [CAS]	162401-32-3	WO 9501338	COPD treatment
rokitamycin	Leucomycin V, 4B-butanolate 3B- propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic
Rokitamycin		74014-51-0		
Rollipram		61413-54-5		
Rolltetracyclin		751-97-3		
R muritide		78113-36-7		
Ronifibrate		42597-57-9		
Ropinrole		91374-21-9		
ropinrole hydrochloride	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]- 1,3-dihydro-, monohydrochloride- [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian
ropinrole, GEOMATRIX				Formulation, oral, other
ropivacaine	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]- 1,3-dihydro-, monohydrochloride- [CAS]	91374-20-8 91374-21-9		
R pivacaine	2-Piperidinecarboxamide, N-(2,6- dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-95-4 98717-15-8	EP 239710	Anaesthetic, local
R quinimex		84057-95-4		
rosaprostol	Cyclopentanepentanoic acid, 2-hexyl-5- hydroxy- [CAS]	56695-65-9	GB 1523355	Prostaglandin
Rosaprostol		56695-65-9		
R saramicin		35834-26-5		
Ros Bengal		632-68-8		
Rosiglitazone		122320-73-4		

Example of Indication
Muscle spasm, general
Arthritis, osteo
Chronic obstructive pulmonary disease
Infection, general
Parkinson's disease
Parkinson's disease
Anaesthesia

Example of Indication
Diabetes, Type II
Diabetes, Type II
Infection, gonorrhoea
Macular degeneration
Hypertlipidaemia, general
Parkinson's disease
Ulcer, gastric
Thrombosis, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP 33255	Macrolide antibiotic
Roxithromycin		80214-83-1		
RPR-109881A	Benzenepropanoic acid, 8-(((1,1'-dimethylethoxy)carbonyl)amino)-Alpha-hydroxy- (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acebutoxy)-1-(benzoyloxy)-1,3,4,7,8,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4)cyclopropa (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, betaS [CAS]	192573-38-9		Anticancer, other
RPR-130401	4,9-Ethano-3aH-benz[fl]isindole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel-[CAS]	210282-69-2	WO 9829390 US 6316456	Anticancer, other Anticancer, other
R-roscovitine	NV-bis(3-hydroxyphenyl)pyridazine-3,6-diamine		US 6316456	Anticancer, other
RS-0406				Neuroprotective
RSR-13		131179-95-8		
Rubijervin		79-58-3		
rubitecan	1H-Pyran(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other
Rubitecan		91421-42-0		
rubitecan, StrykerPharma	1H-Pyran(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]			Formulation, parenteral, other

Example 1 Indication
Infection, general
Cancer, lung, general
Cancer, general
Cancer, lung, non-small cell
Alzheimer's disease
Cancer, pancreatic
Cancer, general

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
	9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-18,20(19H)-dione, 9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	169939-94-0		Symptomatic antidiabetic
ruboxistaurin		106308-44-5		
Rufinamide				
	7H-Pyridol[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP 165375	Quinolone antibacterial
Rufi xacin		101363-10-4		
	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[[1-(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene], trihydrochloride- [CAS]	156611-76-6	EP 0577957	Antiallergic, non-asthma
rupatadine		153-18-4		
Rutin				
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxymino)acetyl]amino]-3-[[[3-[[[2-aminoethyl]thio]methyl]-4-pyridinyl]thio]-8-oxo-, (8R,7R)- [CAS]	189448-35-9	WO 9713772	Cephalosporin, injectable
RWJ-54428				
	Cleian-12-en-28-oic acid, 27-[[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	189369-54-9	WO 9727314	Cardiovascular
S-0139				
	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7		Cognition enhancer
S-15535				
	1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5		Antithrombotic
S-18986				
	7-chloro-6-sulfamoyl-2-(1H)-quinolinone-3-phosphonic acid			Neuroprotective
S-34730				

Exemplification
Retinopathy, diabetic
Infection, general
Rhinitis, allergic, seasonal
Infection, beta-lactamase-resistant
Ischaemia, cerebral
Cognitive disorder, general
Thrombosis, general
Unspecified

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
S-3578	7B-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxy/iminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-methyl-3-cephem-4-carboxylate monosulfate			Cephalosporin, Injectable
S-36496	2-(N-(4-(4-Chlorophenylsulfonylamino)butyl)-N-(3-((4-isopropylthiazol-2-yl)methoxy)benzyl)sulfamoyl)benzoic acid			Antisthma
S-36527	2-(N-(4-(4-Chlorophenylsulfonylamino)butyl)-N-(3-((2-(4-cyclobutylthiazol-2-yl)ethyl)benzyl)sulfamoyl)benzoic acid			Antisthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiofen-3-ylcarboxamido)-6,8-dimethylbicyclo[3.1.1]hept-3yl]-5(Z)-heptanoic acid			Antiallergic, non-asthma
S-8510	Imidazo[4,5-d]pyranol(4,3-b)pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) (CAS)	151466-23-8	EP 556008	Cognition enhancer
S-8921	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester (CAS)	151165-96-7	WO 9308155	Hypolipaeamic/Antiatherosclerosis
Sabcom lin		156912-53-5		
Sabeluzole		104383-17-7		
S-Ad n sylmethi nine		29908-03-0		
safinamide	(S)-(+)-2-[4-(3-fluorobenzoyloxy)benzylamino]propanamide methansulfonate	133865-89-1	AU 711309	Antiepileptic
Salacetamide		487-48-9		
Salaz sulfadimidine		8/4/2315		

Example f Indication
Infection, general
Asthma
Asthma
Allergy, general
Alzheimer's disease
Hypercholesterolaemia
Epilepsy, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
salbutamol, Aerobose	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, topical
salbutamol, Alza	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, modified-release, other
salbutamol, Clickhaler	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, dry powder
salbutamol, Easi-Breathe	Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, solution
salbutamol, Easyhaler	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, dry powder
salbutamol, HFA aerosol, 3M	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, topical
salbutamol, Premaire	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, solution
salbutamol, Pulvinal	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9	EP 451745	Formulation, inhalable, dry powder
salbutamol, Turbutaler	1,3-Benzenedimethanol, Alpha-1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy- [CAS]	18559-94-9		Formulation, inhalable, topical
Salicln		138-52-3		
Salicyl Alc hol		90-01-7		
Salicylanilide		65-45-2		
Salicylamide O-Acetic Acid		25395-22-6		
Salicylanilide		87-17-2		
Salicylic Acid		69-72-7		
Salicylsulfuric Acid		89-45-2		
Salinazid		495-84-1		
Salmeterol		89365-50-4		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
salmeterol xinafoate	1,3-Benzenedimethanol, 4-hydroxy- α -[[(6-(4-phenylbutoxy)hexylamino)methyl]-(+)-1-hydroxy-2-naphthalenecarboxylate (salt)]- [CAS]	89365-50-4 94749-08-3	WO 9006775	Asthma
Salsalat		552-94-3		
Salverine		6376-26-7		
Samarium ¹⁵³ Sm		154427-83-5		
L. xidr nam				
sampatriat	L-Tyrosine, N2-(methylsulfonyl)-L-tyr-1-[(2S)-3-amino-2-carboxypropyl]cyclopentanecarboxyl- [CAS]	129981-36-8	EP 358398	Antihypertensive, renin system
Sampatriat		129981-36-8		
Sancyclin		808-26-4		
Saproconazol		110588-57-3		
Sapropterin		62989-33-7		
sapropterin hydrochloride	4(1H)-Pteridinone, 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-, dihydrochloride, [6R-[6R'(1R',2S'Y)]]- [CAS]	69058-38-8	EP 191335	Antidepressant
	Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[2(1R'(R'),2S'1,3A)phn,4aB,8aB]]- [CAS]	12779-20-8	EP 432695	Antiviral, anti-HIV
Sagunavir		12779-20-8		
Sagunavir				
Sagunavir Mesylate				

Example of Indication
Ashtma
Hypertension, general
Hyperphenylalaninaemia
Infection, HIV/AIDS

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
saquinavir, soft gel	Butanediamide, N1-[3-[3-[(1,1'-dimethyl[ethyl]amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-[3S-[2',1',1'(R'),2S',3,4alpha,4aa,8aa]] [CAS]	127729-20-8		Formulation, oral, other
Saralasin		34273-10-4		
saredurant	Benzamide, N4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl-N-methyl-, (S)- [CAS]	142001-63-6	EP 474561	Antiasthma
sertozan hydrochloride	3-Pyridinemethanamine, N-((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)-5-(4-fluorophenyl)- [CAS]	177875-08-5		Antiparkinsonian
serpogrelate	Butanedioic acid, mono[2-(dimethylamino)-1-[(2-[2-(3-methoxyphenyl)ethyl]phenoxymethyl)ethyl]ester] [CAS]	125926-17-2	EP 398326	Antithrombotic
Satigrel	Platinum, bis(aceto-O)amminedichloro(cyclohexanamine)-, (OC-6-43)- [CAS]	111753-73-2		
satraplatin		129580-63-6	EP 328274	Anticancer, alkylating
Satumomab		144058-40-2		
SB-237376	N4-[3-[(2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide, HCl			Antiarhythmic
SB-238039	[5-(2-phenylamino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole			Anticancer, other
SB-277011	trans-N4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl-4-quinolinecarboxamide			Neuroleptic
Scarlet Red		85-83-6		

Exemplar	Indication
	Infection, HIV/AIDS
	Asthma
	Parkinson's disease
	Cancer, prostate
	Fibrillation, atrial
	Cancer, general
	Schizophrenia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-(2H)-pyridinyl]-1-hydroxyethyl]- (CAS)	217863-18-3	EP 618204	Cardio stimulant
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-S-yl]-N,N-dimethyl)-ethanamine			Immunosuppressant
Sch-57790	1-Piperazineacetoneitrile, 4-cyclohexyl-alpha-[4-(S)-(4-methoxyphenyl)sulfinylphenyl]- (CAS)	221660-80-6		Cognition enhancer
Sch-68390	7H-Pyrazolo[4,3-e][1,2,4]triazole[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- (CAS)	174648-45-4		Antiparkinsonian
Scellar nin		465-22-5		
Sc P lamine		51-34-3		
Sc polamine N-Oxide		97-75-6		
scopolamine, Alza	Benzenecacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl ester, [7(S)-(1Alpha,28,48,5Alpha,78)]- (CAS)	51-34-3	US 4282003	Formulation, transdermal, other
SCS technology			US 6046188	Antasthma
secalcitol, Teva	8,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol, (3S,5Z,7E,24R)- (CAS)	55721-11-4	EP 301167	Osteoporosis treatment
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- (CAS)	3366-95-8	FR M3270	Protozoacide
Secnidazole		3366-95-8		
S c barbital S dium		309-43-3		
selegiline	Benzeneeethanamine, N,Alpha-dimethyl-N-2-propenyl-, (R)- (CAS)	14611-51-9	GB 1153578	Antiparkinsonian
Selegilin		14611-51-9		
Selegiline Hydrochloride				
selegiline transdermal, Somers	Benzeneeethanamine, N,Alpha-dimethyl-N-2-propenyl-, (R)- (CAS)			Formulation, transdermal, patch

Exemplification
Heart failure
Inflammation, general
Alzheimer's disease
Parkinson's disease
Nausea and vomiting, general
Unspecified
Osteodystrophy
Infection, trichomoniasis
Depression, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
selegiline, Zydus	Benzene ethanamine, NAlpha-dimethyl-N-2-propenyl-, (R)- [CAS]	14611-51-9		Formulation, oral, orally-disintegrating
Sel n methionine		1464-42-2		
Semaltide		101526-83-4		
S m tiadil		116476-13-2		
	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1R-(1Alpha(1R',2E,4E),3aB,4E(1R',3S',5Z),7aAlpha))- [CAS]	134404-52-7	WO 9100855	Anticancer, other
Seocalciol		103926-64-3		
Seplm stat				
seratrocast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+)- [CAS]	103187-07-1 112665-43-7	EP 232089	Antiasthma
S rair dast		112665-43-7		
seraconazole	1H-Imidazole, 1-[2-((7-chlorobenzob[b]thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl]- [CAS]	99592-32-2	EP 151477	Antifungal
S raconaz l		99592-32-2		
sertindole	2-Imidazolidinone, 1-[2-(4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinylethyl)- [CAS]	106516-24-9	EP 392959	Neuroleptic
Sertindole		106516-24-9		
sertraline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	79559-97-0 79617-96-2 79617-97-3	EP 30081	Antidepressant
Sertraline		79617-96-2		
Setastin		64294-95-7		
S velam r		52757-95-6		
sevelamer hydrochloride	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US 5496545	Urological
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	28523-86-6	DE 1954268	Anaesthetic, Inhalation
Sevofluran		28523-86-6		

Exempl of Indication
Parkinson's disease
Cancer, liver
Asthma
Infection, dermatological
Schizophrenia
Depression, general
Renal failure
Anaesthesia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifluoro-2-benzothiazoyl)methyl)- [CAS]	143162-65-6		Symptomatic antidiabetic
sibutramine	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)- [CAS]	106850-56-0 84485-00-7	GB 2098602	Anorectic/Antiobesity
Sibutramin	4aS-(4aAlpha,6aAlpha,11bAlpha,13aR,13bAlpha)-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzof[4,3-c]pyridine-11-ol	106850-56-0		
siccantin		22733-60-4	JP 37003548	Antifungal
Siccantin		22733-60-4		
Sildenafil		139755-83-2		
Sildenafil	Piperazine, 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0	WO 9428902	Male sexual dysfunction
sildenafil citrate				
sildenafil	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-((2R)-2-((2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl) [CAS]	160970-54-7	EP 600675	Urological
Sliv r Lactat		128-00-7		
Sliv r Picrat		146-84-9		
silver sulfadiazine	N'-2-pyrimidinylsulfanilamide monosilver salt	22199-08-2 68-35-9		Anti-infective, other
Sim trid		154-82-5		
Simfibrat		14929-11-4		
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-(1Alpha,3Alpha,7B,8B(2S*,4S*),8aB)]-[CAS]	79902-63-9	US 4444784	Hypolipaeemic/Antiatherosclerosis

Example of Indication
Neuropathy, diabetic
Obesity
Impotence
Dysuria
Infection, general
Hyperlipidaemia, general

API Generic Nam	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Simvastatin		79902-63-9		
Sinacalide		25126-32-3		
Sintr pium Br mide		79467-19-9		
Sis mcln		32385-11-8		
Sitafloxacin		127254-12-0		
	3-Quinolonecarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-[1'Alpha(S'),2'Alpha]], hydrate	127254-12-0	EP 341493	Quinolone antibacterial
sitafloxacin hydrate		127254-12-0		
	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolyl)- [CAS]	5330-29-0		Protozoicide
sitamaquine		57695-04-2		
	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(4,5-(methylenedioxy)-o-tolyl)acetyl]-3-thiophenesulfonamide	184036-34-8	US 5464853	Antihypertensive, other
sitaxentan sodium		127373-66-4		
Siv I stat		127373-66-4		
	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropanoyl)phenyl]sulfonyl]amino]benzoyl] [CAS]	127373-66-4	EP 347168	Respiratory
sivlesat sodium hydrate		127373-66-4		
	Butanamide, 2-[[[4-(4-fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl]-3-methyl-, (2S)- [CAS]	190274-53-4	EP 771565	Ophthalmological
SJA-6017		190274-53-4		
	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbamoyl-2,9-dihydro-1H-pyridol[3,4-b]indole-1-one			
SL-65-1498			EP 607076	Analgetic
	(3S,2'R)-3-[1-[2-(Ethoxycarbonyl)-4-phenyl-butyl]-cyclopentan-1-carbonylamino]-2,3,4,5-tetra-hydro-2-oxo-1H-benzapir-1-acetic acid			Antihypertensive, diuretic
SLV-306				
	2[(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride			
SLV-308		269718-83-4		Antiparkinsonian

Example 1 Indication
Dwarfism
Pain, cancer
Angina, general
Cancer, colorectal
Anxiety, general
Asthma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
S b r i	L-valinamide, N,N-dimethyl-L-valyl-N-(2-methoxy-4-[2-(1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl)-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl)-N-methyl-12S-[11R*(R*),2S],2R*(1S*,2S*))]-[CAS]	149606-27-9	WO 9303054	Anticancer, other
		498-71-5		
sobuzoxane	Carbonic acid, 1,2-ethanediybis[(2,6-dioxo-4,1-piperazinediyl)methylene]bis[2-methylpropyl] ester [CAS]	98631-95-9	EP 140327	Anticancer, other
Sobuzoxane		98631-95-9		
Sodium Arsanilate		127-85-5		
Sodium Arspenamine		1936-28-3		
Sodium Chloride				
Sodium Dibunat		14992-59-7		
Sodium Folate		6484-89-5		
Sodium Formaldehydesulfoxylat		149-44-0		
Sodium Glycerophosphate		1334-74-3		
Sodium Hyaluronate				
Sodium Iodomethamate		519-26-6		
Sodium Nitrite		7632-00-0		
Sodium Nitr prusside		14402-89-2		
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant
Sodium Oxybate				
Sodium Phenolsulfonate		1300-51-2		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sodium phenylbutyrate, Ucytyd	Butyric acid, 4-phenyl-, sodium salt- [CAS]	1716-12-7		Formulation, other
sodium phosphate, InKine	Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous		US 6162464	Formulation, oral, other
sodium praslerone sulfate, Akzo	3β-hydroxy-5-androstien-17-one(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical
Sodium Propionate		137-40-6		
sodium salicylate, Amaryn	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7		Formulation, oral, solubility-enhanced
Sodium Ttrad cycl Sulfate		139-88-8		
sotalone	Acetic acid, [5-[(3-methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxyl]- [CAS]	64506-49-6	GB 1523241	Antitumor
Sotalone		64506-49-6		
S lasulf ne		133-65-3		
	Butanedioic acid compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2-(1H)-isooquinolinecarboxylate (1:1) [CAS]	242478-98-2		Urological
solfenacin succinate	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE 883352	Hypolipaeimic/Antiatherosclerosis
Sorbinic acid		50-70-4		
S rbitol		77181-69-2		
Sorivudine				
sotalol	Methanesulfonamide, N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)- [CAS]	3930-20-9 959-24-0		Antiarhythmic
S tal i		3930-20-9		
Sotalol Hydrochloride				
Sotalol Hydrochloride				
Soter nol		13642-52-9		
Soziodolic Acid		554-71-2		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sparglumatic acid, ophthalmol	L-Glutamic acid, N-(N'-acetyl-L-Alpha-aspartyl)- [CAS]	3106-85-2 80619-64-3		Formulation, mucosal, topical
sparfloxacin	3-Quinolincarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8 110871-86-8	EP 221463	Quinolone antibacterial
Sparfloxacine		90-39-1		
SPA-S-843	Candicin D, 18-decarboxy-40-demethyl-3,7-dideoxo-N3'-((dimethylamino)acetyl)-18-(((2-(dimethylamino)ethyl)amino)carbonyl)-3,7-dihydroxy-N47-methyl-5-oxo cyclic 15,19-hemiacetal, comp with L-ascorbic acid (1:2) [CAS]	202748-83-2	US 5298495	Antifungal
Spasim lvt I	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl)- (2R-cis)-	25333-96-4		
SPD-754		160707-69-7	US 6228660	Antiviral, anti-HIV
Sp cllnomycin		1695-77-8		
SPL-339	4-[3-(4-Oxo-4,5,6,7-tetrahydroindol-4-yl)propionylamino]benzoic acid ethyl ester			Cognition enhancer
Spip ron		749-02-0		
splapril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7R*(R*),8R*]]- [CAS]	83647-97-6	EP 50800	Antihypertensive, renin system
Spirapril		83647-97-6		
Spir germanium		41992-23-8		
Spironolactone		52-01-7		
spironolactone, oral, Searle	17Alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7Alpha-mercapto-3-oxo-, Gamma-lactone, acetate [CAS]	52-01-7		Formulation, oral, other

Example 1 Indication
Conjunctivitis
Infection, respiratory tract, general
Infection, fungal, general
Infection, HIV/AIDS
Alzheimer's disease
Hypertension, general
Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
spironolactone, topical, Searle	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, Gamma-lactone, (7Alpha, 17Alpha)- [CAS]	52-01-7	EP 124147	Formulation, dermal, topical
SR-121463	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2H)-yl]sulfonyl]-3-methoxy- [CAS]	185913-78-4	WO 9715556	Cardio stimulant
SR-144190	Morpholine, 4-benzoyl-2-(3,4-difluorophenyl)-2-[2-(4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]- (2R)- [CAS]	201152-86-5	WO 9623787	Anxiolytic
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]	221871-61-0	WO 9915525	Anorectic/Anitobesity
SR-271425	N-[1-(2-(diethylamino)ethylamino)-7-methoxy-9-oxo-9H-thioxanthen-4-yl]methylformamide			Anticancer, alkylating
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]- [CAS]	136381-85-6	EP 432040	Anticancer, other
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376850	Anticancer, other
SR-58611	Acetic acid, [[(7S)-7-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546	GI inflammatory/bowel disorders
SS732			US 5385900	Formulation, mucosal, topical
SS-750	(R)-(-)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol		US 6083968	Antifungal
B-aletthine	Propanamide, N,N'[[difluoro-2,1'-ethanediyl]bis(3-amino)- [CAS]	646-08-2		Anticancer, immunological

Example of Indication
Acne
Heart failure
Anxiety, general
Obesity
Cancer, general
Cancer, pancreatic
Cancer, myeloma
Irritable bowel syndrome
Infection, ocular
Infection, fungal, general
Cancer, myeloma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
	(2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide		WO 0155130	Antidepressant
SSR-149415	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazinol[4,5-g]indol-1-yl)-N,N-dimethylacetamide			Neuroprotective
SSR-180575	(3-Eox)-8-benzoyl-N-[[[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl		US 6221879	Neuroleptic
SSR-181507	(5aS,8S,10aR)-5a,6,9,10-tetrahydro,7H,11H-8,10a-methanopyrido[2,3:5,6]pyranol[2,3-d]azepine			Dependence treatment
SSR-591813	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-39-2		Formulation, transdermal, other
SST-101	(-)-(-R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol		US 5147886	Antifungal
SSY-728				
ST-200	1-Propanaminium, 2-(acetyl(oxyl)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	DE 3015635 WO 9711947	Cognition enhancer Antiviral, other
staachylin				
		636-47-5		
Stallimycin			US 6350736	Antiviral, anti-HIV
Stampidine				
		15578-26-4		
Stannous Pyrophosphate				
	(OC-6-13)-Dihydrogen dichloro[7,12-dielethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropionate(4-)-N21,N22,N23,N24]stannate(2-)			
stannosporfin		106344-20-1		Hepatoprotective

Exempl f Indication
Depression, general
Unspecified
Schizophrenia
Addiction, nicotine
Angina, general
Infection, fungal, general
Dementia, senile, general
Infection, influenza virus
Infection, HIV/AIDS
Hypertlirubinaemia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Stan 1 n		521-18-6		
Stan z i l		10418-03-8 (2'H form); 302-96-5 (1'H form)		
Staph aureus ther, PhageTech			US 6376652	Genomics-based drug discovery
STAT4 inhibitors, Tularik			WO 9629341	Immunosuppressant
stavudine	Thymidine, 2',3'-dideoxy-3'-deoxy- [CAS]	3056-17-5	EP 501511	Antiviral, anti-HIV
Stavudine		3056-17-5		
stavudine, once-daily, BMS	Thymidine, 2',3'-dideoxy-3'-deoxy- [CAS]	3056-17-5		Formulation, modified-release, <=24hr
Stenb l n		5197-58-0		
stipronin	Glycine, N-(1-oxo-2-[(2-thienylcarbonyl)thio]propyl)- [CAS]	72324-18-6	US 4242354	Antitussive
Stepr nin		72324-18-6		
Stib captat		27279-76-1		
Stiboph n		15489-16-4		
Stilbamidine		122-06-5		
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4		Antiepileptic
Streptod mase		37340-82-2		
Str pt mycin		57-92-1		
Streptonicozid		5667-71-0		
Streptoniglin		3930-19-6		
Str ptizocin		18883-66-4		
strontium ranelate	3-Thiophenecetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2)- [CAS]	135459-87-9	EP 415850	Osteoporosis treatment
strontium-89 chloride	Strontium chloride (89SrCl2) [CAS]	38270-90-5		Analgesic, other
Succlimer		304-55-2		
Succinimide		123-56-8		
Succlnylch line Bromide		55-94-7		

Example of Indication
Infection, MRSA
Unspecified
Infection, HIV/AIDS
Infection, HIV/AIDS
Cough
Epilepsy, general
Osteoporosis
Pain, cancer

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Succinylcholine Chlorid		71-27-2		
Succinylsulfathiazole		116-43-8		
Succsulfon		5934-14-5		
Suclofenid		30279-49-3		
sucraltate	Alumilium, hexadeca- <i>r</i> -hydroxytetraacosahydroxy(μ 8-(1,3,4,6-tetra-O-sulfo- β -D-fructofuranosyl)-Alpha-D-glucopyranoside tetrakis(hydrogen sulfo)(8-))hexadeca- [CAS]	54182-58-0	JP 58208233	Antilucer
Sucralfat		54182-58-0		
	Alumilium, hexadeca- <i>r</i> -hydroxytetraacosahydroxy(μ 8-(1,3,4,6-tetra-O-sulfo- β -D-fructofuranosyl)-Alpha-D-glucopyranoside tetrakis(sulfo-kappaO))(8-))hexadeca- [CAS]	54182-58-0		Formulation, oral, other
sucraltate, APR				
	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US 3998634	Analgesic, other
sufentanil		56030-54-7		
Sufentanil	Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7		Formulation, implant
sufentanil, S BioSystems				
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68373-14-8	GB 2000138	Antibiotic, other
sulbactam		68373-14-8		
Sulbactam		68373-14-8		
sulbactam + ampicillin		117060-71-6	US 4234579	Antibiotic, other
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenylsulfonamido]amino], (2S-[2Alpha,5Alpha,6S(S')])-[CAS]	28002-18-8		
sulbenicillin		41744-40-5	GB 1289358	Penicillin, injectable
Sulbenicillin		41744-40-5		
Sulbentine		350-12-9		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
subbutamine	Propanoic acid, 2-methyl-, dithiois[3-1'-[[[4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene]-3,1'-propanediyl] ester [CAS]	3286-46-2 67-16-3		Neurological
sulfonazole	11H-Imidazole, 1-[2-[[[4-chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]- (±)- [CAS]	61318-90-9 61318-91-0	US 4055652	Antifungal
Sulc naz le		61318-90-9		
Sules mab		167747-19-5		
Sulfabenzamide		127-71-9		
Sulfacetamid		144-80-9		
Sulfachlorpyridazine		80-32-0		
Sulfachrys idline		485-41-6		
Sulfacytin		17784-12-2		
Sulfadiazine		68-35-9		
Sulfadiazolid		115-68-4		
Sulfadlm th xine		122-11-2		
Sulfadoxine		2447-57-6		
Sulta thidol		94-19-9		
Sulfaguanidin		57-67-0		
Sulfaguanole		27031-08-9		
Sulfalen		152-47-6		
Sulfaloxic Acid		14376-16-0		
Sulfam razine		127-79-7		
Sulfam ter		651-06-9		
Sulfam thazin		57-68-1		
Sulfamethiz le		144-82-1		
Sulfameth midline		3772-76-7		
Sulfamethoxazole		723-46-6		
Sulfamethoxypyridazine		80-35-3		
Sulfametr l		32909-92-5		
Sulfamidochrysoidine		103-12-8		
Sulfamoxole		729-99-7		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Sulfanilamide		63-74-1		
Sulfanilic Acid		121-57-3		
Sulfanilylurea		547-44-4		
Sulfap rine		599-88-2		
Sulfaph nazol		526-08-9		
Sulfaproxylin		116-42-7		
Sulfapyrazin		116-44-9		
Sulfapyridin		144-83-2		
Sulfarsid		1134-98-1		
Sulfarsphenamine		618-82-6		
Sulfasalazin		599-79-1		
sulfasalazine, Pharmacia	Benzolic acid, 2-hydroxy-5-[4-(2-pyridinylamino)sulfonylphenyl]azol- [CAS]	599-79-1		Formulation, oral, enteric-coated
Sulfas miz le		632-00-8		
Sulfasymazin		1984-94-7		
Sulfathiazol		72-14-0		
Sulfathiourea		515-49-1		
Sulfinalol		66264-77-5		
Sulfipyraz ne		57-96-5		
Sulfiram		95-05-6		
Sulfis midline		515-64-0		
Sulfis xazol		127-69-5		
Sulfobrom phthalein		71-67-0		
Sodium				
Sulfonethylmethane		76-20-0		
Sulfonlazid		3691-81-4		
Sulfonmethan		115-24-2		
Sulf ridazin		14759-06-9		
Sulfox ne Sodium		144-75-2		
sulindac	cis-5-fluoro-2-methyl-1-[(p-methylsulfinyl)benzylidene]indene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory
Sulindac		38194-50-2		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Sulisatin		54935-03-4		
Sulisobenzon		4065-45-6		
Sulmarin		29334-07-4		
Sulmaz I		73384-60-8		
Sulcildil		54063-56-8		
Sulphan Blu		129-17-9		
Sulpiride		15676-16-1		
sulpiride, Delegrange	Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrroldinyl)methyl)-2-methoxy-[CAS]	15676-16-1		Alimentary/Metabolic, other
subprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1Alpha(Z),28(E,3R),3Alpha]]-[CAS]	60325-46-4	US	Prostaglandin
Sulprostone		60325-46-4		
	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyloxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R,5S),5.alpha.,6.beta.(S')))-[CAS]	117060-71-6 76497-13-7	GB	Penicillin, oral
sulamicillin		76497-13-7		
Sulthiame		61-56-3		
sulopride	Benzamide, N-((1-ethyl-2-pyrroldinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR	Neuroleptic
Sult pride		53583-79-2		
Sult silic Acid		57775-26-5		
sumanrole	4H-imidazo[4,5,1-f]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-butenedioate (1:1) [CAS]	179386-44-8	WO	Antiparkinsonian
Sumatriptan		103628-46-2		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
sumatriptan succinate	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-48-2 103628-48-4	EP 147107	Antimigraine
sumatriptan, BEMA	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]			Formulation, modified-release, other
sumatriptan, Intraject	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-48-2 103628-48-4		Formulation, parenteral, needle-free
sumatriptan, WOVTAB	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-48-2 103628-48-4		Formulation, oral, orally-disintegrating
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxy)-3-(4-(4-fluorobenzyl)phenyl)piperazin-1-yl]propan-2(s)-ol dimethanesulfonate			Neuroprotective
suplatast tosylate	Sulfonium, [3-[14-(3-ethoxy-2-hydroxypropoxy)phenylamino]-3-oxopropyl]dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1) [CAS]	84055-76-2	JP 59167564	Asthma
Suplatast T sylate		94055-76-2		
Suprofen		40828-46-4		
Suramin Sodium		129-46-4		
surfactant TA	Betactant [CAS]	108778-82-1	WO 9117766	Lung Surfactant
Suriclone		53813-83-5		
Suxibuzon		27470-51-5		
SYM-1010			US 5630998	Antiepileptic
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3		Analgesic, other
	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide			Neuroprotective
SYM-2207				
Symcl s n		87-90-1		
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-tiazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline 3-carboxylic acid			Quinolone antibacterial

Exempl of Indication
Migraine
Migraine
Migraine
Migraine
Infarction, cerebral
Asthma
Respiratory distress syndrome, general
Epilepsy, general
Pain, general
Ischaemia, cerebral
Infection, peritoneum

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Syn-2180	1-Azetidinanesulfonic acid, 3-[[[(2E)-1-(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]-2-thienylacetyl]amino]-2-methyl-4-oxo, (2S,3S)- [CAS]	214863-75-4	WO 9847895	Antibacterial, other
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)- [CAS]	210562-98-4	US 6153616	Antifungal
Synephrin		94-07-5		
Syr sling pin		84-36-6		
T-1095	1-Propanone, 3-(5-benzotriazanyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-8-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]	209746-59-8	EP 850948	Antidiabetic
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminyl-L-lysyl-L-Alpha-glutamyl-L-glutaminyl-L-tyrosyl-L-leucyl-L-Alpha-glutamyl-L-glutaminyl-L-alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl-[CAS]	251562-00-2	WO 9939615	Antiviral, anti-HIV
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid			Quinolone antibacterial
T-588	Benzo(b)thiophene-5-methanol, Alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP 565965	Cognition enhancer

Example of Indication
Infection, general
Infection, Aspergillus
Diabetes, general
Infection, HIV/AIDS
Infection, dermatological
Alzheimer's disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
T-67	Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0	US 5180951	Anticancer, other Cognition enhancer
T-92	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*, R*)]- [CAS]	137888-11-0	US 4579854	Asthma
TA-2005	Other 2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*, R*)]- [CAS]			Formulation, inhalable, dry powder
TA-2005, dry powder, inhaler	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*, R*)]- [CAS]		WO 189480	Formulation, inhalable, solution
TA-2005, HFA Modulife, Chiesi				
TA-993	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-(+)-, (2Z)-2-butenedioate [CAS]	122024-98-0	JP 01045376	Antithrombotic
	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenepropanamide	170851-70-4 198079-69-5		Releasing hormones
tabimorelin				
taclitotol	9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,38,5Z,7E,24R)- [CAS]	57333-96-7 93129-94-3	EP 129003	Antipsoriasis
Tacalcitol		57333-96-7	WO 9630049	Dependence treatment
TA-CD				
	Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-64-2 1684-40-8	DE 3613571	Anticancer, other
tacredinaline				
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	321-64-2	EP 332147	Cognition enhancer
Tacr'in		321-64-2		
Tacr ilmus		104987-11-3		

Example of Indication
Cancer, liver
Alzheimer's disease
Asthma
Asthma
Asthma
Peripheral vascular disease
Growth hormone deficiency
Keratosis
Addiction, cocaine
Cancer, pancreatic
Alzheimer's disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
	Pyrazino(1',2':1,6)pyrido(3,4-b)indole 1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]	171596-29-5	US 6143746	Male sexual dysfunction
tadalafil	1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- [CAS]	106635-80-7 106635-81-8 80085-55-0	US 4617394	Antimalarial
tatenoguin		106635-80-7		
taliposide		179067-42-6	WO 9612727	Anticancer, other
TAK-375	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide			Hypnotic/Sedative
TAK-427	2-[6-[[3-[4-(Diphenylmethoxy)-piperidin-1-ylidene]-2-benzimidazol-2-yl]-2-methylpropionic acid dihydrate			Antipruritic/Inflam, allergic
	(E)-4-[4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyl]oxy]mimo)-4-phenylbutyric acid			Antidiabetic
TAK-559		9001-19-8		
Taka-Diastase				
talampanel	7H-1,3-Dioxol[4,5-h][2,3]benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)-[CAS]	161832-65-1	US 5639751	Antiepileptic
Talampanel		161832-65-1		
Talampicillin		47747-56-8		
talaporfin sodium	N-[[[(2S,3S)-18-Carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl]-L-aspartic acid	220201-34-3		Radio/chemosensitizer
Talastin		16188-61-7		
Talbutal		115-44-6		
Talin 11		57460-41-0		
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4 36086-79-1	DE 3503963	Antiparkinsonian

Example f Indication
Impotence
Infection, malaria
Cancer, general
Insomnia
Eczema, atopic
Diabetes, general
Epilepsy, general
Cancer, lung, general
Schizophrenia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Talipex le	4-Quinolincarboxamide, 3-hydroxy-2-phenyl-N-[1-(S)-1-phenylpropyl]- [CAS]	101626-70-4		
Tamrelant	3-Pyridinecarboxylic acid, 2-[13-(trifluoromethyl)phenyl]amino-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester [CAS]	174636-32-9	WO 9532948	GI inflammatory/bowel disorders
Tamiflumate	66898-62-2	BE 858864		Anti-inflammatory
Talitrilin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	103300-74-9	JP 61033197	Neurological
Taltir lin	103300-74-9			
Tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1	US 4536516	Anticancer, hormonal
Tam xifen	10540-29-1			
Tamoxifen, Douglas	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Formulation, other
Tamoxifen, liposomal, BTG	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Formulation, optimized, liposomes
Tamsulosin	Benzenesulfonamide, 5-[2-[(2-(ethoxyphenoxy)ethyl)amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders
Tamsulosin	106133-20-4			
Tamsulosin, OCAS	Benzenesulfonamide, 5-[2-[(2-(ethoxyphenoxy)ethyl)amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0		Formulation, modified-release, other
Tamsulosin, immediate-release	4,7-Methano-1H-isindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3aAlpha,4b,7b,7aAlpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	106133-20-4		Formulation, oral, orally-disintegrating
Tandospirone	8760-53-0	EP 82402		Anxiolytic
Tandospirone	8760-53-0			
Tandospirone	8760-53-0			

Examp^l of Indication
Irritable bowel syndrome
Inflammation, ocular
Dyskinesia, general
Cancer, breast
Cancer, breast
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Benign prostatic hyperplasia
Anxiety, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tamoxifen		9010-29-1		
Tamoxifen		108945-35-3		
Tamoxifen	3-Quinolincarboxamide, N-[2-[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isochinolyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl- (CAS)	208673-63-4	WO	Radio/chemosensitizer
Tamoxifen	6-[2-(Dimethyl-amino)ethyl]amino-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride			
TAS-103		174634-09-4	WO	Anticancer, other
Tasosartan		145733-36-4		
Taur ch ilic Acid		81-24-3		
Taur lidine		19388-87-5		
Tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester (CAS)	82989-25-1	US	Antiasthma
Tazan last		82989-25-1		
Tazarotene	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothio)pyran-6-yl]ethyl-, ethyl ester (CAS)	118292-40-3	EP	Antipsoriasis
Tazar tene		118292-40-3		
Taz baciam		89786-04-9		
Tazobactam + piperacillin			JP	Antibiotic, other
TBC-3711		374680-51-0		Cardiovascular
TCH-346	N-Methyl-N-propargyl-10-aminomethyl-dibenzo[b,f]oxepin			Neuroprotective
Tebipenem	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethyl-1H-imidazole (CAS)	82200-24-6		Beta-lactam antibiotic
Tecadenoson	Adenosine, N'[(3R)-tetrahydro-3-furanyl]- (CAS)	204512-90-3	WO	Antiarrhythmic
Tecastemizole	1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (CAS)	75970-99-9	US	Antiallergic, non-asthma
Technetium ^{99m} Tc		121281-41-2		
Bicisat				

Examp	Indication
	Cancer, lung, non-small cell
	Cancer, lung, non-small cell
	Psoriasis
	Infection, general
	Heart failure
	Amyotrophic lateral sclerosis
	Infection, streptococcal
	Tachycardia, supraventricular
	Rhinitis, allergic, seasonal

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Technetium ^{99m} Tc		125224-05-7;		
Meritaid		104348-91-6		
T chnelium ^{99m} Tc		109581-73-9		
Sestamibi		104716-22-5		
Technetium ^{99m} Tc				
Teboroxime		5/4/4267		
Teclothiazide		5560-78-1		
T cl zan	Spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)- [CAS]			
Tedisamil		90961-53-8	EP 102833	Antiarrhythmic
Tedisamil		90961-53-8		
T fluorane		124-72-1		
Tegafur	2,4-(1H,3H)-Pyrimidinone, 5-fluoro-1-(tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB 1168391	Anticancer, antimetabolite
Tegafur		17902-23-7		
Tegafur + uracil, Taiho	2,4-(1H,3H)-Pyrimidinone, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4-(1H,3H)-pyrimidinone- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite
Tegaserod	Hydrazinecarboximidamide, 2-((5-methoxy-1H-indol-3-yl)methylene)-N-penyl-, (Z)-2-butenedioate (1:1) [CAS]	145158-71-0		
Tegaserod maleate		189188-57-6		GI inflammatory/bowel disorders
Telcoplanin		61036-64-4		
Telbivudine	β-L-2'-deoxythymidine	3424-88-4		Antiviral, other
T lenzepine		80880-90-6		
	3-De((2,6-dideoxy-3-C-methyl-β-O-methyl-Alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))- [CAS]	191114-48-4	EP 680967	Macrolide antibiotic
Telithromycin		191114-48-4		
telmestine	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122948-43-4		COPD treatment

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
telmisartan	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-dimethyl-2-propyl(2,6-bi-1H-benzimidazol-1-yl)methyl)- [CAS]	144701-48-4	EP 502314	Antihypertensive, renin system
Telmisartan		144701-48-4	WO 9941261	Anticancer, other
telomerase inhbs, Chugai				
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative
Temazepam		846-50-4		
temverine hydrochloride hydra	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1'-dimethyl-2-butynyl ester, hydrochloride [CAS]	129927-33-9	GB 2222828	Urological
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[1-(ethoxycarbonyl)-3-phenylpropylamino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2Alpha,6S(R)]]- [CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system
Tem capril		111902-57-9		
T m cillin		66148-78-5		
temopofin	Phenol, 3,3',3''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- [CAS]	122341-38-2	EP 337601	Radio/chemosensitizer
T mopofin		122341-38-2		
temozolomide	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE 3231255	Anticancer, alkylating
Tem zolomide		85622-93-1		
temozolomide, SkeyPharma	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]			Formulation, parenteral, other
tenatoprazole	1H-Imidazo[4,5-b]pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	113712-96-4	US 4806596	Antulcer
Tenecteplase		191588-94-0		
T nidap		120210-48-2		

Example of Indication
Hypertension, general
Cancer, general
Insomnia
Poliaktsuria
Hypertension, general
Cancer, head and neck
Cancer, brain
Cancer, general
Ulcer, gastric

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
teniposide	Furo[3,4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethyl)ene]-8-D-glucopyranosyl]oxy]-, [5R-[5A]phen,5aB,8aAlphen,9a(R*)]- [CAS]	29767-20-2	US 3524844	Anticancer, other
T nilposid		29767-20-2		
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS]	147127-20-6		Antiviral, anti-HIV
Tenofovir		147127-20-6		
	2,4,6,8-tetraoxa-5-phosphanonanediolic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl) bis(1-methylethyl)ester, 5-oxide (R), (E)-2-butenedioate (1:1)			Antiviral, anti-HIV
tenofovir disoproxil fumarate		202138-50-9		
Tenofovir Disoproxil Fumarate				
Tenonitr zol		3810-35-3		
	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]			
tenoxicam		59804-37-4	GB 1518811	Antiarthritic, other
Tenoxicam		59804-37-4		
Tenuaz nic Acid		610-88-8		
	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS]	3796-83-2		Antilucer
tepernone		6809-52-5		
T pr none		6809-52-5		
	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furan)carbonyl]- [CAS]	63074-08-8		
terazosin		63590-64-7	US 4112097	Antihypertensive, adrenergic
T razosin		63590-64-7		
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)- [CAS]	78628-80-5	EP 24587	Antifungal
Terbinafine		91161-71-6		
		91161-71-6		

TABLE IV

Exempl f Indication
Cancer, lymphoma, non-Hodgkin's
Infection, HIV/AIDS
Infection, HIV/AIDS
Hypertension, general
Infection, dermatological

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Terbutaline	1,3-Benzenediol, 5-[2-[(1,1'-dimethylethyl)amino]-1-hydroxyethyl]-[CAS]	23031-25-6		Formulation, mucosal, topical
terbutaline gel, Columbia		23031-25-6		
	Piperazine, 1-[4-[(2-(2,4-dichlorophenyl)-2-(1H-1,2,4-tiazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy]phenyl]-4-(1-methylethyl)-, cis-[CAS]	67915-31-5	US	Antifungal
terconazole		67915-31-5		
Terconazole		67915-31-5		
	1-Piperidinebutanol, Alpha-[4-(1,1'-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-[CAS]	50679-08-8	US	Antiallergic, non-asthma
Terfenadine		50679-08-8		
Tifenadine		50679-08-8		
terguride	Urea, N,N-diethyl-N'-(8alpha)-6-methylergolin-8-yl)-[CAS]	37686-84-3	EP	Antiprolactin
Tergurid		37686-84-3		
Teriprassin		14636-12-5		
Terodiline		15793-40-5		
Terof namat		29098-15-5		
Terpin		80-53-5		
	2-Propanol, 1-[(3,4-dihydro-2H-1'-benzothio[pyran-8-yl]oxy)-3-[(1,1'-dimethylethyl)amino]-, hydrochloride, (+)-[CAS]	33580-30-2 83688-84-0	GB	Antihypertensive, adrenergic
teratolol				
Teratolol		34784-64-0		
tert-Pentyl Alcohol		75-85-4		
	(2S)-2-ethoxy-3-[4-[2-[4-[(methanesulfonyl)oxy]phenyl]ethoxy]phenyl]propanoic acid			Antidiabetic
tesaglitazar				
tesmilene hydrochloride	Ethinamine, N,N-Diethyl-2-(4-(phenylmethyl)phenoxy)- hydrochloride [CAS]	92961-78-7		Radio/chemosensitizer
Testosterone		968-93-4		
Testosterone		58-22-0		
Testosterone				

TABLE IV

Example f indication
Dysmenorrhoea
Vaginitis
Hyperprolactinaemia
Hypertension, general
Diabetes, Type II
Cancer, breast

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
testosterone undecanoate, Sche	androst-4-en-3-one, 17-hydroxy-, (17 β)-[CAS]	5949-44-0		Formulation, other
testosterone, TDS				Formulation, transdermal, systemic
tetrabamate		60763-47-5	DE 2748794	Anxiolytic
T trabarthal		76-23-3		
Tetrabenazine		58-46-8		
T tracaln		136-47-0		
Hydrochl ride				
T trachlor thylene		127-18-4		
tetracine, percutaneous	Benzic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic
Tetracycline		60-54-8		
	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4A)pha,4aAlpha,5aAlpha,6b,12aAlpha)]-[CAS]	60-54-8		Formulation, oral, other
tetracycline, Actisite				
	2-Naphthacene-carboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4A)pha,4aAlpha,5aAlpha,6b,12aAlpha)]-[CAS]	60-54-8		Formulation, other
tetracycline, Procter & Gamble		60-54-8		
T trahydr z line		84-22-0		
Tetradrine		518-34-3		
T trantoin		52094-70-9		
T trazepam		10379-14-3		
Tetrofosmin		127502-06-1		
tetoxoprim	2,4-Pyrimidinamine, 5-[3,5-dimethoxy-4-(2-methoxyethoxy)phenylmethyl]-[CAS]	53808-87-0 74515-38-1	US 3992379	Trimethoprim and analogues
Tetoxoprim		53808-87-0		
Teven 10		4302-95-8		
tezactabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)-[CAS]	130306-02-4	US 5816702	Anticancer, antimetabolite

TABLE IV

Example of Indication
Hormone replacement therapy
Hormone replacement therapy
Addiction, alcohol
Pain, general
Infection, oral
Acne
Infection, general
Cancer, colorectal

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardio stimulant
Thalidomide	1H-Isindole-1,3(2H)-dione, 2-(2,6-dioxo-3-phenylidene)- [CAS]	50-35-1		
thalidomide, Celgene		50-35-1		Dermatological
Thenaldine		86-12-4		
Thenylamine		91-79-2		
Th br mine		83-67-0		
Th fibrat		54504-70-0		
Th phyllin		58-55-9		
theophylline, 3M	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Aliana	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Amarin	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	5967-84-0		Formulation, modified-release, other
theophylline, bioMerieux-Pier	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, other
theophylline, Biovail	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Diftulab	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Eisai	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Elan	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Elan PharmaZome	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, optimized, microparticles
theophylline, Forest	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Gebro	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Key	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other

TABLE IV

Example of Indication
Cedema, general
Infection, dermatological
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Asthma
Bronchitis, chronic
Asthma

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
theophylline, Klinge	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, other
theophylline, KV	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Liquidard	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, <=24hr
theophylline, Mayne	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Mundipharma	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Napp	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Scherer	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other
theophylline, Schering-Plough	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, other
Thiabendazole		148-79-8		
		104-06-3		
Thiacetazone	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4		Cognition enhancer
thiacyserine		467-36-7		
Thalbarbital		59-43-8		
Thiamin		154-87-0		
Thiamin Diphosphate		67-16-3		
Thiamine Disulfide		5581-52-2		
Thiamprin		15318-45-3		
Thiamphenicol		77-27-0		
Thiamylal		5845-26-1		
Thiazesin		58-34-4		
Thiazinamium				
M thylsulfat		54749-86-9		
Thiazolinobutazone		473-30-3		
Thiazosulfone		6028-35-9		
Thib nazonin		1420-55-9		
Thiethylperazine				

TABLE IV

[illegible]

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Thim rfonat Sodium		5964-24-9		
Thimerosal		54-64-8		
Thioarbital		77-32-7		
Thiobutabarbital		2095-57-0		
Thi carbamizin		91-71-4		
Thiocarbarson		120-02-5		
Thi c Ichlicn		2730-71-4		
Thiocres l		26445-03-4		
Thioctic Acid		62-46-4		
Thioglycerol		96-27-5		
Thioguanin		154-42-7		
Thioimreg	L-Thiogrosiny-glyciny-glycine			Anticancer, Immunological
Thiopental Sodium		71-73-8		
Thl pr pazat		84-06-0		
Thl propetazine		316-81-4		
Thl ridazine		50-52-2		
Thioridazine Hydrochloride				
Thiothixene		5591-45-7		
Thiothixene				
Thiothixene				
Thiothixene				
Thiovir	Thiophosphonomoformic acid			Antiviral, anti-HIV
Thiopenamil		82-99-5		
Thiram		137-26-8		
Thonzylamine Hydrochloride		63-56-9		
Thozalin n		655-05-0		
Thr mboplastin		9035-58-9		
Thurtyl Nicotinate		70-19-9		
Thymecicin			US 6245750	Anticancer, other

TABLE IV

[illegible]

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Thym I		89-83-8		
Thymopentin		69558-55-0		
Thymyl N-		578-20-1		
Is amylcarbamate				
Thyropic Acid		51-26-3		
Thyr xine		51-48-9		
Tiadenol		6964-20-1		
tiagabine	3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (R)- [CAS]	115103-54-3	WO 87/00171	Antiepileptic
Tiagabine		115103-54-3		
Tiamenidin		31428-61-2		
tiarephrine	Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methyl(1,2)thiazepin-11-yl)amino], S,S-dioxide [CAS]	72797-41-2	GB 1269551	Antidepressant
Tian ptin		66981-73-5		
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394563	Neuroleptic
Tiapi rid		51012-32-9		
tiaprofenic acid	2-Thiophenacetic acid, 5-benzoyl-Alpha-methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other
Tiaprofenic Acid		33005-95-7		
Tiaramid		32527-55-2		
tiazolurin	4-Thiazolecarboxamide, 2,6-D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite
Tiaz furin		60084-10-8		
Tibezonium Iodide		54663-47-7		
tibolone	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7Alpha, 17Alpha)- [CAS]	5630-53-5	EP 389035	Menopausal disorders
Tibolone		5630-53-5		
Ticarcillin		34787-01-4		
ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53985-35-1 55142-85-3	GB 1554424	Antithrombotic

TABLE IV

Example of Indication
Epilepsy, general
Depression, general
Cancer, leukaemia, chronic myelogenous
Hormone replacement therapy

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ticlopidin		55142-85-3		
Ticrynafen		40180-04-9		
Tiemonium I dide		144-12-7		
tiemonium methylsulfate	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium methylsulfate	6252-92-2		Antispasmodic
tigecycline	2-Naphthacene-9-carboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP 582829	Tetracycline
Tigemonam		102507-71-1		
Tigloidine		495-83-0		
Tilidin		20380-58-9		
Tilisol I		85136-71-6		
timacoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other
tiludronic acid	Phosphonic acid, [[(4-chlorophenyl)thio]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment
Tiludr nlc Acid		89987-06-4		
Timenlin		86482-18-0		Antibiotic, other
timepidium bromide	Piperidinium, 3-(di-2-thienylmethylene)-5-methoxy-1,1-dimethyl-, bromide- [CAS]	35035-05-3	GB 1358446	Antispasmodic
Timepidium Bromide		35035-05-3		
Timip r n		57648-21-2		
Timolol		26839-75-8		
timolol maleate	(-)-1-(1-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)oxy-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB 1253709	Antihypertensive, adrenergic
timolol maleate, Wakamoto	2-Propanol, 1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiazol-3-yl)oxy, (-)-maleate (1:1) (salt) [CAS]	26921-17-5		Formulation, mucosal, topical

TABLE IV

Example t Indication	
Infection, general	
Polyp	
Paget's disease	
Infection, general	
Glaucoma	

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
timolol, antiglaucoma	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy], (S), (Z)-2-butenedicarboxylate (1:1) (salt) [CAS]	26839-75-8 26921-17-5		Antiglaucoma
timolol, ophthalmic	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy], (S)- [CAS]	26839-75-8		Antiglaucoma
timolol, topical, Senju	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy], (S), (Z)-2-butenedicarboxylate (1:1) (salt) [CAS]			Formulation, mucosal, topical
Timonac		444-27-9		
Tin Ethyl Eri purpurin		113471-15-1		
tinazoline	1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral
Tinidazol		19387-91-8		
Tinoridine		24237-54-5		
Ti carlid		910-86-1		
Ti cl marol		22619-35-8		
ticconazole	1H-imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- [CAS]	61675-64-7 65899-73-2	US 4062866	Antifungal
Tioc naz I		65899-73-2		
tiopronin	Glycine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US 3246025	Urological
Ti pr nin		2/2/1953		
tiotropium bromide	3-Oxa-9-azoniatricyclo[3.3.1.0 ^{2,4}]nonane, 7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-, bromide- (1 Alpha,2B,4B,5Alpha,7B) [CAS]	136310-93-5	EP 418716	COPD treatment
TI tropium Bromide		136310-93-5		
Tioxolone		4991-65-5		
Tipepidine		5169-78-8		

TABLE IV

Example of Indication
Glaucoma
Infection, fungal, genital
.
Hemogystinuria
Chronic obstructive pulmonary disease

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tipilamib	2-(1H)-Quinolone, 6-(amino(4-chlorophenyl)-(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 8716443	Anticancer, other
tipranavir	N-[3-(1(R)-[4-Hydroxy-2-oxo-6(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide 2H-Quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-, bromide, trans- [CAS]	174484-41-4		Antiviral, anti-HIV
tiqizium bromide		71731-58-3	US 4205074	Antispasmodic
Tiqizium Bromide		71731-58-3		
tiropazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	20028-80-2 27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer
Tirapazamin		27314-97-2		
Tiratric I		51-24-1		
Tirilazad		110101-66-1		
	Pregna-1,4,9(1)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrroldinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16Alpha)-, monomethanesulfonate- [CAS]	110101-65-0 110101-67-2	WO 8701706	Neuroprotective
Tir fiban		144494-65-5		
tirofiban hydrochloride	L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl-, monohydrochloride- [CAS]	142373-60-2	EP 478363	Antithrombotic
Tirofiban Hydrochloride				
tiropamide	Benzenepropanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+)- [CAS]	55837-29-1	DE 2503992	Antispasmodic
Tiropamide		55837-29-1		
Titanium Sulfate		13825-74-6		
Tixoc rtoI		61951-99-3		

TABLE IV

Example 1 Indication
Cancer, breast
Infection, HIV/AIDS
Cancer, lung, non-small cell
Haemorrhage, subarachnoid
Infarction, myocardial
Muscle spasm, general

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
lixocortol pivalate	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11B)-[CAS]	55560-96-8 61951-99-3	GB 1475795	Antiallergic, non-asthma
lixocortol pivalate enema	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11B)-[CAS]	55560-96-8	US 4014909	Formulation, mucosal, topical
lizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	GB 1429926	Muscle relaxant
Tizanidine	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteiny-2-phenyl-, diethyl ester, (2R)-[CAS]	166882-53-9	US 5679643	Immunosuppressant, other
TLK-199	Glycine, L-Gamma-glutamyl-3-[(2-[(bis[2-chloroethyl]amino]phosphinyloxy)ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)-[CAS]	158382-97-7	US 5545621 RU 2035185	Anticancer, other Anticancer, immunological
TNF- β analogue, SFC VB		129298-91-5		
TNP-470	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 β ,17,21-trihydroxy-16 β ,20 β -methyl-, 17-butyrate 21-propionate [CAS]	5534-02-1		Antipruritic/inflamm, allergic
TO-186		32986-56-4		
Tobramycin	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, topical
tobramycin, Nektar	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, solution
tobramycin, Pathogenesis	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US 4218477	Antiarhythmic
locaine		41708-72-9		
T caine		41708-72-9		
Tocamphyl		5634-42-4		

Example of Indication
Rhinitis, allergic, general
Colitis, ulcerative
Spastic paralysis
Myelodysplastic syndrome
Cancer, ovarian
Cancer, general
Infection, respiratory tract, general
Infection, respiratory tract, lower
Fibrillation, ventricular

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
loclesine	8-Chloroadenosine 3',5'-cyclic phosphate	41941-56-4		Anticancer, other
Tocoretate		40516-48-1		
Todralazine		14679-73-3		
T fenacin		15301-93-6		
	5H-Pyrazolo[3,4-c]1,2,4-triazolo[4,3-a]pyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-			
tolimilast		185954-27-2		Asthma
tolisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-(CAS)	22345-47-7	GB 1334271	Anxiolytic
Tofis pam		22345-47-7		
T lazamide		1156-19-0		
Tolazoline		59-98-3		
Tolbutamide		64-77-7		
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- (CAS)	134308-13-7	EP 237929	Antiparkinsonian
T icapone		134308-13-7		
Tolcapone				
	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester (CAS)	50838-36-3	GB 1364407	Antifungal
Tolciclate		50838-36-3		
Tolciclamid		664-95-9		
tolvamer sodium	Benzenesulfonic acid, 4-ethenyl-, homopolymer, sodium salt	28038-50-8		Antibacterial, other
tolenamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- (CAS)	13710-19-5	DE 1543295	Anti-inflammatory
Toltenamic Acid		13710-19-5		
Tolindate		27877-51-6		
Toliprolol		2933-94-0		
Tolmetin		26171-23-3		

TABLE IV

Example of Indication
Cancer, colorectal
Asthma
Anxiety, general
Parkinson's disease
Infection, dermatological
Infection, Clostridium, general
Inflammation, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
T Inafate		2398-96-1		
Tol midin		4201-22-3		
Tolonium Chloride		92-31-9		
Toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB 1250538	Antidepressant
Tol xatone		29218-27-7		
Tolp rison		728-88-1		
Tolpr pamine		5632-44-0		
T Ir stat		82964-04-3		
Tolserine	Carbamic acid, (2-methylphenyl)-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9		Cognition enhancer
Tolterodine	Phenol, 2-(3-(bis(1-methylallyl)amino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EP 325571	Urological
Tolterodine	Phenol, 2-(3-(bis(1-methylallyl)amino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5		
Tolterodine, extended-release	Phenol, 2-(3-(bis(1-methylallyl)amino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]			Formulation, modified-release, <=24hr
Toltrapien	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP 450097	Cardiovascular
Tolycain		3686-58-6		
Tolpramate	B-D-Fructopyranose, 2,3,4,5-bis-O-(1-methylethylidene)-, sulfate [CAS]	97240-79-4	EP 533483	Antiepileptic
Topiramate		97240-79-4		
topoisomerase inhibitors, BIG			US 5733860	Anticancer, other
topotecan	1H-Pyranol[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8	EP 321122	Anticancer, other
Topotecan		123948-87-8		
topotecan TCS, Inex	1H-Pyranol[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8		Formulation, optimized, liposomes

TABLE IV

Example of Indication
Alzheimer's disease
Incontinence
Incontinence
Heart failure
Epilepsy, generalized, tonic-clonic
Cancer, general
Cancer, ovarian
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
torasemide	3-Pyridinesulfonamide, N-[(1-(3-methylethyl)amino)carbonyl]-4-[(3-methylphenyl)amino]- [CAS]	56211-40-6	US 4018929	Antihypertensive, diuretic
torcetrapib	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262352-17-0		Hypolipæmic/Antiatherosclerosis
torcitabine	β -L-2'Deoxyctydine			Antiviral, other
torémfiene	Etiracarine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 89778-27-8	EP 95875	Anticancer, hormonal
Toremif ne		89778-26-7		
Tors mde		56211-40-6		
Tositumomab		208921-02-2		
T sufi xacin		100490-36-6		
tosufloxacin tosilate	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrididinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, mono(4-methylbenzenesulfonate)- [CAS]	100490-36-6 115964-29-9	US 4704459	Quinolone antibacterial
tramadol	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-)-[CAS]	27203-92-5 36282-47-0		Analgesic, other
Tramadol		27203-92-5		
tramadol + acetaminophen, Ortho	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-)- + Acetamide, N-(4-hydroxyphenyl)-			Formulation, fixed-dose combinations
tramadol SR, Ethypharm	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-)-[CAS]	27203-92-5 36282-47-0		Formulation, modified-release, other
tramadol, Biovail	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(±)- [CAS]	27203-92-5 36282-47-0		Formulation, modified-release, <=24hr

TABLE IV

Exempl of Indication
Hypertension, general
Atherosclerosis
Infection, hepatitis-B virus
Cancer, breast
Infection, urinary tract
Pain, general
Pain, general
Pain, general
Pain, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tramadol, Flashtab	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-) [CAS]	27203-92-5 36282-47-0		Formulation, oral, orally-disintegrating
tramadol, Labopharm	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(±) [CAS]	27203-92-5 36282-47-0		Formulation, modified-release, <=24hr
tramadol, Purdue	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(±) [CAS]	27203-92-5 36282-47-0		Formulation, modified-release, other
Tramazoline		1082-57-1		
trandolapril	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, [2S-(11R*(R*))], 2Alpha,3aAlpha,7a8]]- [CAS]	87679-71-8 87679-37-6 52-53-9 87679-71-8	DE 3151690	Antihypertensive, renin system
trandolapril + verapamil, Aven				Formulation, fixed-dose combinations
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8 1197-18-8	US 3950405	Antifibrinolytic
Tranexamic Acid				
tranilast	Benzoic acid, 2-[[3-(4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- [CAS]	53902-12-8	US 3940422	Vulnerary
Tranilast		53902-12-8		
trans-retinoic acid, NIH	Retinoic acid [CAS]	302-79-4		Anticancer, other
Tranylcypromine		155-09-9		
trapidil	[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	DD 55956	Vasodilator, coronary
Trapidil		15421-84-8		
Trastuzumab		180288-69-1		
Trastuzumab				

TABLE IV

Exempl of Indication
Pain, general
Pain, general
Pain, general
Hypertension, general
Hypertension, general
Menstrual disorder, general
Wound healing
Cancer, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
travoprost, Alcon	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R(1Alpha,2),2B(1E,3H*),3Alpha,5Alpha) [CAS]	157283-68-6		Formulation, mucosal, topical
Traxan x	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-8-methyl-4-phenyl-, (AlphaS,6S)-methanesulfonate [CAS]	58712-69-9		
traxoprodil mesylate	1,2,4-Triazole[4,3-a]pyridin-3(2H)-one, 2-[3-(4-(3-chlorophenyl)-1-piperazinyl)propyl]- [CAS]	134234-12-1 188591-67-5		Analgescic, other
trazodone		19794-93-5 25332-39-2	US 4215104	Antidepressant
Traz d n		19794-93-5		
Tremacamra		155576-45-7		
Trenbolone		10161-33-8		
Tr ng st ne		5192-84-7		
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*,R*)]- [CAS]	299-75-2	WO 8401506	Anticancer, alkylating
trepibutone	Benzenebutanoic acid, 2,4,5-trimethoxy-Gamma-oxo- [CAS]	41826-92-0	GB 1387733	Antispasmodic
Trepibutone		41826-92-0		
treprostamol	Prosta-5,13-dien-1-ol-acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US 6054486	Formulation, parenteral, other
tretinoin, Connetics	Retinoic acid [CAS]	302-79-4		Formulation, dermal, topical
tretinoin, Ortho	Retinoic acid [CAS]	302-79-4	US 4247547	Antiacne
tretinoin, Roche	Retinoic acid- [CAS]	302-79-4		Anticancer, other
treloquinol	6,7-Isosquinalinediol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl]-, (S)- [CAS]	18559-59-6 30418-38-3	ZA 6802416	Antitasthma
Tr toquin I		21650-42-0		
TRI		24305-27-9		
TRI-50b, iv	TRI 50b [CAS]	228214-49-9		Antithrombotic
TRI-50b, oral	TRI 50b [CAS]	228214-49-9		Antithrombotic

TABLE IV

Example 1 Indication
Glaucoma
Pain, general
Hypertension, pulmonary
Acne
Acne
Cancer, leukaemia, acute myelogenous
Thrombosis, general
Thrombosis, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Triacetone		102-76-1		
Triacetone		124-94-7		
Triacetone		76-25-5		
Triacetone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)-[CAS]	76-25-5		Formulation, inhalable, topical
Triacetone acetate, Astra	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)-[CAS]	76-25-5		Formulation, transdermal, enhanced
Triacetone acetate, IDEA	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)-[CAS]	76-25-5		Formulation, other
Triacetone acetate, Telj		31002-79-6		
Triacetone		5611-51-8		
Triacetone		396-01-0		
Triacetone	Triapine [CAS]	296392-56-6	US 6458816	Anticancer, antimetabolite
Triacetone		68-76-8		
Triacetone	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US 3980790	Hypnotic/Sedative
Triacetone		28911-01-5		
Triacetone	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- [CAS]	28911-01-5		Formulation, transmucosal, nasal
Triacetone	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- [CAS]	28911-01-5		Formulation, transmucosal, systemic
Triacetone		10310-32-4		
Triacetone		52-68-6		
Triacetone		133-67-5		

TABLE IV

Exempl f Indication
Asthma
Eczema, general
Ulcer, aphthous
Cancer, leukaemia, general
Insomnia
Insomnia
Insomnia

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Trichloromethine		555-77-1		
Trichloroethylene		79-01-6		
Triclobisonium Chloride		79-90-3		
Triclorcarban		101-20-2		
Triclorofenol Piperazine		5714-82-9		
Triclorofos		306-52-5		
Triclorosan		3380-34-5		
Tricromyl		85-90-5		
Tridihexethyl dide		125-99-5		
Trientin		112-24-3		
Trientine dihydrochloride	1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, dihydrochloride [CAS]	38260-01-4		Metabolic and enzyme disorders
Triethanolamin		102-71-6		
Triethylenemelamine		51-18-3		
Triethylen phosphorami de		545-55-1		
Triethylenethiophosphor amide		52-24-4		
Triflu perazine		117-89-5		
Trifluoperazine Hydrochloride				
Trifluoperidol		749-13-3		
Trifluoprazine		146-54-3		
Trifluridine	Thymidine, Alpha,Alpha-trifluoro- [CAS]	70-00-8	US 3201387	Antiviral, other
Trifluridin	Benzolic acid, 2-(acetyloxy)-4- (trifluoromethyl)- [CAS]	70-00-8		
Triflusal		322-79-2	US 4096252	Antithrombotic
Trihexaphenylidyl Hydrochloride		322-79-2 52-49-3		

TABLE IV

[illegible]

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17beta)- [CAS]	13847-35-3	US 3296255	Anticancer, hormonal
Trilostane		13647-35-3		
Trimazosin		35795-16-5		
Trimebutine		39133-31-8		
trimebutine maleate	Benzolic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-butenedioate (1:1) [CAS]	34140-59-5	DE 2151716	Antispasmodic
Trim calin		616-68-2		
Trimeprazin		84-96-8		
Trimetazidin		5011-34-7		
Trim thadi n		127-48-0		
Trimethaphan		68-91-7		
Camsylate		138-56-7		
Trimethobenzamide		738-70-5		
Trim thoprim		635-41-6		
Trimetozine		52128-35-5		
Trimetr xat		52128-35-5		
trimetrexate glucuronate	2,4-Quinazolinodiamine, 5-methyl-6-[[[3,4,5-trimethoxyphenyl]amino]methyl]- [CAS]	82952-64-5	US 4391809	Antifungal
Trimipramin		739-71-9		
tripramine maleate	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9		Antidepressant
Trimoprostil		69900-72-7		
Trioxsalen		3902-71-4		
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isoindol-2-yl)-, (3aAlpha,4Alpha,7Alpha,7aAlpha)- [CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic
Tripamide		73803-48-2		
Triparanol		78-41-1		
Tripelennamine		91-81-6		

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tripr lidin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan- [CAS]	486-12-4 124508-66-3 57773-63-4	US 4010125	Releasing hormones
triptorelin				
Tript r lin		57773-63-4		
Trithiozine		35619-65-9		
trithiozine	Morpholine, 4-(thioxo(3,4,5-trimethoxyphenyl)methyl)- [CAS]	35619-65-9	US 3882138	Antitumor
Tritoqualine		14504-73-5		
TRK-530	Phosphonic acid, [[4-(methylthio)phenyl]thio]methylene]bis-, disodium salt [CAS]	151425-92-2	WO 9410181	Antiarthritic, other
TRK-820	2-Propenamide, N-[(5Alpha,6B)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/inflam, non-allergic
Tr cios n Potassium		2244-21-5		
trofosamide	3,2-(chloroethyl)-2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1188159	Anticancer, alkylating
Trof sfamid		22089-22-1		
Tr glitazon		97322-87-7		
Tr leandomycin		9/9/2751		
TroIntrate Phosphate		588-42-1		
tromantidine	N-(1-adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other
Tromantadin		53783-83-8		
Tromethamine		77-86-1		
Tropacin		6878-98-4		
Tr p sin		65189-78-8		
Tr plicamide		1508-75-4		
tropine indometacinatate, Spofa	1H-Indole-3-acetic acid, 1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/-)- [CAS]	65189-78-8		Antiarthritic, other

TABLE IV

Example f Indication
Cancer, prostate
Arthritis, rheumatoid
Pruritus
Infection, herpes simplex virus

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
tropisetron	1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-[CAS]	89565-68-4	GB 2125398	Antiemetic
Tr pils tron		89565-68-4		
Tr spect mycin		88669-04-9		
trosplum chloride	3Alpha-Hydroxy Spiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinum] chloride benzilate	10405-02-4		Urological
Trosplum Chloride		10405-02-4		
trosplum chloride, extended re	3Alpha-Hydroxy Spiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinum] chloride benzilate	10405-02-4		Formulation, modified-release, other
trosplum chloride, Pflger	3Alpha-Hydroxy Spiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinum] chloride benzilate	10405-02-4		Formulation, parenteral, other
Tr vafi xacin		147059-72-1		
trovalfoxacin mesilate	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1Alpha,5Alpha,6Alpha)-monomethanesulfonate- [CAS]	147059-72-1 147059-75-4	US 5164402	Quinolone antibacterial
troxactabine	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S-cis)-[CAS]	145918-75-8		Anticancer, other
Troxerutin		7085-55-4		
troxipide	Benzamide, 3,4,5-trimethoxy-N-3-piperidinyl-, (+/-)- [CAS]	30751-05-4	US 3647805	Antiulcer
Troxipide		99777-81-8		
Trypan Red		574-64-1		
Tryparsamide		554-72-3		
Tryptophan		73-22-3		
TSH		9002-71-5		

TABLE IV

Example	Indication
Chemotherapy-induced nausea and vomiting	
Pollakisuria	
Pollakisuria	
Pollakisuria	
Infection, respiratory tract, general	
Cancer, leukaemia, acute myelogenous	
Ulcer, gastric	

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
TSN-09	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-[(1,1-dimethylethyl)-5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha,(S)]-, [CAS]	52485-79-7		Formulation, transdermal, patch
TU-2100	Nonanedioic acid, bis[(2-(ethoxycarbonyl)phenyl)] ester		US 6180669	Anti-acne
Tuamin h ptane		123-82-0		
Tubercidin		69-33-0		
Tubocurarin Chloride		57-94-3		
tulobuterol	Benzenemethanol, 2-chloro-Alpha-[(1,1-dimethylethyl)amino]methyl-, [CAS]	41570-61-0	DE 2244737	Antiasthma
Tulobut rol	N-(Propargyl-(3R)aminoinidan-5-yl)-ethyl methyl carbamate	41570-61-0		Cognition enhancer
TV-3326				
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-noradiny)]-1H-inden-5-yl]ethoxy]-, [1S-[1'Alpha(R'),2',3aAlpha,7aAlpha]]-, [CAS]	140694-43-5	US 4837342	Antithrombotic
TY-12533	6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate		US 6258829	Antiarrhythmic
TYB-3215	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, modified-release, other
Tybamat		4268-36-4		
Tyl xapol		25301-02-4		
tyloxapol, Discovery	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4		Formulation, inhalable, topical
Tymazoline		24243-97-8		
Tyramine		51-67-2		

TABLE IV

Example f Indication
Pain, cancer
Acne
Asthma
Alzheimer's disease
Unspecified
Unspecified
Angina, general
Cystic fibrosis

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Tyr pan ate Sodium		7246-21-1		
Ubenlmax		58970-76-6		
ufenamate	Benzoic acid, 2-[(3-(trifluoromethyl)phenyl)amino]-, butyl ester [CAS]	67330-25-0	BE 861852	Antipruritic/inflam, non-allergic
Undecyl nic Acid		112-38-9		
Unopr st n		120373-36-6		
UR-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-imidazol-1-yl]benzenesulfonamide- [CAS]			Anti-inflammatory
Uracil Mustard		66-75-1		
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US 4400535	Urological
urapidil	2,4-(1H,3H)-Pyrimidinedione, 6-[[3-(4-(2-methoxyphenyl)-1-piperazinylpropyl)amino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic
Urabidil		34661-75-1		
urea, Kabi Pharmacia	Urea [CAS]	57-13-8		Antipsoriasis
urea, Viras	Urea [CAS]	57-13-8		Antipruritic/inflam, allergic
Ur depa		302-49-8		
Urethan		51-79-6		
Uridine 5'-Triphosphate		63-39-8		
uridine, Polifarma	Uridine [CAS]	58-96-8	EP 348360	Formulation, other
Urinastatin		80449-31-6		
ursodeoxycholic acid, Axcan	3Alpha,7B-dihydroxy-5B-cholan-24-olic acid [CAS]	128-13-2		Formulation, other
ursodeoxycholic acid, Axcan-2	3Alpha,7B-dihydroxy-5B-cholan-24-olic acid [CAS]	128-13-2		Formulation, other
ursodeoxycholic acid, Mitsub	3Alpha,7B-dihydroxy-5B-cholan-24-olic acid [CAS]	128-13-2		Formulation, oral, other
ursodeoxycholic acid, Novartis	3Alpha,7B-dihydroxy-5B-cholan-24-olic acid [CAS]	128-13-2		Gallstone therapy
Ursodi l		128-13-2		

TABLE IV

Example of Indication
Inflammation, general
Hypertension, general
Eczema, contact
Schizophrenia
Cirrhosis, primary biliary
Hepatic dysfunction, general
Cirrhosis, primary biliary
Biliary calculus

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Ursodiol			US 6083773	Formulation, mucosal, topical
Usthercell				
Uzarin		20231-81-6		
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other
Valacyclovir		124832-26-4		
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US 5859257	Antiarthritic, other
Valdetamid		512-48-1		
Valethamate Bromide		90-22-2		
	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8	EP 694547	Antiviral, other
valganciclovir		175865-60-8		
Valganciclovir		4171-13-5		
Valnoctamid	L-Valine (3R)-3-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]-4-[(1-oxooctadecyl)oxy]butyl ester [CAS]	195156-77-5		Antiviral, other
valomaciclovir stearate	Pentanoic acid, 2-propyl-, sodium salt (2:1) [CAS]	76584-70-8	US 4988731	Antiepileptic
valproate semisodium	Pentanoic acid, 2-propyl-, sodium salt (2:1) [CAS]	76584-70-8		Formulation, modified-release, <=24hr
valproate semisodium, ER	Pentanoic acid, 2-propyl-, sodium salt- [CAS]	1069-86-5		Formulation, modified-release, <=24hr
valproate sodium, Nikken	Valeric acid, 2-propyl-, sodium salt [CAS]	1069-86-5		Formulation, modified-release, <=24hr
valproate sodium, Sanofi-Synth		99-66-1		
Valproic Acid		2430-27-5		
Valproic mld	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl- [CAS]	92262-58-3	US 5585358	Antiepileptic
valroceamide	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthaceny)-2-oxoethyl ester (2S-cis) [CAS]	56124-62-0	US 4035566	Anticancer, antibiotic
valrubicin		56124-62-0		
Valrubicin		56124-62-0		

TABLE IV

Exempl of Indication
Contraceptive, female
Infection, herpes simplex virus
Arthritis, rheumatoid
Infection, cytomegalovirus
Infection, herpes simplex virus
Epilepsy, generalized, tonic-clonic
Migraine
Epilepsy, general
Epilepsy, general
Epilepsy, general
Cancer, bladder

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
valsartan	L-Valine, N-(1-oxopentyl)-N-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl- [CAS]	137862-53-4	EP 443983	Antihypertensive, renin system
Valsartan		137862-53-4		
Valspodar		121584-18-7		
varidenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl(-4-oxo-7-propylimidazo[5,1-f][1,2,4]-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS]	224785-90-4		Male sexual dysfunction
varepladib sodium	Acetic acid, ((3-(aminooxocetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- [CAS]	172732-68-2 172733-42-5	EP 675110	Septic shock treatment
Varicella Virus Vaccine, Live				
vatanidipine hydrochloride	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(4-(diphenylmethyl)-1-piperazinyl)phenyl]ethyl methyl ester, dihydrochloride- [CAS]	118308-55-5 133743-71-2	EP 257616 US 6007817	Neuroprotective Radio/chemosensitizer
VEA, Peregrine				
vecuronium bromide	Piperidinium, 1-[[20,3Alpha,5Alpha,16B,17B)-3,17-bis(acetoxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, bromide [CAS]	50700-72-6 50700-72-6 104675-29-8 93413-69-5	US 4237128	Muscle relaxant
Vecur nium Bromide				
Veinacrine				
Venlafaxin				
venlafaxine hydrochloride	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride [CAS]	93413-69-5 93300-79-4	GB 2227743	Antidepressant
venlafaxine XR	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride [CAS]	93300-78-4		Formulation, modified-release, <=24hr
venlafaxine, Phoenix	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, hydrochloride [CAS]	93300-78-4		Formulation, modified-release, other
V raliipride		66644-81-3		

TABLE IV

Examp f Indication
Hypertension, general
Sexual dysfunction, male, general
Sepsis
Hypertension, general
Cancer, general
Anaesthesia, adjunct
Depression, general
Depression, general
Depression, general

TABLE IV

API Gen ric Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Verapamil	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9		
verapamil SR, Ethypharm	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9		Formulation, modified-release, other
verapamil, Elan	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9	US 4863742	Formulation, oral, other
verapamil, Mylan	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9		Formulation, modified-release, other
verapamil, Orion-Farnos	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9		Formulation, modified-release, <=24hr
verapamil, OROS, Alza	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9		Formulation, modified-release, other
verapamil, Verex	Benzeneacetoneitrile, Alpha-[3-[(2-(3,4-dimethoxyphenyl)ethyl)methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-[CAS]	52-53-9	US 4461759	Formulation, modified-release, <=24hr
verteporfin	23H,25H-Benzobisporphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-[CAS]	129497-78-5	US 5238940	Ophthalmological
Verteporfin	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-8-quinolinyl)-[CAS]	81840-15-5	GB 2086896	Cardiovascular
vesnarinone		81840-15-5		
Vesnarinone		3735-45-3		
Vetrabutine	Benzene carboximidamide, N,3,4,5-tetrahydroxy- [CAS]	95933-74-7	US 4623659	Cardiovascular
VF-233			US 6403597	Male sexual dysfunction
VI-0134				

TABLE IV

Example of Indication
Hypertension, general
Hypertension, general
Hypertension, general
Tachycardia, supraventricular
Hypertension, general
Hypertension, general
Macular degeneration
Heart failure
Reperfusion injury
Premature ejaculation

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
vidarabine	9H-Purin-6-amine, 9-β-D-arabinofuranosyl- [CAS]	24356-66-9 5536-17-4	GB 1159290	Antiviral, other
Vidarabine		5536-17-4		
vigabatrin	5-Hexenoic acid, 4-amino- [CAS]	68506-86-5 60643-86-9	GB 1472525	Antiepileptic
Vigabatrin				
vilazodone	2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]- [CAS]	163521-12-8	EP 648767	Antidepressant
Vil xazine		46817-91-8		
Vimin I		21363-18-8		
Vinbarbital Sodium		125-44-0		
Vinblastine		865-21-4		
vinbumine	Eburnamenin-14(15H)-one, (3α,16α)- [CAS]	474-00-0 4880-88-0	DE 1932245	Cognition enhancer
Vincamine		1617-90-9		
Vinconate		70704-03-9		
Vincristine		57-22-7		
vincristine solution	Vincalcalcoloblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2	EP 207831	Formulation, parenteral, other
vincristine, Alza	Vincalcalcoloblastine, 22-oxo- [CAS]	57-22-7		Formulation, optimized, liposomes
vincristine, bioMérieux-Pierre	Vincalcalcoloblastine, 22-oxo- [CAS]	57-22-7		Formulation, parenteral, other
vindesine	Vincalcalcoloblastine, 3-(aminocarbonyl)-O-4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB 1463575	Anticancer, other
Vindesine		53643-48-4		
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3S,4S,5A,12B,19A)- [CAS]	162652-95-1	FR 2707988	Anticancer, other
vinorelbine	C-Norvincalcalcoloblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP 10458	Anticancer, other

TABLE IV

Example of Indication
Infection, herpes virus, general
Epilepsy, partial (focal, local)
Depression, general
Cancer, general
Cancer, lymphoma, Hodgkin's
Cancer, general
Cancer, leukaemia, acute lymphocytic
Cancer, general
Cancer, lung, non-small cell

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
vinorelbine, oral	C-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1		Formulation, oral, other
vinpocetine	Eburnamenine-14-carboxylic acid, ethyl ester, (3Alpha, 16Alpha)- [CAS]	42971-09-5	GB 1405127	Cognition enhancer
Vinpocetine		42971-09-5		
Vinyl Ether		109-93-3		
Vinylbital		2430-49-1		
Viquidil		84-55-9		
Viridin		3306-52-3		
Visnadine		477-32-7		
Vitamin A		68-26-8		
Vitamin B12, Nastech	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal
Vitamin C, Alza	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr
Vitamin D2		50-14-6		
Vitamin D3		67-97-0		
Vitamin K5		83-70-5		
Vitamins, Prenatal				
VLA-4 antagonists, Aventis	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioxolimidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine			Anticancer, alkylating
voglibose	D-epi-Inositol, 3,4'-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- [CAS]	83480-29-9	US 6040338	Antidiabetic
Voglibose		83480-29-9	EP 56194	
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-8-methyl-Alpha-(1H-1,2,4-triazol-1-ylmethyl)-; (R-(R*, S*))-[CAS]			
Voriconazole		137234-62-9	EP 440372	Antifungal
		137234-62-9		

TABLE IV

Exempl of Indication
Cancer, lung, non-small cell
Cognitive disorder, general
Anaemia, general
Nutrition
Asthma
Cancer, general
Diabetes, Type II
Infection, fungal, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Vor zole	7-[3-[4-(2-Quinolinylmethyl)-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one	129731-10-8		
VUF-K-8788		81-81-2		Antiasthma
Warfarin		92047-76-2		Radio/chemoprotective
WF-10	Tetrachlorodecaoxide [CAS]			
	2-[3-[4-(3-(6-oxo-6H-2,10b-diazaaceanthrylen-5-ylamino)propyl)piperazin-1-yl]propyl]-5-nitro-2-azaphenylene-1,3-dione			Anticancer, other
WMC-79			US 5897890	Formulation, transdermal, patch
wound healing matrix, IPM, LAM			US 6531121	Cytokine
WP-170		135354-02-8		
Xaliproden	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, hydrochloride [CAS]	90494-79-4	EP 101381	Neuroprotective
xaliproden hydrochloride				
	4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenox)propyl]amino]ethyl]-, (+/-) [CAS]	73210-73-8 81801-12-9	GB 2002748	Cardio stimulant
xamoterol		81801-12-9		
Xamoterol		131986-45-3		
Xanomeline		437-74-1		
Xanthinol Niacinate		149820-74-6		
Xemil fiban		959-10-4		
Xenbucin		81584-06-7		
Xibenolol				
	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-, exo- [CAS]	13741-18-9	GB 1205774	Antibacterial, other
xibornol		13741-18-9		
Xibornol				

TABLE IV

Example of Indication
Asthma
Chemotherapy-induced injury, bone marrow, general
Cancer, colorectal
Ulcer, diabetic
Unspecified
Amorphous lateral sclerosis
Heart failure
Infection, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
ximelagatran	Glycine, N-((R)-cyclohexyl-2-(2S)-2-(((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl-2-oxoethyl ethyl ester [CAS]	192939-46-1		Antithrombotic
Ximoprof n		56187-89-4		
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic
Xipamid		14293-44-8		
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8S)- [CAS]	77287-89-9		Analgescic, other
	2,5-Piperazinedione, 3-[5-[2-(dimethylamino)ethylthio]-2-(dimethylamino)-6-(phenylmethylene)-, thienyl]methylene]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9532190	Anticancer, other
XR-5118	N,N'-(1,2-Ethanediy)bis(imino-2,1-ethanediy)bis(9-methylphenazine-1-carboxamide)		EP 934278	Anticancer, other
XR-5944		526-36-3		
Xylometazoline		58-86-6		
Xylose				
	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isouinolyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO 9605177	Anticancer
YH-1885				
	Benzonitrile, 4-[[[4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO 9305027	Anticancer, hormonal
YM-511	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide			Anticancer, other
YM-598		146-48-5		
Yohimbine		90596-75-1	US 5270304	Anti-inflammatory
YT-146	Adenosine, 2-(1-octynyl)- [CAS]			
	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- [CAS]			
Z-321		130849-58-0	EP 372484	Cognition enhancer

TABLE IV

Example of Indication
Thrombosis, venous
Pain, cancer
Cancer, general
Cancer, general
Ulcer, GI, general
Cancer, breast
Cancer, prostate
Inflammation, general
Dementia, senile, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
Z-335	(1H-Indene-5-acetic acid, 2[[[(4-chlorophenyl)sulfonyl]amino]methyl]-2,3-dihydro, monosodium salt) [CAS]	146731-14-8	JP 92506077	Antithrombotic
zafirlukast	Carbamic acid, [3-[[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenylmethyl]-1-methyl-1H-indol-5-yl]-cyclopentyl ester] [CAS]	107753-78-6	EP 189543	Antiasthma
Zafirlukast		107753-78-6		
Zafirlukast				
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV
Zalcitabine		7481-89-2		
Zalcitabine				
Zalcitabine		109826-26-8		
Zaldaride	Acetamide, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative
zaleplon		151319-34-5		
Zaleplon		151319-34-5		
zalclofen	Dibenzol[b,f]thiepin-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	74711-43-6	JP 55063282	Anti-inflammatory
Zalclofen		74711-43-6		
zanamivir	5-Acetamido-2,8-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO 9116320	Antiviral, other
Zanamivir		139110-80-8		
Zanamivir				
zanapexil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP 487071	Cognition enhancer
Zat bradine		85175-67-3		
ZD-0473	Platinum, amminedichloro(2-methylpyridine)- (SP-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating
ZD-0947	N-acetylcolchicinol-O-phosphate		WO 9528388	Urological
ZD-6126				Anticancer, other
	1H-Tetrazole-5-butanolic acid, Alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino) (S)- [CAS]	153537-73-6	GB 2264946	Anticancer, antimetabolite
ZD-9331		153537-73-6		

TABLE IV

Examp ^l of Indication
Peripheral vascular disease
Asthma
Infection, HIV/AIDS
Insomnia
Infection, influenza virus
Alzheimer's disease
Cancer, ovarian
Overactive bladder
Cancer, general
Cancer, pancreatic

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
zebularine	2(1H)-Pyrimidinone, 1-β-D-ribofuranosyl- [CAS]	3690-10-6		Anticancer, other
zelandopam hydrochloride	7,8-Isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, hydrochloride, (S)- [CAS]	138086-00-7	JP 03190818	Vasodilator, renal
Zenarestat		112733-06-9		
Ziconotide		107452-89-1		
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1	US 4724232	Antiviral, anti-HIV
Zidovudine		30516-87-1		
Zidovudine				
Zidovudine				
zidovudine, Verex	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1		Formulation, modified-release, ≤24hr
zileuton	Urea, N-(1-benzotriazin-2-ylthio)-N-hydroxy- [CAS]	111406-87-2	EP 279263	Antiasthma
Zileuton		111406-87-2		
Zimeldine		56775-88-3		
zinc acetate, basic	hexakis(μ-acetato-μ4-oxotetrazinc	12129-82-7		Antiviral, other
zinc aceexamate	Hexanoic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS]	70020-71-2	EP 369088	Antitumor
zinc ibuprofenate, Vinas		78416-80-5		Anti-inflammatory, topical
Zinc p-Phenolsulfonate		127-82-2		
Zinc Salicylate		16283-36-6		
Zin statin		2/29014		
zinc statin stimalamer		123760-07-6	EP 136791	Anticancer, antibiotic
Zip prol		34758-83-3		
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP 281309	Neuroleptic
Ziprasidone		146939-27-7		
zofenopril	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R'),2Alpha,4Alpha]- [CAS]	75176-37-3 81872-10-8 81938-43-4	GB 2028327	Antihypertensive, renin system

TABLE IV

Example f Indication
Cancer, general
Hypertension, general
Infection, HIV/AIDS
Infection, HIV/AIDS
Asthma
Infection, herpes simplex virus prophylaxis
Ulcer, duodenal
Inflammation, dermal
Cancer, liver
Schizophrenia
Hypertension, general

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
zofenopril + HCTZ	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R*),2Alpha,4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]			Formulation, fixed-dose combinations
zoledronic acid	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8	EP 531253	Osteoporosis treatment
Zoledronic Acid		118072-93-8; 165800-06-6 (monohydrate)		
zolimidine	2-[p-methylsulfonylphenyl]imidazo[1,2-a]pyridine	1222-57-7	US 3318880	Antilucer
Zolimidin		1222-57-7		
zolmitriptan	2-Oxazolidinone, 4-[(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl], (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine
Zolmitriptan		139264-17-8		
zolmitriptan, DuraSol	2-Oxazolidinone, 4-[(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl], (S)- [CAS]	139264-17-8		Formulation, modified-release, immediate
Zolpidem		82626-48-0		
zolpidem tartrate	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R*(R*))-, 2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6	EP 50563	Hypnotic/Sedative
Zolpidem Tartrate				
zolpidem tartrate MR	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R*(R*))-, 2,3-dihydroxybutanedioate (2:1)	99294-93-6		Formulation, modified-release, other
zolpidem tartrate, Flash Dose	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R*(R*), R*))-, 2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6		Formulation, optimized, microparticles
Zomepirac	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo- [CAS]	33369-31-2		
zonampanel		210245-80-0		Neuroprotective

TABLE IV

Exemplification of Indication
Hypertension, general
Hypercalcaemia of malignancy
Gastritis
Migraine
Migraine
Insomnia
Insomnia
Insomnia
Ischaemia, cerebral

TABLE IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use
zonipride mesylate	1H-pyrazole-4-carboxamide, N-(aminolimo- methyl)-5-cyclopropyl-1-(5-quinolinyl)- monomethanesulfonate	249296-45-5		Cardiovascular
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5 68291-97-4	GB 2025931	Antiepileptic
Z nisamid				
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6- (5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H- pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2 43200-80-2 110703-94-1 54083-22-6	GB 1358680	Hypnotic/Sedative
Z piclone				
Zopolr stat				
Z rubicin				
zosuquidar trihydrochloride	1-Piperazineethanol, 4-(1,1-difluoro- 1,1a,6,10b- tetrahydrodibenzof[a,e]cyclopropa[c]cyclohe- pten-6-yl)-Alpha-[(5-quinolinyl)oxy]methyl]- trihydrochloride, [6(R)- (1aAlpha,6Alpha,10bAlpha)]- [CAS]	167485-36-3		Radio/chemosensitizer
zotepine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin 10-yl)oxy]-N,N-dimethyl- [CAS]	26615-21-4 26615-21-4	GB 1247067	Neuroleptic
Zotepine				
ZP-123			WO 0182775	Antiarhythmic
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1- butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Anticancer, hormonal
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H- thioxanthen-9-ylidene)propyl]-, (Z)-[CAS]	53772-83-1 982-24-1	EP 270282	Neuroleptic
zuclopenthixol acetate	1-Piperazineethanol, 4-[3-(2-chloro-9H- thioxanthen-9-ylidene)propyl]-, acetate (ester), (Z)- [CAS]	85721-05-7		Neuroleptic
zuclopenthixol decanoate	Decanoic acid, 2-[4-[3-(2-chloro-9H- thioxanthen-9-ylidene)propyl]-1- piperazinyl]ethyl ester, (Z)- [CAS]	64053-00-5		Neuroleptic

TABLE IV

Example of Indication
Unspecified
Epilepsy, generalized, tonic-clonic
Insomnia
Cancer, leukaemia, acute myelogenous
Schizophrenia
Arrhythmia, general
Cancer, colorectal
Psychosis, general
Schizophrenia
Schizophrenia

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**